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ABSTRACT 
Introduction.  The inflammatory bowel diseases (IBD), Crohn’s disease (CD) and ulcerative 
colitis (UC), are common in Western Europe (200-400 cases /100,000) and associated with 
substantial morbidity, although mortality is now low. There is presently a great unmet need 
for novel therapeutics in IBD as present agents are limited by lack of efficacy, toxicity and 
poor patient acceptance. Recent findings from genome-wide association studies (GWAS) 
have characterised the genetic architecture of CD and UC. Defects in innate and adaptive 
immunity have been clearly established, and substantial novel insights into disease 
pathogenesis have been gained. Over 30 genes / loci are now associated with CD; a number 
of these, along with a few specific loci, are also associated with UC. The hedgehog (HH) 
signalling pathway is critical to gastrointestinal development and plays key roles in intestinal 
and immune homeostasis. Furthermore, in addition to well described roles in tumorigenesis, 
it is evident that recapitulation of embryonic HH signals play critical roles in response to 
acute and chronic inflammatory challenge in diverse tissues.  
Aims.  The main aims of the work presented in this thesis were to characterise the expression 
of key HH signalling components in the healthy and inflamed human intestine, establish 
whether germline variation in HH genes is associated with IBD and describe the in vitro 
responses of intestinal epithelial cells to pathogen associated molecular patterns.  The WNT 
pathway, antagonised by HH in the intestine, and two HH target genes (NKX2.3 and CCL20) 
were also analysed for evidence of association with IBD. 
Methods.  Expression of HH and WNT signalling components was described by 
immunohistochemistry and microarray analysis in healthy controls (HC), CD, UC, and non-
IBD inflamed terminal ileal and colonic samples.  Gene-wide haplotype-tagging studies were 
performed for GLI1 in Scottish, English and Swedish CD and UC, and Scottish early-onset 
colo-rectal cancer, IHH in Scottish IBD, NKX2.3 in Scottish and UK IBD, and CCL20 in 
Scottish, Swedish and Japanese IBD.  Evidence for association of all HH (n=13) and WNT 
(n=27) signalling genes in CD was established by analysis of UK GWAS data and meta-
analysis from UK, French/Belgium and N American studies.  The effect of 
lipopolysaccharide (LPS) and muramyl dipeptide (MDP) on HH signalling was assessed in 
colonic epithelial cells (SW480).  The effect of HH pathway agonists and antagonists on 
NFκB activity and cytokine expression was analysed in SW480 cells and peripheral blood 
mononuclear cells (HC and IBD patients) in vitro. 
Results.  The expression of HH pathway ligand is present in the intestinal epithelium and the 
pathway response network in the lamina propria demonstrating the paracrine nature of HH 
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signalling in the intestine. Immunohistochemical studies and microarray analysis 
demonstrates that HH pathway activity is decreased in all forms of colonic inflammation 
studied in man.  Variation in Glioma-associated oncogene homolog 1 (GLI1), a key HH 
transcription factor located at 12q13 (IBD2), was associated with IBD (p<0.0001), UC 
(p<0.0001) and to a lesser extent CD (p=0.03) in Scotland, a finding replicated in English 
IBD and UC. This association was attributed to a non-synonymous SNP (rs2228226C→G) 
with pools odds ratio of 1.194 in meta-analysis of over 5000 individuals from Scotland, 
England and Sweden (p=0.0002).  There was association of this SNP with early-onset colo-
rectal cancer, but of borderline significance (p=0.05). The variant protein (Q1100E) is 50% 
less active than wild-type protein in vitro.  IHH was not associated with CD or UC.  
Preliminary evidence was produced for association at SUFU (10q24; p=0.005), a GLI1-
binding protein, and at the WNT3 / WNT9B locus (17q21; p=0.0005).  MDP stimulation of 
colonic epithelial cells decreased HH pathway activity.  Exogenous HH increased expression 
of CCL20.  CCL20 promoter polymorphisms were associated with UC in Japanese patients 
(p=0.018) but not in Scotland or Sweden.  NKX2.3 was associated with IBD in Scotland 
(UC>CD), but there was insufficient power for fine-mapping of causative variants. 
Conclusions.  Multiple lines of evidence presented here demonstrate that the HH signalling 
pathway is involved in IBD pathogenesis.  In key complementary in vivo studies (conceived 
by CWL; conducted in collaboration with the Gumucio lab in Ann Arbor) we have 
demonstrated that Gli1+/- mice develop early, severe colitis with high mortality in response to 
acute inflammatory challenge. Furthermore, lamina propria antigen presenting cells are 
identified as the key HH target cells.  With HH agonists and antagonists in extensive pre-
clinical and early clinical testing, these studies have real potential to translate into novel 
therapeutics for patients with IBD. 
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1.1   Inflammatory Bowel Disease - Background 
Crohn’s disease (CD; MIM 266600) and ulcerative colitis (UC; MIM 191390) are idiopathic, 
chronic relapsing inflammatory bowel diseases (IBD) of high prevalence in the UK, N 
Europe and N America (200-400 IBD cases per 100,000).1  After sharp increases in the past 
50 years, incidence rates are now stabilising in these countries.  In contrast, rates continue to 
rise in S Europe, Asia and other developing countries where IBD was essentially unheard up 
until a few decades ago.2  Changes in prevalence after migration have been documented in 
Jewish populations, the Chinese (moving from the mainland to Hong Kong) and in migrants 
from the Indian sub-continent to England.   
 
Whilst mortality rates have fallen considerably in the last 50 years, significant morbidity 
associated with disabling symptoms (abdominal pain, diarrhoea and lethargy), medical 
therapies and surgical intervention is common.  This is of particular concern in patients with 
early-onset disease, where problems with growth, puberty, schooling, employment prospects, 
social and sexual well-being are all too frequently documented.  IBD is associated with extra-
intestinal manifestations affecting the joints, skin, eyes and liver, and with an increased risk 
of colo-rectal cancer, related to the duration and extent of active colonic inflammation.   
1.2 Treatment of IBD 
Since the first trials of corticosteroids,3 medical management has evolved with the only 
paradigm shift in the past two decades following the licensing of anti-tumour necrosis factor 
alpha (TNFα) antibody therapy for CD in the past 10 years. The ‘traditional’ therapeutic 
options available for the management of IBD consist of 5-aminosalicylates (5-ASA), 
corticosteroids, immunosuppressants and surgery (Figure 1-1).  Corticosteroid dependence 
and resistance,4 and complications with existing therapies remain important limiting factors 
in clinical practice.  There is very little evidence to demonstrate that any existing therapies 
alter the natural history of disease, with the exception of colectomy which is curative in UC 
(even now, some commentators are challenging this supposition, describing pouchitis as 
‘recurrent IBD’ of the pouch).5   However, there is great excitement and hope for novel 
therapies following a revolution in our understanding in the pathogenesis of IBD, largely 
catalysed by recent insights resulting from genetic studies. 
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1.2.1 Thiopurines 
Immunosuppression with azathioprine (AZA) or mercaptopurine (MP) is now regarded as the 
standard of care for patients with steroid refractory or steroid dependant IBD. There is 
proven efficacy for the induction of remission (OR 2.36, NNT=5) and there is also a potent 
steroid sparing effect (OR 3.86, NNT=3).6  For patients entering a medically induced 
remission, AZA or MP are an effective maintenance strategy (OR 3.17, NNT=3.3 favouring 
AZA 2mg/kg over placebo),7 offering an acceptable balance of efficacy, tolerability and cost. 
However, ability to tolerate thiopurines is not universal with between 5.7% and 22.0% of 
patients will need to stop AZA or MP due to adverse events.8 Myelosuppresssion, a 
potentially life threatening adverse event, is fortunately relatively infrequent with treatment 
more often limited by nausea, allergy and a flu like illness.8  The toxicities of thiopurine 
therapy have long been of concern to physicians, with patients routinely counselled about 
short term concerns of leucopenia and infectious complications as well as the small, but 
definite increased risk of lymphoma in later life.9-11  The choice of whether to use AZA or 
MP has largely been based on historical preference rather than clinical evidence, with AZA 
use commonplace in Europe, whilst MP has been favoured in N America.  We have shown 
that 59% of AZA intolerant patients were subsequently able to tolerate MP (Lees et al, AP&T 
2008).12 
 
Inter-individual variations in drug metabolism are important determinants of tolerability to 
AZA and MP. The thioguanine derivative AZA is a prodrug, which is rapidly, and almost 
completely (88%) broken down in the liver by non-enzymatic cleavage of the 
methylnitroimidazole ring to MP.  This reaction is aided by glutathione and other 
endogenous sulphydryl-containing proteins, levels of which decrease in smokers and with 
advancing age.13  Assuming 100% bioavailability, a conversion factor of 2.07 should be used 
to convert a dose of MP to that of AZA.14  There is then extensive metabolic transformation 
by competing catabolic (xanthine oxidase and thiopurine methyltransferase (TPMT)) and 
anabolic (hypoxanthine phosphoribosyl transferase) enzymatic pathways.15  Once formed, 6-
thiosine-5′-monophosphate may be transformed either into 6-thioguanine nucleotides (6-
TGN) by inosine monophosphate dehydrogenase and guanine monophosphate synthetase 
enzymatic pathways or methylated to 6-methylmercaptopurine (6-MMPR).  
 
The thioguanine nucleotide (TGN) metabolites act as purine antagonists and induce 
cytotoxicity and immunosuppression by inhibition of RNA, DNA and protein synthesis. 
  -  - 26
These cytotoxic properties are, at least in part, due to the direct incorporation of TGN into 
DNA.16  There is also direct evidence that AZA/MP induces T cell apoptosis by blocking 
CD28 signalling via Rac-1.  It is thought that AZA metabolite 6-thioguanine triphosphate 
binds directly to Rac-1 and on CD28 costimulation brings about apoptosis and thus 
suppresses the activation of Rac1 target genes, such as mitogen-activated protein kinase 
kinase, NF B, and bclxL.17, 18 
 
The assessment of the activity of TPMT, one of the key metabolising enzymes, has allowed 
clinicians to identify the 1 in 300 patients who are deficient and at are at very high risk of 
potentially fatal neutropenia on AZA.13  Mutations in the TMPT gene have been shown to 
correlate with enzyme activity.  The commonest variant alleles are TPMT*3A, *3C and *2.  In 
a healthy population these occurred at a frequency of 4.4%, 0.4% and 0.2% respectively.  All 
individuals that were deficient in TPMT were homozygous or compound heterozygous at one 
or more of these sites.19  Emerging evidence suggests that dose reduction in TPMT carriers 
with intermediate enzyme activity can limit treatment related adverse events20, 21 but other 
studies have failed to demonstrate this association.22, 23 
1.2.2 Anti-TNF therapy 
There are presently two biological agents licenced for the treatment of IBD in the UK; both 
are monoclonal antibodies against TNFα.  Infliximab is a chimeric anti-TNF antibody, 
consisting of 75% human IgG and 25% murine component that actively binds membrane 
bound and soluble TNFa.  Infliximab is given by intravenous infusion only.  Adalimumab is 
a humanized anti-TNF antibody, given by sub-cutaneous injection only.  The efficacy of anti-
TNF antibodies in CD is well established with infliximab, adalimumab and certolizumab 
pegol (N America only) presently licensed for luminal and fistulising disease.24-31  Infliximab 
is also licensed for moderate UC based on data from ACT1/2 trials,5 and has become an 
alternative to ciclosporine as rescue therapy in acute severe UC failing first-line medical 
therapy.32, 33  Infliximab is the only anti-TNF antibody licensed for paediatric use in North 
America and Europe.34  In CD, most current guidelines recommend that these agents are 
reserved for those patients refractory to standard medical therapy, thus maximising the 
relative benefit in any particular patient.   
1.2.3 Safety of anti-TNF therapy 
The most common reported side-effects with anti-TNF therapy are acute infusion reactions, 
delayed hypersensitivity reactions and infections.35, 36  In particular, anti-TNF therapy has 
  -  - 27
been shown to be associated with tuberculosis37 and opportunistic infections.38, 39  While 
concomitant immunosuppression has been shown to decrease formation of antibodies to 
infliximab and hence the likelihood of infusion reactions,40, 41 it has also been shown to 
increase the likelihood of  opportunistic infections.38  Anti-TNF therapy has also been 
associated with drug-induced lupus and demyelinating complications.   
 
We have recently reported on the full safety profile of the use of anti-TNF agents in IBD in 
Edinburgh (Lees et al, AP&T 2009).42  This cohort comprised 202 patients (157 CD, 42 UC, 
and 3 coeliac disease), with median follow-up of 2.4 years (IQR 1.0-4.9) and a total of 620 
patient-years. 19.1% of CD patients were subsequently treated with adalimumab.  There were 
7 deaths (3.3%) during follow-up – only one death was <1 year post-infliximab (at day 72, 
from lung cancer). 6 malignancies (3 haematological, 3 bronchogenic) and 6 cases of 
suspected demyelination (3 with confirmed neurological disease) were reported. In the 90 
days following infliximab, 95 adverse events (36 serious) occurred in 58/202 (28.7%) 
patients.  42/202 (20.8%) had an infectious event (22 serious).   27/202 (13.4%) of patients 
had an infusion reaction - 19 acute (4 serious); 8 delayed (3 serious).  
 
New signals for real concern have continued to emerge over recent years.  Most recently, a 
series of 8 cases of hepatosplenic T cell lymphoma (HSTCL) were reported in young CD 
patients concomitantly treated with infliximab and a thiopurine;43 this had risen to 13 in 
predominantly paediatric IBD with such concomitant treatment by November 2007 (letter 
from Schering-Plough).  The aggressive and near universal fatality of these lymphomas has 
coloured physicians approach to maintenance therapy with both agents in this patient group. 
 
There are also reports of lung cancers in smokers treated with anti-TNF therapy.  In the 
Mayo Clinic series of 500 CD patients, two lung cancers, deemed ‘possibly related’ to 
infliximab, were reported in elderly smokers.35  A 24-week trial in COPD reported on 157 
infliximab treated patients; in total 11 malignancies including 6 lung cancers were diagnosed 
in this group.44  In our Unit, we have seen three lung cancers in anti-TNF treated patients, all 
smokers/ex-smokers over the age of 65.42 
 
One of these was in a 69 year old female with CD colitis, diagnosed in 2000, who had 
required treatment with methotrexate (2003-present), together with anti-TNF therapies - 
initially episodic infliximab (2000-2004), and thereafter maintenance adalimumab (Lees et 
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al, NEJM 2008).45  In 1999, the patient, an ex-smoker (35 pack years) was noted to have 
finger clubbing. CT scan demonstrated interstitial lung disease; she had normal pulmonary 
function tests, but remained under respiratory review. On repeat CT in June 2006, a 
2.5x2.5cm pleural-based spiculated mass was noted in the right lower lobe (Figure 1-2a) 
with two small satellite appendages. Mediastinal and hilar lymphadenopathy were present. 
CT-guided biopsy of the main lesion confirmed non-small cell lung cancer (Figure 1-2b), 
TNFR1 and TNFR2 positive on immunostaining (Figure 1-2b).  The tumour stage was 
T4N2M0.  Adalimumab was withdrawn but methotrexate was continued. She received no 
surgery, radiotherapy, chemotherapy or biological therapy.  In April 2007, on repeat CT scan 
there was virtually no evidence of primary lung tumour, nodules or lymphadenopathy 
(Figure 1-2c). To date, she remains in complete clinical and radiological remission. 
 
The remarkable aspect of this case is the sustained remission on withdrawal of anti-TNF 
therapy.  The over-expression of TNFR1/R2 implicates TNF blockade in carcinogenesis. 
This hypothesis is supported by data demonstrating a critical role for adaptive immunity in 
maintaining tumour dormancy following exposure to a carcinogen in cigarette smoke.46  We 
recommend special vigilance in the use of anti-TNF therapy in patients with smoking 
histories, or chronic lung disease, especially those over 65.45 
1.2.4 Step-up versus top-down therapy in CD  
Some investigators have recently suggested inverting the therapeutic pyramid in CD, in much 
the same way as has been successfully implemented in rheumatoid arthritis.  In the first trial 
to report on an early combined immunosuppression strategy in CD, patients were randomised 
to ‘top-down’ (AZA and infliximab) or ‘step-up’ (convential treatment escalation from 
corticosteroids to AZA to anti-TNF therapy only if required).47  In this trial, there was an 
increased likelihood of remission at 54 weeks in patients treated with this strategy, compared 
with a conventional approach. However, on grounds of limited efficacy as well as unproven 
safety, caution should be exercised in any attempts to translate these data directly to clinical 
practice. 
 
Firstly, the data provided no evidence for sustained benefit. At all time points beyond 54 
weeks, remission rates were the same, regardless of treatment strategies. Indeed, the ‘top-
down’ cohort is disadvantaged in the treatment of a subsequent relapse, as these patients will 
have an increased risk of a hypersensitivity reaction to infliximab on repeat exposure. 
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Secondly, a ‘top-down’ strategy for all newly-diagnosed patients will expose a significant 
number to risks of anti-TNF therapy unnecessarily. The long-term safety of anti-TNF 
strategy is unproven, and has not been adequately addressed by existing registries.  
We advise strongly against changing treatment algorithms in CD until we are able to identify, 
by clinical, serological, proteomic or genetic testing, those patients who will derive most 
benefit, and thereby protect those at most risk (Lees and Satsangi, Lancet 2008).48 
1.2.5 Medical treatment of acute severe UC 
The use of corticosteroids and appropriate early surgical intervention for acute severe 
ulcerative colitis (UC) has reduced the mortality from 31-60% to 1-2%.49  Reproducible data 
have demonstrated that 30-40% of patients will not respond to corticosteroid therapy and will 
need urgent colectomy.50-56  This may be a life saving procedure, but is feared by patients: 
quality of life is diminished,57 psychological morbidity may be considerable,58 and a 48% 
reduction in female fecundity has been reported following pouch surgery.59  There is 
therefore a need for medical ‘rescue’ therapy for patients failing steroids.  Historically, 
cyclosporine has been the only option, but recently infliximab has emerged as an alternative. 
1.2.6 Rescue therapy in acute severe UC: infliximab or ciclosporine? 
In 1994 Lichtiger and colleagues analysed the use of ciclosporine as rescue therapy for acute 
severe UC.  In a small RCT of 20 patients they observed significantly lower colectomy rates 
in patients given active drug (18%) rather than placebo (100%).60  Further RCTs have failed 
to fully replicate these results and longer-term outcomes have been disappointing.61  A recent 
Cochrane meta-analysis of the use of ciclosporine in acute severe UC concluded that 
“…there is limited evidence that cyclosporine is more effective than standard treatment alone 
for severe UC. The relatively quick response makes the short-term use of cyclosporine 
potentially attractive, but the long-term benefit is unclear…”.62  This uncertainty, together 
with widely-held concerns regarding toxicity, has led to only sporadic use in UK or indeed 
worldwide.  
 
The first RCT of infliximab in UC assessed 42 patients with moderately active steroid 
resistant disease.63  This was a negative but probably underpowered study.  Observational 
case series implied modest response rates in heterogeneous groups of UC patients.64-70  In 
December 2005, the Centocor sponsored ACT1 and ACT2 trials demonstrated the efficacy of 
infliximab in 728 patients with moderately active UC (mean Mayo score 8.4).5  Patients were 
included if there was evidence of active UC together with previous lack of efficacy or 
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intolerance of at least one treatment.  In ACT2 this may have been 5-ASA alone. Combined 
ACT1 and ACT2 data in patients treated with infliximab 5mg/kg demonstrated an 8-week 
remission rate of 33.2%, a response in 66.9% (the primary efficacy endpoint) and mucosal 
healing (including mild inflammation) in 61.1%. There were no differences between the 
5mg/kg and 10mg/kg doses.  At 1 year (ACT1 only) sustained remission was seen in 19.8% 
and sustained response in 38.8% of patients; significantly better results being seen in patients 
on active treatment rather than placebo. It is of note that steroid-free remission was seen in 
only 22%. Colectomy data are presently not available for this trial.  
 
Jarnerot and colleagues assessed the use of infliximab in acute severe UC in a publicly 
funded RCT in Scandinavia.32  45 patients who were admitted to hospital with acute severe 
UC (defined by the Seo index) were randomised to receive a single infusion of infliximab 
5mg/kg (24 patients) or placebo (21 patients) either with fulminant colitis on day 4 or severe 
colitis on days 6-8. The primary outcome analysis was colectomy or death at 90 days. 
Patients who received infliximab required colectomy less frequently than those who received 
placebo (7/24 [29.2%] v 14/21 [66.7%], p=0.017, OR 4.9, C.I. 1-4-17).  We observed very 
similar response rates at the Western General Hospital (Edinburgh) in a preliminary report in 
2006; 6 out of 9 patients with acute severe UC (Truelove and Witts criteria) responded and 
avoided colectomy with relatively few adverse events.71   
 
We have subsequently reported a retrospective cohort of 39 patients (median age 31.7 years) 
from throughout Scotland who received infliximab as rescue therapy for acute severe UC 
(Lees et al, AP&T 2007).33  26/39 (66%) responded, avoided colectomy during the acute 
admission, and were followed up for a median of 203 days [IQR 135.5–328.5]). 
Hypoalbuminaemia was a consistent predictor of non-response on univariate and multivariate 
analysis.  At day 3 of iv steroids, 9/18 (50.0%) with serum albumin <34g/l had urgent 
colectomy versus 1/13 (7.7%) ≥34g/l (p = 0.02, OR 12.0, C.I. 1.28-112.7).  Two serious 
adverse events occurred in this study – one death due to Pseudomonas pneumonia, and one 
post-operative fungal septicaemia. 
1.3   Pathogenesis of IBD 
The intestine has the primary function of absorbing the nutrients required for all post-natal 
developmental and homeostatic processes. Having been colonised by ~1014 bacteria during 
early life, intestinal homeostasis is critical to simultaneously protect the host against 
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pathogens whilst avoiding excessive inflammatory responses to commensal flora. The single-
layered epithelium, consisting of enterocytes, goblet cells, Paneth cells, and microfold (M) 
cells, is all that stands between the intestinal lumen and the mucosal immune system. Key 
epithelial-microbial interactions occur across the epithelium.  This active barrier, expressing 
a host of receptors designed to interact with different bacterial motifs (e.g. toll-like receptors 
(TLRs)), is in constant contact with the luminal contents and communicates with the richly 
diverse commensal flora under healthy conditions to establish immune homeostasis. Paneth 
cells secrete specialised antimicrobial peptides known as defensins.  M cells and lamina 
propria dendritic cells (DCs) can directly sample intraluminal microbial components.  
 
The precise aetiology of CD and UC remains unknown.  However, recent advances in basic 
molecular science, animal models and clinical studies, have highlighted the relative 
importance of genetic and environmental contributions to the pathogenesis of IBD (Figure 1-
3 and Table 1-1).72, 73 The currently accepted hypothesis is that specific defects in barrier 
function, dysregulated immune responses and/or ineffective bacterial clearance in genetically 
susceptible hosts, may lead to the establishment of T-cell mediated chronic mucosal 
inflammation. Factors known to disturb intestinal homeostasis that likely play a role in IBD 
pathogenesis include alterations in the barrier function of epithelial cells, innate immune cells 
(including macrophages and DCs), lymphocyte function and stromally-derived factors (e.g. 
TGFβ).74  Professional antigen presenting cells (APCs), notably DCs, activated by either 
pathogenic bacteria or disturbed epithelium (via direct cell contact or indirectly through 
chemokines and other signalling molecules) translocate to the mesenteric lymph node (mLN) 
where they instruct naïve T cells to adopt a pro-inflammatory phenotype. Recent data 
demonstrates the importance of IL17 producing T cells (Th17) in intestinal inflammation.  
 
The most important ‘environmental’ factor contributing to IBD pathogenesis is undoubtedly 
the intestinal flora.  This is perhaps best illustrated in animal models of colitis.  In the vast 
majority, gut inflammation does not develop when animals are raised in germ-free (GF) 
conditions (see below).  It is also supported by the efficacy of antibiotics and probiotics in 
various clinical settings (e.g. pouchitis).  Epidemiological data add further compelling 
evidence: IBD is more prevalent in urban populations, where increased industrialisation and 
sanitation, combine in a variation on the ‘hygeine hypothesis’.  In essence the theory goes 
that lack of exposure to environemental antigens during childhood leads to sup-optimal 
priming of gut immune responses.  Whilst direct evidence for this is presently lacking, lower 
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rates of CD are reported for lower birth rank, absence of tap / hot water, large / poor families,  
and crowded living conditions.2 
 
Other environemental stimuli implicated in IBD pathogenesis include cigarette smoking, 
appendicectomy, breast feeding, oral contraceptive pill use, sunlight / vitamin D exposure 
and various dietary factors.  The evidence for some of these factors is rather limited and the 
literature conflicting.  However, consistent themes are established for cigarette consumption.  
Smoking is detrimental in CD; not only is CD more common in smokers but also in children 
born to mothers who smoke during pregnancy and at birth.75  After diagnosis, patients that 
continue to smoke do worse with, for example, increased rates of resectional surgery.  
Furthermore, smoking cessation is a very effective intervention in CD; although incompletely 
documented, the clinical benefit is probably equivalent to immunosuppression with a 
thiopurine or biologic.  In contrast, smoking has a protective effect in UC as best illustrated 
by the significant proportion who first present within months to years of cigarette cessation.  
Anecdotaly, whilst these patients have a more aggressive disease course, many of them can 
subsequently control their disease by a ‘prescribed’ number of daily cigarettes.  However, the 
failure of nicotine replacement therapy, both via transdermal and rectal routes,76, 77 opens to 
question which alternative chemical component of cigarette smoke is responsible for these 
powerful effects.  
 
The genetic contribution to IBD pathogenesis was conclusively demonstrated by twin 
studies, and further refined to multiple replicated loci at certain chromosomal locations by 
genome-wide linkage studies in sib-pairs and multiply-affected families.78  Fine mapping of 
the IBD1 locus on chromosome 16 led to the discovery that NOD2 variants are associated 
with CD.79, 80  Our most recent understanding of the genetic architecture of these diseases 
strongly indicates that many disease genes confer susceptibility to CD (nucleotide-binding 
oligomerization domain containing 2 [NOD2], autophagy-related 16-like 1 [ATG16L1], 
immunity-related GTPase family, M [IRGM], leucine-rich repeat kinase 2 [LRRK2], CC 
chemokine receptor 6 [CCR6], inducible T cell co-stimulator ligand [ICOSLG], intelectin 1 
[ITLN1]); or specifically to UC (extracellular matrix protein 1 [ECM1] and IL10); whilst 
many invoke risk to both (interleukin-23 receptor [IL23R], NK2 transcription factor related 
locus 3 (Drosophila) [NKX2.3], janus kinase 2 [JAK2], signal transducer and activator of 
transcription 3 [STAT3], IL12B, cyclin fold protein-1 [CCNY], IL18 receptor accessory 
protein [IL18RAP], LYRM4, and CDKAL1).81-90 
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1.4  Importance of gene-environment interactions 
Defects in the intestinal epithelium, the mucosal immune system, and bacterial receptors may 
be genetic or environmental, with the complex interactions between these critical to the 
establishment and phenotype of disease (Figure 1-3). Gene-environmental interactions 
therefore appear critical to the initiation of the exaggerated and inappropriate inflammatory 
response that characterises these relapses and remitting inflammatory disorders.  The 
mucosal interface where commensal and pathogenic bacterial antigens interact, directly and 
indirectly, with the epithelium is the front-line to a healthy well-regulated mucosal immune 
system.  Defects in barrier genes and those that interact directly with bacterial antigen, may 
predispose to the development of IBD (Table 1-1).  Dysregulation of innate immune signals 
are increasingly recognised to be important in pathogenesis. Epithelial-mesenchymal 
interactions via a raft of cytokines (e.g. TNFα, IFNγ and IL23) and chemokines (e.g. 
CCL20), initiate further downstream immune responses that in the healthy state bring about 
resolution of the inflammatory episode. However, in CD and UC a loss of immune tolerance 
leads to a breakdown in this homeostasis paving the way for chronic inflammation and the 
sequelae thereof. 
 
Perhaps the most compelling recent evidence in support of gene-environment interactions 
comes from Sartor’s work in animal models of colitis.91  Both mice with targeted deleted of 
the IL10 gene (Il10-/-) and Hla-B27 transgenic (TG) rats develop colitis in specific pathogen 
free (SPF) conditions, but not when kept completely germ-free (GF).  However, it is now 
clear that selective colonisation with different bacterial species critically affects aspects of 
disease phenotype, notably severity and anatomical location.  In Il10-/- mice monoassociated 
with Enterococcus faecalis or Escherichia coli a progressive chronic colitis develops, 
although the regional distribution and kinetics of this colitis varies with the bacteria.  It is 
noteworthy that interferon gamma (IFNγ) secretion from meseneteric lymph node CD4+ T 
cells precedes the onset of microscopic inflammation.  Mice monoassociated with 
Pseudomonas fluorescens or Bacteroides vulgatus do not develop colitis.  In stark contrast, 
Hla-B27 TG rats monoassociated with B vulgatus develop an aggressive colitis, but no 
inflammation with E coli.  Clearly the interaction of both genetic factors (Il10-/- or Hla-B27 
TG) and environmental factors (E coli or B vulgatus) is fundamentally importance for the 
establishment of colitis in these animal models. 
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1.5 Genetic basis of IBD 
There are considerable epidemiological data, which implicate genetic susceptibility in the 
pathogenesis of CD and UC.  Most notably these include the familial prevalence of IBD, 
concordance rates in twin pairs, and ethnic differences in disease susceptibility.  In fact, the 
studies of twin pairs have provided the strongest impetus towards further investigation of 
genetic susceptibility in IBD.  Three studies have been carried out in Europe, including 
Tysk’s important review of the Swedish Twin Registry in 1988.92-94  The data from these 
studies, in Sweden, Denmark and the UK combine to provide powerful evidence for the role 
of both genetic and environmental factors in disease susceptibility.  The concordance rates 
for CD in monozygotic and dizygotic twin pairs from these studies are estimated as, 
respectively 37% and 7%; in UC, the equivalent results are 10% and 3%.   
1.5.1 Whole-genome studies: from linkage to association 
The establishment of a linkage map of the human genome using informative microsatellite 
markers in the 1990s paved the way for hypothesis-free scanning for loci of association in 
monogenic and complex genetic disorders.  Using this model 9 IBD susceptibility loci 
(designated IBD1-9, Figure 1-4) have been discovered and replicated to varying extent.  
Some of these loci appear to be relatively specific for CD (e.g. IBD1 on 16q - OMIM 
266600)95, 96 and UC (e.g. IBD2 on 12q - OMIM 601458)97-99  whereas others are associated 
with IBD as a whole (e.g. IBD3 on 6p – OMIM 604519).100-102  Very recently, microarray 
chip technology has become sophisticated enough to allow genome-wide association studies 
(GWAS) detailing variation up to ~500,000 SNPs across the human genome.  This approach 
has in the past 12 months yielded up to 10 new CD susceptibility genes including IL23R,83 
ATG16L1,87 IRGM,81, 89 NKX2.3, PTPN2 and a gene desert on chromosome 5.88  
Furthermore, meta-analysis of the GWAS studies from N America, U.K. and Belgium has 
identified a total of 30 CD genes / loci many of which did not meet genome-wide levels of 
significance in the individual studies (p < 10-7).103 
1.5.1.1 Nucleotide-binding oligomerization domain containing 2 (NOD2) 
The first genome-wide scan, reported in 1996, provided the strongest evidence for linkage on 
the pericentromeric region of chromosome 16 (IBD1),96 a region that has subsequently been 
widely replicated.  Fine-mapping of the IBD1 region, and two positional candidate gene 
studies, identified NOD2 (formerly CARD15) as a CD susceptibility gene in 2001.79, 80, 104  
Structural changes are induced in the muramyl dipeptide (MDP)-sensing NOD2 protein by 
two SNPs (Gly908Arg/rs2066845 and Arg702Trp/rs2066844) and one frameshift mutation 
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(Leu1007fsincC/rs2066847), located in the leucine-rich repeat (LRR) region of the gene.    
Carriage rates range widely (0-50%) with the highest rates seen in central Europe.79, 105  The 
contribution of NOD2 to disease susceptibility is relatively lower in Northern European 
(Scottish106, 107 and Scandinavian108, 109) populations, where the population attributable risk 
(PAR) ranges from 7.9% (early-onset Scottish CD) to 11.4% (Swedish CD).  In Japanese,110 
Chinese,111 and S Korean112 populations these NOD2 mutations (Gly908Arg, Arg702Trp, 
and Leu1007fsincC) are absent (Figure 1-5).   
 
Recent studies have further shown a number of associations between genotype and 
phenotype,113, 114 thus adding to the complexities of IBD and reinforcing the point that the 
term ‘IBD’ may in fact represent several forms of diseases. Cuthbert and colleagues 
demonstrated the association between NOD2 mutations and IBD are primarily based on the 
phenotype of ileal CD.114  This association was also shown in the Oxford dataset by Ahmad 
and colleagues who reported detail genotype-phenotype analysis of 244 patients with CD.113  
The phenotype of fibro-stenosing CD was also associated with NOD2 mutations, but this 
association was not shown to be independent of the association with ileal involvement. The 
NOD2 gene does not appear to be associated with colonic involvement, and may indeed be 
protective against colonic involvement in CD and UC.   
 
There has been much debate arising out of apparently conflicting experimental data as to 
whether the NOD2 mutations represent a ‘loss-of-function’ or ‘gain-of-function’ phenotype.  
Two different animal models (Nod2-/- and Nod22939iC) published simultaneously in Science in 
2005 added extra insight but failed to resolve this unsettling paradox.115, 116  Neither mutant 
developed chronic intestinal inflammation spontaneously; indeed, neither model 
demonstrated any abnormality in intestinal microstructure. However, when stressed with 
dextran sodium sulphate (DSS) the Nod22939iC mouse behaved very differently to wild-type 
(WT) littermates, developing much more severe colitis with increased mortality (35% vs. 
0%).  However, the Karin group was unable to breed this Nod2 knock-in mouse (Nod22939iC) 
onto a pure Black-6 background.116  These in vivo data from a mixed background therefore 
need to be interpreted with some caution.  Nod2-/- mice responded less well than WT mice 
to challenge with oral Listeria monocytogenes,115 an observation which may be related to 
decreased Paneth cell antimicrobial activity.  NOD2 is constitutively expressed by 
macrophages, DCs and Paneth cells,117 the latter being specialised epithelial cells located in 
the small intestine that secrete antimicrobial peptides, including alpha defensins (HD5 and 
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HD6) into the base of the crypt.  Patients with ileal CD have decreased HD5 and HD6 
expression, particularly those carrying NOD2 mutations,118 although this latter observation 
has not replicated in a subsuequent study from Australia.119  Peripheral blood monocytes 
from CD patients with NOD2 mutations have defective cytokine production and NFκB 
activity in response to MDP,120 lending further support to the loss-of-function hypothesis.    
1.5.1.2 IBD5 locus (5q31) 
The first evidence for a susceptibility locus on the chromosome 5q31 cytokine gene cluster 
was generated by a Canadian genome-wide scan using ~300 microsatellite markers in 158 
affected sibling pair families.121  The linkage signal covered 18 cM including the IL4, IL13, 
IL5 and interferon regulatory factor-1 (IRF1) genes.  Further fine-mapping of this region with 
56 additional markers demonstrated significant over-transmission of two adjacent markers 
using transmission disequilibrium testing (TDT).122  However, due to very tight linkage 
disequilibrium (LD) across this region it was not possible to narrow the signal associated 
with CD to less than ~500 kb.  In the pre-HapMap era (http://www.hapmap.org), re-
sequencing of this region (in 8 individuals) was required to define haplotype blocks; this 
approach revealed a region of very limited recombination.122, 123 Association studies 
performed with haplotype-tagging SNPs (tSNPs) in at least 6 large, independent CD 
populations has found that a single common haplotype spanning ~250 kb was associated with 
CD.124-127   
 
The IBD5 risk haplotype has proved to be the most widely and robustly replicated inherited 
risk for IBD after NOD2.128-133  A report in 2004 suggested that two variants within the 
OCTN1 (SLC22A4-1672C/T) and OCTN2 (SLC22A5-207G/C) genes, proposed to alter gene 
function and expression, were associated with CD independent of the IBD5 risk haplotype.134  
Whilst this may yet prove to be a valid finding, a series of replication studies have 
discredited the suggestion from the index study that these variants are independent of the 
IBD5 risk haplotype.128, 130-133, 135  The tight LD across this region remains the limiting factor 
in further delineating the specific CD risk in IBD5.  It has been calculated that cohorts with 
several thousand CD patients and controls will be required to demonstrate independence of 
the causative IBD5 variant(s) from the background haplotype.  There are 5 genes within this 
region: IRF1, OCTN1, OCTN2, PDLIM4 and P4HA2 (for a detailed review of the expression 
and function of each of these genes see Reinhard and Rioux, 2006).130  Detailed expression 
and functional studies of these genes in CD compared with healthy controls may informative 
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in further determining the causative IBD5 gene.  Finally, it is noteworthy that 5q31 is also 
associated with psoriasis, although the variants typed to date appear to be distinct to those 
associated with CD.136-138  
1.5.1.3 IBD2 (12q13) 
A susceptibility locus on chromosome 12q13 was discovered in a two-stage U.K. genome-
wide linkage scan in 186 affected sibling pairs from 160 nuclear families.99  The initial 
screening of 260 autosomal microsatellite markers in 89 affected siblings suggested evidence 
for linkage with IBD across four adjacent markers on chromosome 12 spanning 16 cM 
(Figure 1-6).  This was confirmed in a second cohort of 97 additional affected siblings.  The 
best scoring marker on chromosome 12 was D12S83 (p = 2.66 x 10-7, lod score 5.47).  
Subsequent re-analysis of the IBD2 region (with 12 microsatellite markers) in a larger cohort 
(252 CD-only, 138 UC-only and 191 mixed families) demonstrated that the locus makes a 
major contribution to UC susceptibility (lod score 3.91) but has only a mild influence on CD 
(lod score 1.66).98  A large linkage study, stratified for phenotype, has demonstrated strong 
evidence for linkage with extensive UC (p < 0.001, lod score 3.27).97  Candidate gene studies 
in IBD2 have largely been negative (e.g. STAT6139, 140 and AVIL141).  However, a very recent 
UC GWAS has provided evidence for association at the edge of the IBD2 linkage region at 
12q15, in the region of IL26 and IFNγ (see 1.5.4.6 below).142 
1.5.1.4 HBD2 (DEF4B) and Copy Number Variation 
It is becoming increasingly clear that copy number variation (CNV) of DNA sequences has 
important functional consequences and likely plays a large role in both microdeletion and 
microduplication disorders as well as susceptibility to complex diseases. CNVs can influence 
gene expression directly and indirectly through position effects, alter gene dosage, and 
predispose to deleterious genetic changes.  Recently, CNV across the genome has been 
described in the four HapMap populations by both SNP genotyping array and clone-based 
comparative genomic hybridization.143  These data provide a map of human genomic CNV 
that will provide a great resource to future genetic studies.  Indeed, it is suggested by these 
authors that assessment of CNV should become a standard component of studies into the 
genetic basis of disease susceptibility. 
 
In the first study of its kind in IBD, Fellermann and colleagues performed an array-based 
comparative genomic hybridization analysis using ~8000 genomic fragments to give 
genome-wide coverage with an average resolution of ~0.5Mb.144  Comparing 10 patients 
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with colonic CD and 10 HCs, they demonstrated that the β-defensin cluster at 8p23.1 showed 
altered copy number between CD and HC.  This region, spanning ~750kb, did not extend 
into the adjacent α-defensin cluster.  8/10 CD patients showed small copy number loss 
compared with HC, whereas none showed copy number gain.  On quantitative PCR of the 
HBD2 (DEF4B) gene in 169 HC there was a median of 4 copies (range 2-10).  A U.S. cohort 
of 85 CD patients who had either ileal or colonic surgical resections were analysed.  Patients 
with ileal CD had HBD2 copy number identical to HC.  However, in the colonic CD group 
the median copy number was 3, with 72% having <4 copies of the gene (ileal vs. colonic 
copy number p = 0.008).  These findings were confirmed in a separate cohort of CD from 
Europe.  Whilst the difference in copy number appears small, HBD2 mRNA analysis from 
patients with active colonic CD demonstrated decreased mucosal HBD2 expression in 
patients with copy number <4 compared with those with ≥4 copies of the gene (IL8 levels 
were not significantly different in these groups).  
1.5.1.5 NLR family, pyrin domain containing 3 (NLRP3) 
The NLRP3 gene (1q44) encodes cryopyrin, a protein that controls the inflammasome and 
thus regulates activation of caspase-1 and IL1β.  NLRP3, like NOD2, is a CATERPILLER 
gene, in that it has both NOD and LRR domains.  Gain-of-function mutations in the NOD 
domain of NLRP3 cause Muckle-Wells, familial cold autoinflammatory syndrome and 
neonatal-onset multisystem inflammatory disease, three hereditary periodic fever 
syndromes.145, 146  Villani and colleagues recently took a candidate gene approach to study 
the contribution of germline variation in NLRP3 to CD.147 
 
3 tSNPs were associated with CD in the first phase, where 47 tSNPs were genotyped in 296 
trios from Leuven [Belgium].  In phase two, these 3 tSNPs were genotyped in 3 further 
family-based cohorts (Liege [Belgium], Quebec and Toronto).  All 3 tSNPs, spanning a 
5.3kb region replicated, with the strongest association at rs10733113 (pcombined = 3.49 x 10-9, 
OR 1.78, CI 1.47 - 2.16) reaching genome-wide association levels of significance (see 
below).  None of these SNPs was in LD with any genotyped SNPs within NLRP3.  Deep 
resequencing of a 9kb region (from the NLRP3 3′ UTR to the associated 5.3kb region) in 16 
CD and 8 HC (selected on the basis of genotype) yielded 79 SNPs, 60 of which had a MAF ≥ 
0.05 and 14 of which were novel to dbSNP 129.  Following a further detailed tagging study 
of this region in the Leuven cohort and subsequent replication, 3 additional SNPs were 
consistently associated with CD (p = 10-6 – 10-7).   
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Villani and colleagues went on to analyse the effect of the 6 CD associated mutations on 
NLRP3 expression in peripheral blood cells and monocytes.147  rs4353135 genotype was 
significantly associated with altered expression, with homozygosity at the risk allele 
conferring low expression levels.  In a separate assay in cultured monocytes, homozygosity 
of the risk allele at a different SNP (rs6672995) was associated with decreased levels of IL1β 
following stimulation with LPS (p = 0.0059).  Finally, the authors demonstrate significant 
elevation of NLRP3 expression in human CD biopsies (fold change = 4.08, p < 0.0028), and 
acute TNBS –induced colitis (fold change = 9.38, p < 0.0009). 
 
1.5.1.6 X-box binding protein 1 (XBP1) 
In a recent report in Cell, Kaser and colleagues have provided in vivo, cellular and genetic 
evidence for a role of the endoplasmic reticulum (ER) stress reponse in IECs.148  The cellular 
response that allows cells to survive ER stress involves a highly coordinated unfolded protein 
response (UPR), and the transcription factor X-box-binding protein 1 (XBP1).  XBP1, 
activated by excision of 26 bp from its mRNA, induces transcription in a subset of UPR 
target genes.149  ER stress and XBP1 mRNA expression is increased in the inflamed and non-
inflamed terminal ileum of patients with CD and inflamed and non-inflamed colons of 
patients with CD and UC.  Mice with deletion of Xbp1 specifically in IECs (Xbp1flox/floxVCre) 
demonstrate increased ER stress in small intestinal epithelial cells and subsequent mild, 
patchy, spontaneous mucosal inflammation.  These animals were almost completely devoid 
of Paneth cells, in addition to a minor defect in small intestinal (but not colonic) goblet cells.  
Oral challenge with Listeria monocytogenes, was impaired with significantly increased 
numbers of bacteria retrieved in faeces and the liver, but not spleen compared with WT 
animals.  Although the basal phenotype in the colon of these mice demonstrated increased 
ER stress, there was no evidence of spontaneous inflammation.  However, stressing these 
animals with 4.5% DSS for 5 days led to a marked increase in the severity of colitis 
compared with WT.   
 
The XBP1 gene is an excellent biological candidate for IBD susceptibility based on 
expression, function (as above) and position.  It is located on 22q12 in a previously identified 
linkage region.150-152  The Schreiber group performed a tSNP study of XBP1 variation in 
German IBD with subsequent replication in two independent panels.148  In the index cohort, 3 
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of 20 tSNPs were significant, all of which replicated.  In the combined cohort of 4389 IBD 
patients and 5322 HC, and after correction for multiple testing, 6 XBP1 SNPs were 
significantly associated with IBD after 10,000 permutations.  rs35873774 was the strongest 
SNP with OR 0.74 (C.I. 0.66-0.84, p = 1.6 x 10-5).  The complex haplotype structure of 
XBP1, and deep resequencing in 564 IBD patients and 282 HC, strongly indicated that 
multiple, rare, private SNPs contribute to the association with IBD.  Indeed, several of these 
rare nsSNPs demonstrated decreased transactivating function in a series of in vitro assays. 
1.5.2 Genome-wide association studies (GWAS) 
Up until about 2 years ago, researchers were becoming increasing frustrated by the 
limitations of genome-wide linkage studies, fine-mapping of these large regions and 
candidate gene approaches to describing the inherited risk of complex genetic diseases.  
Despite a few notable exceptions, including NOD2 in CD, progress had become slow and the 
field muddied by the inability of new disease ‘susceptibility genes’ to consistently replicate 
in different populations (e.g. DLG5 in CD).  It was clear that a radical new approach was 
required.  However, before genome-wide association studies (GWAS) could be implemented, 
a number of scientific and technological hurdles had to be passed.153  The first step followed 
quickly on from the premature announcement by the popular media of the sequencing of the 
human genome in 2000, with the discovery of over 10 x 106 SNPs.  Second was the 
generation of the hapmap (www.hapmap.org), a high-resolution map of genome variation 
that utilised measures of association between SNPs (LD) to define haplotypes.  This provided 
a means by which ~70% of variation across the genome (in populations of European 
ancestry) could be described by genotyping 300-500k SNPs.  Third was the development of 
high-throughput genotyping platforms with capability of sequencing up to 1x106 SNPs 
simulataneously on a single chip, all at a reasonable cost.153  The two commonly used 
platforms to date are the Illumina 317k (used in the N American CD GWAS)83 and 
Affymetrix 500k (WTCCC study)81 chips.  Other studies have taken a more limited (but 
more cost effective) initial approach by typing just nsSNPs (~14k).  Whilst much less 
extensive in their coverage of the genome, these studies have the advantage that any ‘hits’ 
have almost immediate functional potential (although we now recognise that a large number 
of causative SNPs function without altering the amino acid sequence).  This approach has 
been successfully employed by the Schreiber group in CD and the UK IBD genetics 
consortium in UC.84, 87 
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When considering GWAS design, it is widely agreed that a large sample size of cases and 
controls is critical to enable sufficient power to detect association of variants with modest 
increase in disease risk at a genome-wide significance threshold (now widely established at p 
< 1 x 10-7).  The GWAS approach is particularly effective at detecting relatively common 
variants, as the ability to detect association at a particular SNP decreases with the frequency 
of its minor allele (↓ frequency = ↓ power).  Several studies have adopted different 
techniques to improve study power by attempting to enrich for specific disease-predisposing 
alleles.  Two common approaches have been to minimise population heterogeneity 
(successfully adopted in the N American CD GWAS [ileal diseae only])83 and to focus on 
extreme / familial cases (e.g. early-onset IBD; N American UC GWAS [excluding 
proctitis]).142, 154  The true value of such approaches has yet to be determined and is cast 
partially into doubt by the high success of CD in the WTCCC study where this was not 
adopted.81, 155   
 
Selection of appropriate HCs remains controversial.  The WTCCC study demonstrated the 
success of a common pool of controls for comparison with 7 different complex diseases.  The 
WTCCC HCs consisted of both a population-based birth cohort (1958) and opportunistic 
blood donors.  Comparison of these two sources was reassuring in the minimal impact that 
ascertainment, selection and survival biases had on genotype distributions.  Another issue 
with control populations that will decrease study power is that in most studies they are not 
extensively screened for latent disease.  For most relatively rare complex diseases this is not 
such a big issue as it can be circumvented by sufficiently increased sample size.  For 
common traits, selection of extreme phenotypes (e.g. very obese or very tall) can also 
minimise this error.  
 
Once the cohort has been collected and genotyped on the chosen platform, a series of 
important quality control steps are implemented prior to a case-control association study.  
The most critical next step is to distinguish between artefact and a true positive result through 
validation of positive hits by replication in suitably powered independent cohorts of cases 
and controls.156  The hard challenge following this is fine-mapping (a particular challenge in 
areas of tight LD) to determine causative mutations followed by functional studies to 
understand the true biology behind the increased disease risk (or protection).  McCarthy and 
colleagues have recently published a very thorough review of the technical and statistical 
aspects of all stages of GWAS design, implementation and follow-up.155 
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In the past 2 years, more than 300 replicated associations have been reported in over 70 
common diseases and traits.157  Along with CD, particular success has been obtained in type 
II diabetes mellitus (~20 loci)158 and height (over 40 loci),159, 160 a number of common 
cancers (including colo-rectal,161-163 and prostate164-169) and other continuous traits (e.g. 
obesity).170-173  Furthermore, it is of great interest that many disease associated genes have 
demonstrated overlap between dinstinct disease types.157  The best characterised overlap to 
date is with coeliac disease and type I diabetes mellitus.174  It was previously known that both 
diseases are associated with class II HLA genes.  In their comprehensive study, Smyth and 
colleagues discovered shared association of 6 additional loci with both diseases (RSG1 at 
1q31, IL18RAP at 2q12, and TAGAP at 6q25, a 32-bp insertion-deletion variant at 3p21, 
PTPN2 at 18p11, CTLA4 at 2q33).174  Intriguingly, not all the effects were in the same 
direction.  Variants in IL18RAP and TAGAP had protective effects in type I diabetes whilst 
conferring susceptibility to coeliac disease.  As discussed further below, both IL18RAP and 
PTPN2 are also confirmed CD suscpetiblity loci.103  Other examples of disease overlap 
include a region at 8q24 associated with both prostate and colo-rectal cancer, and the TCF2 
and JAZF1 loci conferring risk (or protection) to both type II diabetes and prostate cancer.157 
 
Despite this undisputed success, the known variants to date only explain a fraction of the 
observed familial aggregation.175  For example, Barrett estimates that the 30 known CD loci 
account for only ~20% of the genetic contribution to CD.103  There are several explanations 
for this.  Firstly, the present GWAS provide only relatively limited surveys of potential 
sequence variation.  Secondly, many ‘hits’ from the index studies are surrogate markers for 
the true disease causative mutations that will in most cases confer greater risk.  Thirdly, the 
risk at some loci will be attributed to multiple independent mutations.  Some GWAS are 
limited to specific phenotypes (e.g. ileal only CD, or adult-onset only IBD).  In addition, very 
few studies into CNVs have been performed on a genome-wide scale; time will tell whether 
these will add siginificantly to the genetic risk (see 1.5.1.4).  Finally, it is unclear yet how the 
newly discovered disease mutations will interact with important environmental factors.  For 
several or all of these reasons, we are probably currently underestimating the known genetic 
risk already accounted for.  However, the shortfall that remains is (and almost certainly 
should) presently limit the early application of genetics to determinging individual disease 
risk.   
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The immediate future involves more GWAS in different disease types, sub-phenotypes and 
common traits (the Wellcome Trust is spending over £30 million typing DNA from 120,000 
individuals over 27 phenotypes)157, meta-analysis of existing individual GWAS (as has been 
particularly successful in CD103, colo-rectal cancer176 and type II diabetes158), fine-mapping 
of loci (a major on-going phase of the WTCCC follow-up studies, with CD prioritised for 
deep resequencing of associated loci), and detailed molecular and functional studies to truly 
understand the biology of various disease associated mutations.  In the meantime, the major 
evolving paradigm for complex disease genetics, is that the biological insights gained (and 
subsequent abundance of novel therapeutic targets) will turn out to have far greater 
importance than the relatively small contribution to disease risk conferred by each individual 
mutation or locus, as will now be illustrated for first CD and subsequently UC. 
1.5.2.1 Interleukin 23 receptor (IL23R) 
Duerr and colleagues performed the first full GWAS in IBD, analysing over 300,000 SNPs 
on the Illumina HumanHap300 Genotyping BeadChip.83  To minimize pathogenic 
heterogeneity their study population was limited to ileal CD, analysing 567 cases and 571 
controls, all of non-Jewish, European ancestry.  It was noteworthy that after applying 
Bonferroni correction, only 3 SNPs remained significant at the 0.05 level (and nearly two 
orders of magnitude more significant than the next best scoring marker).  Two of these SNPs 
were in NOD2 (rs2066843 and rs2076756) effectively providing proof-of-principle for this 
technique in discovering CD susceptibility genes.  The third was a non-synonymous SNP in 
the IL23R gene (located on chromosome 1p31), rs11209026 Arg381Gln (p = 5.05 x 10-9, 
corrected p = 1.56 x 10-3).  Several other SNPs within IL23R were subsequently shown to be 
associated with ileal CD, including some that were independent of the rs11209026 variant.  It 
is proposed that the functional significance of these multiple variants within IL23R may in 
part be due to differential splicing, as at least six alternatively spliced mRNAs of IL23R are 
described.83  Duerr and colleagues demonstrated replication of the IL23R association in an 
independent case-control association study of non-Jewish and Jewish ileal CD patients, and 
in a family-based association study in 833 nuclear families (data on both parents plus 
affected offspring – CD and UC – were available).  Further replication studies for IL23R 
have been published in adult and paediatric populations from the U.K.,177-179 France / 
Belgium,88 Quebec founder population,180 Italy,181, 182 Canada,183 Holland,184, 185 Spain,186 
Finland,187 Hungary,188 and Brazil.189  There was no consistent genotype-phenotype 
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substratification apparent in these studies.178, 190, 191  IL23R has also recently been confirmed 
as a UC susceptibility gene.84, 85, 142   
 
In addition, the CD meta-analysis (see 1.5.3) has confirmed 3 addition members of the IL23 
signalling pathway as CD susceptibility genes.103  IL12B (5q33; OR 1.11, p = 3.86 x 10-13), 
JAK2 (9p24; OR 1.12, p = 3.46 x 10-9) and STAT3 (17q21; OR 1.18, p = 6.82 x 10-12) were 
all shown to be associated with CD.  Furthermore, they are also UC susceptibility genes,84, 85 
confirming that defects in IL23 signalling confer risk to IBD as a whole, without any specific 
phenotypic associations. 
 
Furthermore, IL23R variants have been associated with ankylosing spondylosis,192, 193 and 
both IL23R and IL12B with psoriasis,194-197 but not with rheumatoid arthritis,198, 199 or 
systemic sclerosis.200 
 
The timing of the initial IL23R gene discovery study in CD was interesting, as it coincided 
with detailed murine studies of bacterial induced intestinal inflammation demonstrating a 
critical role for IL23 in innate immune pathology.201, 202  The proinflammatory cytokine IL12 
has long been thought to be a critical element in the development of pathogenic Th1 CD4+ 
effector cells.  The discovery that IL23 is a heterodimer of p19 and the IL12p40 (IL12B) 
subunit has led to a critical reappraisal of the relative roles that IL12 (a heterodimer of p40 
and p35 subunits) and IL23 play in inflammatory disorders.203  IL23 is secreted by activated 
DCs, monocytes and macrophages.  Transgenic mice that constitutively overexpress IL23p19 
develop a fatal multiorgan inflammation.204  IL23 supports the development of the Th17 
subset of CD4+ inflammatory T cells (that produce IL17, IL6 and T and TNFα)205-207 and has 
potent effects on innate immune cells (monocytes and macrophages) by inducing production 
of IL1, IL6 and TNFα.207, 208  IL23 and IL17 synthesis and secretion is increased in the 
inflamed murine intestine (Helicobacter hepaticus infected Rag-/- mice that develop a chronic 
typhlocolitis characterised by the accumulation of innate immune cells), whereas IL12 
expression is unchanged.201  IL23 blockade with an anti-p19 monoclonal antibody 
significantly decreased H hepaticus induced intestinal inflammation as well as decreasing 
proinflammatory cytokine (TNFα, IFNγ, IL6, IL1β and IL17) in the intestine.  Equivalent 
findings have been demonstrated with anti-IL10R antibody treatment of H hepaticus infected 
T-cell sufficient hosts and CD4+ T cell transfer into various Rag-/- recipients.202  Combined 
these data demonstrate the crucial role for IL23, but not IL12 in intestinal inflammation, by 
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sustained activation of adaptive and / or innate immune mechanisms.  These data make 
critical re-evaluation of early clinical studies using anti-p40 monoclonal antibody therapy in 
CD of paramount importance.209  Anti-p19 monoclonal antibodies, that are likely to provide a 
more specific anti-inflammatory intervention in IBD, are presesntly in development. 
1.5.2.2 Autophagy genes – ATG16L1 and IRGM 
Perhaps the most exciting and novel insight to arise from the GWAS reports in CD is the 
discovery that defective autophagy may play a critical role in disease pathogenesis.  Two 
autophagy genes are now known to be associated with CD: ATG16L1 and IRGM.  
 
Autophagy, the process by which cells digest parts of their own cytoplasm for removal, 
functions as a homeostatic “house-keeping” mechanism, a pathogenic process in a variety of 
cancers and neurodegenerative disorders, and as an innate immune mechanism against 
intracellular bacteria.210  It is a degradative, membrane-based system by which long-lived 
intracellular products are removed and turned-over via the lysosome. As such, it 
complements the ubiquitin–proteasome pathway that degrades short-lived proteins. 
Autophagy is highly conserved; in a unicellular world, it probably evolved as an essential 
survival mechanism to provide an alternative energy source during periods of starvation, thus 
ensuring continued minimal cellular function.  Most of the upstream regulation of autophagy 
occurs directly through the mammalian target of rapamycin (mTOR). The autophagy-related 
(ATG) proteins control the execution of autophagy, as outlined in Figure 1-7. 
 
In the same way that damaged organelles are homeostatically removed by autophagy, 
intracellular bacteria are engulfed by autophagosomes and transferred to lysosomes for 
degradation; this process is termed xenophagy. This has been demonstrated in vitro for 
several pathogens, including group A Streptococcus, Mycobacterium tuberculosis, Shigella 
flexneri, and Salmonella enterica, as well as viruses such as herpes simplex virus type-1, 
although direct in vivo evidence is presently lacking. 
 
ATG16L1 was originally identified as a CD gene in a German nsSNP GWAS, and has 
subsequently been confirmed in UK, North American, and French/Belgium GWAS as well as 
a handful of independent replication cohorts.81, 87-90  Hampe and colleagues analyzed 
approximately 20,000 coding SNPs (SNPlex Genotyping system) in a German cohort of 735 
CD patients and 368 HCs.87  Of the 16,360 successful assays, 7159 had a MAF of >1%. On 
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allele-based testing for association, 72 of these 7159 were significant at p<0.01. These SNPs 
were then tested in a second panel consisting of 380 CD trios, 498 CD singletons, and 1032 
HC.  Three of 72 SNPs satisfied a pre-defined statistical cut-off of p<0.05: rs2066845 in 
NOD2, rs1050152 (L503F) in SLC22A4, and rs2241880 (Thr300Ala) in ATG16L1 at 2q37 
near a locus of susceptibility (pcase–control = 1.6 × 10–5; pTDT = 2.7 × 10–5). After re-sequencing 
of all exons, splice sites, and the promoter region of ATG16L1 in 47 CD samples failed to 
detect any further coding or splice site variants, 28 tSNPs (r2 >0.8; MAF >1%) were selected 
from the CEU HapMap data.  The results of logistic regression and haplotype analysis 
suggested that the CD risk from ATG16L1 was confined to the G allele of Thr300Ala.  
Analysis of the combined cohorts gave an OR of 1.45 (C.I. 1.21–1.74) and a PAR of 0.26 for 
carriage of this variant, with some evidence of a gene dosage effect (homozygote OR 1.77, 
CI 1.43–2.18; PAR 0.17). It is noteworthy that the variant confers an amino acid change at 
the evolutionary conserved position 300 of the N terminus, located in exon 9, which is 
translated into the same reading frame of all six known splice variants of ATG16L1. 
 
Subsequent to this index publication, the full results of the N American GWAS were 
published.90  In this study, the authors reported association of Thr300Ala with CD at p = 6.4 
× 10–8, with additional replication in two further cohorts (530 CD trios; 353 patients with 
ileal CD and 207 HC) at p = 4.1 × 10–8.  Furthermore, expression of ATG16L1 (along with 
ATG5 and ATG7) was demonstrated in a variety of epithelial and immune cell lines.  
ATG16L1 was additionally expressed in a number of primary human immune cells, notably 
CD4+ and CD8+ T cells and CD19+ B cells.  Finally, the requirement of ATG16L1 for 
mammalian autophagy was demonstrated by small interfering RNA (siRNA) knock-down of 
ATG16L1 in an immortalized cell line (HeLa cells) subsequently challenged with Salmonella 
typhimurium.  In this system there was decreased targeting of intracellular bacteria to 
autophagic LC3+ vacuoles within 1 hour (2% compared with 17.5% in WT cells).  
 
Hampe and colleagues demonstrated expression of ATG16L1 mRNA and protein in colon, 
small intestine, intestinal epithelial cells, and leukocytes. However, they did not detect any 
difference in protein expression in intestinal tissue between CD and HC, although the 
numbers for analysis were small and the methods descriptive in nature.87  Furthermore, 
protein and cDNA expression levels were independent of Thr300Ala genotype. We have 
demonstrated downregulation of ATG16L1 mRNA in colonic CD biopsies compared with 
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healthy controls in our large microarray dataset (Noble, Lees et al, manuscript in 
preparation). 
 
Three different murine models of ATG16L1 deficiency have recently been described in two 
publications in Nature.211, 212  Cadwell and colleagues generated two mouse lines with gene-
trap mutations (which introduce a false splice acceptor into introns to inhibit expression of 
intact mRNA) in Atg16l1 (Atg6l1HM1 and Atg16l1HM2).211  Atg16l1HM mice had defective 
autophagy. In vitro experiments with murine embryonic fibroblasts demonstrated diminished 
rapamycin-induced and autophagy-dependent degradation of the adaptor protein 
sequestonome (SQSTM1 or p62), reduced production of LC3-II, and decreased 
autophagosome induction. In vivo, Atg16l1HM mice expressed Atg16l1 at 23–37% of the 
expected level in the intestine. Ileal and colonic morphology was normal. In addition to 
providing evidence of defective intestinal autophagy (increased LC3-II and p62 levels), the 
investigators demonstrated that these mice have abnormalities in Paneth cells (decreased 
lysozyme in mucus, aberrant disorganized granules, and reduced granule number) indicating 
that Atg16l1 is required for maintenance of the Paneth cell granule exocytosis pathway. 
Given this key observation, it is noteworthy that in contrast to Nod2–/– mice, Atg16l1HM 
animals had no alterations in handling oral Listeria monocytogenes challenge (bacterial titers 
in the spleen, liver, and mesenteric lymph nodes were the same as those in wild-type mice). 
This suggests that the phenotypes of ATG16L1 and NOD2 mutations appear to be distinct. 
The Paneth cell defects seen in Atg16l1HM mice on transmission electron microscopy 
(including degenerating mitochondria, loss of granules, and frequent absence of apical 
microvilli) were not present in epithelial progenitors or enterocytes, indicating that Paneth 
cells have a unique sensitivity to autophagy mutation. 
 
Cadwell and colleagues proceeded to examine RNA profiles in laser microdissected Paneth 
cells from mutant and wild-type mice.211  Approximately 1.5% of the probe set was altered 
by greater or less than 1.3-fold in Atg16l1HM Paneth cells including those related to 
peroxisome proliferator-activated receptor (PPAR) signaling, adipocytokine signaling, and 
lipid metabolism, as well as the acute phase response (serum amyloid A, haptoglobin, and 
complement factors D and I). The same analysis was performed in T cells; remarkably, only 
one gene had similarly altered expression profiles in T cells and Paneth cells. Therefore, the 
transcriptional signature of ATG16L1 deficiency is specific to Paneth cells. 
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Saitoh and colleagues generated mice that lack the entire coiled-coil domain of Atg16l1.212  
These Atg16l1–/– mice die on the first postnatal day. Interestingly, the authors speculate that 
this is because intact autophagy may be essential for surviving through neonatal starvation. 
To circumvent this lethal mutation, a chimeric mouse was generated by transplanting 
Atg16l1–/– fetal liver cells into lethally irradiated CD45.1+ mice. Under SPF conditions these 
chimeric mice did not develop spontaneous colitis. However, when stressed with DSS, the 
mortality rate was 100% at day 7 compared with 0% in WT mice. The mutant animals had 
severe inflammation in the distal colon with large areas of ulceration and increased 
lymphocytic infiltration.  
 
The investigators then stimulated peritoneal and bone-marrow derived macrophages from 
chimeric and WT animals with LPS, MDP, and different bacterial strains.212  A robust 
increase in IL1β levels was demonstrated upon stimulation with LPS and non-invasive 
Gram-negative bacteria (such as Escherichia coli) but not with invasive strains (such as 
Salmonella typhimurium).  Intriguingly, a normal inflammatory cytokine response was noted 
following MDP stimulation, providing further evidence that ATG16L1 is not involved in 
NOD2 signaling.  In addition, stimulation with TLR3, TLR4, TLR7, and TLR9 ligands (but 
not TLR2 or TLR5 ligands) also induced IL1β production.  In Atg16l1–/– macrophages, 
autophagosomes were hardly detected and p62 was markedly increased under nutrient-rich 
conditions.  Together, these data indicate that reductions in basal autophagy induce IL-1β 
overproduction.  The relevance of this was demonstrated in vivo as injection of neutralizing 
anti-IL1β antibodies significantly improved mortality rate and weight loss in the DSS-
stressed chimeric animals. 
 
Translating these mechanistic studies directly back to man, Cadwell and colleagues tested the 
effect of the CD-associated ATG16L1 mutation on the histopathology of ileal resection 
specimens from patients who were either homozygous mutant or WT at Thr300Ala (none of 
these patients had NOD2 or IL23R mutations).211  Analysis of healthy tissue at resection 
margins in patients with the ATG16L1 mutation demonstrated that Paneth cells had 
disorganized granules with reduced granule formation, diffuse cytoplasmic staining of 
lysozyme, and positive staining for leptin.  This was strikingly concordant with the 
phenotype of Atg16l1HM mice. 
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1.5.2.3 WTCCC study and immunity-related GTPase family, M (IRGM) 
In a landmark study published in the Nature journal in June 2007, the WTCCC performed a 
GWAS on 500,000 markers in 2000 patients with seven different diseases (CD, rheumatoid 
arthritis, type I and II diabetes mellitus, coronary artery disease, bipolar disorder and 
hypertension) and 3000 shared HC.81 This study was particularly successful in CD, with nine 
genes or loci reaching genome-wide significance at p < 10–7. These included established CD 
genes (including NOD2, IL23R, and ATG16L1) and four novel associations (IRGM, 
NKX2.3, PTPN2, and 3p21). All were subsequently replicated in an independent UK 
population (1182 patients with CD and 2024 independent HC).89  
 
Two SNPs (rs13361189 and rs4958847) flanking IRGM on chromosome 5q33.1 were 
strongly associated with CD on the index WTCCC scan and subsequent replication cohort 
(pcombined = 2.1 x 10–10 and 3.8 x 10–9). Neither of these SNPs is known to be functional. Re-
sequencing of the major IRGM exon identified two new SNPs, one that confers an amino 
acid change, and another that does not. Only the silent of these two SNPs was associated with 
CD, and was noted to be in near perfect LD with rs11361189. This strongly suggests that the 
disease-associated variants in IRGM do not cause simple amino acid substitutions, but more 
likely function via regulation of gene expression, gene splicing, or the rate of protein 
translation.  
 
Most recently, a 20kb deletion immediately upstream of IRGM, and in perfect LD with 
rs13361189, has been described by the laboratory of Ramnik Xavier.213  This 
insertion/deletion polymorphism was typed in a N American case–control population 
consisting of 685 individuals.  The frequency of the deletion in the reference population was 
10%, compared with 15% in CD patients (OR 1.6; p < 0.01) and 14% in UC (OR 1.4; p < 
0.05). It is intriguing that the deletion was associated with UC in this study, given the 
absence of association noted for IRGM SNPs in previous studies.84, 85  Replication of this 
observation in independent UC cohorts is required to validate or refute this point.  McCarroll 
and colleagues went on to demonstrate in vitro that the CD risk (deletion) and protective 
(reference) haplotypes differentially activate IRGM expression in distinctive cellular 
contexts.213 
 
The immunity-related guanosine triphosphatase (IRG or p47 GTPase) genes are critical to 
innate immunity against intracellular pathogens214.  Whilst there are 23 complete Irg genes in 
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mice, only three have been identified in man214, 215.  Of these, IRGM (OMIM 608212) is the 
human homologue of murine Irgm1 (Lrg-47), a key mediator of IFNγ-induced autophagy216.  
Human IRGM is constitutively expressed and contains no interferon-inducible elements in 
the promoter, leading to initial reports that humans lacked a p47 resistance system215.  
However, despite being unresponsive to IFNγ, IRGM plays a critical role in IFNγ-induced or 
conventionally induced autophagy in human macrophages.216  siRNA knockdown of IRGM 
in human macrophages infected with mycobacterium leads to defective autophagy, with 
increased bacterial survival compared with control cells.216  Lrg-47 knockout mice (Lrg-47-/-) 
fail to control mycobacterium tuberculosis infection (succumbing after several weeks 
following aerosol or intravenous inoculation), despite the formation of well-organized 
granulomas replete with infiltrating lympocytes217.  Lrg-47-/- macrophages have defective 
bacterial killing with impaired maturation of mycobacterium tuberculosis containing 
phagosomes; Lrg-47 is recruited to these vesicles in WT cells.216   Similarly, Lrg-47-/- mice 
infected with mycobacterium avium are unable to control bacterial replication; although 
surviving the acute illness they succumb 11-16 weeks later.218  The phenotype of these 
animals suggests a regulatory role for Lrg-47 on lymphocyte survival, as they have a 
profound systemic anaemia and lymphopenia, with marked lymphocyte deficiency in 
mycobacterium granulomas.218   
1.5.2.4 Autophagy, innate immunity and intestinal luminal bacteria 
It is highly likely that autophagy and innate immunity, both ancient and highly conserved 
processes, co-evolved as primitive defenses against pathogens. Direct links have now been 
established between TLR signaling, autophagy, and phagocytosis219 and, although the 
relative contributions of each in different tissues remains to be established, both are likely to 
be important for clearance of intracellular pathogens in the gastrointestinal tract.  It has been 
demonstrated that microtubule-associated protein 1 light chain 3 (LC3) and beclin 1 are 
recruited to phagosomes under the control of ATG5 and ATG7, but without the formation of 
double-membrane structure around the TLR-induced phagosomes (in contrast to 
conventional autophagosomes). This process results in more rapid and extensive acidification 
of the phagosomes and enhanced pathogenic killing.219  
 
It is intriguing to speculate that there might be a link between NOD2 signalling and 
autophagy in GI tract homeostasis and in CD pathogenesis.  This is being actively 
investigated in several laboratories internationally.  It has already been demonstrated that 
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NOD-like receptor (NLR) signalling interacts with autophagy.  The activation of caspase 1 
and subsequent cell death in macrophages following Shigella infection is mediated via the 
NLR-family member IL1-converting enzyme-protease activating factor (Ipaf) and the 
adaptor protein apoptosis-associated speck-like protein containing a C-terminal caspase 
recruitment domain (ASC).  Shigella-infected macrophages undergo increased autophagy in 
the absence of caspase 1 and Ipaf, but not ASC.220 This demonstrates that autophagy in this 
context is regulated by the Ipaf inflammasome. 
  
In recent years, much attention has focused on the role of enteroadherent strains of E coli and 
M avium subsp. paratuberculosis (MAP). Whilst different international groups have isolated 
very similar strains of E coli from patients with CD, the role of MAP remains highly 
contentious. This is largely due to the wide-ranging recovery rates reported for MAP culture 
and DNA in cases and controls (0–100%), and the lack of a functional role for bacteria 
recovered from ulcerated mucosa.221  However, given the defective mycobacterial killing 
demonstrated with IRGM knock-down, the MAP “story” may see a resurgence.  It will be of 
great interest to establish whether this effect is seen in those with the CD-associated IRGM 
insertion-deletion polymorphism and, furthermore, whether MAP is isolated more frequently 
from the intestines of these patients. 
 
Determining whether defects in autophagy are related to specific bacterial strains will be an 
exciting avenue of future exploration. Indeed, careful dissection of the mechanisms by which 
the host (with a variety of disease-associated mutations in ATG16L1, IRGM, and LRRK2) 
handles different strains of intracellular pathogens could provide fundamental insights into 
disease pathogenesis. Furthermore, autophagy looks like a readily ‘druggable’ target for CD 
therapeutics.  It is noteworthy that rapamycin, the most commonly used laboratory agent to 
induce autophagy (via mTOR), has been in clinical use in a number of different arenas for 
several years, where it is now known as sirolimus (Rapamune; Wyeth). Sirolimus is 
frequently used as an immunosuppressant post-solid organ transplantation, either as 
monotherapy or in conjunction with calcineurin inhibitors and/or mycophenolate mofetil. 
Sirolimus-eluting coronary stents (Cypher; Cordis Corporation) used in coronary artery 
disease patients are reported to have lower re-stenosis rates when compared with bare metal 
stents. Sirolimus has also been shown to shrink tumors (astrocytomas and renal tumors) in 
patients with tuberous sclerosis complex.  Indeed, there is much hope that the anti-
  -  - 52
proliferative effects of agents such as this will be of clinical benefit in a number of different 
malignancies. 
 
Very recently, a single case report has described the clinical use of sirolimus in a patient with 
severe CD, with the drug inducing a marked and sustained improvement in symptoms and 
endoscopic appearances.222  In animal models, rapamycin has been demonstrated to be as 
effective as cyclosporine in reducing experimental chronic colitis induced by DSS.223  These 
observations lead to the prospect of early clinical trials of these agents to induce autophagy in 
patients with CD. However, due to the wide-ranging effects of autophagy in both 
homeostasis and pathogenesis in a variety of organs and tissues, not to mention the GI tract 
itself, it is likely that more specific targeting of defined autophagy pathways will be required, 
and delivery mechanisms developed to limit unwanted or dangerous systemic side effects. 
1.5.2.5 NK2 transcription factor related, locus 3 (NKX2.3) 
The WTCCC study identified a cluster of associated SNPs around rs10883365 (p = 1.4 x10-8) 
at 10q24.2, the location of NKX2.3.81  Evidence for association at NKX2.3 was also obtained 
in the UK CD replication study of rs10883365 (p = 0.0037, pcombined = 3.7 x 10-10; OR 1.18, 
C.I. 1.05-1.32)89 and in a German tSNP study where the best marker was rs11190140 (p = 
8.87 x 10-6; OR 1.22, C.I.1.05-1.42).85  Recently, rs10883365 has also been shown to be 
associated with Japanese CD (p = 0.0065; OR 1.29, C.I. 1.07-1.54).224  Of note, these two 
markers from the UK (rs10883365) and German (rs11190140) studies are in perfect LD.85  
NKX2.3 has also been confirmed as a susceptibility gene for UC, in both the UK (p = 2.4 x 
10-6; OR 1.20, C.I. 1.05-1.38, at rs10883365) and Germany (p = 1.33 x 10-8; OR 1.39, C.I. 
1.16-1.37, at rs11190140).84, 85  
 
NKX2.3 is a member of the NKX family of homeodomain-containing transcription factors 
implicated in cell type specification and maintenance of differentiation in a number of 
different tissue types.  In mouse,  Nkx2.3 is expressed in gut mesoderm and branchial arches 
from E9.5, persisting in the hindgut until adulthood.225  During later stages of murine 
development, expression is confined to the inner ring of gut mesoderm (smooth muscle), 
immediately underlying the mucosal endodermal epithelium.226  In the adult, highest levels of 
expression are noted in the ileum with lowest levels of expression in the duodenum and 
rectum.  In addition to smooth muscle expression, NKX2.3 is expressed in numerous 
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mesenchymal cells in the intestinal lamina propria and in endothelial cells of small blood 
vessels. 
 
A significant proportion of Nkx2.3-/- mice die from acute intestinal malaborption within two 
weeks of birth.226, 227  In the early postnatal period, these animals have steatorrhoea and 
bloody diarrhoea, with lipid-staining vesicles predominant in the intestinal mucosa.  Whilst 
TNFα expression was increased in one study of mutant intestine, no acute inflammation was 
detected at any post-natal stage.226  Those mice that survive this period have reduced 
intestinal length and intestinal distension secondary to hyperplasia (not dilatation), but 
otherwise appear healthy as adults and are fertile.226  Meanwhile, heterozygotes are viable 
and appear to develop normally.226, 227  The homozygous mutant animals have severe defects 
in both the spleen and intestine.  Of note, 1 in 3 of these mice are asplenic; the spleens in the 
remaining animals are approximately 10-fold smaller than wild-type animals and 
demonstrate severe structural abnormalities.226, 227  They lack a marginal zone, have 
abnormal segregation of B and T lymphocytes, and a paucity of macrophages in red pulp.  
They are noted to have a smaller caecum than WT mice, from E15.5 onwards.226  In the small 
intestine, villus formation is delayed during development; however, normal differentiation of 
epithelial cell types is present in surviving adult mutants.227  Furthermore, these animals have 
significant abnormalities of gut-associated lymphoid tissue with fewer and smaller Peyer’s 
patches and lymphoid aggregates than WT.  Moreover, MadCAM-1 expression is 
significantly down-regulated (about 10-fold reduction) in areas that normally express 
NKX2.3, providing a potential mechanism by which they have deranged lymphocyte 
homing.226  The importance of lymphocyte homing via MadCAM-1 in IBD pathogenesis has 
been clearly demonstrated as testified by the clinical efficacy of the anti-alpha4 monoclonal 
antibody, natalizumab, in CD. 
1.5.2.6 Protein tyrosine phosphatase non-receptor type 2 (PTPN2) 
The strongest hit at 18p11 in the WTCCC study was at rs2542151 (p = 4.6 x 10-8), 5.5kb 
upstream of PTPN2.81  Whilst only modest evidence for replication at rs2542151 was 
provided in both the index study (p = 0.048)89 and in the German cohort (p = 0.01)85, this 
SNP was robustly replicated in the meta-analysis (preplication = 2.41 x 10-7, pcombined = 5.10 x 10-
17).103  There was no evidence for association at PTPN2 in the smaller Japanese CD cohort.224  
As mentioned above (1.5.2), PTPN2 has also subsequently been associated with coeliac 
disease and type I diabetes mellitus. 
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PTPN2 (OMIM 176887) encodes the T cell protein tyrosine phosphatase (TCPTP) that is a 
key negative regulator of inflammatory responses.  TCPTP is located intracellularly, 
containing no transmembrane domains.228  It is expressed in all tissues and at all stages of 
development. There are two splice variants in humans (48kDa: ER targeted; 45kDa:  nuclear 
and cytoplasm targeted) but only one is mice (45kDa).  Expression is ubiquitous, but highest 
in cells of haematopoietic origin; the knock-out mouse dies of severe anaemia by post-natal 
weeks 3-5.229  Interestingly, this mouse, although apparently normal through embryonic 
development, develops a severe systemic inflammatory disease / wasting disease 
characterised by runting, hunched posture, diarrhoea, splenomegaly (caused by macrophage 
infiltrates) and weight loss.229  The severe immunosuppression is characterised by defective 
T-cell-dependent B-cell responses. TCPTP is an important regulator of CSF1 (colony 
stimulating factor-1) and mononuclear-phagocyte development (Tcptp-/- show increased 
granulocyte-macrophage precursors).230  Furthermore, the Tcptp-/- mice show widespread 
lymphocytic infiltrates in nonlymphoid tissues correlating with increased IFNγ, TNFα, IL12, 
nitric oxide, and increased LPS sensitivity.231 Increased cytokine production is detected as 
early as day 3 post-partum, preceding the onset of systemic disease (symptoms develop at 
day 10-14 post-partum), suggesting this is a primary abnormality in these animals.  
IL12/IL23-p40 expression is massively up-regulated in the liver and to a lesser extent in the 
spleen at day 3.  Intra-peritoneal injection of 4µg LPS to 20 day old Tcptp-/- mice led to the 
development of septic shock, not seen in WT littermates, with massive induction of serum 
IFNγ.  
 
TCPTP has been shown to dephosphorylate distinct substrates, including the insulin 
receptor,232 EGFR,233 JAK1,234 JAK3,234 STAT1,235 STAT3,236 and most recently STAT6.237, 
238  As a result, it can regulate signalling pathways that are induced by various growth factors 
(e.g. EGF) and cytokines (e.g. TNFα).  In the case of TNFα, MAPK signalling is suppressed 
by TCPTP (it interacts with TRAF2 to dephosphorylate and hence inactive Src tyrosine 
kinases).239  TCPTP-deficient cells show enhanced IL-6 production in response to TNFα, an 
effect blocked with inhibition of ERK1/2 activation.239  TCPTP dephosphorylates nuclear 
STAT6 (PTPN1 does the same to cytoplasmic STAT6), inducing the expression of IL4 target 
genes.237 The 45kDa TCPTP recognises mutant EGFR (a common rearrangement with a 
truncated protein with an in-frame deletion of 267 amino acids that is detected in 
glioblastoma, breast, lung and prostate cancer) as a cellular substrate and dephosphorylates it 
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leading to decreased MAPK ERK2 and PI-3K, suppressing the tumorigenicity of mutant 
EGFR-expressing glioblastoma cells.240  
1.5.3 CD GWAS meta-analysis 
The individual GWAS reports mentioned were powered to identify associations with OR of 
≥1.3 (WTCCC) or ≥1.5 (N American and French / Belgium).  Combining these datasets 
gives a total population of 3230 CD patients and 4829 HC and as a result 74% power to 
detecte OR of ≥1.2.  Barrett and colleagues recently performed a meta-analysis on this 
combined cohort.103  This would previously have been technically impossible as the different 
scans were done on two contrasting platforms.  However, recently developed algorithms 
(IMPUTE and MACH) were employed to impute genotypes on the relevant ‘missing’ SNPs 
for each platform to generate data for all studies on 635,547 SNPs.  This process relies on the 
observed haplotype patterns in the HapMap cohort, used as a reference population.  
Imputation was performed on all samples irrespective of case status to avoid introducing 
artefact.  As the 3 different GWAS had carefully matched population controls, Barrett 
performed the meta-analysis on the results on each study, rather than combining the raw data.   
 
526 SNPs in 74 distinct loci achieved a nominal significance threshold for replication (p < 5 
x 10-5).  11/74 loci were previously reported.  Therefore 63 loci were genotyped in a 
replication panel consisting 2325 CD patients, 1809 HCs, and 1339 trios for case-control and 
TDT analysis.  21/63 loci were successfully replicated (19 meeting replication threshold of p 
< 0.0008; 2 additional loci otherwise satisfying genome-wide significance levels – p < 5 x 
10-8 - in combined cohort), thus bringing to 32 the number of confirmed loci for CD. 
 
In addition to those results already mentioned above in the context of IL23 signalling, the 
meta-analysis data provide substantial new insights into CD pathogenesis.  ICOSLG is 
expressed in intestinal epithelial cells where it acts as a costimulatory signal for T-cell 
proliferation and cytokine secretion.241  In addition, ICOSLG is upregulated in mature 
plasmacytoid DCs; as a result they can induce IL10 producing TREGS from naieve CD4 T 
cells.242   
 
Intelectin-1 (ITLN1) is a lectin that recognises sugar motifs specific to bacterial cells walls.  
ITLN1 is expressed in the gut, specifically Paneth cells, and induced by parasitic infection in 
a STAT6 dependent manner.243, 244  It has also recently been shown to be decreased in lung 
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epithelium from both ‘healthy’ and diseased lungs from cigarette smokers (there was no 
change in the expression of all other lectin genes studied).245  It will therefore be of interest to 
see whether ITLN1 expression is decreased in the terminal ileum or colon from smokers, 
potentially decreasing pathogen clearance.   
 
LRRK2 is implicated in the pathogenesis of Parkinson’s disease, is expressed in myeloid 
cells, and is strongly implicated in autophagy.246  ZNF365 is a zinc finger protein that is a 
cause of susceptibility to uric acid neprolithiasis in a founder population in Sardinia.247  Little 
is known about CDKAL1, but of note it has also been confirmed as a susceptibility gene for 
both type II diabetes mellitus and psoriasis.248, 249  CCR6 is the receptor for the chemokines 
CCL20, which is discussed in much more detail in Chapter 10. 
1.5.4 Ulcerative colitis genetics 
The genetic architecture of IBD genetics has become better defined in recent months, thanks 
to a series of large studies in UC, previously lagging significantly behind the progress in CD. 
As already discussed, whilst several loci are common to both CD and UC, several (notably 
NOD2 and the autophagy genes) are distinct to CD.  In addition to historic associations in the 
HLA region and with MDR1, 3 UC GWAS studies from the UK, Germany and N America 
have added a number of novel, specific UC loci.84, 86, 142 
1.5.4.1 Human Leukocyte Antigen (HLA) region 
In UC, a stronger association exists between genes of the HLA region (6p21), involved in 
regulating the immune response, than for CD.  Despite confounding effects of ethnic origin 
and disease heterogeneity, this association is strongest in patients with extensive UC; a 
positive association with DR2 (in particular, the DRB1*1502 subtype) and the rare alleles 
DRB1*0103 and DRB1*12, and a negative association with DR4 and DRw6 have been 
reported.250  The HLA DRB1*0103 allele situated at the HLA Class II region has been shown 
to be associated with extensive disease, the need for surgery and extraintestinal manifestation 
in the Caucasian population.  Although a rare allele in the general population, this association 
has been consistently replicated in at least three independent studies and a meta analysis.251-
253  While the allele is only carried by 1-3% of the general population, carriage is 7.4-11% in 
UC patients with extensive or pan-colitis. Furthermore, in a study of patients who have 
undergone surgery and ileo-anal anastamosis for severe UC, HLA DRB1*0103 allele was 
present in 15.8% of patients with extensive colitis at time of surgery, and in 22.8% of a 
subset of patients who also had extraintestinal manifestations.  An association between the 
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HLA DRB1*1502 (DR2) with UC has also been observed in several studies, notably in USA 
and Japan.254-256  Moreover, in the Japanese population, HLA DRB1*1502 (a sub-group of 
DR1*15) is common and has been associated with intractable disease.  HLA-DR4 allele has 
been shown in several studies to be protective against UC, and this was confirmed in a meta-
analysis.257 
 
In the UK nsSNP study MHC tSNPs were also genotyped in the discovery cohort.84  The 
association in this region peaked at rs6927022 (p = 4.7 x 10-8).  As this SNP failed 
genotyping in the replication cohort, a surrogate marker (rs660895) in tight LD with 
rs6927022 was used with evidence of replication (p = 0.0035, pcombined = 2.8 x 10-8).  This 
SNP lies in a 400kb haplotype block containing BTNL2, HLA-DRA, HLA-DRB5, HLA-DRB1, 
and HLA-DQA1.  The design of this study, with high marker density in this region, 
demonstrated that the association is confined to this block and does not extend beyond the 
recombination hotspots at either end.  In an initial attempt to identify the causative mutations 
within this large region, the BTLN2 variants were stratified by HLA-DRB1*1502 status 
providing clear evidence for residual association at BTLN2 (p = 0.0036).  The German UC 
GWAS (see 1.5.4.5) demonstrated genome-wide levels of significance at 3 SNPs in this 
region: rs9268877 (p = 5.23 x 10-7, pcombined = 6.48 x 10-18) and rs9268858 (p = 5.41 x  10-7, 
pcombined = 2.58 x 10-12) in HLA-DRA, and rs9268480 in BTLN2 (p = 2.21 x 10-6, pcombined = 
3.15 x 10-9).86  The HLA SNPs in the WTCCC study were stratified by disease location 
(colonic only and ileal only).  This provided additional evidence that the HLA region confers 
risk of colonic IBD – i.e. both UC and colonic CD.84 
1.5.4.2 Multi-drug resistance gene 1 (MDR1/ABCB1) 
MDR1 (ABCB1; encoding P-glycoprotein 170) is located at chromosome 7q22, in a 
susceptibility locus described by a UK genome-wide scan in 1996.99  The knockout mouse 
(Mdr1-/-) develops a spontaneous colitis in specific pathogen-free conditions that is reversed 
by antibiotics and absent in germ-free housing.258  Expression of MDR1 decreases with 
inflammation in various animal models of colitis, and in colonic biopsies from patients with 
UC.259  Inherited variation in MDR1 has been associated with UC susceptibility in most, but 
not all, populations studied.  A Scottish gene-wide haplotype-tagging study has demonstrated 
a significant association in MDR1 variation with UC (p =  4.22 x 10-7), but not CD.260 The 
variants most extensively studied in association studies are C3435T and A2677G/T, although 
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results are variable and it is not clear if either of these SNPs is causative.   Phenotypic sub-
studies have reported a strong association with extensive disease in UC.   
1.5.4.3 Myosin-IXb (MYO9B) 
Recently, inherited variations of the myosin-IXb (MYO9B) gene have also been shown to be 
associated with UC in four independent populations.261, 262  It is of interest to note that the 
initial association was primarily observed with coeliac disease in the Dutch population.263 
The mechanism underlying this is unclear. Overexpression of rat myosin-IXb leads to actin 
filament related morphological changes in epithelial cells, and human myosin-IXb is 
expressed in intestinal epithelial cells. It is postulated that variations of the MYO9B gene may 
influence intestinal permeability leading to inflammatory intestinal disease susceptibility.  
1.5.4.4 Extracellular matrix protein 1 (ECM1) 
In the UK nsSNP GWAS, the strongest novel association was with a locus on 1q21.2 
containing ECM1, MRPS21, PRPF3 and TARS2.84  The strongest markers in this region, 
rs3737240 and rs13294) withstood replication in two independent cohort (pcombined = 2.3 x10-6 
and 7.9 x 10-6 respectively).  Whilst additional tagging at ECM1 provided evidence of 
association in two snSNPs within the gene, conditional regression analysis showed that these 
did not fully explain the association.  Therefore, further fine-mapping and deep re-
sequencing is required to determine whether the causative mutations lie within ECM1 or 
elsewhere in the haplotype block.  Despite this, ECM1 remains an excellent biological 
candidate for a UC susceptibility gene.  It is expression throughout the intestine, interacts 
with the basement membrane, inhibits MMP9 and strongly activates NFκB.  It is noteworthy 
that rs3737240 and rs13294 were also associated with ankylosing spondylitis (p = 0.0041 and 
0.0044 respectively)192 given the overlap between these two diseases clinically. 
1.5.4.5 Interleukin 10 (IL10) 
Despite only finding GWAS levels of significance at the HLA region in the gene discovery 
cohort in the German GWAS, the extensive replication stages in this study (3 additional large 
cohorts from Germany, UK and Belgium/Netherlands, totalling 3022 UC cases and 3867 
HCs) also provided robust evidence for association at IL10.86  Following on from the limited 
UK nsSNP study, this was the first full GWAS in UC using the Affymetrix 500k chip and 
leaving 440k SNPs for analysis after quality control.  With a gene discovery cohort of 1,167 
UC cases and 777 HC, Franke estimates 80% power to detect a variant with OR ≥ 1.5 (α = 
0.05) assuming MAF of ≥0.20 in HC.86  The 20 most significant SNPs in this cohort were 
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replicated across all 3 additional panels.  The lead SNP in IL10 was rs3024505 located 1kb 
downstream of the 3 UTR (pcombined = 1.35 x 10-12, OR 1.46, C.I. 1.31-1.62).  Following an 
IL10 tSNP (n=22) supplementary study in all 4 panels, 2 additional SNPs (both intronic) 
were associated with UC: rs3024495 (pcombined = 2.69 x 10-11) and rs3024493 (pcombined = 6.16 
x 10-12).  The 3 associated SNPs were in perfect LD; regression analysis suggested they 
might act independently of each other.  Of note, rs3024505 was also associated with German 
CD, albeit weakly (p = 0.013, OR 1.17, C.I. 1.01-1.34).  The location of this SNP – 79bp 
from a highly conserved stretch of DNA at the 3′ end of IL10 – is of some interest, at it 
contains a putative AP-1 binding site. 
 
As many as 10 historic studies (from 1999 to 2006) in multiple different populations have 
analysed the IL10 promoter (at -592 [rs1800872], -819 [1800871], and -1082 [rs1800896]) 
for evidence of association with UC and CD with very variable results.  None of these 3 
promoter SNPs were associated with UC in the German GWAS.86  This does provide a 
salutary reminder of the strength of GWAS design, compared with these older candidate gene 
studies. 
 
As previously mentioned (see 1.4), Il10-/- mice develop spontaneous colitis in SPF conditions 
due to defective counter-regulatory anti-cytokine responses.  Indeed, these animals provide 
one of the oldest (first reported in 1993), most widely used and best characterised genetic 
animal models of colitis.  Physiologically important defects in IL10 signalling in LPMCs 
from UC patients were described in 1995,264 and by 1998 very early clinical trials of 
subcutaneous recombinant IL10 produced some evidence of benefit in UC patients.265  For 
some reason, the phase II trials of this protein (rHuIL-10) were in CD, and when they failed 
to demonstrate efficacy this avenue was quietly dropped from further investigation.266, 267  
However, given these new genetic data, further exploration of IL10 delivery should be 
explored as a therapeutic avenue in UC, perhaps utilising Larry Steidler’s ingenious delivery 
mechanism via recombinant IL10 producing Lactococcus lactis.268   
1.5.4.6 N American UC GWAS: 1p36 and 12q15 
The N American group recently reported their GWAS in UC.142  In this study they only 
included patients with inflammation extending proximal to the rectum (Montreal E2 or E3).  
In the gene discovery cohort, 1052 patients with UC and 2571 geographically matched HC 
were included.  Two independent replication panels were used: 786 UC and 721 HC from N 
  -  - 60
America and 619 UC and 394 HC from S Italy.  Two novel regions met genome-wide levels 
of significance.  At 1p36 there were two independent signals (r2 < 0.01) from rs6426833 (p = 
6.8 x 10-10, pcombined = 5.1 x 10-13; OR 0.73) and rs3806308 (p = 4.7 x 10-8; pcombined = 
6.7 x 10-9; OR 0.78), separated by recombination hotspots.  rs6426833 maps to OTUD3 and 
PLA2G2E (phospholipase A2, group IIE), whilst rs3806308 maps to RNF186 (ring finger 
protein 186). 
 
At 12q15, rs1558744 (p = 5.5 x 10-10, pcombined = 2.5 x 10-12; OR 1.35) and rs2870946 (p = 
1.0 x 10-5, pcombined = 4.8 x 10-7; OR 1.54) were independently associated with UC (r2 = 
0.031).142  This region is particularly noteworthy as it maps to the edge of the IBD2 region 
(see 1.5.1.3), and contains IFNγ, IL26, and IL22.  These genes are 44 – 137kb from 
rs1558744, whilst rs2870946 is located in IL26.  IL26 and IL22 are both secreted by Th17 
cells.269  The role of IFNγ in the regulation of multiple areas of mucosal immune homeostasis 
and in the response to pathogens is well established.   
1.6 The hedgehog (HH) signalling pathway in gastrointestinal 
development, homoestasis and disease 
It is becoming increasingly clear that signalling pathways important in pre-natal development 
continue to have vital roles in adult life by directing differentiation, determining cell fate, 
maintaining stem cell niches, and co-ordinating appropriate cellular responses to injury.  
These pathways influence many disease processes; in some situations the normal critical 
balance of signalling components is upset by inherited variants, whereas in others ligand-
driven upregulation of signalling is a sufficient driving force.  In the GI tract, the hedgehog 
(HH) signalling pathway has been shown to have critical roles in development, homeostasis 
and disease (Figure 1-8) (Lees et al, Gastroenterology 2005).270 
1.6.1 HH signalling (Figure 1-8) 
The HH signalling pathway was originally described in the development of Drosophila 
melanogaster as a segment polarity gene required for embryonic patterning,271 a discovery 
that led to Nusslein-Volhard and Wieschaus winning the 1995 Nobel Prize for Medicine.  
The genes involved in Drosophila are Hedgehog (Hh), Patched (Ptc), Smoothened (Smo), 
Hedgehog-Interacting Protein (Hhip), Costal-2 (Cos-2), Fused (Fu), Suppressor of Fused 
(Su(Fu)), and Cubitus interruptus (Ci). The pathway components demonstrate high inter-
species conservation.272  There are three vertebrate homologues of Hh, Sonic hedgehog 
(SHH), Indian hedgehog (IHH), and Desert hedgehog (DHH).  These demonstrate different, 
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but frequently overlapping, expression patterns.  They have remarkably similar biological 
properties, albeit with differing potency [SHH>IHH>DHH] noted in some, but not all, 
experimental assays.273  Increasing evidence implicates accessory molecules in mediating 
HH activity,274-276 and there may be a role for these in modulating this potency.  Most 
research has centred on SHH.  The two homologues for patched, patched-1 (PTCH) and 
patched-2 (PTCH-2), both bind vertebrate HH with similar affinity.  PTCH is found in target 
cells and upregulated by HH signalling.277  PTCH-2, although little studied, is co-expressed 
with HH and does not depend on it for transcription.278  The three homologues for Ci, GLI1, 
GLI2, and GLI3, are responsible for many of the refined complexities and intricacies 
observed in mammalian HH signalling. 
 
HH is synthesised as a 45 kDa precursor protein that undergoes autoproteolysis.279-281  The 
active N-terminal signalling domain (N-HH) is released once the catalytic C-terminal portion 
has been removed and a cholesterol molecule has been added (N-HHp).282  With the addition 
of cholesterol, a modification to N-HHp that is unique amongst signalling molecules, N-HHp 
is rendered hydrophobic and thus able to bind to the cell membrane where it mediates local 
signals.  In an independent step, the N-terminus can be further modified by palmitoylation, 
increasing hydrophobicity.283  Furthermore, N-HHp, once released from the cell via the 
transmembrane protein Dispatched (DISP1),284 functions to provide a long-range, paracrine 
signal to target cells.285  At the present time, the mechanisms involved in short-range and 
long-range signalling remain contentious and under investigation.  The transduction of the 
HH signal has many interesting and unique facets (Figure 1-9), that share some similarities 
with WNT signalling.286-288 
 
As with most cell signalling pathways, regulatory mechanisms exist for HH signalling.  HH 
activity induces further expression of its transmembrane receptor PTCH, thus simultaneously 
initiating signalling whilst restricting the range of movement by sequestering HH protein.  
Another cell-surface protein that binds to and sequesters HH, HHIP,289, 290 is also upregulated 
by pathway activation, thus serving to downregulate HH activity.  The phenotype of HHIP 
knockout mice is consistent with increased HH signalling.291  GLI1 is a direct transcriptional 
target of HH and a robust indicator of pathway activity.  Megalin, a LDL receptor-related 
protein, is also active on the cell surface and controls the endocytic uptake of the HH protein 
by acting as a direct binding partner in vitro, although little is known of its function in 
vivo.292, 293  The regulation of HH signalling at different levels indicates that tight control is 
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crucial to its proper function, analogous to regulation of other key signalling pathways, such 
as NFκB, whose activation induces inhibitory molecules (IκBα and others).294 
1.7 HH signalling in gastrointestinal development 
The gut develops from a primitive endodermal tube that gives rise to the pharynx, 
oesophagus, stomach, small intestine and colon.  Endodermal buds grow into mesenchyme 
closely associated with the tube and form the liver and pancreas.  The key molecular 
pathways involved are the HH, bone morphogenetic protein (BMP), Notch, and WNT/β-
catenin signalling pathways, the Hox and Sox transcription factors, and the Eph 
receptor/ephrin ligand signalling system.295  Patterned gene expression within the endoderm 
and surrounding mesoderm regulates the morphogenesis, differentiation and boundaries of 
these organ primordial.296  The cross-talk generated between endoderm and mesoderm is 
critical to this process and later establishes radial patterning within the developing digestive 
tract.  HH signals are a vital component of this cross-talk and thus essential to the normal 
patterning of the GI track along anterior-posterior (A-P), dorsal-ventral (D-V) and radial 
axes.297  In the animal models studied high levels of the HH receptor, PTCH, in the 
mesenchyme allows for processing of the signals generated endodermally.298-302  Paracrine 
signalling in the late gestational (E18.5), murine small intestine has been elegantly 
demonstrated after careful separation of these components.303  SHH and IHH are present in 
epithelial cells, with PTCH and GLI1-3 mRNAs detected almost exclusively in the 
mesenchymal compartment.  Outside of the intestine, HH signals have been reported to act 
cell-autonomously; in developing and adult pancreatic islets IHH and PTCH co-localize.304, 
305  Of great relevance, manipulation / interruption of HH components in animal models 
bears a close resemblance to many human congenital malformations arising from 
abnormalities in fore- and hindgut development.  
 
Developmental patterning by Hh in Drosophila is largely dependent on concentration 
gradients.306  In the mammalian ventral neural tube, the morphogenic gradients of SHH setup 
in the notochord and floorplate determine the differentiation of progenitors into several 
different cell types.307  In the developing gut, the overlap in expression of two HH 
homologues, SHH and IHH, may serve to generate greater variation in concentration 
gradients.  Additionally, the different phenotypes of the knockout mice (Shh-/- and Ihh-/-) 
suggests that the two homologues have different functions during intestinal development. 
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HH proteins are highly expressed in the murine embryonic gut and decrease after birth.302  
Shh and Ihh are expressed in mouse gut endoderm in overlapping patterns.  From day 8.5 of 
gestation (E8.5) the proteins are present in two ventrolateral strips in gut endoderm.308  This 
is noted first in the caudal hindgut, followed by foregut pocket and then hindgut.  Shh is 
downregulated in two critical areas – in the prospective pancreatic endoderm to allow normal 
pancreatic development, and along the small intestine, possibly to allow normal intestinal 
epithelial differentiation.309  By E18.5, there is expression of Shh and Ihh in the glandular 
stomach, small intestine and colon.  Shh is mostly restricted to colonic crypts at this time.   
1.7.1 Shh, Ihh, and Gli knockout mice 
Shh-/- & Ihh-/- mice die peri- or immediately post-natally.299  Both mutant embryos (examined 
at E18.5) show significant gastrointestinal defects, both common (smaller, overtly malrotated 
GI tracts) and distinct (Table 1-2).  There are no data reporting any such defects in Dhh-/- 
mice (males are viable, but sterile due to defective spermatogenesis).310 
 
The Shh-/- embryo displays a hyperplastic stomach epithelium with some intestinal 
transformation of the glandular epithelium.  Overgrown villi in the duodenum are seen to 
cause an occlusion similar to duodenal stenosis in humans.  On dissection, the colon 
terminates in a blind dilatation leading to imperforate anus.299  Furthermore, Gli2-/- and Gli3-/- 
mice exhibit, respectively, imperforate anus with recto-urethral fistula and anal stenosis.311  
Mice with a truncated Gli3 (Gli3Δ699/Δ699), resembling the aberrant transcription factor in 
Pallister-Hall syndrome, display imperforate anus, reduced size of small intestinal villi, 
dilated intestine and thin walled colons.312  Gli1-/-;Gli2-/- double knockouts have a persistent 
cloaca whilst the mixed homo-heterozygous mutants show interim changes consistent with a 
gene dose-dependent effect.311  Hh signalling is involved in the development of a normal 
hindgut and although probably important to the pathogenesis of human anorectal 
malformations, this has yet to be studied in detail. Of great interest, the Gli1-/- mouse appears 
to develop normally, although the published literature does not extend to a detailed analysis 
of gastro-intestinal ultrastructure.313 
 
In both Hh knockouts there is decreased thickness of the circular smooth muscle layer along 
the small intestine (34% reduction for Ihh-/- and 21% for Shh-/- when compared with WT).299  
Both also show abnormalities of the enteric nervous system (ENS).  Shh-/- mice have neurons 
that differentiate abnormally under the epithelium and migrate into the villi.  The healthy 
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epithelium is known to inhibit proliferation of enteric neurons, an effect that is lost when Shh 
signalling is blocked with the general Hh pathway-inhibitor cyclopamine (Figure 1-9).314  
Grafting Shh-expressing cells into the mesenchyme limits neural proliferation in the vicinity.  
Furthermore, Shh promotes proliferation of neural crest cells whilst inhibiting differentiation 
and modulating their responsiveness to glial cell line-derived neurotrophic factor.315  Taken 
together, these data strongly implicate Shh signalling in proper radial patterning of the ENS.   
 
Ihh-/- mice (and to a lesser extent Gli3Δ699/Δ699 mice)312 macroscopically exhibit marked 
dilatation of the small intestine and parts of the colon, corresponding to a microscopic 
absence of neurones.299  Some neurones are present in a normal pattern in patches of non-
dilated colon.  This colonic phenotype is observed with a penetrance of about 50%.  The 
inference is that neural crest cells can migrate into the gut and differentiate, but in the 
absence of Ihh locally they fail to survive or proliferate.  Interestingly, this phenotype 
resembles Hirschsprung disease in humans.  The one study to assess a genetic link failed to 
associate IHH polymorphisms with Hirschsprung’s, but was probably under-powered.316 
   
Ihh is normally expressed in the intervilli region of the small intestine, the presumed stem 
cell compartment.299, 317  In Ihh-/- animals there is decreased size of the villi, and a 54% 
reduction in cell proliferation in the stem cell compartment.  Abnormalities are also noted in 
the colon.  The normal epithelial monoloayer with organised crypts is replaced by 
multilayered epithelial cells lacking crypts.318  These data implicate Ihh in the regulation of 
stem cell proliferation and possibly epithelial cell migration in the intestine. 
 
The Shh and Ihh double knockout embryo arrests development at early somite stages (E8.0).  
Utilising the pan-Hh inhibitor Hhip under control of the mouse villin promoter, Madison and 
Gumucio have generated a viable murine model to study the effects of abrogating all Hh 
signals in the postnatal small intestine.303  The epithelium was noted to be flattened, with 
significant interference of villus formation and epithelial remodelling.  Changes in the 
mesenchyme (expansion of smooth muscle progenitors, and mislocalization of intestinal 
subepithelial myofibroblasts (ISEMFs)) were found, in turn, to impact further on the 
epithelium with increased proliferation and enhanced β-catenin/Tcf4 activity.  In this manner, 
the Hh pathway patterns the intestinal crypt-villus axis via a paracrine signal. 
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A further role for Hh signalling in the development and/or function of the murine postnatal 
intestine has been suggested by Wang and co-workers.302  In view of the lethality of Shh-/- 
and Ihh-/- knockout mice above, these authors studied WT animals, and blocked Hh 
signalling at late stages of pregnancy and immediately post-natally with tail-vein injection of 
the anti-Hh monoclonal antibody 5E1, which blocks Shh, Ihh and Dhh.  All pups died by 3 
weeks, having displayed a runting and wasting phenotype post-natally.  It is of some interest 
that this corresponded with the development of significant diarrhoea.  The small intestines of 
these animals showed significant histopathological abnormalities, notably disorganised villi 
projecting into the lumen, and hyperplastic crypts with a 73% increase in proliferation 
compared with control animals.  Furthermore, a prominent vesicular vacuolation was noted 
in enterocytes, predominantly affecting ileum and caecum.  This defect became apparent only 
on post-natal day two (having been absent one day previously even in animals treated with 
5E1 from E12.5), suggesting it might be dependent on colonisation of the GI tract with 
commensal bacteria.  It was also noted to be an intestinal specific phenomenon with no such 
vacuolation identified in other cell types, including hepatocytes.  Further characterisation 
showed that these vacuoles represent an intracellular accumulation of neutral lipid (Oil Red 
O positive, PAS negative).  The possible involvement of Hh signalling post-natally in lipid 
absorption and secretion is also suggested by the numerous microscopic fat droplets in the 
stool of treated mice; and by decreases in serum apolipoprotein A-IV, total cholesterol and 
high-density lipoprotein cholesterol, in these animals. 
 
This is further supported by a study in adults, demonstrating that monoclonal antibody-
mediated inactivation of Hh signalling in mice fed a high-fat diet protects against weight 
gain319.  Similarly treated leptin-deficient mice (ob-ob) that ordinarily gain weight on a low-
fat diet, showed decreased weight gain compared to controls.  Whilst total lipid absorption 
was normal, the rate of triglyceride absorption was significantly slowed and there was 
increased faecal free fatty acid excretion in the mAb treated animals.  Indeed, the hepatic 
steatosis noted in the high-fat control group was abolished with abrogation of Hh signalling.  
However, these data need to be interpreted with caution, as detailed studies of cyclopamine 
treated animals demonstrate increased WNT/β-catenin activity and colonic cancers 
(discussed in detail in 1.9.1.2).318  This could account for at least a proportion of the weight 
loss demonstrated here. 
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1.7.2 Shh, foegut development and oesophageal fistula / 
tracheoesophageal fistula (EA/TEF) 
The development of EA/TEF in Shh-/- mice suggests a role for Hh signalling in the 
pathogenesis of this condition and in normal foregut development.298, 299  Furthermore, the 
human GLI genes are implicated in congenital foregut malformations by the significant 
abnormalities noted in the Gli2-/- and Gli3-/- mice (Table 1-2).320  In normal murine 
development, foregut expression of Shh is particularly high when the trachea and oesophagus 
split.321, 322  At E10.5 the normal undivided foregut has a ventrally placed prospective trachea 
that is positive for Shh.323  By E11.5 this pattern is reversed with the separated trachea now 
negative for Shh.298, 323  However, analysis of the adriamycin-induced rat model of EA/TEF 
shows that when the trachea is still undivided (at E11.5 in the rat, a slightly different 
developmental time point to the mouse), there is a diffuse Shh staining pattern that lacks any 
dorsal-ventral gradient.323  The rat fistula tract shows much lower Gli2 levels than the 
adjacent oesophagus.324  Furthermore, culture of fistula tract with exogenous Shh induces 
branching, a known Shh effect on the developing lung.324  Examination of one resected 
human fistula tract in a newborn showed SHH in the proximal oesophageal pouch, but not in 
the distal fistula tract.325 
 
Combined, these data show that the fistula tract is of respiratory, not oesophageal, origin.  
Shh is vital to the normal development of the oesophagus and trachea, and heavily involved 
in the pathogenesis of EA/TEF and the VACTERL association that the adriamycin model 
mimics.  In humans, both foregut and hindgut anomalies are seen in some patients with 
holoprosencephaly (where mutant Shh causes cyclopia).  As EA/TEF in humans do not 
appear to be caused by genetic defects, an environmental association in the early embryo that 
manipulates HH signalling is more probable than a HH mutation.  What the relevant trigger 
is remains unclear, although it has been shown to be unrelated to maternal cocaine use as had 
been hypothesised.326 
1.8 HH signalling in the healthy adult gastrointestinal tract 
1.8.1 Patterns of expression in the adult GI tract 
The main published survey of the HH signalling pathway in the gastrointestinal system in 
adult humans and rodents was carried out by van den Brink et al.327  These authors 
demonstrated SHH mRNA to be abundantly expressed in the gastric fundus, in small 
quantities in the crypts of the small intestine, and in a few colonic crypts, but not in the 
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oesophagus or gastric antrum.327  When they used commercially available goat polyclonal 
anti-SHH antibody they did not find any positive staining for SHH protein anywhere apart 
from in the gastric fundus.327  Subsequently, work from three separate teams has now shown 
that SHH protein is present in the human colon, as will be discussed in more detail in Chapter 
4.328-330   
1.8.2 Functional aspects of HH signalling in the adult GI tract 
1.8.2.1 SHH and fundic gland differentiation in the stomach 
Within the stomach there are two compartments relative to the position of the epithelial stem 
cell.  In the pit region cells are migrating toward the gastric lumen, and in the gland region 
they migrate in the opposite direction.  SHH expression is restricted to the glandular portion 
of both human and murine stomach (utilising gastric mucins as genetic markers for each 
compartment).  In humans, SHH expression has been shown to be greatest at the pit-gland 
transition and restricted to parietal cells (as confirmed by double staining with 
H+K+ATPase).328, 331  PTCH is expressed on the epithelial cells of the gastric gland region 
and some of the interstitial cells.  Pit cells are PTCH negative but parietal cells and epithelial 
cells at the base of the glands express PTCH.331 
 
SHH expression correlates with fundic gland type, as seen where there is loss or gain of 
fundic gland differentiation.  In chronic gastritis, where there is intestinal metaplasia (as 
identified by the presence of MUC2) there is a loss of SHH expression.331  However, 
Dimmler et al suggest that this may be related to the process of atrophy, as SHH is highly 
expressed in non-atrophic gastritis.328  In the oesophagus, SHH is present in parietal cells in 
Barrett’s resection specimens, and in areas of Meckel’s diverticulum.331 
 
These data show that SHH may play a role as an essential polarising signal for fundic gland 
differentiation.  It has been postulated that an intestinal epithelium may be the default state 
during development.  SHH expression is part of a regulatory network that induces the 
character of gastric epithelium compared with intestinal type.  This is then maintained by 
SHH signalling throughout adult life. 
1.8.2.2 IHH and colonic enterocyte differentiation. 
Cyclopamine treatment markedly alters the slender nucleus and cytoplasm of normal 
terminally differentiated enterocytes.318  Without Hh pathway activity the enterocytes at the 
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luminal end of the crypt have an enlarged nucleus and large cytoplasm.  In addition, they 
show significantly altered expression of three molecular markers of enterocyte 
differentiation, with redistribution of villin to the cytoplasm, decreased carbonic anhydrase 
and increased intestinal trefoil factor.318  In the HT-29 colon carcinoma differentiation model, 
treatment of cells with butyrate induces expression of villin and Cip-1, and induces Ihh 
expression.  Blocking Hh signalling with cyclopamine substantially decreases the Cip-1 and 
villin induction with butyrate.  In addition, giving recombinant N-terminal Shh (91% 
homologous to Ihh) leads to induction of Cip-1 and villin.  These data suggest a role for Ihh 
in regulating colonic epithelial differentiation in vivo and in vitro. 
 
Furthermore Hh signalling restricts expression of Bmp4 (a Dpp homolog co-expressed with 
Hh genes during development) and engrailed-1 (a WNT target gene) to the precursor cell 
compartment at the base of the colonic crypt.  β-catenin-TCF (a marker of WNT pathway 
activity) signalling can be completely abrogated by Ihh in colon cancer cells.318 
 
Where WNT pathway activity is constitutively overexpressed (APC gene mutations in 
familial adenomatous polyposis) IHH expression is lost.  This phenomenon is observed in 
FAP resection specimens that contain both normal and dysplastic epithelial cells 
(corresponding to APC mutations and WNT over-activity).  Normal IHH expression is noted 
in the normal epithelial cells, but this is lost in dysplastic cells.  Inhibiting β-catenin-TCF 
signalling in colon cancer cells causes rapid induction of IHH expression.  These data 
together indicate that IHH expression is negatively regulated by β-catenin-TCF signalling.  
Furthermore, decreased IHH expression in colonic polyps is seen in response to the WNT-
activating APC mutation.  Because the loss of differentiation observed in the cyclopamine 
treated colonic epithelial cells mirrors that seen in colorectal carcinogenesis, loss of IHH may 
have a role to play in the development of dysplasia.318 
 
As discussed, all methods currently available to manipulate HH pathway activity are non-
specific for SHH or IHH.  The reported data are heavily reliant on expression studies, and as 
previously shown there remains some conflict with other published literature (as is further 
discussed below in the specific context of colon cancer).  It is therefore once again difficult 
to ascribe the effects seen here to one HH homologue or another.  Greater specificity could 
now be achieved through the appropriate application of RNA interference technology, 
utilising specific sequences of double-stranded RNA to knock down the expression of 
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complementary genes, and determine the relative contributions of SHH and IHH in 
homeostasis of the adult digestive tract.   
1.8.2.3 HH and Paneth cell differentiation 
Varnat and colleagues have described a role for PPARβ and HH signalling in Paneth cell 
differentiation.332  First, they demonstrated the widespread expression of PPARβ in the 
murine small intestine.  Examination of the Pparβ-/- mouse revealed it to have not only a 
decreased number of Paneth cells and altered intestinal luminal flora when compared with 
WT, but also a 3-fold induction of IHH expression.  Conversely, treatment of WT mice with 
L-165041, a PPARβ-specific agonist, led to increased IHH expression.  PPARβ, therefore 
appears to negatively regulate IHH in the murine small intestine.   
 
Of potential importance to future trials of clinical HH antagonists, intraperitoneal delivery of 
cyclopamine to WT mice led to a 30% increase in the number of mature Paneth cells in the 
small intestine.333  In a series of elegant co-localisation experiments the authors demonstrated 
expression of IHH in mature Paneth cells, with the pathway response elements, PTCH and 
HHIP, located in Paneth cell precursors.332  The data support a working model whereby IHH, 
synthesised and secreted by mature Paneth cells, is processed by HH response elements in 
precursor cells, thus negatively regulating their differentiation.  However, it should be noted 
that this model is out of keeping with the present over-riding body of evidence that HH 
signalling is purely paracrine from epithelium to mesenchyme in the intestine.  The Varnat 
studies used polyclonal HH antibodies which may be a source of error as some researchers 
have found them to be potentially non-specific.334 
1.9 HH signalling and gastrointestinal disease 
We have seen that HH signalling is critical to normal gastrointestinal development, and that 
it may have an important role to play in homeostatic processes of the adult stomach, colon 
and pancreas.  These processes rely on time-dependent and tissue-specific signalling at 
distinct concentrations.  This is made possible by differential expression of HH signalling 
components, the tight positive transcriptional and negative feedback loops (created by ligand-
induced activation of negative regulators, PTCH and HHIP), regulatory interactions with 
WNT/β-catenin signalling, and by the pathway’s ability to function as a bistable genetic 
switch, flipping cell fates at precise, threshold SHH concentrations.335  However, as a result 
of this reliance on such tight control, increases or decreases in pathway activity can result in 
severe defects.  It is important to consider how a developmental pathway that normally 
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directs differentiation and proliferation may, with the loss of its normal strict controls, 
contribute to cancer formation and maintenance, and chronic intestinal inflammation.  
1.9.1 HH signalling and tumorigenesis 
The HH signalling pathway interacts directly with cell-cycle components to increase cell 
proliferation.  The G1-S transition is promoted by cyclins D and E, both transcriptional 
targets of Ci in Drosophila,336 a finding confirmed in mammalian cells.337  The G2-M 
transition is in part controlled by PTCH, which regulates the activation of cyclin B (part of 
the mitosis-promoting-factor complex).338  SHH also blocks p21(CIP1/WAF1)-induced 
growth arrest.339  Furthermore, there is some evidence that PTCH, like DCC, UNC5 and 
RET, functions as a dependence receptor.340, 341  Dependence receptors are characterised by a 
cellular state of dependence on their ligand, such that absence of ligand induces apoptosis.342  
The presence of ligand (HH) prevents the induction of apoptosis.  In the absence of HH, 
caspase-3-mediated cleavage of the intra-cellular PTCH domain exposes a receptor region 
that transduces the apoptotic signal via GLI3.  It is noteworthy that many of the HH pathway 
activating PTCH mutations implicated in CNS, skin and muscle tumours map to the carboxy-
terminus in the vicinity of the caspase-3 site.343  Such critical functions as cell cycle control 
help to explain the importance of tight, multi-layered control on the pathway.  It is perhaps, 
however, not surprising to learn that HH signalling is implicated in the induction and 
maintenance of cancer.  This is, in part, by promoting cell cycle proliferation and opposing 
the normal stimuli for cell cycle arrest. 
 
To date, aberrant HH signalling has been described in tumours of the skin, brain, lung, and 
digestive tracts.344-349  A subset of HH-responsive cancers is, in part, caused by mutations in 
HH pathway components.  This phenomenon was first identified in patients with Gorlin 
syndrome who, along with generalised body overgrowth, cysts and skeletal developmental 
abnormalities, have a predisposition to benign and malignant neoplasia, notably multiple 
basal cell carcinomas (BCCs).350, 351  Patients inherit a mutant PTCH that permits constitutive 
pathway activation.  A mutation in PTCH is also present in a proportion of medulloblastomas 
and rhabdomyosarcomas, where there is evidence that this confers on tumour cells the ability 
to resist apoptosis.352  This loss of function phenotype defines PTCH as a tumour suppressor 
gene, and is consistent with its role as a dependence receptor.  Somatic mutations in the 
PTCH gene are reported in oesophageal squamous cell carcinomas and transitional cell 
carcinomas of the bladder.353, 354  Other oncogenic mutations include SMO in BCC (where 
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the pathway becomes independent of HH-PTCH binding),355 and SUFU in 
medulloblastoma,356 whereas ectopic expression of GLI causes glioma.357  
 
It is now known that the HH pathway is also involved in the formation and maintenance of 
some sporadic tumours without implicating pathway-activating mutations.  This is seen to be 
the case for small cell lung cancer,349 prostate cancer,358 pancreatic cancer,348 
cholangiocarcinoma and other tumours of the digestive tract.346  
1.9.1.1 Cancers of the upper GI tract  
The HH signalling pathway is active in many digestive tract cell lines.  SHH and IHH mRNA 
is present in virtually all cell lines from oesophageal, stomach, biliary tract, pancreatic and 
colonic carcinomas.  However, PTCH and GLI1, used as markers of HH pathway activity, 
are co-expressed only in oesophageal (4/6), stomach (6/6), biliary tract (5/9) and pancreatic 
(5/6) tumours.  In these cell lines the GLI-luciferase reporter assay shows a high level of 
activity and therefore confirms autonomous pathway activity.  Of the PTCH mRNA positive 
cell lines, treatment with cyclopamine resulted in a 75-95% decrease in growth.  PTCH 
negative cell lines show no difference in growth with cyclopamine treatment.  
 
The dramatic in vivo responses of pancreatic tumours to HH blockade have been paralleled 
by experiments described by Berman and colleagues, who have studied murine xenografts 
created from a human metastatic cholangiocarcinoma cell line.346  180mm3 tumours treated 
with cyclopamine regressed completely in 12 days and remained histologically undetectable 
in mice that by 3 months post-treatment had shown no ill-effects of the cyclopamine 
treatment.  The control animals euthanized at 22 days had tumours averaging 800mm3.  In 
contrast to the constitutional activation of HH signalling caused by mutant PTCH in Gorlin 
syndrome, these tumours are dependent on HH-ligand for growth.  This has been 
demonstrated by the concentration-dependent decrease in tumour growth and luciferase 
activity with the ligand blockade (SHH and IHH) achieved using the 5E1 monoclonal 
antibody.346  Tumour growth was partly rescued with the addition of endogenous SHH. 
1.9.1.2 Colon cancer 
Although the survey of digestive tract tumours by Berman et al failed to establish active HH 
signalling within a panel of 11 cell lines, SHH and IHH mRNA were detected in all cell 
lines, and GLI was present in 4 out of 11.346  Furthermore, Qualtrough et al have shown 
expression of mRNA and protein of SHH, IHH, PTCH, SMO and GLI1 in all five cell lines 
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they tested.359  Of these, the adenoma-derived cell lines (AA/C1 & RG/C2) have higher 
levels of IHH expression than the adenocarcinoma-derived lines (CaCo2, HT29, & SW480), 
but slightly lower levels of PTCH, SMO and GLI.  These observations may reflect the 
evolving role of HH signalling with tumour phenotypic progression.  All these cell lines, 
however, show a dose-dependent response to cyclopamine treatment, with decreased cell 
yield, increased apoptosis, and a decrease in autocrine HH signalling (decreased GLI-
luciferase reporter activity).  This effect is partially rescued with endogenous SHH-N protein.  
Similarly, Oniscu et al demonstrate SHH to have a mitogenic effect on primary murine 
colonocytes that is reversible with cyclopamine.330  Furthermore, these authors were able to 
show increased SHH, PTCH and SMO expression in resected human adenocarcinomas, with 
intermediate levels in dysplastic tissue and benign adenomas.   
 
In a subsequent study published in 2007, Chatel and colleagues concluded that HH signalling 
in inactive in colonc cancer cell lines following a detailed survey in 7 different lines.360  
None of the lines they examined had a full complement of HH signalling components.  No 
HH ligand mRNA was expressed in Colo320 and HCT116 cells, no SMO in Colo205, HT29 
and WiDr cells, no GLI1 in their SW480 cells and no GLI2 or GLI3 in Colo205 and Caco-2 
cells.  In their experience, cyclopamine treatment did not alter PTCH or GLI1 mRNA 
expression. 
 
These data certainly appear conflicting and hard to reconcile with the van den Brink studies 
on IHH in colon cancer.  However, Yauch and colleagues from Genentech have very recently 
published in Nature an extensive series of in vitro and in vivo studies that clarify matters 
substantially.361  In essence, they demonstrated that HH signalling in colonic and pancreatic 
cancer is paracrine, just as Madison and Gumucio had demonstrated in gut development.303  
Their studies are probably conclusive, although they have been met by initial scepticism in 
some quarters.362  The paracrine model clearly demonstrates that ligand driven autonomous 
HH signalling does not occur in colonic or pancreatic cancer.  It remains to be seen whether 
or not these observations also hold for all epithelial-derived tumours and other solid organ 
malignancies.  Whilst they definitely cast into serious doubt the accuracy of a series of high-
profile papers in Nature published between 2003 and 2004,346, 348, 349, 358 Yauch’s paper has 
other important sequelae.  Firstly, it demonstrates the fundamental mechanisms by which HH 
signalling drives colon cancer development and progression.  This has provided the basis for 
a phase II clinical trial of a small molecule HH antagonist produced by Curis Inc. 
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(Cambridge, MA, USA) in advanced colo-rectal cancer (with concurrent chemotherapy and 
Bevacizumab) for which Genentech are currently actively recruiting patients 
(www.clinicaltrials.gov).  Secondly, it demonstres the futility of studying HH signalling in 
cancer cells in isolation, certainly for intestinal lines and quite probably for a number of other 
tissues. 
 
Yauch first studied the effect of a potent small molecule SMO-acting HH antagonist 
(HhAntag) on a large number of cancer cell lines from the colon, pancreas and lung.361  Not 
only was a high concentration of HhAntag required for growth inhibition in these cells (~400 
times higher than in a mesenchymal cell line expressing a GLI luciferase reporter construct), 
but no correlation was observed with markers of HH pathway activation (including GLI1 
expression), strongly suggesting that the observed effect was indirect.  This effect was also 
observed with cyclopamine (also SMO-acting), but not with alternative methods of 
antagonism (forskolin [PKA activation inhibits HH] or 5E1 antibody) (Figure 1-9).  
Importantly, they used mRNA analysis of GLI1 in this study in comparison to the previous 
reports where a GLI luciferase reporter was transfected to monitor pathway activity.   
 
Whilst Yauch had shown no evidence of HH pathway activity in epithelial cells in vitro, RT-
PCR on a panel of colo-rectal, pancreatic and ovarian (but not lung) cancers demonstrated 
significant upregulation of HH ligand.361  The paracrine nature of HH signalling in these 
tumours was first illustrated in a co-culture model.  In this system, epithelial cancer cells 
expressing HH ligand were shown to induce HH pathway activity in fibroblasts (10T1/2 
cells) stably transfected with a GLI reporter construct.  HH pathway activity was 
subsequently assessed in vivo using Ptch-LacZ mice to give an accurate readout of HH 
pathway activity in xenografts.  The stromal compartments of pancreatic xenografts 
demonstrated high levels of β-galactosidase staining but only where the cancer cells were 
known to express high levels of HH ligand.  Separate experiments in xenografts from human 
cancers (surgical biopsies of patients) confirmed using species-specific primer sets that the 
activation of HH pathway activity in tumour stroma was not an artefact of cell culture.  
Therefore, HH ligand in tumour cells activates the pathway in surrounding stroma in a 
paracrine manner.  Finally, it was demonstrated that tumour growth was dependent on 
paracrine activation of HH pathway.  HhAntag induced growth inhibition of pancreatic and 
colonic cancer xenografts was observed and directly related to HH pathway inhibition in the 
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stromal microenvironment.  Canonical HH target genes were unaltered in tumour epithelium 
but down-regulated in stroma, strongly supporting the paracrine model. 
1.9.2 HH and the immune system 
Shh has been shown to be an important regulator of T-cell differentiation at the transitions 
from double negative (DN) 1 to DN2 cells and from DN3 to the double positive (DP) stage, 
as well as in T-cell receptor (TCR) repertoire selection (DP to SP stage).363  Ihh and Shh have 
distinct but overlapping functions in the thymus.  Whereas Shh is secreted by the epithelium, 
Ihh is produced by thymocytes and functions to control thymocyte number by providing 
concentration-dependent feedback on the production of DP cells.364  The Howie lab in 
Edinburgh has shown SHH-mediated signalling to be a physiological component of 
peripheral T lymphocyte responses,365-367 (reviewed in Benson et al, 2004368).  SHH acts to 
modulate CD4+ T cell effector function in man,366 with endogenously produced SHH playing 
a role in sustaining normal CD4+ T cell proliferation.365  This response was enhanced by 
adding exogenous SHH with increased synthesis and secretion of of IL2, IFNγ and IL10 in 
CD3/CD28 activated CD4+ T cells.366  The neutralising 5E1 antibody subsequently reduced 
IL2 and IFNγ expression, but not IL10.  IFNγ has also been shown to induce STAT1-
dependent expression of SHH in medulloblastomas.369 
 
Varas and colleagues recently demonstrated physiological effects of autocrine HH signalling 
on thymic DCs in man.370  They showed expression of PTCH, SMO and GLI1-3 mRNA in 
thymic DCs.  On flow cytometric analysis, 50-60% of DCs expressed SHH protetin.  
Exogenous SHH led to increased expression of BCL2 and BCLXL and increased cell 
survival.  CD40 activation of DCs, which increases HLA-DR, CD86, CD80 and CD83, 
down-regulated SHH and PTCH expression.  Cyclopamine, on the other hand, increased 
apoptosis as well as abrogating the up-regulation of the co-stimulatory molecules as above. 
 
Intriguingly, the pro-inflammatory mediator NFκB appears to upregulate SHH expression. In 
pancreatic cancer, blockade of NFκB was shown to suppress SHH mRNA.371  Furthermore, 
IL1β, TNFα and LPS treatment of pancreatic cancer cells increased levels of SHH as well as 
NFκB, activated HH pathway activity and increased cell proliferation.  NFκB inhibition 
abrogated these effects.  NFκB is also required for the induction of SHH critical in hair 
placode down growth.372  Furthermore, putative NFκB binding motifs have been identified in 
the SHH promoter region (at position +139), p65 binds to the SHH promoter in vivo, and 
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SHH expression is up-regulated on induction of NFκB in vivo in a genetic mouse model of 
inducible NFκB expression.373   
1.9.3 HH signalling and inflammation 
There is increasing evidence to implicate a recapitulation of embryonic HH signalling in 
normal and pathogenic inflammation.  This has been shown in response to several insults, 
including acute epithelial injury in the lung349 and prostate,358 skeletal muscle ischaemia,374 
bone fracture,375 multiple sclerosis / experimental autoimmune encephalomyelitis (MS / 
EAE),376 chronic pancreatitis / pancreatic regeneration,377, 378 liver / biliary injury,379, 380 as 
well as in chronic GI tract inflammation.329  In chronic pancreatitis there is increased IHH, 
PTCH and SMO with expression identified in the cells forming tubular complexes, and in the 
islets (with loss of the punctuate staining pattern seen previously).378  In the lung epithelium 
there is extensive activation of the HH pathway in response to acute airway injury,349 and in 
chronic lung fibrosis.367  Much of the work done in the lung suggests that SHH (like KGF 
and FGF10)381, 382 is involved in repair to epithelial injury, with the primary aim of restoring 
continuity to areas of denuded epithelium, thus minimising input of pathogenic agents across 
this barrier.  In psoriasis, carefully controlled microarray experiments have shown down-
regulation of HH pathway activity,383 contradicting earlier reports where GLI1 protein 
expression was increased,384 and a small uncontrolled ‘proof of concept’ study where 
cyclopamine ‘cleared’ psoriatic skin lesions.385 
1.9.3.1 Liver and biliary injury 
The Diehl laboratory at Duke University (N Carolina USA) has in the past 2 years published  
a series of papers outlining the role of the HH signalling pathway in liver and biliary 
injury.386-392  With respect biliary injury, they first demonstrated that both cholangiocytes and 
fibroblastic cells have active HH pathway signalling in experimental models and patients 
with primary biliary cirrhosis (PBC).389, 391  Subsequently, they showed in a rat model of 
reversible chronic bile duct obstruction that injured cholangiocytes express HH proteins, 
which are also co-expressed with mesenchymal markers in ductular cells in patients with 
PBC.390  In a co-culture model (cholangiocyte and hepatic stellate cell lines) it was shown 
that hepatic stellate cells influence cholangiocyte migratory behaviour via soluble HH protein 
paracrine signalling.390  In Ptch+/- mice (with increased Hh signalling activity), enhanced 
fibrogenesis with increased expression of various mesenchymal markers and Gli2, was 
evidenced in response to bile duct ligation.390  This study suggests that HH has both 
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physiological and pathogenic actions in biliary injury, depending on its relative effects in 
cholangiocytes (as a survival factor) and as a profibrogenic agent.387   
 
In a separate study from the same group, the role of the HH signalling pathway in alcohol 
mediated liver injury was assessed in mice and man.388  The number of Hh-responsive cells 
were increased in mice fed high-fat [HF] diets and ethanol [Etoh] (in progenitor and stromal 
cell populations) and in patients with alcoholic liver disease [ALD] (in immature ductular 
cells).  Fatty liver disease by itself (mice fed HF chow) led to increased expression of Shh, 
Ptch, Gli2 and sFrp1.  The addition of Etoh to this model potentiated the increase in Shh, 
Ptch and Gli2 but not sFrp1.  As predicted by the previous studies, Hh target gene expression 
(Ptch and Gli2) was restricted to rare bile ductular or hepatocytic cells in control mice.  Hh-
responsive cells were increased in HF mice (localised in or around the portal tract), with 
much greater expansion noted in HF + Etoh animals.  The Hh-responsive ductular type 
progenitors expanded in HF + Etoh mice expressed high levels of TGFβ1.  Subsequent in 
vitro experiments demonstrated that TGFβ1 promoted the survival of Hh-responsive 
immature liver cells, whilst increasing the production of Hh ligand (Ihh mRNA and protein, 
but not Hh target genes) in surviving mature hepatocytes undergoing epithelial-mesenchymal 
transition.  On parallel analysis of liver biopsies specimens from patients with ALD, 
expansion of liver cell populations expressing PTCH and GLI2 were identified.  GLI2 
expression was co-localised with α-smooth muscle actin and vimentin in ductular structures 
and the epithelial progenitor marker CK7.  Interestingly, there was close correlation between 
GLI2/CK7 expressing liver progenitors and Maddrey discriminant function (cut-off 32) (r2 = 
0.71). 
1.9.3.2 Multiple sclerosis / EAE 
The Gli1 expression data in the EAE model of MS is interesting.376  Whilst Shh and Gli1 
were increased during early inflammatory stages in EAE, Gli1 was subsequently decreased in 
spinal cord oligodendrocyte precursor cells in the chronic phases.   GLI1 expression in MS 
lesions mirrored this with high levels in acutely active lesions but low levels in chronic active 
and quiescent lesions.376  These effects were predominantly downstream of IFNγ.  These data 
demonstrate paradoxical regulation of HH signalling during different phases of 
demyelination in man and mouse. 
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1.9.3.3 Chronic GI tract inflammation 
Preliminary findings from Nielson and co-workers suggest that SHH may be  upregulated in 
areas of chronic gastrointestinal inflammation.329  This was shown by immunohistochemistry 
and in situ hybridization in Barrett’s oesophagus, gastritis, CD and UC.  While not 
quantitative, their findings show that during chronic inflammation mRNA expression was 
strong throughout the epithelium from base to lumen, with loss of the crypt-villous pattern 
normally identified in normal intestinal tissues.  They also report increased SHH protein 
expression, although this is not readily evident in the published photographs.  PTCH mRNA 
and protein was expressed in metaplastic and regenerating epithelial cells and in the crypts, 
but not in the inflamed colonic surface epithelium.  Inflammatory cells in inflamed mucosa 
stained for SHH and PTCH protein and mRNA.  The extension of SHH mRNA from crypt 
base to include luminal epithelium, may represent either expansion of the stem cell 
compartment or delayed differentiation. 
1.9.3.4 HH, chronic inflammation and cancer 
Could HH signalling play a role in cancers arising in areas of chronic inflammation?  Beachy 
and colleagues hypothesize that these cancers represent the continuous operation of an 
upregulated state of tissue repair associated with chronic activation of pathways such as HH 
and WNT.393  This is compatible with the probability that increasing cellular resistance to 
injury and death creates an epithelium populated by genetically damaged cells.  Additionally, 
the persistence of stem cells or the abnormal distribution of SHH may contribute to the 
malignant transformation.  Clinically relevant scenarios where present data suggest that HH 
could play such a role include hepatomas, cholangiocarcinomas and pancreatic neoplasms 
arising on a background of cirrhosis, primary sclerosing cholangitis and chronic pancreatitis 
respectively. However, as will be shown in this thesis, the situation is rather different in 
colonic inflammation, and an alternative model will be argued for colonic cancer resulting 
from chronic active UC. 
1.10 WNT signalling pathway 
The fly Wingless (Wg) gene, homologous to mammalian WNTs, was originally described by 
Nusslein-Volhard and Wieschaus in the same seminal segment polarity study that led to the 
discovery of Hh.271  The first mammalian gene homologous to Wg, Integrase-1 (Int1), was 
subsequently identified by Nusse and Varmus in 1982.394  The term WNT was originally 
coined by combining Wingless and Integrase.395  The WNT signalling pathway consists of a 
family of small secreted WNT proteins present in all animal genomes (~20 in mammals).  
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They are involved in virtually all aspects of embryonic development (notably establishment 
of the dorsal axis), homeostatic self-renewal, and disease pathogenesis (frequently via 
germline and / or somatic mutation of critical pathway components).396  Like HH, they are 
morphogens.397  3 different modalities of WNT signalling are described: canonical WNT/β-
catenin, non-canonical planar cell polarity (PCP) and WNT/Ca2+ signalling.  All discussion 
from here on refers to the former which is detailed in the schematic presented in Figure 1-10.   
 
WNT signals activate transcriptional programs via a raft of different WNT/TCF target genes 
depending on the developmental identity of the responding cell (i.e. cell specific).  As such, 
disparate events – cell proliferation, fate determination or terminal differentiation – can be 
activated by WNT within the same organ (e.g. intestine or hair follicle).  Like HH, WNT 
target genes include both positive and negative regulators of the pathway (including FZD, 
LRP, HSPG, AXIN2 and TCF/LEF). 
 
In the GI tract, WNT is the dominant force in controlling cell fate along the crypt-villus axis.  
WNT proteins are expressed by crypt epithelial cells, rather than in the surrounding 
mesenchyme.398  They are pro-mitogenic to crypt progenitors and promote terminal 
differentiation of Paneth cells.399  Tcf4-/- mice have absent crypt progenitor compartments, 
whilst maintaining normally differentiated epithelium.400  Transgenic overexpression of the 
WNT inhibitor Dkk1 results in complete absence of crypts.401 
 
The WNT signalling pathway has recently been shown to have multiple and varied roles in 
immunology, from self-renewal of haematopoietic stem cells, to T and B cell development, 
DC maturation, peripheral T-cell activation, and the induction/maintenance of a regulatory 
immune response.402  In the thymus, WNTs regulate the survival of both DN and DP T cells, 
as well as promoting T cell development at various points in between.  In the periphery, 
naïve T cells continue to express LEF1, TCF1 and FZD (in a dynamic fashion reflecting the 
activation status of the cell), and there is active WNT signalling in mature splenic 
lymphocytes.403  Furthermore, TREGS with constitutively active WNT signalling 
(overexpression of stabilised β-catenin) demonstrate increased survival with the ability to 
induce an anergic phenotype in CD4+CD25- effector T cells.404  Finally, WNTs from 
endothelial cells signal to activated T cells to synthesis and secrete MMPs and aid 
extravasation into sites of tissue injury / inflammation.  Blockade of WNT signalling (by 
FZD5) decreases T cell migration. 
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Myeloid DCs and macrophages, but not lymphocytes, stimulated with TLR ligands (LPS and 
Pam3CSK4) or IL4 induced WNT5A expression in a NFκB dependent manner.405, 406  In 
response to infection, WNT5A (and FZD5) led to the generation of IFNγ-producing T cells 
by inhibiting IL12 production.405 
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PHENOTYPE Genotype 
Lethality GI defects 
Shh-/-  298, 299, 
304 
General: Body size 30% of WT; small, malrotated GI tract. 
Foregut:  EA/TEF with severe lung hypoplasia. 
Stomach:  Hyperplastic gastric epithelium, increased number of glucagon-
positive cells. 
Small intestine:  Decreased smooth muscle thickness; overgrowth of 
duodenal villi. 
Pancreas: Annular; increased size and endocrine cell number. 
Lower GI:  Imperforate anus. 
ENS: Abnormal differentiation of neurons under epithelium, with migration 
into villi. 







death General:  Body size 67% of WT; small, malrotated GI tract. 
Pancreas:  Annular pancreas. 
Lower GI:  Dilated segments resemble Hirschprung’s. 
ENS:  Microscopic absence of neurons, corresponding to dilated segments of 
SI and colon. 
Shh-/-/Ihh-/- 299 Die:  E8.0  
Ipf1/Pdx1-
Shh † 407 
Viable Pancreas:  Disrupted morphogenesis; pancreatic mesoderm develops into 
intestinal mesenchyme. 
Ptch1-/- 304, 408 Die: E9-10.5 Pancreas:  Pdx1, glucagon absent from pancreas at E9.5. 
Ptch1+/- 304 Viable Pancreas:  Males have impaired glucose-tolerance. 
Hhip-/- 290, 291 Post-natal 
death  
Pancreas:  Impaired morphogenesis, islet formation and endocrine cell 
proliferation (enhanced effect in HIP-/-;Ptc+/- that die before E13); small 
deformed spleen. 




Viable Small intestine:  Flattened hyperproliferative epithelium; mislocalized 
ISEMFs; ectopic precrypt structures 
Gli1-/- Viable No obvious defects phenotypically* 
Gli2-/- 320 Peri-natal 
death 
Foregut:  Hypoplastic esophagus, with no development of smooth muscle and 
small lumen. 
Hindgut:  Imperforate anus with recto-urethral fistula. 
Gli3-/- 311  Hindgut:  Anal stenosis. 
Gli2+/-/Gli3+/- 
311, 320 




Peri-natal. Foregut:  EA/TEF 
Hindgut:  Persistent cloaca, less severe than double knockout 
Gli-2-/-/Gli-3-/- 
311, 320  
Die: 
E10.5-E13.5 
Foregut:  Endoderm does not develop into oesophagus, trachea and lungs. 
Small hepatic and pancreatic buds. 
Hindgut:  Persistent cloaca, same severity as Shh-/- 
 
Table 1-2  Summary of Hh signalling component knockout and transgenic phenotypes. 
Note the similarity between the phenotypes of Shh-/-, Gli2-/- and Gli3-/- mice, with the severest defects 
demonstrated in the Gli2/Gli3 double ko.  † In the Ipf1/Pdx1-Shh mouse Shh is selectively expressed in 
developing pancreatic epithelium.  ‡ The villin-Hhip mouse puts the pan-Hh inhibitor HIP under the control of 
the intestinal specific villin promoter.  In this manner, only intestinal Hh signals are blocked from mid-gestation 
onwards, allowing viability post-natally.  *The Gli1 null mutant is the only mouse with deletion of a major 
hedgehog family gene that appears to develop normally.  However, the published data do not extend to a 
detailed analysis of the intestines of these mice.  Our collaborators at Ann Arbor have pilot data indicating an 
increased basal level of inflammation in the intestines of these mice as they age (Zacharias, Gummucio 
unpublished data), but as discussed in chapter 4 it may be only in response to injury / inflammation that the 
apparent redundancy in Gli1 signalling is lost.  EA/TEF: Oesophageal atresia / tracheo-oesophageal fistula.  
ISEMFs: intestinal subepithelial myofibroblasts. WT: wild-type. 
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Figure 1-1  Therapeutic ‘pyramid’ in IBD. 
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Figure 1-2 Resolution of non-small cell lung cancer on withdrawal of anti-TNF therapy. 
A) CT coronal reformat from June 2006 (whilst the patient was on anti-TNF therapy) of the primary lung 
tumour in the right lower lobe (solid white arrow, left panel). The middle panel shows the mediastinal lymph 
node enlargement (hollow white arrows) on the same CR scan.  Endoscopic ultrasound from July 2006 shows 
mediastinal lymph node enlargement (right panel).  B) CT-guided core biopsy of the primary tumour 
demonstrates classical features of non-small cell lung cancer on haematoxylin and eosin staining (left panel, 
original magnification x200), and TNFR1 (middle panel) and TNFR2 (right panel) positivity on 
immunostaining. Endoscopic ultrasound core biopsy of the mediastinal lymph nodes showed necrotic debris 
consistent with necrotic tumour within malignant lymph nodes (not shown).  C)  Representative CT images are 
shown before (June 2006, left panel) and after withdrawal of adalimumab therapy (April 2007, middle panel 
and July 2007, right panel) demonstrating no measurable disease at the site of the primary lung tumour (solid 








Figure 1-3 Model of IBD pathogenesis. 
UC and CD can be thought of as overlapping syndromes sharing some phenotypes, and additionally sharing 
some genetic and environmental susceptibility and modifying stimuli. However, some phenotypic features and 
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Figure 1-4 IBD Genetics Map. 
Susceptibility loci (IBD1-9), confirmed and replicated by linkage analysis, candidate genes (including GLI1 and CCL20) and IBD susceptibility genes / loci identified by 
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Figure 1-5 Population heterogeneity of IBD susceptibility genes: NOD2 and CCL20. 
Allelic frequencies of NOD2 frameshift mutation (Leu1007fsincC/rs2066847) [white boxes] and CCL20 promoter polymorphism [blue circles] in Western Europe and the far 
East.  Of particular note is the North – South gradient of increasing frequency of NOD2 frameshift mutation in Europe, and the absence of all CD-associated NOD2 mutations 
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Figure 1-6 The IBD2 locus on chromosome 12q13. 
The position of associated micro-satellite markers and various candidate genes, including GLI1, are demonstrated on this schematic of IBD2. 
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Figure 1-7 Mechanisms of autophagy. 
The majority of upstream regulation of autophagy is through the mTOR, and subsequently the autophagy-related proteins (including ATG16L1), the class III PI3K VPS34, 
and beclin 1. In the steady-state and with a plentiful supply of amino acids, VPS34 activates mTOR with subsequent inhibition of autophagy. Under starvation conditions, 
mTOR inhibition leads to activation of the autophagy cascade to provide an alternative energy source by recycling intracellular organelles. The autophagy cascade may also 
be activated by damaged cellular products (e.g. mitochondria) and intracellular pathogens, thus avoiding apoptosis. Intracellular organelles or pathogens are enclosed into an 
autophagosome. This forms from a double-layered membrane called a phagophore (formed out of various large molecules in the cytoplasm) that elongates to surround the 
pathogen before closing in on itself. This elongation step is controlled by two protein (and lipid) conjugation systems: the ATG12 and the LC3 pathways. The formed 
autophagosome then fuses with a lysosome (forming an autophagolysosome). Lysosomal enzymes first cut through the inner membrane of the autophagosome and then break 
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Figure 1-8  The role of the HH signalling pathway in GI tract development, homeostasis and disease 
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Figure 1-9 Schematic of hedgehog (HH) signalling pathway.  
Fully processed HH protein is manufactured in the Golgi apparatus and released via the transmembrane protein dispatched (DISP1) (dotted green arrow).  On binding to the 
HH receptor patched (PTCH), the inhibition of PTCH on another transmembrane protein smoothened (SMO) is released.  Subsequent signalling occurs via the 3 zinc-
fingered nuclear transcription factors (GLI1, GLI2 and GLI3).  GLI2 and GLI3 exist in both repressor and activator forms.  When the pathway is activated by HH binding to 
PTCH, GLI1 shuttles from the cytoplasm to the nucleus (indicated by dotted green arrow), whereupon transcription is activated in a raft of downstream targets.  These 
include positive and negative regulatory pathway components (GLI1, PTCH and hedgehog-interacting protein (HHIP)). HH pathway agonists and antagonists are indicated 
(white text in black boxes) including the small molecule agonists and antogonists under development by Curis, Inc. 
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Figure 1-10  Canonical WNT signalling pathway. 
In the absence of WNT ligand (left panel), β-catenin is targeted for proteosomal degradation via phosphorylation; this process is mediated via a dedicated destruction 
complex consisting adenomatous polyposis coli (APC), casein kinase I (CKI), glycogen synthase kinase 3 (GSK3) and axin.  When WNT binds to the transmembrane 
receptors frizzled and low-density lipoprotein receptor-related protein (LRP) (right panel), the pathway is activated.  β-catenin is stabilised, levels rise, it translocates to the 













































2 Rationale, hypothesis and aims 
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2.1 Rationale 
As detailed throughout Chapter 1, multiple strands of evidence support a role for the 
HH signalling pathway in the pathogenesis of IBD (Table 2-1).  This pathway is 
critical to normal gastrointestinal development,270 as well as enterocyte and Paneth 
cell differentiation.318, 332  Chronic injury, inflammation and repair are critical aspects 
of IBD, and thus it is pertinent that the HH pathway is centrally involved in these 
processes in several other tissues, including muscle,374 bone,409 liver,388-391 and 
lung.349, 367  Indeed, HH signalling may play a central role in the inflammatory 
response since SHH is critical for T lymphocyte development,410 adult human CD4+ 
T cell activation,365, 366 and myeloid cell maturation in the spleen.370  Furthermore, 
SHH has recently been suggested to be a direct transcriptional target of NFκB.373  
Dysregulation of components of the HH pathway has also been noted in inflammatory 
diseases of the gut, including Barrett’s esophagus, chronic gastritis and IBD.329  Of 
great interest, there are two GLI consensus motifs upstream of the NOD2 gene.411  
Furthermore, an alternative splice variant of the NOD2-interacting Centaurin beta-1 
(CENTB1) protein412 is KCTD11 (REN), a negative regulator of the HH pathway that 
prohibits GLI1 nuclear translocation.413  In addition, there exists a large Ashkenazi 
pedigree that has a high degree of overlap between basal cell naevus syndrome (MIM 
109400; cause by truncating mutations of the HH receptor, PTCH) and IBD,414, 415 and 
an isolated case report of a 14 year old Japanese patient with the same syndrome who 
also developed early-onset UC.416 
 
WNT and HH are both secreted morphogens with roles in developmental processes 
including cell-fate specification and progenitor cell differentiation.  Physiological and 
pathological links between the HH and WNT signalling pathways have been 
established in the GI tract and other tissues.  Both pathways play critical roles in the 
healthy development of the intestine.  In villin-Hhip mice, where Hh is inhibited in 
the intestine, cytoplasmic and nuclear β-catenin is noted in the intervillus epithelial 
cells, compared with low levels of membrane associated expression in WT villus 
tips.303  WNT/Tcf4 target gene expression is also increased.  In colonic epithelial cell 
differentiation and in colo-rectal cancer pathogenesis, IHH - GLI1 signalling has been 
shown to antagonise the WNT pathway.318, 417  A similar phenomenon has been 
observed in skin, hair follicles and BCC.418  There is a conserved GLI1 binding site in 
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sFRP1,419 and sFRP1 expression in murine fibroblasts in dependent on GLI1 and 
GLI2.420  Furthermore, it has been shown in gastric cancer cell lines (SIIA) that the 
HH antagonist cyclopamine leads to WNT1-mediated β-catenin accumulation in the 
cytosol.  
 
The WNT signalling intestinal expression signature has been described in full 
allowing for a detailed, targeted assessment of this pathway in IBD.398  Recent reports 
have described reduced WNT/TCF4, a known regulator of Paneth cell differentiation, 
in ileal CD with a direct and functional correlation to α-defensin levels.399, 421  
 
With the advent of GWAS and their successful application now to both CD and UC, a 
more reliable and detailed understanding of the genetic architecture of IBD is 
unfolding (see 1.5).  However, the 32 CD susceptibility genes / loci identified in the 
meta-analysis only accounts for about 20% of the genetic contribution to disease 
pathogenesis (see 1.5.3).  Therefore, there remains a role for alternative approaches to 
identifying candidate susceptibility genes in IBD. 
2.2 Hypothesis 
On this background, the initial working hypothesis was that the HH signalling 
pathway plays a critical role in the pathogenesis of IBD.  Furthermore, the genomic 
location of the GLI1 gene within IBD2 led to the supplementary hypothesis that 
inherited variation in GLI1 is associated with the development of IBD.   
2.3 Specific Aims 
1. To describe the expression of HH signalling components by 
immunohistochemistry, RT-PCR and microarray analysis in the healthy adult 
human colon (Chapter 4). 
2. To determine whether the expression of HH ligands (SHH and IHH) and pathway 
response elements (GLI1, PTCH, HHIP) are dysregulated in intestinal tissue from 
IBD patients compared with healthy adult controls (Chapter 4). 
3. To describe the expression patterns of all WNT pathway genes with documented 
intestinal expression in healthy intestine and IBD (Chapter 4). 
4. To analyse the contribution of germ-line variation in GLI1, a key transcriptional 
regulator of HH signalling, to disease susceptibility in a large Scottish cohort of 
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UC and CD patients, with replication in 2 independent N European populations 
and 1 from the Far East (Chapter 5). 
5. To assess the contribution of germ-line variation in GLI1, dysregulated in colon 
cancer, to the inherited susceptibility of early-onset colo-rectal cancer (Chapter 
6). 
6. To determine whether germ-line variation in IHH, down-regulated in UC 
(irrespective of inflammation), is associated with IBD pathogenesis (Chapter 7). 
7. To analyse WTCCC GWAS and meta-analysis data for association of all HH and 
WNT pathway genes with CD (Chapter 8). 
8. To analyse the effect of PAMPs (LPS and MDP) on HH pathway activity in 
colonic epithelial cells in vitro (Chapter 9). 
9. To assess the effect of HH agonists / antagonists on NFκB signalling and cytokine 
synthesis and secretion in colonic epithelial cells and PBMCs from patients with 
acute severe UC in vitro (Chapter 9). 
10. To assess the contribution of promoter polymorphisms in CCL20, a key pro-
inflammatory cytokine that is downstream of HH (demonstrated in 9), to disease 
susceptibility in N European and Far Eastern populations with UC (Chapter 10). 
11. To further assess the contribution of genetic variation in NKX2.3 to adult and 
early-onset IBD (Chapter 11).  This homeobox gene, critical to normal GI tract 
development, is a target of HH and was identified as a CD susceptibility gene in 
the WTCCC GWAS.  
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Hh pathway is critical to normal gut development 299, 303 
Present in normal adult GI tract with gradients mirroring increasing bacterial 
burden and clinical distribution of UC (Chapter 4) 
Role in enterocyte and Paneth cell differentiation318, 332 
Recapitulation of embryonic signalling in response to injury: 
– skeletal muscle ischaemia374 
– liver388-391 
– acute pulmonary epithelial injury349 
– prostate epithelial regeneration358 
Essential mediator of progenitor T cell differentiation410 and myeloid cell maturation in 
the spleen.370 
Physiological role in human peripheral CD4+ T lymphocytes, increasing the 
proliferative index and altering cytokine profiles.365, 366, 368, 422 
FOXP3 is a predicted HH-GLI1 target gene.411 
IFNγ activates SHH expression in the brain369 
SHH is a direct transcriptional target of NFκB,373 and is downstream of NFκB in 
epidermal keratinocytes and the pancreas371, 372 
Two GLI1 consensus sequences identified upstream of NOD2 gene.  NOD2 
expression levels in healthy colon correlate closely with HH pathway activity 
(GLI1 expression) (Chapter 4). 
Large Ashkenazi pedigree that has a high degree of overlap between basal cell naevus 
syndrome (MIM 109400; caused by truncating mutations of the HH receptor, PTCH) 
and IBD;414, 415 case reports of mutated HH signalling components and UC 416 
GLI1 is located in the IBD2 locus (OMIM 601458; spanning 25 Mb on chromosome 
12q13),98, 99 most strongly implicated in UC.97, 98 
HH response elements (GLI1, PTCH and HHIP) are decreased in UC (Chapter 4) 
GLI1 variation is associated with UC, specifically a transactivationally defective 
non-synonymous SNP in a highly conserved domain of exon 12 near a known 
activation domain (Chapter 5) 
Gli1+/LacZ mice develop early, severe colitis with high mortality when stressed with 
DSS.  Lamina propria myeloid cells are direct targets of HH in reponse to this 
acute inflammatory challenge (Lees, Zacharias et al, PLoS Med 2008).423 
 
Table 2-1  Summary of evidence implicating HH signalling in IBD. 
The evidence compiled from published literature and data generated within this thesis (bold text) is 
summarised. 
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3.1 Definitions 
The diagnosis of IBD, and specifically UC or CD, was made on the basis of Lennard-
Jones criteria.424  This seminal classification originated from St Mark’s Hospital, 
London in 1989 and remains in widespread use both clinically and for research 
purposes.  Essentially, the system first details alternative causes for bowel 
inflammation (including infection, ischaemia and trauma) that must be excluded prior 
to establishing a positive diagnosis of IBD.  The diagnosis of UC or CD is then made 
on the basis of macroscopic (from clinical and endoscopic features, imaging and 
inspection of surgical resection specimens) and microscopic (analsysed by an expert 
histopathologist) changes.  In his original classification, Lennard-Jones did not allow 
for indeterminate IBD to be diagnosed.  Later systems designed to classify IBD 
phenotype primarily for research purposes (e.g. Vienna and Montreal)425, 426 allow for 
this.  The Montreal classification system, detailed below (3.5.2), is used for 
phenotyping throughout the clinical studies presented here.426 
3.2 Ethical approval  
Written, informed consent was obtained from all patients and controls.  The study 
protocol was approved by the Lothian Research and Ethics Committee (LREC-
2000/4/192 and 2004/S1103/22); Cambridge (LREC-01/418; MREC-03/5/012) and 
Regional Ethics Committee, Karolinska Institutet.  
3.3 Patients for expression studies 
3.3.1 Patients for immunohistochemistry 
Suitable cases were identified retrospectively (2000-2005) from the archives of the 
Department of Pathology, WGH, Edinburgh.  Samples were taken at endoscopy and 
surgery for CD (n=22) and UC (n=17), with colonic location clearly established by 
the endoscopist.  Where accurate location could not be established, the sample was 
excluded.  Healthy controls (HC) (n=16) were taken from patients with normal 
histology following colonoscopy for investigation of diarrhoea (full colonoscopic 
series, n=6), and following surgery for non-inflammatory, non-ischaemic obstruction 
(n=4).  Patients were initially consented retrospectively for permission to use 
historical pathology specimens for research.  Subsequently a new system was 
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developed, such that all patients recruited onto the IBD genetics database were all 
asked if they would consent for use of historical and future pathology specimens.  
After selection of cases, samples numbers were provided to the pathology department 
who retrieved wax blocks and cut samples ‘in-house’ so as to retain wax blocks in the 
central pathology stores (located at NRIE, Edinburgh) for future use.  All histological 
slides were reviewed by a consultant gastrointestinal pathologist (J Loane), and used 
for immunohistochemistry as early as possible after cutting (maximum 3 months) to 
avoid excess degradation of protein epitopes once exposed to air. 
3.3.2 Patients for microarray 
The cohort of patients used in the microarray studies consisted of 67 patients with 
UC, 53 with CD and 31 HC all undergoing colonoscopy ± ileoscopy at WGH, 
Edinburgh (Table 3-1).  Mucosal biopsies from specified anatomical locations 
(terminal ileum, caecum, ascending colon, transverse colon, descending colon, 
sigmoid colon and rectum; location determined by operator experience, distance from 
insertion and colonoscope configuration on a Scope GuideTM) were immediately flash 
frozen in liquid nitrogen before storage at -80°C.  Inflammatory status was graded 
(inflamed or non-inflamed) on paired biopsies, formalin-fixed and stained with 
haematoxylin and eosin for histological analysis of lamina propria inflammatory cell 
infiltrate, by an experienced gastrointestinal pathologist.   
 
For UC patients, 8 were recruited at diagnosis (treatment naïve), 18 had active disease 
and 41 quiescent disease; 10 were on systemic corticosteroid therapy, 11 on 
immunosuppressants (AZA, MP or MTX) and 40 on 5-ASA therapy (Table 3-1).  
4/53 patients with CD were on corticosteroids, 13/53 on immunosuppressants and 
21/53 on a 5-ASA.  8/31 HC had non-IBD inflammation: 2 scattered lymphoid 
aggregates with history of gastroenteritis, 2 microscopic colitis, 1 pseudomembranous 
colitis, 1 diverticulitis, 1 amoebiasis and 1 eosinophilic infiltrate.   
3.4 Expression studies on human intestinal tissue 
3.4.1 General immunohistochemistry protocol 
3μm sections from formalin-fixed, paraffin-embedded samples were cut onto 
Superfrost Plus slides (BDH laboratory supplies), dewaxed in xylene and rehydrated 
in graded alcohols.  Antigen retrieval was performed in unmasking solution (H-3300, 
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Vector Labs, Burlingame, CA) at 1000W for 15 minutes, and sections were cooled in 
running tap water for 20 minutes.  To enhance antibody-binding specificity and 
decrease non-specific background staining several blocking steps were employed.  
Endogenous peroxidase activity was blocked with 2% hydrogen peroxide (H202) for 
15 minutes, endogenous avidin and biotin was blocked for 10 minutes (Avidin/Biotin 
Blocking Kit, SP-2001, Vector Labs), and non-specific antibody-binding was blocked 
with a commercially available serum-free protein block for 10 minutes (X0909, 
DakoCytomation, Denmark).  All antibodies were diluted in DAKO diluent.  
Following H202 treatment, slides were loaded into Sequenza™ (Thermo Shandon) 
immuno-staining chambers.  In between all steps, except following application of 
protein block, slides were washed twice with PBS.  Sections were incubated with goat 
polyclonal primary antibodies overnight at 4°C, and mouse monoclonal antibodies for 
30-60 minutes at room temperature (RT).  Prior to addition of secondary antibody, 
slides incubated at 4°C overnight were allowed to come to RT on the laboratory 
bench.  Biotinylated secondary antibodies were applied at RT for 30 minutes, 
followed by avidin-biotin complex for a further 30 minutes (Vector R.T.U. Vectastain 
Elite ABC Reagent, PK-7100; Vectastain ABC Kit Alkaline Phosphatase Standard, 
AK-5000).  Substrate was visualised with diaminobenzidine (Liquid DAB+, DAKO), 
developed for 5 minutes to reveal a brown precipitate under light microscopy.  
Finally, samples were washed in PBS, transferred to a staining rack, counterstained 
with Harris’ haematoxylin (15 seconds), ‘blued’ in tap water, dehydrated through 
serial alcohols and xylene (x2) before mounting coverslips with DPX glue (Sigma).  
Negative controls were included for all samples with omission of primary antibody.   
3.4.2 Dual immunofluorescence and con-focal microscopy 
For double immunofluorescent staining, antigen retrieval was performed as above, 
and 2% H202 and protein block were applied.  Both primary antibodies (diluted in 
PBS) were applied on their own with both secondary antibodies, in first and second 
positions sequentially, and with PBS as a negative control.  All washing steps were in 
Tris-buffered saline (TBS).  Secondary antibodies were applied for 2 hours at RT.  
TO-PRO-3 (Molecular Probes, Invitrogen) was applied for 10 minutes as a nuclear 
counter-stain, slides were washed in de-ionised water and mounted in Mowiol 
medium (gift from Anne Grant, MRC CIR, University of Edinburgh).  Digital images 
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were captured on a Leica confocal laser scanning microscope with assistance from 
Linda Sharp (IMPACT facility, University of Edinburgh).   
3.4.3 Primary and secondary antibodies for immunohistochemistry 
All antibodies were optimised prior to use by running serial dilutions on slides from 
tissues with known expression.  SHH and PTCH were optimised on rat lung, IHH on 
human kidney, GLI1-3 and CD56 on human glioblastoma, and immune stains on 
murine spleen and human tonsil.  Primary antibodies used were anti-SHH (N-19; 1:30 
*see note below), anti-IHH (C-15; 1:25), anti-PTCH (C-20; 1:30), anti-HHIP (M-17; 
1:400) (all goat polyclonal antibodies from Santa Cruz Biotechnology, California, 
USA), anti-GLI1 (ab7523-50; 1:400), anti-GLI2 (ab7181; 1:1000), anti-GLI3 
(ab6050; 1:1000) (all rabbit polyclonal antibodies from Abcam, Cambridge, UK); 
anti-CD3 (clone F7.2.38; 1:20; DAKO), anti-CD4 (clone 4B12; Vector; VP-C319), 
anti-CD8, anti-CD20 (M755; 1:50; DAKO), anti-CD56 (MCA1814T; Serotec), anti-
CD68 (clone PG-M1, 1:100; DAKO), anti-p65 (SC370; Santa-Cruz), and anti-
chromogranin A (clone DAK-A3, DAKO; 1:200).  Secondary antibodies used were 
rabbit anti-goat (1:400), rabbit anti-mouse (1:200), and donkey anti-rabbit (1:300) (all 
DAKO) for DAB, and donkey anti-goat (588) Alexa Fluor and rabbit anti-mouse 
(488) Alexa Fluor (both Molecular Probes) for immunofluoresence. 
3.4.3.1 SHH immunohistochemistry 
Using the N-19 antibody at a dilution of 1:250 SHH was not detectable in the caecum, 
ascending colon, transverse or descending colon, whilst maintaining a strong signal in 
the sigmoid colon and rectum (data not shown).  The precise anatomical locations 
studied may explain the differences in this data compared with the original published 
study, which did not specify colonic location of samples.327, 427  Utilising various 
commercial blocking agents described above, N-19 was used at a 1:30 titre, detecting 
low levels of expression, without non-specific background staining.  At this 
concentration, SHH protein was detectable in the proximal colon, albeit with a much 
lower signal compared with the rectum within the same individual colonoscopic series 
(Figure 4-3).  SHH expression was blocked following pre-incubation (overnight at 
4°C) with 5x blocking peptide (sc-1194P); no signal was detected with omission of 
the primary antibody (Figure 3-1).  However the close homology between SHH and 
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IHH amino acid sequences means that the probability that N-19 is also detecting IHH 
protein cannot be excluded. 
3.4.4 RT-PCR 
Q-PCR on human intestinal tissue (microarray cohort) was performed by Jenine 
Cornelius (Genentech, Inc.) in close collaboration, after unsuccessful attempts to 
complete a Materials Transfer Agreement to transfer the cDNA back to Edinburgh for 
further analysis.  One RNA amplification cycle was carried out using the 
MessageAmp™ II aRNA Amplification Kit protocol (Ambion technologies, Austin, 
TX).  The amplified cRNA was purified using the RNeasy Mini Kit protocol (Qiagen) 
and 1 µl of amplified cRNA was quantified using the NanoDrop ND-1000 
Spectrophotometer.  RT-PCR was then performed on 50ng of RNA using Stratagene 
model MX4000 (La Jolla, Ca, USA).  The primers and probes were designed in 
conjunction with JC using Primer3 software (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi) and are as follows:  SHH forward 
cgcagctgctctaccaaata; SHH reverse ggcttcagctggacttgac; SHH probe 
tcctggacagcgaggccctg; IHH forward cttcagcgatgtgctcattt; IHH reverse 
ctgagtctcgatgacctgga; IHH probe tactggaccgcgagccccac. 
3.4.5 Microarray methodology 
The full details of the microarray methods are described in Noble, Cornelius, Abbas, 
Lees et al, GUT 2008.428  Briefly, 750ng of the test sample labelled with Cy-5 and 
750ng of Agilent universal human reference labelled with Cy-3 were fragmented for 
30 minutes at 60°C and then loaded onto Agilent whole human genome oligo 
microarray chips G4112A (Agilent technologies, Palo Alto, CA).  The samples were 
hybridized for 18 hours at 60°C with constant rotation. Slides were washed and dried 
using the Agilent stabilization and drying solution protocol (Agilent technologies), 
and scanned using the Agilent G2505B model (Agilent Technologies). Expression 
signals were calculated using the Agilent feature extraction software (version 7.5, 
Agilent Technologies). The distribution of log intensities for each sample were plotted 
and outlying samples (greater than 2 standard deviations from the mean) were 
excluded from analysis. 
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3.4.6 Microarray data analysis 
Raw microarray data was provided by Alex Abbas (Genentech, Inc.) as 3 Excel 
spreedsheets (UC, CD and HC).  Each Agilent probe was listed with Agilent universal 
reference value given for every sample.  The Agilent universal reference describes the 
value of expression for each sample relative to an arbitrary reference value set by 
Agilent.  As a crude measure, values of <1.0 indicate low levels of expression; 
however, this is poorly characterised for many of the probes in the genechip dataset.  
Importantly, it provides a standard reference point for each probe by which expression 
changes can be measured.  Agilent probe IDs for genes of interest were selected from 
Ensembl (www.ensembl.org). The raw microarray data for each probe of interest was 
then copied into a separate Excel spreadsheet and transformed into a workable format, 
for transfer into GraphPad Prism 4.04 (GraphPad Software Inc., San Diego, USA).   
 
Expression profiles were first plotted for all probes in non-inflamed (N-I) HC samples 
to establish the presence or absence of differential expression along the length of the 
healthy human colon.  Where no significant gradient (Kruskall-Wallis test) was 
evident the whole dataset was used for analysis of UC vs. HC and CD vs. HC (Mann-
Whitney U test).  Where expression gradients were present, this analysis was 
performed in samples from the sigmoid colon only (standardised for all datasets; most 
frequent sampling point). For CD, analysis was also performed in terminal ileal tissue.  
All IBD analyses were compared against N-I HC samples from the same location.  
Finally, comparison was made between I and N-I HC samples from the same 
sampling point.  All datasets were plotted against the Agilent universal reference as 
individual datapoints with medians represented by horizontal lines.   
3.5 Patients for genetics studies 
3.5.1 DNA extraction and storage 
DNA was extracted from whole blood (collected in 10ml EDTA tubes) ‘in-house’ by 
a modified salting-out technique.429  40mls of red cell lysis buffer (RCLB) was added 
to 10mls whole blood in a 50ml conical tube and re-suspended for 5 minutes.  After 
centrifuging for 10 minutes at 3000rpm the supernatant was removed.  The resulting 
pellet was re-suspended in 40mls RCLB and centrifuged for a futher 5 minutes.  The 
pellet was resuspended in 3mls nuclear lysis buffer and sodium dodecyl sulphate, plus 
1ml of 6M NaCl and 3mls chloroform before thorough mixing and centrifuging for 20 
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minutes.  The middle layer of the resulting solution was removed by pipette and 
added to 20mls of 100% ethanol.  The precipitated DNA was dried at RT for 5 
minutes, re-suspended in 0.5mls TE at 4°C.  The DNA was quantified, the stock 
stored at -80°C and working solutions stored at 100ng/ml at 4°C. 
 
Recently, the DNA extraction procedure has been out-sourced to the MRC Human 
Genetics Unit.  Storage of stock has also been transferred to the Wellcome Trust 
Clinical Research Facility (WTCRF) Genetics Core.  At WTCRF, DNA is quantified 
by nanodrop technology and plated out onto 384 well stock plates, stored at 4°C for 
robotic transfer to working 384 well plates for genotyping.  These plates were 
previously ordered by disease (i.e. HC1-5, CD1-7, UC1-8), but after careful 
consideration were fully randomised in 2007 to avoid significant biais from single 
plate errors and to ensure WTCRF personal are fully blinded to sample identification. 
3.5.2 Disease phenotyping 
Phenotypic data were collected by patient questionnaire, interview, and case-note 
review.  Age at diagnosis, disease behaviour and disease location were classified 
initially by Vienna425 and since 2005 by Montreal criteria (both classifications are 
stored on the database for all patients).426  Data consisted of demographics, date of 
onset and diagnosis, disease location, disease behaviour and severity, progression of 
disease type, extraintestinal manifestations, surgery, smoking history and family 
history.   
 
In CD, disease location is defined as terminal ileal (L1), colonic (L2), ileo-colonic 
(L3) or upper GI (L4).  L4 is also applied as a modifier to L1, L2 and L3 when upper 
GI disease is also present.  Disease behaviour is defined as purely inflammatory (B1), 
stricturing (B2), or penetrating (B3), with perianal disease added as a modifier (p).  In 
UC, disease extent is defined by endoscopic appearance as the maximum extent 
during follow-up and is categorised as ulcerative proctitis (E1; disease limited to the 
rectum), left-sided (E2; involvement limited to the colorectum distal to the splenic 
flexure), or extensive colitis (E3; involvement extends proximal to the splenic 
flexure). Disease severity is defined as patients suffering at least one acute severe 
attack of UC, satisfying Truelove and Witts criteria, and requiring intensive in-patient 
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medical therapy.  Colectomy is surgery for active UC not adequately responding to 
medical therapy, and does not include surgery for dysplasia or neoplasia.   
3.5.3 Databases 
The Scottish adult and early-onset cohorts are both stored as password-protected files 
in separate, purpose-designed Microsoft Access databases kept on a single non-
networked PC.  Data is backed up once a week onto CD-ROM and stored in a locked, 
fire-proof case. The databases are presently being transferred onto the secure 
University of Edinburgh network and stored as encrypted files for additional security 
of personal data. They are managed by a dedicated database manager (H Drummond). 
3.5.4 Scottish adult-onset IBD population and healthy controls 
For the Scottish adult IBD database patients were recruited from the Western General 
Hospital (Edinburgh) by clinical research fellows and research nurses within the GI 
unit.  HCs consisted of volunteers from hospital staff and blood donors from the 
Lothian region.  They were not extensively screened for latent disease.  Detailed 
demographics and phenotype are presented in Chapters 5, 7, 10 and 11.   
3.5.5 Scottish early-onset IBD population 
The Scottish early-onset cohort recruited patients with IBD diagnosed at <16 years of 
age from the specialist paediatric hospitals in Edinburgh, Glasgow and Aberdeen 
(recruitment primarily by R Russell and J van Limbergen).  Detailed demographics 
and phenotype are presented in Chapters 10 and 11. 
3.5.6 English IBD population and healthy controls 
The study of GLI1 in the English IBD population described in Chapter 5 was 
performed in collaboration with Miles Parkes and Mark Tremelling (IBD Research 
Group, Addenbrooke’s Hospital, University of Cambridge).  Genotyping was done in 
Cambridge, with raw data provided for analysis.  This cohort is from East Anglia with 
HCs recruited from the EPIC study.  Full details presented in Chapter 5. 
3.5.7 Swedish IBD population and healthy controls 
The Swedish IBD and HC population was provided by Leif Torkvist and Robert 
Lofberg (Karolinska Institutet, Stockholm, Sweden).  Extracted DNA was shipped to 
Edinburgh for storage.  All genotyping was performed as for Scottish samples at the 
WTCRF.  Full details are provided in Chapters 5 and 10. 
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3.5.8 Japanese IBD population and healthy controls 
The Japanese population of IBD patients and HC was provided by Nobuhide Oshitani 
(Department of Gastroenterology, Osaka City University Graduate School of 
Medicine, Osaka, Japan), Nagamu Inoue and Toshifumi Hibi (Department of Internal 
Medicine, Keio University, Tokyo, Japan).  DNA was shipped to Edinburgh for 
genotyping at the WTCRF.  Details are provided in Chapter 10 (limited phenotypic 
data available on this cohort). 
3.5.9 Scottish colo-rectal cancer population and healthy controls 
The Scottish colo-rectal cancer population and HC were provided by Malcolm 
Dunlop (MRC Human Genetics Unit, University of Edinburgh).  DNA from this 
cohort is stored in the WTCRF.  Full details are provided in Chapter 6.  The HCs from 
this population were also used for aspects of the IBD GLI1 study in Chapter 5. 
3.6 Methods for genetic studies 
3.6.1 Polymerase chain reaction (PCR) 
All primer pairs (Sigma, Table 3-2) for PCR, shipped in lyophilised form, were first 
reconstituted in TE to make 100μM solutions. Optimisation PCRs were run using a 
gradient (60°C∆10) to find optimal annealing temperatures.  The standard annealing 
time was 30s, increased to 60s for products of ~1kb. The polymerase amplification 
was performed in a total volume of 20μL containing 10× PCR buffer (160mM 
(NH4)2SO4, 670mM Tris-HCl [pH 8.8], 0.1% Tween-20 (Sigma)) 50mM MgCl2 
(Sigma), 1μM dNTP (Bioline) and 5U/μl Biotaq DNA polymerase (gift from Elaine 
Nimmo.)  The PCR program using a Techne PCR machine was as follows: 35 cycles 
of 30s at 92ºC, 1-3min at 55-65ºC, 45s at 72ºC, followed by a 5 min 72ºC extension 
and then a 4ºC hold.  These samples were then electrophoresed (150V, 400mA, 30 
min) on a 1% agarose gel (agarose multi-purpose, Bioline; 2.25g to 150ml half-
strength TBE, microwaved for 2-3m and cooled to 50°C) containing 1μg/ml of 
ethidium bromide (Sigma) for visualisation of the bands.  Orange G dye (Sigma) and 
ethidium bromide in a ratio of 25:1 were added to the samples before being pipetted 
onto the gel, adjacent a 100 base pair marker lane (Bioline).  Visualisation of bands 
was achieved in a high performance UV transilluminator with a Kodak Edas 290 
Digital Zoom camera and a Kodak 1D-Scientific Imaging Systems computer package.  
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3.6.2 DNA sequencing and SNP identification 
Direct sequencing was performed by at the MRC Human Genetics Unit (University of 
Edinburgh) on a 7900HT sequence detection system.  Sequence was analysed with 
Sequencher v4.5 (Gene Codes Coporation, Ann Arbor, MI, USA.  SNP frequencies 
were scored on a purpose-designed spreadsheet. 
3.6.3 Taqman methodology 
The Taqman method is a PCR-based assay.  Purpose-designed Taqman probes contain 
fluorescent dyes that are excited by a built-in laser.  The reporter dye fluoresces when 
a quencher is removed from a specific DNA fragment during PCR.  This allows the 
detection of the increasing amount of PCR product to be quantified in real-time.  This 
is done cycle-by-cycle, giving a cycling threshold (Ct) required to detect the product, 
of relevance in expression studies.  For genotyping studies, allele specific primers are 
designed such that one allele of the SNP is assigned to VIC and the other to FAM.  
The primers and corresponding probes for Taqman genotyping are ordered from ABIs 
Assay-on-Demand and Assay-by-Design services.  Taqman genotyping was 
performed at the WTCRF on ABI PRISM 7900HT machine with the following 
thermal cycling conditions: 50°C for 2minutes, 95°C for 10 minutes, then 40-cycle 
program of alternating 95°C for 15 seconds and 60°C for 1 minute. 
 
For each Taqman run, the allelic discrimination assay is visualised by plotting FAM 
and on opposing axes, given clusters for each genotype (AA, AB, BB) (Figure 3-2).  
At WTCRF alleles are called by two personnel blinded to the study’s aims.  Where a 
genotype cannot be called the sample is dropped from analysis.  Taqman genotyping 
accuracy was assessed by duplicate analysis for all SNPs (5-10% of samples) and 
direct sequencing of 10% of all samples (for GLI1 and CCL20). 
3.7 Statistics for genetic studies 
Individual SNP analysis was performed on GraphPad InStat 3 statistical package 
(GraphPad Software Inc., San Diego, USA), using chi2 or Fisher’s exact test, where 
appropriate, with two-tailed p-values given and odds ratios (OR) presented with 95% 
confidence intervals (C.I.). 
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3.7.1 Gene-wide haplotype-tagging methodology 
The gene-wide haplotype-tagging studies presented in this thesis each use slightly 
different methodologies reflecting the timescale over which these experiments were 
performed (2004-2008).  All use the same premise.  tSNPs were selected that describe 
the variation across the gene or region of choice.  This requires knowledge of the LD 
across this region.  In the pre-Hapmap era this meant resequencing in a select number 
of controls or cases.  Hence, for GLI1, coding regions were sequenced in 32 cases (16 
UC, 16 CD), SNPs identified, genotypes scored, and then analysed in Haploview 
(vers 3.2) to select multi-marker tSNPs (Chapter 5).  De Bakker has demonstrated that 
multi-marker tSNPs have increased tagging efficiency compared with single-markers 
without loss of power.430  Subsequent to the publication of Phase I Hapmap data, re-
sequencing was not a pre-requisite.431  For IHH and NKX2.3 (Chapters 7 and 11), 
multi-marker tSNPs were selected on the basis of phase II Hapmap data using de 
Bakker’s Tagger algorithm embedded in Haploview (r2 > 0.8).430  
3.7.2 Log-likelihood statistic 
Haplotype frequencies of the tSNPs were inferred using the expectation-maximization 
algorithm and used to test whether haplotype frequencies were different in cases and 
controls as implemented in the EH and PM programmes (log-likelihood test).  The 
test statistic 2*(In(Lcase) + In(Lcontrol) – In(Lcase/Lcontrol)), which has a chi2 
distribution with n-1 degrees of freedom (where n = number of possible haplotypes) 
was calculated and empirical p values obtained by permuting the data either 1000 or 
10,000 times.   
3.7.3 Population attributable risk (PAR) 
The PAR is defined as the excess rate of disease in individuals with a mutation 
compared with those without.  This is calculated from the attributable risk as a 
function of prevalence in the exposed population (100/100,000), divided by the 
incidence of IBD.432 
3.7.4 Haplotype analysis 
Haplotype analysis was performed in Haploview (versions as indicated throughout 
text). 
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3.7.5 Transmission disequilibrium testing (TDT) 
TDT was performed using TRANSMIT software for CCL20 (Chapter 10, with 
assistance from Niall Anderson, Department of Statistics, University of Edinburgh) 
and in Haploview for NKX2.3 (Chapter 11). 
3.7.6 Meta-analysis 
The meta-analysis for rs222826 in GLI1 was performed using the Mantel-Haenszel 
method (fixed-effects model) embedded in the R softward package (assistance from 
Albert Tenesa, MRC Human Genetics Unit, University of Edinburgh). 
3.7.7 False positive reporter probability (FPRP) 
We estimated the posterior probability that the observed association (meta-analysis of 
GLI1 SNP rs2228226) with disease risk represents a true positive by estimating 1 – 
FPRP using the method described by Wacholder433 and the prior probabilities for a 
candidate gene study proposed by Newton-Cheh and Hirschhorn (Chapter 5; 
assistance from H Campbell, MRC Human Genetics Unit).434  This approach is based 
on the fact that the probability of a false positive is dependent not only on the 
observed p value but also the statistical power of the study and the prior probability 
that the association is true. We made calculations using the spreadsheet written by El 
Ghormli and Wacholder and made freely available for non-commercial use.433  
3.8 Phylogeny analysis and protein alignment 
GLI1 protein sequences from several mammalian species (human, rhesus, mouse, rat, 
dog, and cow) were obtained from UCSC (genome.ucsc.edu) or Entrez Protein 
(http://www.ncbi.nlm.nih.gov).  Sequences were loaded into MacVector 
(www.macvector.com) for alignment and analysis.  Regional conservations scores 
were calculated individually by comparing the most different mammalian GLI1 
proteins (human and mouse) (CL and WZ in collaboration). 
3.9 Cell culture 
3.9.1 SW480 cells 
Cells from the adherent transformed colonic epithelial adenocarcinoma cell line 
SW480 (gift from Marian Aldhous) were cultured in L-15 Leibovitz medium (Gibco).  
Each 500ml of medium contained 2mM L-glutamine (5ml of 200mM solution, 
Sigma), supplemented with 5ml penicillin-streptomycin solution (10,000 U/ml 
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penicillin, 10mg/ml streptomycin, Sigma), 10% foetal calf serum (FCS) (56ml, 
Sigma-Aldrich; Gibco) and 2.5mg/ml plasmosin (Invivogen) for prophylaxis against 
mycoplasma infection.  Cells were kept in 75cm2 tissue culture flasks at 37ºC (5% 
CO2).  Once at confluence, cells were washed with PBS and split 1 in 8 into 25cm2 
flasks with 3ml trypsin/EDTA (10×, Sigma).  These flasks were left at 37ºC to 
achieve 70-80% confluence prior to stimulation.  
3.9.2 Peripheral blood mononuclear cells (PBMCs) 
PBMCs were extracted over a Ficoll-histopaque gradient from 30ml of heparinised 
blood collected form healthy volunteers and patients in Lithium-heparin tubes. 30ml 
blood was carefully layed over 15ml Histopaque (H8889, Sigma) in a 50ml conical 
tube.  This was centrifuged at 2100rpm (brake off) for 30 minutes.  The interface 
layer was removed with a Pasteur pipette and added to a new 50ml conical tube with 
at least an equal volume of PBS.  This was centrifuged at 1200rpm for 5 minutes.  
The resulting cell pellet was re-suspended in 50ml PBS and centrifuged for a further 5 
minutes.  This last step was repeated.  After decanting of supernatant and cell 
counting, (see below) PBMCs were resuspending in RPMI (1640, Irvine Scientific) 
and 10% FCS (Gibco).  Extraction of PBMCs was optimised in blood samples from 3 
healthy volunteers before use in patients with active UC (patient details in Chapter 9).  
3.9.3 Cell counting 
To count cells, 5ml of RPMI was added to the cell pellet, which was re-suspended and 
mixed thoroughly.  50μl was added to 50μl of 0.4% tryptan blue (T8154, Sigma).  A 
fresh coverslip was placed on top a haemcounter and a drop of the resulting mixture 
added to the groove on either end.  The number of cells was counted on the in-built 5 
x 5 grid.  This was multiplied by 105 to give the total cell count (i.e. 104 for volume 
plus x2 for dilution with tryptan blue and x5 for dilution in medium).  
3.9.4 RNA extraction from cells 
The culture supernatant was retained, centrifuged (1000 rpm, 5 min) and stored in 
aliquots at -20ºC for later protein analysis by ELISA.  SW480 cells were dislodged 
from the base of tissue culture flasks using cell scrapers (Corning Inc.) and 
centrifuged at 14,000 rpm for 15 seconds.  RLT lysis buffer (RNeasy kit, Qiagen) and 
2-mercapto-ethanol (≥98%; Sigma) in a ratio of 100:1 was added to the cellular 
fraction, before storage at -80ºC. 
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The SW480 cellular suspensions in RLT lysis buffer were pipetted into QIAshredder 
spin columns (RNeasy kit, Qiagen) and centrifuged at 14,000 rpm for 2 minutes, to 
homogenise the samples.  The homogenised lysates plus 70% ethanol were transferred 
to RNeasy mini columns (Qiagen) and centrifuged for a further 15 seconds at ≥ 
10,000 rpm, allowing the RNA to adsorb to the silica-gel membrane.  After washing 
with buffer RW1 (Qiagen, 15s ≥ 10,000 rpm) the RNA was treated with DNase I 
(RNase-Free DNase set).  The solid DNase I (Qiagen, 1500 Kunitz units) was 
reconstituted with RNase-free water (Qiagen) and pipetted directly onto the RNeasy 
silica-gel membrane in a ratio of 1:7 with the DNA digest buffer RDD (Qiagen.)  
After 15 minutes the DNase was removed by a second wash with buffer RW1.  
Contaminants were removed with two wash spins using buffer RPE (Qiagen, 2min ≥ 
10,000 rpm to dry the membrane.)  The RNA was eluted with RNase free water 
(Qiagen, 1min ≥ 10,000 rpm) and the second elution step was performed with the first 
eluate to achieve a higher total RNA concentration.  The RNA concentrations were 
determined by measuring the absorbance at 260nm in a spectrophotometer.  The ratio 
of readings at 260nm and 280 nm and 260nm and 230nm provide an estimate of the 
purity of RNA with respect to DNA contamination and protein contamination 
respectively. 
3.9.5 RNA purity 
To check that no residual DNA remained with the RNA, a GAPDH PCR was 
conducted on the RNA samples, DNA from untreated SW480 cells (positive controls) 
and water (negative control).  GAPDH primers were: forward primer (fp): 5’-
TCATCTCTGCCCCCTCTGCT-3’ and reverse primer (rp): 5’-
CGACGCCTGCTTCACCACCT-3’.  
3.9.6 cDNA synthesis 
Each sample was diluted to an RNA concentration of 100ng/μl and 400ng was reverse 
transcribed using the Taqman Multiscribe Reverse Transcriptase kit (Applied 
Biosystems) consisting of RT buffer (10×), 25mM MgCl2, 10mM dNTP mix, 50μM 
random hexamers, 20U/μl RNase inhibitor, 50U/μl multiscribe reverse transcriptase 
and nuclease free water.  Samples were incubated for 10min at 25ºC, 40 min at 48ºC 
and 5min at 90ºC, diluted 1:5 in nuclease free water for Q-PCR and frozen at –80ºC. 
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3.9.7 Q-PCR on SW480 cells 
The real-time mastermix consisted of Taqman Universal PCR mastermix (Applied 
Biosystems), a primer/probe mix specific for the SHH or PTCH gene sequence (fp, rp, 
probe and water) with the probe labelled with the fluorochrome FAM, a primer/probe 
mix specific to 18s rRNA control reagent, with the probe labelled with the 
fluorochrome VIC (Applied Biosystems) and nuclease free water (Promega.)  The 
following primer/probe sequences were used SHH fp: taaggacaagttgaacgctttgc, SHH 
rp: tcggtcacccgcagtttcac; SHH probe: catctcggtgatgaaccagtggcca; PTCH fp: 
tgcaaaccggcagccgcgataag; PTCH rp: ttaatgatgccatctgcatcca; PTCH probe: 
atcgacatcagccagttgactaaacagcgtc.  2.5μl of each cDNA sample was run in duplicate 
25μl volumes on a capped 96-well optical reaction plate (Applied Biosystems.)  The 
plate was run in the Applied Biosystems Prism 7700 sequence detector using SDS 
software.  The PCR conditions were as follows: 50ºC for 2 min, 95ºC for 10 min, then 
40 cycles of 15s at 95ºC and 1 min at 60ºC.  The software analysed the data and 
output a Ct for the gene of interest and 18s.  The raw Ct values were processed as 
follows: Ct(FAM) – Ct(VIC) to give ∆Ct; sample (∆Ct) was divided by control (∆Ct) 
to give ∆∆Ct; this was transposed into a fold change by the function 2-∆∆Ct. 
3.9.8 RT-PCR on SW480 cells. 
A standard RT-PCR reaction was run on the Q-PCR primer pairs used above. The 
bands were resolved on a Nusieve 3:1 agarose gel (Cambrex BioScience) which is 
used for analysis of nucleic acids which are ≤ 1kb.  Product sizes were as follows: 
SHH 211bp; PTCH 462bp; GLI1 244bp. 
3.9.9 Immunohistochemistry on cells 
SW480 cells were grown in Lab-Tek II chamber slide systems (Nunc) at 37˚C.  After 
stimulation, the culture medium was washed off with PBS and the cells were air dried 
and fixed in anhydrous acetone (90%, Fissure Chemicals) and methanol (10%, Fissure 
Chemicals) for 10 minutes at RT.  Blocking of endogenous peroxidase, non-specific 
binding and biotin as for tissue sections was not required.  Slides were incubated with 
the primary antibody (anti-GLI1 [1:400]; anti-p65 [1:100]) diluted with antibody 
diluent (Dako) and left covered for an hour at RT.   
 
After washing with PBS the biotinylated secondary goat anti-rabbit antibody (Dako) 
was added to the sections for 30 minutes.  The slides were washed again and Vector 
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RTU ABC was applied for another 30 minutes, followed by DAB+ for 5 minutes.  
The wells were snapped off and the slides were counterstained.  After a final 
deionised water wash, coverslips were mounted over each well indentation on the 
slide using aqueous mounting medium (Biømeda.)  Images were captured using an 
Axioskop microscope (× 400) and a Q-imaging 5.0 RTV camera and computer 
package. Cells counts were performed at ×63 magnification, on 5 fields /well.  The 
total number of cells and the number with nuclear staining were recorded per field. 
3.9.10 Enzyme-linked immunosorbent assay (ELISA) on cell culture 
supernatant 
ELISAs were performed for CCL20 (DT360), IL1β (DY201), IL8 (DY208), IL10 
(DY217B), TNFα (DY210), and IFNγ (DY285) using DuoSet ELISA Development 
System (R&D Systems) according the to the manufacturers’ instructions for each kit.  
All samples were run in duplicate.  As an example, the CCL20 protocol was as 
follows.  100μl of capture antibody was applied to each well (COSTAR 9018 high-
binding, polystyrene-coated 96-well plate) and incubated overnight at RT.  300μl 
/well of blocking solution (1% BSA in PBS) was added for 1 hour.  100μl /well of 
standards and samples were added for 2 hours at RT.  Standards underwent a 7-point 
2-fold dilution (top 1000pg/ml).  ≥2 wells were left blank as controls.  100μl /well of 
detection antibody was added for 2 hours at RT.  In between each of these stages, all 
wells were thoroughly washed with PBS x3.  100μl /well streptavidin-HRP solution 
(1:200) was added to each well, followed by 100μl /well 3′,3′,4,51-
Tetramethylbenzidine (TMB, T0440, Sigma), both for 20 minutes in the dark.  The 
reaction was stopped with 50μl of stop solution /well and read at 540 or 570nm.  
3.9.10.1 Buffers and solutions for ELISA 
• Wash buffer (all) 
o 0.05% Tween 20 in PBS, pH 7.2-7.4 
• Reagent diluent (TGFβ2 & CCL20)  
o 1% BSA in PBS, pH7.2-7.4, 0.2μm filtered 
• Block buffer (IFNγ) 
o 1% BSA in PBS with 0.05% NaN3 
• TBS  
o 20mM Trizma base, 150mM NaCl) 
o To 800ml dH20 add 8g NaCl and 0.2g KCl and 3g Tris Base 
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 Adjust pH with conc HCl 
 dH20- to 1000mL 
• Reagent diluent (IFNγ) 
o 0.1% BSA, 0.05% Tween 20 in TBS, pH7.2-7.4, 0.2μm filtered 
• 1N HCl 
o To 91.67mL dH20 slowly add 8.33mL 12 N HCl. Mix well. 
• 1.2 N NaOH / 0.5M HEPES (100Ml)  
o To 75mL dH20 slowly add 12mL 10N NaOH. Mix well. Add 11.9g 
HEPES. Mix will. Bring final volume to 100mL with dH20. 
3.9.11 NFκB luciferase reporter assay 
For the NFκB luciferase reporter assay, SW480 cells were grown to ~50% confluence 
in 6-well plates with 5 ml medium. The ConA NFκB and δκB constructs were gifts 
from Lesley Stark (MRC Human Genetics Unit, University of Edinburgh).  For the 
transfections, 10μl of lipofectamine 2000 (1mg/ml Invitrogen 11668-019) plus 100μl 
Optimem (serum-free medium; Gibco 51985-026) per well were mixed and added to 
an equal volume of both NFκB and δκB (3μg construct plus 1.5μg pCMVβ in 100μl 
Optimem).  This solution was mixed and made up to 1ml/well with Optimem.  For 
each control and treatment, samples were duplicated to allow for both NFκB and δκB 
constructs.  The transfections were incubated at 37°C for 5 hours, before the medium 
was changed for 0.5% serum.   
 
After 24 hours the cells were stimulated for the desired time (all 24 hours for the data 
reported here in Chapter 9).  At timepoint 0 the cells were harvested and incubated 
with reporter lysis buffer through a series of centrifugations and washing steps.  
Samples were then immediately analysed on a luminometer or frozen at -80°C.  The 
samples were normalised for the transfection efficacy by dividing the luminescence 
reading by the concentration of pCMVβ calculated by ELISA.  This was then ‘zero’d’ 
to the experimental control to generate fold changes in NFκB activity. 
 
 





30 HC; 67 UC; 53 CD 
Sex (% male) 
HC 33.3%;  
UC 49.3%;  
CD 50.9% 
Median age at diagnosis/ 
recruitment (years) 




Terminal ileum (L1) 6/53 (11.3%) 
Colon (L2) 28/53 (52.8%) 
Ileocolon (L3) 19/53 (35.8%) 
UC location 
Proctitis (E1) 15/67 (22.4%) 
Left-sided colitis (E2)  27/67 (40.3%) 
Extensive colitis (E3) 25/67 (37.3%) 
CD 5 year behaviour 
Inflammatory (B1) 32/53 
Stricturing (B2) 8/53 
Penetrating (B3) 12/53 
 
Surgery  CD 20/53 (37.7%) UC 2/67 (3.0%) 
Medical therapy for microarray cohort 
5-ASA  CD 21/53 (39.6%);  UC 40/67 (59.7%) 
Corticosteroids 4/53 (7.5%);  UC 10/67 (14.9%) 
Immunosuppressants 13/53 (24.5%);  11/67 (16.4%) 
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Gene Forward primer Reverse primer Annealing 
conditions 
GLI1 GTCTCAGCTTGTGTGTAATTATG TTCTGGAAGGATAGAAACCC 59°C; 1min 
GLI1 CAACTGACCTCAGGTGATCCTC AGAGTCATGGGGACCACAAG 62°C; 3min 
GLI1 GGAGATGTGAGGCGTCAGAG GTTGATGAAAGCTACGAGGGAG 60°C; 1min 
GLI1 TCCTTCTGCTTACTTCCACCCTC GGAAGAGACCCTGGACTTGG 60°C; 1min 
GLI1 CAGTCACTGGGACACAGGC CAAGGGTGACTTCCTCCTCTC 60°C; 1min 
GLI1 TCTCTGATGTGTGTCCTGTTGG GTGGGTGCTGGGCTAAGG 60°C; 1min 
GLI1 GTCTCAAGCCCTCAAACTACC CTAGGGCAAGAGAGGCAATC 64°C; 1min 
GLI1 GGGCACTTAGGGCAGGAA CTTTATGCCAACACAGTCACAC 63°C; 1min 
GLI1 CATGGGAGAAGTAGGAGAC GCACTTGTCCATAATGTTC 59°C; 1min 
GLI1 CCCAGCAGGCCTCATATC CCAGCCCATACCTCCCATCC 64°C; 1min 
GLI1 GTAAAACGACGGCCAGAGCATCAATAGGGCAAAGCAG 
CAGGAAACAGCTATGACCTTGGG
ATTTGTAGTGGTTG 50°C; 1min 
GLI1 GTAAAACGACGGCCAGCCAGGAGTTCGAGGCTATG 
CAGGAAACAGCTATGACGGGACA
GAGTTGCGGTTTG 61°C; 1min 
CCL20 TATGTGGTTTCCTTTCTGTCTG GTAACACAAAATTAACCCATTGG 60°C; 1min 
CCL20 ATTTCCTATTCTTCCCTTCAATTC CTCAAACCTCAGCTTCACC 60°C; 1min 
NKX2.3 GCCAAGCAAGAGCTGTCG TTACAGCCACTGCAGGGACTG 64°C; 1min 
NKX2.3 CCACATGAGCCAGAACCTATAG TTTGTGGAGCTGTCGGTGAC 64°C; 1min 
NKX2.3 GGCGAGGAGGATGACTGGG TCGCACCTTTTCCTCCCCTTC 64°C; 1min 
 
Table 3-2  Primer pairs for DNA sequencing 








Figure 3-1 Controls for HH (N-19) immunohistochemsitry 
The specificity of the N-19 HH antibody is demonstrated with application of the primary antibody, 
primary antibody + SHH blocking peptide pre-absorbed overnight, and with primary antibody omitted.  
This demonstrates that the antibody reacts with the peptide but does not preclude it from cross-reacting 
with other proteins.  Indeed, we would agree with other commentators in urging caution in the use of 




























4 Expression analysis of key HH and 
WNT signalling components in the 
healthy GI tract and IBD. 
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4.1 Abstract 
Introduction.  The HH and WNT pathways have critical and overlapping roles in the 
development of a healthy mammalian gastrointestinal tract.  The expression of various 
HH signalling components has been previously reported in the healthy adult small 
intestine and colon.  However, these existing reports are somewhat limited and 
conflicting in their nature.  In contrast, the profile of WNT pathway genes has been 
documented in great detail in the murine intestine.  Multiple lines of evidence suggest 
that HH may play an important role in the pathogenesis of IBD. 
Aims.  The aim of the present study was therefore to document the expression profiles 
of HH and WNT signalling components in the health small bowel and colon, in UC 
and CD, and in non-IBD colonic inflammation. 
Methods.  Immunohistochemistry, microarray and RT-PCR were used to document 
the protein and mRNA expression of key HH signalling components in endoscopic 
biopsies and surgical resection specimens from healthy controls and patients with UC 
and CD.  GLI1 expression, a direct target of HH signalling and robust indicator of 
pathway activity, was compared by linear regression analysis with expression of 
known and potential HH target genes.  In addition, the microarray dataset was mined 
for all 27 WNT signalling components with known intestinal expression to provide a 
detailed profile of this pathway in IBD. 
Results.  In the healthy adult colon, HH protein is primarily expressed in terminally 
differentiated enterocytes on the luminal surface.  There is a gradient of increasing 
HH protein expression along the length of the colon, with greatest expression in the 
rectum.  This is mirrored by increased mRNA of the HH response network (GLI1, 
PTCH and HHIP) in the distal colon.  GLI1, PTCH and HHIP mRNA was lower in 
inflamed UC compared with HC tissues.  IHH mRNA was decreased in UC regardless 
of inflammatory status.  GLI1 and PTCH were also decreased in colonic CD and non-
IBD inflammation.  GLI1 expression closely correlated with BCL2, BMP4, P21/CIP1, 
NOD2, a raft of inflammatory cytokines, and NKX2.3.  There were less significant 
alterations in the WNT signalling pathway noted in IBD, although several WNT 
genes did exhibit differential expression.  TCF4, FZD4, DKK3 and LRP5 expression 
profiles were closely correlated with GLI1 in non-inflamed control samples.  The 
GSK3 genes, with key roles in the phosphorylation of WNT and HH pathway 
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components, were dysregulated in inflamed UC and CD but not in non-IBD 
inflammation.   
Conclusions.  This study provides to date the most detailed expression analysis of the 
HH signalling pathway in the healthy colon and in IBD.  Of note, the gradients of 
increasing HH pathway activity in the healthy colon mirror the clinical distribution of 
UC and the increasing bacterial burden in the colon. The pathway is down-regulated 
in IBD and non-IBD inflammation, suggesting a key role in the regulation of colonic 
inflammatory pathways. The down-regulation of IHH in UC, regardless of 
inflammatory status, suggests a possible role for germline variation in IHH in disease 
pathogenesis.  The WNT pathway analysis indicates multiple over-lapping roles for 
both pathways in IBD.  
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4.2 Introduction 
Various groups have demonstrated expression of key HH signalling components in 
the small intestine and colon; however, the published literature is somewhat 
conflicting.  Oniscu and co-workers in Edinburgh found protein in the cytoplasm at 
the top of normal colonic crypts.330  This localisation was confirmed by the presence 
of SHH mRNA in laser microdissected crypts.  Similar protein findings were reported 
by Dimmler et al, who showed SHH expression in the distal colon only.328  Most 
recently, Nielson et al have reported the presence of SHH mRNA by in situ 
hybridization and protein by immunohistochemistry in small intestinal and colonic 
crypts, predominantly in the bases but with some focal surface epithelial 
expression.329  The discrepancy in protein data likely reflects varying protein 
detection sensitivities in differing immunohistochemistry protocols, since different 
labs used the same antibody, and may also reflect differences in colonic sampling.  
Colonic gradients of HH signalling are potentially of functional relevance.  It is of 
note that the differential expression of many different genes in the right and left colon 
has recently been described.435   
 
Van den Brink’s group has subsequently shown expression of IHH mRNA and 
protein in the human colon localising to surface absorptive enterocytes.318  These 
same cells were negative for SHH mRNA by in situ hybridization.327  There are no 
published data examining DHH expression in the adult mammalian digestive tract. 
 
PTCH mRNA and protein have previously been reported to be expressed in similar 
locations to SHH in the adult human gut.  mRNA has been identified in the base of 
the villi and the lamina propria of the small intestine, with protein also detected in tips 
of villi.329  In the colon PTCH mRNA and protein has been detected in the luminal 
epithelium and subadjacent lamina propria,318 and also basally in isolated crypt 
cells.330  GLI1 protein expression has been described at the surface epithelium and the 
top of colonic crypts.417  Analysis of foetal and adult colonic mRNAs by RT-PCR 
confirms expression, if not location, of all essential Hh signalling components (SHH, 
PTCH, SMO, GLI1, GLI2 and GLI3).436 
 
 - 122 - 
Recent data reported by Nielson et al indicates that SHH and PTCH are increased in a 
variety of intestinal inflammatory conditions, including IBD, but their findings are 
rather preliminary and warrant further investigation.329 
 
Several lines of evidence implicate the WNT signalling pathway in IBD pathogenesis.  
Furthermore, WNT and HH pathways have been shown to interact in colo-rectal 
cancer pathogenesis.318, 417, 437  In contrast to HH, the murine intestinal expression 
profiles of all WNT signalling components has previously been described in great 
detail by carefully conducted in situ hybridisation studies.398 
 
GSK3 is a key enzyme in WNT signalling.  It main role is phosphorylation of β-
catenin leading to its degradation.  Additionally, it is known to phosphorylate the tail 
of LRP, AXIN, APC and TCF.  Furthermore, it has important roles in HH signalling, 
as well as insulin signalling and NFAT phosphorylation. 
 
In the present study, a detailed analysis of protein and mRNA expression of key HH 
and WNT signalling components in the healthy human colon and small intestine was 
performed, along with comparison between inflamed and non-inflamed UC, CD, non-
IBD inflammation and HC. 
4.3 Methods 
To investigate the functional integrity of the HH and WNT signalling pathways, 
expression of pathway components in the intestine by microarray, RT-PCR and 
immunohistochemistry was examined.  Microarray data from 129 UC, 99 CD and 76 
HC intestinal biopsies were available for all HH signalling components except IHH, 
which was analysed by RT-PCR (these experiments were performed at Genentech, 
Inc; all data analysis performed by CWL).  Immunohistochemsitry was performed on 
formalin-fixed and paraffin-embedded human small intestine and colon from HC and 
patients with CD and UC collected at colonoscopy and surgery.  
4.3.1 Immunohistochemistry, microarray and Q-PCR 
The full details of the methodology for immunohistochemistry, microarray and Q-
PCR presented here are detailed in Chapter 3, including all reagents, antibodies, 
primers and probes, and statistical analysis. 
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4.3.2 Analysis of HH target genes 
GLI1 expression is a robust indicator of HH pathway activity.  This readout was used 
to assess a panel of known and potential HH target genes for correlation with HH 
pathway activity in the non-inflamed terminal ileum and colon from the microarray 
dataset.  HH target genes were selected from a number of different sources.  Firstly, a 
detailed survey of the published literature was performed, including a study by 
Hallikas et al, where a high-throughput bioinformatics model (enhancer element 
locator) was used to examine gene promoters for DNA with homology to the GLI 
consensus sequence.411  Secondly, Professor Gumucio (Ann Arbor, MI) provided a 
list of inflammatory genes (searched under gene ontology [GO] terms relating to 
inflammation) that were dysregulated in a microarray performed on total small 
intestine from  villin-Hhip mice vs. WT at birth (18 days) (full list of inflammatory 
genes and fold-changes listed in Table 13-1).303  The TG promoter (villin) is switched 
on at embryonic day 14-15 in this model, resulting in over-expression of the pan-Hh 
inhibitor Hhip, and subsequent down-regulation of Hh pathway activity (further 
discussion of this model and the results in Chapter 12).  The target gene of choice was 
plotted individually (x-axis) against GLI1 (y-axis) in GraphPad Prism, and correlation 
assessed with linear regression (95% confidence intervals plotted) to obtain r2 and p 
values. 
4.4 Results 
In healthy colons, HH protein (N-19 antibody) was primarily present in terminally 
differentiated enterocytes on the luminal surface, with extension into the upper two-
thirds of colonic crypts (Figure 4-1a-c and 4-2a).  This antibody is meant to detect 
SHH and was successfully blocked with the specific blocking peptide (3.4.3.1 and 
Figure 3-1).  However, it is widely thought that it also detects IHH at higher 
concentrations due to the tight homology of SHH and IHH amino acid sequences, and 
it is therefore referred hereafter as simply HH (N-19).  IHH, PTCH and HHIP were 
expressed in a proportion of basal crypt cells, identified as entero-endocrine cells by 
morphology and co-localisation of PTCH with chromogranin A (Figure 4-1d-g;h and 
Figure 4-2b-c).  PTCH protein was also detected in the mesenchyme - in immune 
cells below the epithelium and in germinal centres of some lymphoid follicles (Figure 
4-1g and Figure 4-2d-g).  These expression patterns map to those of macrophages 
and lymphocytes (Figure 4-2i).  Smoothened was expressed only in colonic 
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epithelium (Figure 4-1h).  The transmembrane pathway inhibitor HHIP was 
expressed in enterocytes, predominantly at the luminal surface, in entero-endocrine 
cells, and in the lamina propria (Figure 4-1i).  GLI1 immunoreactivity was detected 
in predominantly cytoplasmic compartments of epithelial and lamina propria cells 
(Figure 4-1j), although some nuclear staining was also evident.  GLI2 expression was 
exclusively nuclear in both epithelium and mesenchyme (Figure 4-1k), whilst GLI3 
was only present in endothelial cells in blood vessel walls (Figure 4-1l). 
4.4.1 Developmental gradients of HH expression persist in the 
healthy adult colon 
In HC tissue, it was evident that HH gradients present during development270 persist 
in the healthy adult colon. Basal GLI1 (p<0.0001, Kruskal-Wallis), GLI3 (p<0.0001), 
PTCH (p=0.002), and HHIP (p=0.03) mRNA levels were greater in the distal than 
proximal colon (Table 4-1 and Figure 4-3b).  GLI1, PTCH and HHIP are key HH 
response genes, providing positive and negative regulation; as direct transcriptional 
targets of HH pathway activation, mRNA levels predict pathway activity.  HH protein 
(N-19) was similarly greater along the length of the colon (Figure 4-3a); however, 
SHH mRNA levels were similar whatever the location.  Similarly, there was no 
differential expression of DHH, GLI2, SUFU, SMO or DISP1 expression along the 
colon, whereas KCTD11 (p=0.0001) and PTCH2 (p=0.001) levels were lower in 
distal compared with proximal colon (Figure 4-3b).   
4.4.2 The HH response network (GLI1, PTCH, HHIP) is 
downregulated in UC 
GLI1 (p=0.0003), PTCH (p=0.002), and HHIP (p=0.0003) mRNA transcripts were all 
lower in inflamed UC compared with HC tissue from equivalent colonic location; 
KCTD11 (p=0.0002) and PTCH2 (p=0.0009) were greater (Figure 4-4).  These 
expression profiles were not altered by medical therapy for UC (5-ASA, thiopurines 
or corticosteroids) (Figure 4-5).  We observed lower IHH mRNA in UC samples, 
irrespective of inflammatory status (p=0.02) (Figure 4-4).  There was no difference in 
IHH between non-inflamed UC and HC.  GLI1 and PTCH were also lower in CD 
(Figure 4-6), although with a less distinct response to inflammatory status, and in 
non-IBD inflammation (Figure 4-7).   
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In contrast with IHH expression, SHH mRNA was increased in UC (UC vs. HC 
p=0.0003) (Figure 4-4) and non-IBD colonic inflammation (Figure 4-7), but not in 
CD (Figure 4-6).  These microarray data were confirmed by RT-PCR in a second UC 
cohort.  Notably, the higher levels of SHH were present only with inflammation 
(p=0.02) (Figure 4-4).  There was no change in levels of DHH, PTCH2, GLI2, GLI3, 
SUFU or DISP1 in either UC or CD compared with HC, or in non-IBD inflammation 
(Table 4-1).   
 
HH protein (N-19) was increased in a proportion of UC and CD tissues, with 
expression identified in enterocytes throughout the crypt length, compared with HC 
tissue from the same colonic sampling point (Fig 4-8a, ascending colon).  It was 
notable that in most areas of ulceration no significant HH expression was detected.  
PTCH expression was predominant in the inflammatory infiltrate, in lymphocytes and 
macrophages (Figure 4-8c-e).  GLI1 expression was largely decreased in the 
epithelium; however, marked staining of expanded plasma cell populations was noted 
in 7/17 UC colectomy specimens (Figure 4-8b). 
 
These data demonstrate down-regulation of IHH and the HH response genes (GLI1, 
PTCH, HHIP) with greater SHH expression in association with colonic inflammation. 
4.4.3 HH pathway activity (GLI1 expression) vs. target genes 
A panel of known and potential HH target genes (Table 4-2) was assessed using GLI1 
expression as a readout of HH pathway activity.  Close correlation of GLI1 expression 
was found with NOD2, BCL2, BMP4 and P21/CIP1 expression in the healthy adult 
intestine (Figure 4-9a).  Given the presence of GLI1 enhancer elements upstream of 
NOD2, the correlation between GLI1 and NOD2 expression was analysed in more 
detail in control and disease biopsies (Figure 4-10).  Of note, the gene expression 
profiles of GLI1 correlated closely with the expression of these target genes in non-
inflamed samples from HC and CD.  This correlation was lost in UC.  Other genes of 
interest that significantly correlated with GLI1 included a panel of cytokines (IL10, 
IL5, IL1R1, IL17A, IL21, IL4 and TGFβ3), FOXP3, the peptidoglycan recognition 
proteins (PGLYRP1-4), and NKX genes (NKX2.8 and NKX2.3) (Table 4-2). 
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4.4.4 Expression of WNT signalling components in health and UC, 
and interactions with HH 
Interactions between the HH and WNT signalling pathways, both critical to intestinal 
development, have been described in intestinal homeostasis,303 and colon cancer 
pathogenesis.318, 417  To explore the relative contribution of WNT signalling to IBD 
pathogenesis the microarray dataset was first interrogated for expression profiles of 
WNT components with previously documented intestinal expression profiles (Table 
4-3).398  Of note, differential expression along the length of the healthy adult colon 
was noted for WNT6 (p=0.037), FZD4 (p<0.0001), FZD7 (p=0.0007), LRP5 
(p<0.0001), LRP6 (p=0.0026), TCF3 (p=0.0018), TCF4 (p=0.028), DKK3 
(p=0.0005), APC (p=0.0017), CTNNB1 (p=0.014), and AXIN1 (p<0.0001) (Table 4-
3, Figure 4-11a and 13-1 - 13-3).   
 
Comparison of UC and HC samples revealed relatively greater expression of WNT2B 
(p=0.044), WNT9B (p=0.022), FZD4 (p=0.030), DKK4 (p=0.0026), TCF1 
(p=0.0010), TCF4 (p=0.021), and ATOH (p=0.0017) in inflamed UC compared with 
non-inflamed HC (Table 4-3 and Figure 4-11b).  Of these genes, DKK4 and TCF1 
showed comparable changes in non-IBD colonic inflammation (Table 4-3 and 
Figures 13-7 – 13-9).  The expression of AXIN1 was significantly lower in both 
inflamed (p<0.0001) and non-inflamed (p=0.0002) UC samples compared with HC.   
 
FZD5 expression was lower in both colonic (p<0.0001) and terminal ileal (p=0.018) 
CD compared with HC (Table 4-3 and Figures 13-10 – 13-15).  Other notable 
changes in colonic CD were increased expression of TCF4 (p=0.0038) and decreased 
expression of WNT6 (p=0.0003, non-inflamed samples only), LRP6 (p=0.0010) and 
TCF2 (p=0.0025).  In terminal ileal CD, there was increased expression of WNT5a 
(p=0.0016) and decreased expression of FZD7 (p=0.0008).  Of these altertations in 
WNT signalling components in CD, only that of FZD7 was mirrored by a decrease in 
non-IBD colonic inflammation (p=0.022). 
  
GSK3, involved in both WNT and HH signalling, has two mammalian forms (GSK3α 
and GSK3β) that are redundant.438  GSK3 expression did not alter along the length of 
the healthy human colon, nor with non-IBD inflammation (Figure 4-12).  GSK3α 
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expression was lower in inflamed UC (p<0.0001) and inflamed terminal ileal CD 
samples (p=0.036) compared with HC.  GSK3β expression was unchanged in UC, but 
increased in inflamed CD in both colonic (p=0.0007) and terminal ileal samples 
(p=0.0076) (Figure 4-12). 
 
HH pathway activity has been reported to be modulated by the WNT components 
sFRP1420 and beta-catenin.318, 417  There was only minimal correlation between the 
expression profile of sFRP1 with GLI1, but close positive correlations with TCF4, 
FZD4, DKK3 and a negative correlation with LRP5 (Figure 4-9b).  In contrast to the 
decrease in IHH and GLI1 expression in UC, beta-catenin staining is increased with 
greater nuclear accumulation (Figure 4-13).  No clear correlation between GLI1 and 
beta-catenin staining was observed in a panel of 17 UC colectomy specimens. 
4.5 DISCUSSION 
The expression data from the healthy colon indicate that the HH pathway is more 
active in the distal compared with proximal colon, with similarities to the gradients of 
HH signalling previously reported only in development.  The HH protein gradient is 
mirrored by pathway response genes, including GLI1, but not by SHH and DHH 
mRNA, suggesting that IHH is driving the greater HH activity in the distal colon.  
This is consistent with reports that IHH directs enterocyte differentiation and is the 
major epithelial HH signal in the adult colon.318  Here lamina propria immune cells 
have been identified as targets of HH signalling.  The presence of PTCH329 and GLI1 
in these cells indicates they have the ability to receive and process a HH signal.  This 
is entirely consistent with in vitro data that SHH exhibits co-stimulatory activity on 
peripheral CD4 T cells that express PTCH on their surface, potentiating CD3-
mediated proliferation and increasing cytokine production.365, 366, 422  Furthermore, 
germinal centre B cells express key elements of the HH response network, and depend 
on SHH, produced by germinal centre DCs, as a survival signal to prevent 
apoptosis.439 
 
In fact, an emerging body of data strongly supports the notion that the intestinal HH 
signal is purely paracrine, first suggested in murine development by Maddison and 
Gumucio in Ann Arbor,303 and subsequently in homeostasis (Kolterud and Gumucio, 
personal communication) and malignancy.361  We have now clearly demonstrated in 
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the adult mouse, in a series of closely collaborative experiments with Zacharias and 
Gumucio (initiated by CWL and designed with WZ and DG), that epithelial Hh 
signals to underlying mesenchymal cells, predominantly macrophages and DCs (Lees 
et al, PLoS Medicine 2008).423  In Gli1+/LacZ animals, the colonic response to acute 
inflammatory challenge (3% DSS) is exclusively paracrine (further details and 
discussion in Chapter 12).423  The strong advantage of this experimental system is that 
it allows identification of Hh responsive cells by LacZ staining.  This avoids use of 
the polyclonal antibodies (against HH signalling components) described in this 
chapter, doubts over whose specificity have recently been raised by a number of 
researchers in the field.334 
 
There are striking parallels between this distribution of HH signalling in the colon and 
the clinical pattern of UC.  In contrast to CD, the rectum is invariably affected in UC, 
with variable proximal extension to involve the left side of the colon (40.5% in our 
cohort) and more extensively (42.2% with disease proximal to the splenic flexure).  
IHH – GLI1 signalling has been shown to antagonise the WNT pathway in the 
colon.318, 417  The suppression of WNT signalling by high levels of IHH-PTCH-GLI1 
in the distal colon may limit the capacity for effective response to injury and lead to 
chronic inflammation in susceptible individuals.  However, it is difficult to 
extrapolate from the present study any clear functional link between HH and WNT.  
Certainly the present data in HC vs. UC indicate that WNT signalling appears to play 
a lesser role in the pathogenesis of UC than HH, in contrast to the critical role 
established for WNT in colo-rectal cancer. 
 
It has recently been demonstrated that IHH regulates Paneth cell differentiation in the 
murine intestine.332  It would appear that IHH, synthesised and secreted by mature 
Paneth cells, is processed by pathway response elements in Paneth cell precursors, 
thus negatively regulating their differentiation (see 1.8.2.3).332, 333  This observation, 
coupled with the role of HH in inflammation and repair in diverse tissues,349, 358, 367, 
374, 409 links with NFκB / IFNγ signalling,369, 371, 372 the identification of GLI1 response 
elements upstream of the NOD2 gene, and the Ashkenazi pedigree with co-existent 
IBD and basal cell naevus syndrome (BCNS),414-416 strongly suggests a link between 
this developmental pathway and intestinal inflammation.270  The decrease in IHH 
mRNA expression in UC, coupled with evidence of reduced pathway activity 
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(decreased HHIP, PTCH and GLI1) may have two important consequences – Paneth 
cell metaplasia and increased WNT pathway activity.  This link is further enhanced by 
our report demonstrating striking upregulation of alpha-defensins 5 and 6 (HD5 & 
HD6) in UC (compared with HC), with strong correlation to Paneth cell metaplasia 
(Noble, Abbas, Cornelius, Lees et al, GUT 2008).428 
 
In stark contrast to the decrease in IHH signalling, the present study and the published 
literature describes increased SHH protein and mRNA in IBD tissue.329  The 
increased levels of SHH mRNA in UC were restricted to the inflamed group of 
biopsies, suggesting this is a response to NFκB activation.  This induction of SHH 
mRNA with inflammation is all relative to normal tissue; the absolute contribution of 
SHH in this setting may therefore still be low.  This is supported by the global 
decrease in PTCH, HHIP and GLI1, further suggesting that IHH is the dominant 
signal in the colon.  However, we did note the presence of PTCH and GLI1 in the 
inflammatory infiltrate, variably in T lymphocytes, macrophages and plasma cells, 
further supporting the notion of paracrine HH signalling in the colon. 
 
Several WNT signalling components demonstrated differential expression patterns in 
IBD tissue compared with HC.  Whilst the present study was limited to microarray 
data, combined with the thorough pre-existing knowledge of WNT expression in the 
murine intestine this is a reasonably powerful approach.398 Of note, WNT5a, 
increased in terminal ileal CD, is expressed in villus mesenchyme.  WNT6, decreased 
in non-inflamed colonic CD, is expressed in colonic epithelium.  FZD5, decreased in 
colonic and terminal ileal CD is expressed in crypt epithelium, as is FZD7, decreased 
in terminal ileal CD only.  TCF1, increased in UC, is expressed in gut lymphocytes.  
Finally, we noted increased expression of TCF4 in colonic IBD where it is expressed 
in the epithelium.  We did not, however, note differential expression in the terminal 
ileum as has been previously described.  Of note, in this German study the lower 
TCF4 expression mirrored that of α-defensins in CD.421  In a follow-up study, 
presently only in abstract form, Wehkamp’s group found reduced TCF1 in ileal CD.  
In keeping with a strong correlation with TCF4 levels (r2 = 0.52), TCF4 binding sites 
were identified in the TCF1 promoter region.440 
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Somewhat consistent with our results here for TCF1 and TCF4, our data are also 
discordant with Wehkamp’s for the α-defensins.  By microarray and Q-PCR analysis, 
α-defensin expression was unaltered in terminal ileal CD in our study (Noble, Abbas, 
Lees et al, manuscript in preparation).  However, further to the discussion above in 
the context of reduced HH signals in colonic inflammation, the increase in TCF1 and 
TCF4 in UC is consistent with a role for both WNT and HH in Paneth cell metaplasia. 
 
You and colleagues recently utilised a WNT-specific microarray to perform a limited 
survery of WNT gene expression in 6 patients with UC (paired biopsies from 
inflamed and non-inflamed areas) and 6 HCs.441  In this study, and largely in contrast 
to the present data, they noted increased expression of WNT1, WNT2B, WNT3A, 
WNT5B and WNT9A in non-inflamed UC samples versus HC.  Consistent with the 
present data, they noted higher levels of FZD4 and lower levels of FZD5 and, with 
inflammation, higher levels of DKK4.  Their study design was limited by small 
numbers of patients and no control for position of biopsies within the colon. 
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GENE HC gradient HC (N-I) vs. 
HC (I) 
UC (SC) vs. 
HC (SC) 
CD (SC) vs. 
HC (SC) 
CD (TI) vs. 
HC (TI) 
SHH ↑* ↑ P=0.0004 ↑^ P=0.006 - - 
IHH N/A N/A ↓† P=0.02 N/A N/A 
DHH ↓ P=0.002 ↑ P=0.01 ↑ P=0.001 - - 
DISP1 - - - - - 
PTCH ↑ P=0.002 ↓ P=0.005 ↓ P=0.002 ↓ P=0.007 - 
PTCH2 ↓ P=0.001 - ↑ P=0.0009 - - 
SMO - - - - - 
HHIP ↑ P=0.03 - ↓ P=0.0003 - - 
SUFU ↑ P=0.05 - - - - 
GLI1 ↑ P<0.0001 ↓ P=0.0005 ↓ P=0.0003 ↓ P=0.004 - 
GLI2 - - - - - 
GLI3 ↑ P<0.0001 ↓ P=0.044 - ↓ P=0.024 - 
KCTD11 ↓ P=0.0001 ↑ P=0.0003 ↑ P=0.0002 ↑ P=0.0049 - 
 
Table 4-1 Summary of HH pathway expression profiles in HC, UC and CD. 
HC gradient is calculated by Krusall-Wallis test on expression values in ascending, descending and 
sigmoid colon. Non-inflamed (N-I) HC were analysed versus inflamed (I) HC samples, all from the 
sigmoid colon (SC) to take into account gradients of expression.  UC analysis is presented for inflamed 
UC vs. HC (N-I) for SC samples.  CD analysis is separated in SC and terminal ileal (TI) samples in CD 
and HC.  All p-values (except HC gradient) are 2-tailed and calculated by Mann-Whitney U test. 
* HH protein expression increases along length of healthy human colon (see Figure 4-2); no change in 
SHH or DHH mRNA; no microarray data on IHH. 
^ subsequently confirmed by Q-PCR (p=0.02) 
†Performed by Q-PCR (IHH not represented on microarray chip) 
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GENE r2 value +ve or –ve P-value 
BCL2 0.540 + <0.0001 
BMP4 0.430 + <0.0001 
S100A4 0.420 + <0.0001 
NOD2 0.410 + <0.0001 
P21/CIP1 0.410 - <0.0001 
KCDT11 0.360 - <0.0001 
NKX2.5 0.330  <0.0001 
CENTB1 0.260 - <0.0001 
IL10 0.250 - <0.0001 
NKX2.1 0.250  <0.0001 
IL5 0.240 - <0.0001 
IL1R1 0.220 + <0.0001 
IL17A 0.190 - <0.0001 
PGLYRP2 0.190 - 0.0001 
PGLYRP3 0.190 - 0.0001 
NKX2.8 0.190  0.0009 
MAP2K4 0.180 + 0.0002 
IL21 0.180 - 0.0001 
TRAF4 0.170 - 0.0004 
THBD 0.170 + 0.0003 
NKX2.3(B) 0.170  0.0017 
ICAM1 0.160 + 0.0003 
WNT8B 0.150 - 0.0006 
TGFβ3 0.140 - 0.001 
S100A6 0.140 - 0.0011 
MADCAM1 0.140  0.0056 
TGFβ1 0.130 + 0.0018 
CD24a 0.130 - 0.0021 
NKX2.3(A) 0.130  0.007 
N-MYC 0.120 - 0.0029 
DEFB4 (HBD2) 0.110 - 0.0054 
SOX13 0.110 - 0.005 
SP1 0.110 - 0.0048 
IFNγ 0.110 - 0.0062 
TNFα 0.110 + 0.0044 
IL4 0.110 - 0.022 
PGLYRP1 0.110 - 0.0037 
RIPK2 0.100 + 0.0055 
MMP10 0.100 + 0.0055 
FOXP3 0.100 - 0.0059 
VEGF 0.093 - 0.0085 
PGLYRP4 0.090 - 0.0083 
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PPARβ 0.088  0.0007 
DEFB1 0.084 - 0.013 
RIPK1 0.079 - 0.016 
MMP1  0.069 + 0.025 
MMP12 0.069 + 0.025 
IL12B 0.069 - 0.024 
sFRP2 0.062 - 0.034 
ATOH1 0.059 - 0.039 
sFRP1 0.055 - 0.046 
AREG - n/a ns 
APC - n/a ns 
AXIN2 - n/a ns 
CCL20 - n/a ns 
CCND1 - n/a ns 
DEFA5 - n/a ns 
DEFA6 - n/a ns 
EGR3 - n/a ns 
FGF10 - n/a ns 
FGF8 - n/a ns 
IFNγR1 - n/a ns 
IL10RB - n/a ns 
IL17E - n/a ns 
IL1B - n/a ns 
IL1RA - n/a ns 
IL23 (P19) - n/a ns 
IL27 - n/a ns 
IL6 - n/a ns 
IL8 - n/a ns 
JAG1 - n/a ns 
JUN (AP-1) - n/a ns 
MMP13 - n/a ns 
NKX2.2 - n/a ns 
PAP - n/a ns 
PPARγ - n/a ns 
RELA - n/a ns 
S100A1 - n/a ns 
S100A8 - n/a ns 
S100A9 - n/a ns 
SNAIL - n/a ns 
TGFβ2 - n/a ns 
TRAF6 - n/a ns 
WISP2 - n/a ns 
Table 4-2 Correlation between GLI1 and a panel of known and potential HH target genes. 
r2 and p-values generated by linear regression analysis between GLI1 and target gene of choice. n/a = 
not applicable; ns = non-significant (α = 0.05). ‘+’ and ‘-‘ indicate positive and negative correlations 
with GLI1 respectively. 
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GENE HC gradient HC (N-I) vs. 
HC (I) 
UC vs. HC CD (colon) 
vs. HC 
(colon) 
CD (TI) vs. 
HC (TI) 
WNT2b - - ↑ p=0.044 - - 
WNT3 - - - - - 
WNT4 - - - - ↑ p=0.012 
WNT5a - - - - ↑ p=0.0016 
WNT5b - - - - - 
WNT6 ↑ p=0.037 - - ↓* p=0.0003 - 
WNT9b - - ↑ p=0.022 - - 
FZD4 ↑ p<0.0001 - ↑ p=0.030 ↑ p=0.025 - 
FZD5 - - - ↓ p<0.0001 ↓ p=0.018 
FZD6 - ↓ p=0.0071 ↓ p=0.020 - - 
FZD7 ↑ p=0.0007 ↓ p=0.022 - - ↓ p=0.0008 
LRP5 ↓ p<0.0001 ↑ p=0.030 - - - 
LRP6 ↑ p=0.0026 - - ↓ p=0.0010 - 
sFRP1 - - - - - 
sFRP5 - - - - - 
DKK1 - - - - - 
DKK2 - - - - - 
DKK3 ↑ p=0.0005 - - - - 
DKK4 - ↑ p=0.015 ↑ p=0.0026 - - 
TCF1 - ↑ p=0.0012 ↑ p=0.0010 - - 
TCF2 - - - ↓ p=0.0025 - 
TCF3 ↑ p=0.0018 - - - - 
TCF4 ↑ p=0.028 - ↑ p=0.021 ↑ p=0.0038 - 
APC ↓ p=0.0017 ↑ p=0.032 - - - 
CTNNB1 ↑ p=0.014 - - ↑ p=0.029 ↑ p=0.05 
AXIN1 ↓ p<0.0001 - ↓† p<0.0001 - - 
ATOH - - ↑ p=0.0017 - - 
GSK3α - - ↓ p<0.0001 - ↓ p=0.036 
GSK3β - - - ↑^ p=0.0007 ↑ p=0.0076 
 
Table 4-3 Summary of WNT pathway expression profiles in HC, UC and CD. 
HC gradient is calculated by Krusall-Wallis test on expression values in ascending, descending and 
sigmoid colon. Non-inflamed (N-I) HC were analysed versus inflamed (I) HC samples, all colonic.  UC 
analysis is presented for inflamed UC vs. HC (N-I) for all colonic samples unless where specifically 
indicated.  CD analysis is separated in colonic and terminal ileal (TI) samples in CD and HC.  All p-
values (except HC gradient) are 2-tailed and calculated by Mann-Whitney U test. 
† Also significantly lower expression in UC(N-I) vs. HC (p=0.0002). 
* Expression change between CD(N-I) and HC; no difference for CD(I) vs. HC.  
^ Also significantly higher expression in CD(N-I) vs. HC (p=0.0001). 
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Figure 4-1 Protein expression of HH signalling components in healthy human adult colon. 
Expression of SHH (A-B), IHH (D-F), PTCH (G), SMO (H), HHIP (I), GLI1 (J), GLI2 (K) and GLI3 
(L) in the healthy human adult colon.  SHH is expressed in selected enterocytes in the proximal colon 
(A-B) and throughout the epithelium in the distal colon (C and Figure 4-2). Weak epithelial expression 
of IHH is noted (D), although strong staining was noted in selected crypt cells in the distal colon (black 
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selected crypt cells were strongly positive (black arrow).  SMO (H) is expressed in the epithelium only.  
HHIP (I) is noted in epithelium and mesenchyme with strong staining in selected crypt cells (black 
arrow).  GLI1 is expressed in epithelium and mesenchyme with predominant cytoplasmic staining (J), 
whilst GLI2 expression is exclusively nuclear (K) and GLI3 expression is limited to endothelial layers 
of blood vessels (L). 
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Figure 4-2 Detailed expression of PTCH protein in healthy human intestine. 
PTCH, IHH and HHIP were seen to be expressed in a proportion of colonic crypt cells (Figure 4-1).  
Morphologically these had the appearance of neuro-endocrine cells.  CD56 (A) was expressed in 
myenteric plexus only.  Chromogranin A was expressed in neuro-endocrine cells in crypt bases.  A 
proportion of these cells were PTCH positive, with co-localisation of PTCH and chromogranin A 
identified by con-focal microscopy (B-C).  PTCH was expressed in the mesenchyme near the 
epithelium (Figure 4-1 and D), and in germinal centres of lymphoid follicles (E-G).  To identify 
immune subtypes in the colonic mesenchyme CD3, CD4, CD68 and CD20 expression was analysed.  
These antibodies were first optimised in human tonsil (H) and then in healthy human colon (I).  The 
pattern of PTCH staining resembles macrophages identified by CD68 and is also consistent with CD3 
staining. 
CD3 CD20 CD68 CD4 
CD3 CD20 CD68 CD4 
CD3 CD20 CD68 CD4 
A B C 
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Figure 4-3 Gradients of HH expression along length of healthy human colon. 
HH protein (N-19 antibody) expression (A) is greater in the distal colon compared with proximal colon 
(caecum) and terminal ileum (very weak expression in crypt bases only).  mRNA expression 
(microarray data) for all other HH signalling components (B) is plotted in terminal ileum (TI), 
ascending colon (AC), descending colon (DC) and sigmoid colon (SC).  For each dataset, p-values are 
given for Kruskal-Wallis test across AC, DC and SC (solid lines).  Where p<0.05 a post-hoc Dunn’s 
multiple comparison analysis was applied to compare all sets of columns (* indicated p <0.05 with 
dotted line to indicate columns compared).  Of note SHH mRNA expression does not mirror that for 
protein, suggesting that IHH may be the predominant ligand in the colon (IHH not present on 
microarray chip).  However, the gradient of increasing protein expression is paralleled by the HH 
response genes (GLI1, PTCH and HHIP, upregulated on pathway activation and thus predict pathway 
activity.  KCTD11, a HH pathway inhibitor, is lower in distal compared with proximal colon. 
Rectum Sigmoid colonDescending colonTransverse colonAscending colonCaecum Terminal ileum 
B 
A 
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Figure 4-4  mRNA expression of HH pathway components in UC versus HC. 
Quantitative analysis of mRNA levels of SHH, IHH, PTCH, GLI1, HHIP, PTCH2 and KCTD11 in UC 
compared with non-inflamed HC.  To account for the gradients in healthy colon (Figure 4-2), SHH is 
plotted at each anatomical location studied (ascending (AC); descending (DC) and sigmoid colon (SC).  
These microarray data are further validated in SC by RT-PCR.  Only SC RT-PCR data is presented for 
IHH as this gene was not present on the Agilent microarray chip.  Microarray data for the other probes 
are presented for the SC only.  Disease specimens, where indicated, are sub-categorised into non-
inflamed (N-I) and inflamed (I) tissues.  Individual data points are plotted with horizontal lines 
representing the medians for each dataset.  P-values, plotted where significant (p<0.05) are derived 
from Mann-Whitney U-tests. 




Figure 4-5 Analysis of GLI1 expression in UC by medical therapy 
Data are presented for UC patients on no treatment (Rx), on a 5-amino salicylic acid (5-ASA) only, on 
azathioprine (AZA) or mercaptopurine (MP) with or without a 5-ASA and on steroids (oral and topical) 
with or without a 5-ASA.  Individual data points are represented with horizontal lines representing 
medians.  There was no difference between any of the groups on analysis by Mann-Whitney U testing.   
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Figure 4-6 mRNA expression of HH signalling components in CD versus HC 
Quantitative analysis of mRNA levels by microarray and RT-PCR of SHH, GLI1, PTCH, and HHIP in CD compared with non-inflamed HC.  Disease specimens are taken 
from the terminal ileum (TI), ascending colon (AC) and sigmoid colon (SC), and are sub-categorised into non-inflamed (N-I) and inflamed (I) tissues.  P-values represent 
Kruskal-Wallis analysis of HC, CD (N-I) and CD (I) for each anatomical location. 
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Figure 4-7  mRNA expression of HH signalling components in non-IBD colonic inflammation. 
Analysis of SHH, PTCH, GLI1 and HHIP mRNA levels by microarray in colonoscopic biopsies from 
the sigmoid colon (SC) of non-IBD patients with inflammation (I) compared with non-inflamed HC 
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Figure 4-8  Protein expression of HH, PTCH and GLI1 in IBD. 
Representative images demonstrate HH protein in the epithelium throughout the crypt length (A) in 
contrast to healthy colon where expression is restricted to the upper two-thirds of the crypt.  There was, 
however, considerable variability in SHH staining; no expression was identified in some sections.  
GLI1 protein expression was notable in some UC specimens in plasma cells in the lamina propria (B).  
PTCH protein (C-E) is predominant in mesenchyme consistent with lymphocytes (D) and macrophages 
(E) as per staining of CD3 and CD68 in figure 3.  
A C Ascending Colon (AC); CD AC; CD 
AC; CD TI; CD B D SC; UC E 
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Figure 4-9  Correlation between HH pathway activity and known target genes. 
Correlation between HH pathway activity (represented by GLI1 expression) in putative and known HH 
target genes (A) and WNT signalling components (B) in non-inflamed healthy colon.  There is a strong 
positive correlation with NOD2, BCL-2, and BMP-4 with a negative correlation with P21/CIP1 (A).  
Analysis of all known WNT signalling components was performed in relation to GLI1 expression.  
Significant results are plotted, including positive correlations with TCF4, FZD4 and DKK3 and 
negative correlation with LRP5.  Linear regression analysis is plotted with 95% confidence intervals 
for each analysis. 
A 
B 
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Figure 4-10  Correlation between GLI1 and NOD2 expression profiles. 
Correlation between GLI1 and NOD2 mRNA expression profiles in non-inflamed (N-I) and inflamed 
(I) tissue from all HCs, all patients with UC, all patients with CD and those CD biopsies from the 
terminal ileum (TI) only. 
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Figure 4-11 Expression of selected WNT signalling components in UC versus HC. 
The expression of those WNT signalling components for which significant differences were noted 
between UC and HC are plotted. The full data series for the WNT pathway genes is presented in 
summary form in Table 4-1 and in complete graphical form in the appendix (Figures 13-1 – 13-15)  
Two-tailed p-values comparing inflamed UC samples with non-inflamed HC samples (all from the 
colon) are calculated by Mann-Whitney U test. 
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Figure 4-12 Expression of GSK3α and GSK3β in HC, UC and CD. 
There was no gradient of expression of either GSK3 gene along the length of the healthy colon. 
Individual data points are plotted with horizontal lines representing the medians for each dataset.  P-
values, plotted where significant (p<0.05) are derived from Mann-Whitney U-tests. 
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Figure 4-13 Protein expression of β-catenin in UC and healthy colon. 
The expression of beta-catenin in the healthy colon (A) and UC (B-C). 
 
A C B 














5 Gene-wide haplotype-tagging study 
of GLI1 in IBD. 
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5.1 Abstract 
Background.  Genome-wide linkage analysis has provided compelling evidence for a 
genetic susceptibility locus determining IBD susceptibility/phenotype within 12q13 
(IBD2). The HH signalling pathway plays vital roles in gastrointestinal tract 
development and homeostasis, Paneth cell differentiation, inflammation and 
malignancy. GLI1, a key HH transcription factor, lies within the IBD2 linkage region, 
leading us to hypothesise that GLI1 might play a role in disease causation. In detailed 
expression studies in Chapter 4 it was demonstrated that that IHH – PTCH – GLI1 
signalling is down-regulated in UC, supporting a causal role for HH dysregulation in 
disease pathogenesis. 
Aims.  The aim of the present study was to establish whether germline variation in 
GLI1 was associated with IBD. 
Methods.  A gene-wide haplotype-tagging approach was employed, with 4 multi-
marker tSNPs selected in HaploView on the basis of sequencing across coding 
sequencing in 32 patients and controls.  These were genotyped by TaqMan in 4 
separate populations of IBD patients and controls, from Scotland, Cambridge 
(England), Sweden and Japan.  Log-likelihood, haplotype, individual SNP analysis 
and meta-analysis of associated SNPs (Mantel-Haenszel) was performed.   
Results. Germ-line variation in GLI1 was associated with IBD in the Scottish 
population (n=2256, IBD vs. HC: p<0.0001; UC vs. HC: p<0.0001 on log-likelihood 
analysis).  This effect was confirmed in an independent English population (n=2326, 
IBD vs. HC: p=0.009; UC vs. HC: p<0.0001). This association was confined to GLI1, 
and attributable to a non-synonymous SNP in exon 12 of GLI1 (rs2228226C→G), 
which encodes an amino acid change at Q1100E.  On meta-analysis of Scottish, 
English, and Swedish populations (n=5352), rs2228226 was associated with IBD with 
pooled odds ratio of 1.194 (C.I. 1.09-1.31, p=0.0002) and UC (OR 1.196, C.I. 1.077-
1.327, p=0.0008).  
Conclusions. These findings implicate common genetic variation in GLI1, a key 
component of the HH signalling pathway, in the pathogenesis of IBD as an IBD2 
gene.   
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5.2 Introduction 
The IBD2 locus (OMIM 601458), spanning 25 Mb on chromosome 12q13, was 
identified on a UK genome-wide linkage scan in 1996 (peak LOD score 5.47 at 
D12S83)99 and has subsequently been most strongly implicated in UC (see 1.5.1.3).97, 
98  Located within IBD2 is the gene encoding GLI1, a zinc finger protein that is the 
major transcriptional regulator of the HH signalling pathway (see 1.6.1 and Figure 1-
6).   
 
In Chapter 4, it was shown that HH expression is dysregulated in IBD, with lower 
levels of GLI1 expression in UC compared with HC.  Based on this expression data, 
the function of the HH signalling pathway (see Figure 1-8 and Table 2-1) and the 
position of GLI1 in IBD2, it was hypothesised that inherited variation in GLI1 is 
associated with the development of IBD.  A gene-wide haplotype-tagging SNP 
approach was adopted to examine the contribution of the GLI1 gene to IBD 
pathogenesis.  These genetics studies have involved three independent Northern 
European populations (Scotland, England and Sweden) totalling 5352 individuals.   
5.3 Methods 
5.3.1 Subjects for genotyping 
Scotland:  The population consisted of 809 IBD cases (474 UC; 335 CD) and 1364 
controls (Table 5-1).  The population was 98.5% white, non-Jewish Caucasian.  The 
median age at diagnosis was 31.0 (IQR 23.3-46.0).  Controls were recruited from 
across Scotland; median age was 50.0 (IQR 43.0-55.0), ethnicity >99% white, non-
Jewish Caucasian, and 48.7% male sex.  
Low levels of genetic differentiation in terms of allele frequencies across mainland 
Scotland have previously been reported.442  Since it has been shown that low levels of 
population stratification are likely only to result in weak associations,443 it is unlikely 
that the low levels present in the Scottish population could account for the strong 
associations between GLI1 haplotype and disease risk reported herein. 
Cambridge, England:  1767 unrelated Caucasian IBD patients of north European 
origin attending IBD clinics in East Anglia, UK were recruited comprising 928 UC, 
756 CD, and 83 with indeterminate colitis (IC) (Table 5-1). The population was 
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>99% non-Jewish.  Median age at diagnosis was 36.7 and 26.1 years for UC and CD 
respectively. The 637 ethnically and geographically matched healthy controls were 
previously recruited in East Anglia for the European Prospective Investigation of 
Nutrition and Cancer (EPIC). Median age of controls was 60 years.  
Sweden:  288 UC and 205 CD patients were recruited from various hospitals in 
Stockholm County (Table 5-1).  281 Swedish HC were healthy volunteers from the 
Karolinska University Hospital staff (n=170) and orthopaedic day-case surgery 
patients (n=111) with no previous medical conditions.  The details of this cohort are 
given in methods chapter.  
5.3.2 Sequencing 
Sequencing of GLI1 was performed in 32 patients with UC and CD, initially targeting 
known SNPs from Ensembl to enable selection of tagging SNPs (this stage performed 
prior to on-line publication of HapMap), and subsequently all 12 exons (including 
intron-exon boundaries) and 1kb of the promoter region was sequenced to search for 
novel mutations for genotyping (see Table 3-2 for details of primer pairs used). 
5.3.3 Genotyping 
Scotland and Sweden:  Genotypes were derived using the Taqman system for allelic 
discrimination; the assays were available from Applied Biosystems as Taqman SNP 
Genotyping Assays (7900HT sequence detection system; Applied Biosystems, Foster 
City, CA), except for SNPs rs10783819, rs3809114, rs507562, rs542278, rs730560, 
rs1669296, rs775322 which were genotyped on the Illumina platform.  The accuracy 
of each Taqman assay was checked by repeat analysis in 5% of cases, with 100% 
concordance.  Genotype distributions in control populations were consistent with 
Hardy-Weinberg Equilibrium (p>0.01) for all SNPs.  Genotypes, in cases for the four 
tSNPs that could not be derived by TaqMan were obtained by direct sequencing. 
Cambridge:  DNA was extracted using Nucleon kits. Genotyping of CD cases and 
controls was performed using the Taqman biallelic discrimination system using an 
ABI 7900HT analyser; Applied Biosystems, Foster City, CA. Genotyping of UC 
cases was performed using a 1536 SNP Golden Gate bead array; Illumina, San Diega, 
CA. Concordance between platforms was assessed by genotyping 92 UC cases for 
SNPs rs2228224 and rs2228226 with concordance rates of 100% and 97.9% 
respectively and no evidence of systematic bias between platforms. Genotype 
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distributions in case and control populations were consistent with Hardy-Weinberg 
Equilibrium (p>0.01) for all SNPs. 
5.3.4 Statistical analysis 
Haplotype frequencies of the tSNPs were inferred using the expectation-maximization 
algorithm and imputed 10,000 times using the log-likelihood analysis described in 
Chapter 3 (3.7.2).  Haplotypes were examined using the Haploview programme vers. 
3.2 (www.hapmap.org).  The meta-analysis of SNP rs2228226 was performed using 
the Mantel-Haenszel method using a fixed effects model (R software package; 
assistance from A Tenesa) (3.7.6).   
5.4 Results 
5.4.1 Gene-wide variation in GLI1 is associated with IBD and 
attributable to a non-synonymous SNP (rs2228226C→G) in 
the Scottish population 
Sequencing of the GLI1 gene in 32 IBD cases, informed by Ensembl, confirmed the 
presence of variants from dbSNP in the Scottish population.  Four multi-marker 
tagging SNPs (tSNPs; r2≥0.8) were identified in Haploview (rs3817474, rs2228225, 
rs2228224, and rs2228226), that described haplotypic variation of GLI1, detecting 
haplotypes of a frequency >1% (Figure 5-1).  These 4 tSNPs were genotyped in a 
Scottish IBD population consisting of 474 UC and 335 CD cases, and 1364 well-
matched healthy controls (Table 5-1).  A model-free analysis was then employed to 
test the association of GLI1 and IBD susceptibility.  Haplotype frequencies were 
estimated separately in cases and controls and on the whole sample.  The likelihood of 
the dataset assuming the same frequencies in cases and controls was compared with 
the likelihood when the frequencies were estimated separately in cases and controls.  
Empirical significance levels were obtained by permutation testing. 
 
In the Scottish population, a highly significant association was demonstrated in IBD 
(p<0.0001) and UC (p<0.0001), and an association with CD of borderline significance 
(p=0.03) (Table 5-2A).  On analysis of individual estimated haplotype frequencies in 
Haploview, 3 common haplotypes were described (Table 5-2A).  Haplotype B (2222) 
was a risk haplotype for IBD (OR 1.16, C.I. 1.01-1.32, p=0.036), whereas there was a 
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protective effect with haplotype C (2221; OR 0.71, C.I. 0.54-0.93, p=0.014) (Table 5-
2A).  To determine whether this effect was confined to the GLI1 gene an additional 7 
haplotype-tagging SNPs, chosen from Phase II HapMap data to tag neighbouring 
blocks, were genotyped in 166 CD and 170 UC patients.  This confirmed the presence 
of a GLI1 spanning haplotype block that did not extend into neighbouring genes 
(INHBE and ARHGAP9) (Figure 5-2).   
 
The association on haplotype testing and log-likelihood analysis was attributable to a 
non-synonymous SNP in exon 12 of GLI1 (rs2228226C→G; tSNP4), which encodes 
an amino acid change (glutamic acid to glutamine) at position E1100Q.  rs2228226 
was associated with IBD (allelic frequency OR=1.23, C.I. 1.07-1.40, p=0.0026; 
homozygotes OR=1.56, C.I. 1.15-2.11, p=0.0047), CD (allelic frequency OR=1.30, 
C.I. 1.08-1.55, p=0.0053, homozygotes OR=1.79, C.I. 1.21-2.65, p=0.0048) and UC 
(allelic frequency OR=1.19, C.I. 1.01-1.39, p=0.04) (Table 5-3).  Mutation screening 
of the GLI1 coding regions by direct sequencing failed to identify any novel SNPs.  
Therefore, in addition to the 4 tSNPs above a further 7 GLI1 variants, selected as 
validated SNPs from dbSNP, were genotyped in the Scottish cohort.  There was no 
association between any of these SNPs and IBD susceptibility, suggesting that 
rs2228226 is the causative GLI1 variant (Table 5-4). Despite tight linkage 
disequilibrium (LD) across GLI1 (Figure 5-2), there was notably less LD between 
rs2228226 and other tSNPs (r2 = 0.7) in both cases and controls (Figure 5-3), and this 
is likely to provide the explanation for the lack of association in neighbouring SNPs. 
5.4.2 Replication of GLI1 association in two independent North 
European IBD cohorts 
In order to replicate these findings, a large IBD panel from Cambridge, England was 
examined (n=1000 UC, 737 CD and 589 HC).  The association with GLI1 was 
replicated by log-likelihood analysis in IBD (p=0.009), UC (p<0.0001) and CD 
(p=0.002) (Table 5-2B).  Haplotype C was present in the Cambridge populations with 
very similar frequencies to that in Scotland, and was protective for IBD (OR 0.76, C.I. 
0.58-0.99, p=0.049) and UC (OR 0.66, C.I. 0.49-0.90, p=0.0093).  Furthermore, 
rs2228226 was associated with IBD (OR 1.17, C.I. 1.00-1.36, p=0.042) and UC (OR 
1.24, C.I. 1.05-1.46, p=0.011) but not CD in this population (Table 5-3).  As in 
Scotland, there was no association with tSNPs1-3 (Table 5-5). 
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In the Swedish cohort, there was a similar magnitude of effect with haplotype C in 
association with IBD (OR 0.75, C.I. 0.50-1.10), UC (OR 0.78, C.I. 0.50-1.21) and CD 
(OR 0.68, C.I. 0.41-1.12) (Table 5-2C) and with rs2228226 with IBD (OR 1.14, C.I. 
0.90-1.45), UC (OR 1.11, C.I. 0.90-1.45) and CD (OR 1.19, C.I. 0.90-1.58), albeit 
without significance in this smaller cohort (n=770; Table 5-3).   
 
Finally, a smaller Japanese cohort (n=300) was genotyped for the 4 tSNPs.  There was 
a significant difference in HC minor allelic frequencies compared with the N 
European cohorts.  Whilst analysis of HC vs. IBD, UC and CD was not significant, a 
similar trend existed for rs2228226 as for the other cohorts (Table 5-3). 
5.4.3 Meta-analysis of rs2228226C→G  
A meta-analysis, using the Mantel-Haenszel method with a fixed effects model on the 
IBD cases and healthy controls in Scotland, England and Sweden confirmed the 
association with rs2228226 (OR 1.194, C.I. 1.089-1.309, p=0.0002), achieving 
criteria for significance in a gene-centric study (Figure 5-4A).192, 444  There was no 
evidence of heterogeneity in the contribution of rs2228226 between the 3 cohorts 
(p=0.825).  The meta-analysis changed little with the addition of the smaller Japanese 
cohort (OR 1.188, C.I. 1.087-1.298, p=0.0001).  The meta-analysis was repeated 
separately for UC cases versus healthy controls with a similar effect size noted (OR 
1.196, C.I. 1.077-1.327, p=0.0008) (Figure 5-4B). 
 
Recognising the current problem with the publication of false positive findings in 
genetic association studies we estimated the probability that the association with 
disease risk found in the meta-analysis of GLI1 SNP rs2228226 represents a true 
(rather than false positive) association by adopting the false positive report probability 
(FPRP) approach described by Wacholder.433  This gives an estimated probability that 
these findings represent a true finding of at least 92% (FPRP < 0.08).  This method is 
designed to avoid over-interpretation of statistically significant findings that are not 
likely to signify a true positive but in the present study gives clear support to the 
interpretation of these data. 
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5.4.4 Genotype-phenotype analysis 
On detailed haplotype-phenotype analysis in the Scottish population, the risk 
haplotype B (2222) was associated with left-sided (E2) and extensive UC (E3) 
compared with ulcerative proctitis (E1) (33.8% vs. 24.7%, p=0.034, OR 1.56, C.I. 
1.05-2.32).  Genotype-phenotype analysis of rs2228226 was consistent with this 
(E2+E3 35.1% vs. E1 26.0%, p=0.037, OR 1.54, C.I. 1.04-2.28).  There was no 
association with disease location in CD, or with disease behaviour, surgery, family 
history or age at diagnosis in UC or CD (data not shown).  None of these phenotypic 
associations were replicated in the Cambridge cohort (data not shown).  Genotype-
phenotype analysis was not performed in Swedish or Japanese cohorts due to limited 
sample size. 
5.5 Discussion 
Following on from the extensive expression studies described in Chapter 4, the data 
presented here provide the first evidence that intact HH signalling is critical in the 
mammalian gut response to inflammatory challenge, and that down-regulated GLI1 
signalling is implicated in IBD pathogenesis.  The inherited variation in the GLI1 
gene that we have detected is associated with IBD and UC, in both Scotland and 
England, with findings in individual cohorts confirmed by meta-analysis of over 5000 
individuals, in 3 N European populations with a pooled odds ratio of 1.19.  Evidence 
for an effect in CD is seen in the present study, but the predominant effect is clearly 
related to UC, consistent with the reported IBD2 linkage studies.98, 99  The magnitude 
of this association is entirely in line with the effect size noted in a number of recent 
studies of complex disease genetics, including CD,103 colo-rectal cancer,162 and 
coeliac disease.445  The level of significance attained satisfies suggested criteria of p < 
10-4 - 10-6 for gene-centric studies.192, 444  Population heterogeneity has been 
previously described at the IBD2 linkage region.98, 99, 152, 446  The three N European 
populations studied here have previously demonstrated similar contribution of other 
IBD susceptibility genes / loci, including NOD2 and IBD5.78   
 
Whilst the minor allelic frequencies for rs2228226 are very similar in Scotland and 
Sweden (30.3% and 30.6%), they differ by 3.9% between Scotland and Cambridge 
(30.3% and 26.4%).  This difference is in keeping with that noted for a number of 
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SNPs analysed for population stratification in the recent WTCCC study.81 It has been 
demonstrated that the GLI1 effect is not secondary to LD across the IBD2 region.  
 
rs2228226C→G, a mis-sense mutation in exon 12 of GLI1, encodes a change from 
glutamine to glutamic acid (Q1100E).  The mutation falls within a highly conserved 
motif at the C-terminus of all mammalian GLI1 proteins, near a recognized 
transactivation domain (Figure 5-5).447  The Q1100 residue is itself 100% conserved 
in all mammals examined.   In situ mutagenesis studies, performing in collaboration 
with the Gumucio lab in Ann Arbor, demonstrate that this mutant protein (1100E) is a 
subfunctional transcriptional activator compared with WT GLI1 protein, although it is 
appropriately synthesised and localised.  In a GLI luciferase reporter assay, the mutant 
protein demonstrated a 50% reduction in activity compared with WT protein.  The 
Q1100E mutation causes a significant charge change in a conserved region directly 
adjacent to the known transactivation region of GLI1; this change could directly 
modify transactivation activity, disrupt the structure of the transactivation domain, or 
affect protein stabilization,448 decreasing activity. 
 
Additionally, the SNP and mutation analysis of human GLI1 indicate that 
rs2228226C→G is the only GLI1 coding change observed in the study population.  
Taken together, these data suggest that Q1100E could be the causative GLI1 variant 
associated with IBD.  Whilst the resequencing efforts identify rs2228226 as the only 
coding variant associated with IBD, further deep re-sequencing will be important in 
the future as the haplotype analysis and log-likelihood analyses raise the possibility 
that other germ-line variants may also contribute to IBD risk. These need be explored 
formally – specifically the role of intronic variants, long-range promoter effects and / 
or CNVs.  In this context, several complex disease genes, including NOD2,79, 80 have 
multiple independent mutations conferring disease risk, some disease genes have no 
causative mutations within coding sequences (e.g. IRGM in CD),89, 213 and 
synonymous SNPs may be associated with functional effects.449     
 
It is of note that germline variants in other HH pathway components are associated 
with human disease.  Heterozygous SHH mutations are the most common genetic 
lesion associated with holoprosencephaly (HPE).450, 451  Loss-of-function GLI2 
mutations are associated with HPE-like features along with pan-hypopituitarism.452  
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Mutant PTCH leads to constitutive pathway activation in basal cell naevus syndrome 
(Gorlin’s syndrome), characterised by multiple benign and malignant tumours.350  
Mutations in GLI3 cause Greig cephalopolysyndactyly syndrome and Pallister-Hall 
syndrome.453, 454  A rare syndrome with neonatal diabetes mellitus and congenital 
hypothyroidism is caused by mutations in GLIS3 (GLI similar 3).455   
 
Most recently, germline variation in IHH, PTCH and HHIP has been associated with 
height in two large meta-analyses of GWAS data.159, 160  In phase I of their study, 
Weedon and colleagues analysed data from 13,665 individuals of European ancestry 
from 5 separate GWAS datasets all performed on the Affymetrix 500k chip, including 
the WTCCC study.160  They then took 39 SNPs to replication in a further 16,482 
individuals (in phase II).  20/39 SNPs reached GWAS levels of significance in the 
combined analysis, including SNPs in PTCH (rs10512248; pcombined = 4.2 x 10-11), 
HHIP (rs6854783; pcombined = 2.1 x 10-9) and IHH (rs6724465; pcombined = 2.1 x 10-8).  
Lettre and colleagues performed a 3 phase study, initially in 15,821 individuals from 
6 separate GWAS.159  Imputation of SNP data was required prior to meta-analysis as 
the individual GWAS were performed on different platforms (Affy 500k, Illunina 
317k and Illumina 500k).  78 SNPs from phase I were replicated in a panel of 2189 
European Americans taken from the near-extremes of the normal height distribution 
(short: 5-10th centile; tall: 90-95th centile).  29/78 SNPs were then replicated in 4 
further validation cohorts totalling 17,801 individuals.  Of note, HHIP was also 
associated with height variation in their study (rs1492820; pcombined = 1.2 x 10-11).  
Together, these data strongly implicate IHH signalling in the regulation of human 
height.  It is noteworthy that Ihh-/- mice and TG mice with overexpression of Hhip in 
cartilage, have very similar phenotypes.  Severe skeletal defects are noted, including 
short-limbed dwarfism.289, 456 
 
Intriguingly, whilst most Hh pathway knock-outs are fatal during mouse development 
or peri-natally270 (Shh and Ihh knockouts have shortened, malrotated digestive tracts 
with abnormal epithelial proliferation),299 Gli1-/- mice appear to develop normally 
under standard conditions (Table 1-2).313  The apparently normal phenotype has not 
to date involved a detailed description of the intestinal microstucture.313  Furthermore, 
stressing this model (e.g. with DSS) or crossing it with strains susceptible to colitis 
(e.g. Il10-/-) may provide important insights into pathogenic mechanisms.  This 
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strategy has been successful employed with Nod2-/- and Nod22939iC mice (1.5.1.1).115, 
116  
 
After hypothesising that GLI1 is largely functionally redundant in development but 
plays and important role in response to injury (CWL), we have now tested this 
experimentally in close collaboration with Zacharias and Gummucio (Ann Arbor) 
(Lees, Zacharias et al, PLoS Medicine 2008).423  Intriguingly, we have shown that 
Gli1+/LacZ mice develop early, severe colitis with high mortality when stressed with 
DSS compared with WT (further details in Chapter 12).  These data provide robust 
support for a critical role for HH signalling in the pathogenesis of IBD, and for GLI1 
as an IBD2 gene. 
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(1374 HC; 474 UC; 
335 CD; 8 IBDU) 
2337  
(589 HC; 928 UC; 
737 CD; 83 IBDU) 
774 
(281 HC; 288 UC; 
205 CD; 0 IBDU) 










Median age at diagnosis/ 
recruitment -years (IQR) 
HC 50.0 (43.0-55.0)  
UC 34.1 (25.2-49.9) 
CD 27.8 (20.8-41.1) 
HC 60.0 (53.0-69.0) 
UC 36.7 (26.84-50.35) 
CD 26.1 (20.3-37.2) 
HC 47.6 (36.4-60.7) 
UC 28.6 (20.6-41.6) 
CD 24.5 (19.1-36.7) 
CD location  
Terminal ileum (L1) 35.9% 31.3% 17.4% 
Colon (L2) 36.5% 36.5% 47.9% 
Ileocolon (L3) 25.1% 30.3% 32.6% 
Upper GI disease (L4) 2.5% 1.9% 2.1% 
UC location  
Proctitis (E1) 17.3% 14.8% 10.4% 
Left-sided colitis (E2)  40.5% 34.1% 49.5% 
Extensive colitis (E3) 42.2% 51.1% 40.1% 
CD 5 year behaviour  
Inflammatory (B1) 64.8% 52.3% 70.9% 
Stricturing (B2) 14.8% 35.2% 21.5% 
Penetrating (B3) 20.3% 12.5% 7.5% 
Perianal involvement (p) 17.4% 24.4% 6.4% 
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A.  HAPLOTYPE 







IBD vs. HC 
p-value 
OR (C.I.) 
UC vs. HC 
p-value  
OR (C.I.) 
CD vs. HC 
p-value 
OR (C.I.) 


















Log-likelihood p-value < 0.0001 < 0.0001 0.03 
 
B.  HAPLOTYPE 







IBD vs. HC 
p-value 
OR (C.I.) 
UC vs. HC 
p-value 
OR (C.I.) 
CD vs. HC 
p-value 
OR (C.I.) 


















Log-likelihood p-value 0.009 < 0.0001 0.002 
 
C.  HAPLOTYPE 









IBD vs. HC 
p-value 
OR (C.I.) 
UC vs. HC 
p-value 
OR (C.I.) 
CD vs. HC 
p-value 
OR (C.I.) 


















Log-likelihood p-value 0.13 0.41 0.19 
Table 5-2 GLI1 haplotype frequencies in IBD, UC, CD and HC in A. Scotland, B. Cambridge, England, and C. Sweden.   
tSNP1: rs3817474; tSNP2: rs2228225; tSNP3: rs2228224; tSNP4: rs2228226.  Differences between IBD, CD, UC and HC frequencies are shown, calculated by χ2 test, with 
two-sided p-value, odds ratio (OR) and 95% confidence intervals (C.I.).  Estimated haplotype frequencies were calculated using Haploview, vers. 3.2. Log-likelihood p-
values (calculated on the PM/EH platform with 10,000 permutations and 15 degrees of freedom) are given for each analysis. 
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HC IBD UC CD  
N % N % p value 
OR (C.I.) 
N % p value 
OR (C.I.) 
N % p value 
OR (C.I.) 
Scotland 1374 30.3 884 34.8 0.0026 
1.23 (1.07-1.40) 
549 33.9 0.042 
1.19 (1.01-1.39) 
335 36.1 0.0053 
1.30 (1.08-1.55) 
Cambridge 589 26.4 1737 29.6 0.042 
1.17 (1.00-1.36) 
1000 30.8 0.011 
1.24 (1.05-1.46) 
737 27.9 0.40 
1.08 (0.90-1.28) 
Sweden 277 30.6 493 35.0 0.27 
1.14 (0.90-1.45) 
288 34.4 0.43 
1.11 (0.90-1.45) 
205 35.9 0.24 
1.19 (0.90-1.58) 
Japan  46.8  49.4 0.53       
 
Table 5-3 Minor allelic frequencies for GLI1 non-synonymous SNP rs2228226 (tSNP4) in Scottish, English, and Swedish HC, IBD, CD and UC. 
Two-tailed p-values are given for χ2 analysis of IBD vs. HC, UC vs. HC and CD vs. HC. 
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SNP dbSNP ID & Position Location 
Allele 







UC vs. HC 
P-value 
OR (C.I.) 



































































































































































































































































































































































































































22 vs 11 
N/A 
 




22 vs 11 
N/A 
 







































































































































































Table 5-4 Details of the 11 GLI1 SNPs genotyped in the Scottish population. 
*n=370 for SNPs 1-4 and 7-9. U/K = unknown. 
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SNP dbSNP ID & Position Location 
Allele 







UC vs. HC 
P-value 
OR (C.I.) 

























































































































































































































Table 5-5 Details of the 4 GLI1 tSNPs genotyped in the Cambridge population. 
χ2 analysis of allelic frequency and homozygosity for each tSNP for UC and CD versus HC is 
presented with corresponding p-values, odds ratios (OR) and 95% confidence intervals (C.I.). 
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Figure 5-1 Structure of GLI1 gene. 
Data from Ensembl illustrate the structure of the GLI1 gene, including position of tSNPs1-4 and of 
neighbouring genes. 
 
rs3817474 rs2228225 rs2228224 rs2228226 




Figure 5-2  Haplotype structure at GLI1 and surrounding region from Scottish data. 
The haplotype structure in GLI1 and surrounding haplotype blocks are presented in Haploview from 
genotyping in UC (A) and CD (B).  There is a haplotype block spanning the GLI1 gene that does not 
extend into neighbouring genes.  LD is described here by D′ values. 
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Figure 5-3  r2 linkage disequilibrium between tSNPs1-4. 
 
 




Figure 5-4  Mantel-Haenszel meta-analysis of rs2228226 in Scotland, Cambridge and Sweden. 
A. IBD vs. HC.  B. UC vs. HC.  There was no evidence of heterogeneity in the contribution of 
rs2228226 between the 3 cohorts (p=0.825).  Confidence intervals for individual populations are 
represented by horizontal lines and population sizes by square boxes.  The diamond represents the 
pooled odds ratio (fixed effect model) with 95% C.I. delineated by the diamond’s width.  Note the 
different range of the x axis for A and B. 
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Figure 5-5  Protein structure of GLI1. 
A) Conservation of known functional domains in the Gli1 protein.  Previously described Sufu binding, DNA binding, and transactivation domains447, 457, 458 are shown 
schematically.  Amino acid conservation of each domain is represented numerically and by shading of the bar below the domain.  The Sufu binding sequence is 100% 
conserved in examined mammalian GLI1 proteins.  Red boxes indicate regions known to regulate GLI1 protein stability.448   A highly conserved C-terminal domain which 
includes Q1100E (equating to rs2228226) is identified adjacent to a known transactivation domain.  B) Alignment of the C-terminus of mammalian GLI1 proteins. This 
region (AA 1080-1106) is one of the most conserved portions of the GLI1 protein in mammalian lineages. 
 










6 Germ-line variation in GLI1 and colo-
rectal cancer in Scotland. 
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6.1 Abstract 
Background.  Association of GLI1 with IBD, predominantly UC, has been 
demonstrated.  A putative role for HH signalling and GLI1 in colo-rectal cancer 
pathogenesis has been described.  About one thirds of disease variance has been 
attributed to inherited risk factors.  Only a small proportion of this is explained by 
genetic variants identified through candidate gene studies (e.g. DNA mismatch repair 
genes) and recent GWAS reports (e.g. SMAD7). 
Aims.  The aim of the present study was to determine if germ-line variation in GLI1 
was associated with colo-rectal cancer. 
Methods.  Four gene-wide haplotype-tagging SNPs (rs3817474, rs2228225, 
rs2228224 and rs2228226) were genotyped on the TaqMan platform in a cohort of 
Scottish early-onset colo-rectal cancer patients (n = 983, median age at diagnosis 
50.0) and age and geographically matched healthy controls (n = 1004).  Log-
likelihood, haplotype and individual analysis was performed along with binomial 
logistic regression modelling and subphenotype analysis for location of colonic 
tumour. 
Results.  On log-likelihood analysis, there was overall association of GLI1 with colo-
rectal cancer (p<0.001).  tSNP4 (rs2228226) was associated with colo-rectal cancer on 
genotype analysis only (p=0.05).  There was no association with tSNPs1-3 or 
individual haplotypes.  Binomial logistic regression analysis suggested that overall 
gene association was best explained by a combination of tSNPs3 and 4 (rs2228224 and 
rs2228226).  There was a trend to increased association with rectal tumours but this 
did reach significance. 
Conclusions.  These data suggest that germ-line variation in GLI1 is associated with 
colo-rectal cancer.  However, the effect is much less marked than that observed in UC 
and requires validation by replication in independent cohorts.  Recent determination 
of the paracrine nature of HH signalling in colo-rectal cancer has catalysed clinical 
trials of a small molecule HH antagonist in patients with metastatic disease. 
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6.2 Introduction 
Worldwide, colo-rectal cancer is the fourth leading cause of cancer death (about 
655,000 deaths per annum) with a lifetime risk for an individual in Western Europe of 
about 5%.  It is typically more common in men than women with peak onset in the 
sixth and seventh decades of life; onset of disease before 50 years of age is 
uncommon.459  The location of tumours within the colon largely determines clinical 
features at presentation; the typical distribution is depicted in Figure 6-1.  There is a 
significantly increased risk of colo-rectal cancer in patients with both UC and CD 
colitis. 
 
Sequential molecular changes occur in colonic epithelial cells, including somatic 
mutations in the K-ras protooncogene, APC (18q), the deleted in colorectal cancer 
(DCC) gene and the p53 tumour suppressor gene, and hypomethylation of DNA.  
These are known to be induced by a variety of stimuli including cigarette smoke, 
dietary and other environmental carcinogens, and chronic colonic inflammation.  This 
accumulation of cellular changes drives the healthy colonic epithelium to 
adenocarcinoma via increasing dysplasia and subsequent adenoma.  The colonic stem 
cell is the logical location for the accumulation of these mutations due to its protected 
niche in the colonic crypt (position +4) and subsequent longevity.  Very recently, 
LGR5 has been identified as a putative intestinal stem cell marker.460 
 
It has been calculated that around one third of colo-rectal cancer variance is 
attributable to inherited genetic factors.461  However, in the era pre-GWAS only about 
5% of disease risk could be explained by a series of rare, highly penetrant variants in 
a number of genes : DNA mismatch repair genes,462 APC, SMAD4, BMPR1A and 
MUTYH.463   
 
With the advent of GWAS a number of widely replicated novel loci have been 
identified.  Most recently, Tenesa and colleagues from Scotland,162 and Tomlinson 
and colleagues from across the United Kingdom163 have reported the full details of 
GWAS each involving 3 - 4 stages of replication and tens of thousands of patients and 
controls.  In phase I of the Scottish study, 555,510 SNPs were genotyped in 1,012 
early-onset colo-rectal cancer patients (from the lowest 10th centile by age at 
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diagnosis) and a similar number of age and geographically matched controls.162  After 
replication of 15,008 SNPs in phase II, the top-five ranked SNPs were genotyped in 
14,500 cases from 7 geographically distinct populations (Scotland, England, Canada, 
Germany, Spain, Japan and Israel) along with 13,294 appropriate matched controls.  
In this final stage these regions (along with 2 previously identified) were additionally 
fine mapped.  The best replicated loci to date are: 
• rs7014346 at 8q24 (POU5F1P1 / DQ515897)  
o p = 8.6 x 10-26; OR 1.19 
• rs4939827 at 18q21 (SMAD7) 
o p = 7.77 x 10-28; OR 1.20 
• rs3802842 at 11q23 (high LD across multi-genic locus including LOC120376 / 
FL54803 / C11orf53 / POU2AR1 plus polymorphic binding site target for 
miRNA) 
o p = 5.82 x 10-10; OR 1.11 
In the other large GWAS, Tomlinson reported two additional well replicated loci163: 
• rs10795668 at 10p14 
o p = 2.5 x10-13; OR 0.89 
• rs16892786 at 8q23.3 (EIF3H) 
o p = 3.3 x 10-18; OR 1.25 
A meta-analysis of the Tenesa and Tomlinson GWAS has subsequently identified an 
additional four loci161: 
• rs4444235 at 14q22.2 (BMP4) 
o p = 8.1 x 10-10; OR 1.11 
• rs9929218 at 16q22.1 (CDH1) 
o p = 1.2 x 10-8; OR 0.91 
• rs10411210 at 19q13.1 (RHPN2) 
o p = 4.6 x 10-9; OR 0.87 
• rs961253 at 20p12.3 
o p = 2.0 x 10-10; OR 1.12 
 
In Chapter 5, it was demonstrated that germ-line variation in GLI1 was significantly 
associated with UC, and to a lesser extent CD.  In recent years, there has been much 
debate as to the role HH signalling may or may not play in the pathogenesis of colo-
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rectal cancer.  This literature has been discussed in some detail in Chapter 1 (see 
1.9.1.2). Most pertinent to the present chapter is the demonstration by Akiyoshi and 
colleagues that GLI1 expression is dysregulated in colon cancer.417  Given this 
potential link, the gene-wide haplotype tagging strategy described in the previous 
chapter was employed to ascertain whether GLI1 variation was associated with colo-
rectal cancer. 
6.3 METHODS 
6.3.1 Colo-rectal cancer patients 
The patient population consisted of 983 patients with early-onset colo-rectal cancer 
from Scotland (median age at diagnosis 50.0 years, IQR 45.0-53.0) and 1,004 age and 
geographically matched controls.  This cohort was provided by Professor MG Dunlop 
and, as such, derived from phase I of their GWAS described above.162  The 
demographics and phenotype of the cohort are detailed in Table 6-1.  Location of 
colonic tumours was defined as follows: rectal – rectum and sigmoid; left-sided – 
distal to splenic flexure excluding rectum and recto-sigmoid; right-sided – proximal to 
splenic flexure. 
6.3.2 Genotyping 
The four gene-wide haplotype-tagging SNPs employed in the previous chapter were 
genotyped on the same TaqMan platform.  
6.3.3 Statistical analysis 
In addition to the chi2, haplotype and log-likelihood analysis as described in the 
previous chapter, binomial logistic regression was also performed on this cohort.  
Binomial logistic regression was used in R (by A Tenesa) to test for the overall 
association of the gene with the disease. All 4 SNPs were fitted at a time and dropped 
from the model one by one (dropping always the one less significant). The 2 nested 
models (i.e. with and without the SNP that was dropped from the model) were tested 
using R’s ANOVA command. This tests whether having the extra variable improves 
the fit of the model.  The final model included only tSNP3 and tSNP4.  A genotype-
phenotype analysis stratified by colo-rectal tumour location was performed for the 
four individual tSNPs. 
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6.4 Results 
6.4.1 Germ-line variation in GLI1 and colo-rectal pathogenesis. 
On log-likelihood analysis with 1000 permutations, overall GLI1 variation was 
associated with colo-rectal cancer (p<0.001).  On analysis of individual SNPs (Table 
6-2) there was association with tSNP4 (rs2228226) genotype of borderline 
significance (p=0.05), but not on analysis of allelic frequency (p=0.29).  There was no 
association with tSNPs1-3.  There was no difference in individual haplotype 
frequencies between cases and controls (Table 6-3).  To account for potential 
confounding of the IBD cases within this cohort the analysis was repeated with these 
cases removed with no significant alteration of these results (data not shown). 
 
Using binomial logistic regression to model the association with colo-rectal cancer, a 
best fit was observed when tSNPs3&4 were included in a genotypic model (p=0.023) 
(Table 6-4).  The model was improved further with the addition of an iteration term 
(p=0.0004).  Analysis of the genotype counts at these two tSNPs demonstrates why 
the interaction explains the overall association of GLI1 on log-likelihood testing, 
whilst individual SNP analysis is borderline.  
6.4.2 Genotype-phenotype analysis 
A within-cases genotype-phenotype and haplotype-phenotype analysis was performed 
for colo-rectal cancer patients stratified by location of colonic tumour.  A trend was 
noted towards increased risk with all tSNPs when comparing rectal tumour versus 
left-sided and right-sided tumour (Table 6-5a), but this did not reach statistical 
significance on individual SNP analysis or log-likelihood testing (p=0.35).  In light of 
the gradients of HH expression noted in Chapter 4, a potential association between 
genotype and location of colonic tumour was explored.  There was no evidence of a 
gradient along the length of the colon (rectum – left – right-sided) with increasing 
susceptibility to colonic cancer for individual tSNPs, although MAFs were 
consistently greater for rectal tumours (Figure 6-2).   
6.5 Discussion  
The data herein demonstrate overall association of GLI1 with colo-rectal cancer in a 
single large population of early-onset patients from Scotland.  However, the 
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association on permutation testing with log-likelihood analysis was not seen at either 
the haplotype or the individual SNP level.  This discrepancy has a number of possible 
explanations.  Firstly, as discussed in the previous chapter in the context of the 
contribution of germ-line GLI1 variation to IBD pathogenesis, additional variation in 
the gene – promoter or intronic variants and/or CNVs – may explain the overall gene 
association.  For IBD, it was shown firstly that the association was limited to GLI1 
and did not extend into neighbouring genes and secondly, that the association with 
tSNP4 (rs2228226) explained most, but not all, of the genetic variation.  In this colo-
rectal cancer cohort, there is a trend towards association with this rs2228226, but this 
is only of very borderline significance and unlikely to explain the gene-wide 
association.  However, the binomial logistic regression analysis performed provides 
evidence for an alternative explanation: that the contribution of tSNP4 is dependent on 
the genotype of tSNP3.  These data require replication in an independent cohort of 
colo-rectal cancer patients and controls.  
 
In the recent GWAS in colo-rectal cancer, genotype has been associated with 
subphenotypes, specifically the location of the tumour within the colon.162  For 
example, rs3802842 at 11q23 and rs4939827 at 18q21 (SMAD7) were both associated 
with rectal tumours to a great extent than tumours in the rest of the colon (p=0.008 
and p=0.009 respectively), although the magnitude of this effect is small (OR 1.07 for 
both SNPs).162  A genotype-phenotype analysis was therefore performed within the 
colo-rectal cancer cases for GLI1 in the present cohort.  Whilst there was a trend 
towards greater association with rectal cancers, similar to 11q23 and 18q21, this fell 
short of statistical significance.  However, this may be an issue of sample size and 
power: in the GWAS the subphenotype analysis was performed on a total of 14,500 
cases, compared with 983 in the present study.  It would be of great interest to see if 
this subphenotypic association was confirmed on a larger cohort given the gradients 
of HH pathway expression demonstrated in Chapter 4.  There, it was shown that HH 
ligand plus pathway response elements (PTCH, HHIP and GLI1) were expressed at 
greater levels in the distal compared with the proximal colon.  The inferred greater 
HH pathway activity in the distal colon is notable given the distribution of intestinal 
commensal flora in the healthy human colon and the clinical distribution of UC. 
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The colo-rectal cancer cohort in this study contained a total of 39/983 (4.0%) patients 
with a concomitant medical history of IBD (majority UC), compared with only 
7/1004 (0.7%) of healthy controls (p<0.0001, OR 5.88, C.I. 2.62-13.22).  This 
significant difference is expected as there is a well established increased risk of colo-
rectal cancer in patients with known colitis (both UC and CD colitis, as discussed in 
more detail in Chapter 1).  Although the overall number of patients with co-existent 
IBD is small, this may be sufficient to explain the overall association of GLI1 with 
colo-rectal cancer.  However, repeat log-likelihood, haplotype and individual SNP 
analysis with these 46 cases omitted did not significantly alter any of the data or 
conclusions. 
 
In conclusion, these data suggest that further to the significant association seen 
between GLI1 and IBD, this key transcriptional mediator of HH signalling may also 
be associated with inherited susceptibility to colo-rectal cancer.  However, these data 
should be interpreted with some caution as the results are of borderline significance 
and require validation in independent cohorts.  They do, at least, add to the weight of 
evidence suggesting that HH signalling does have a significant role to play in colo-
rectal cancer pathogenesis (1.9.1.2).361  Finally, the role of HH in the development of 
colo-rectal cancer in patients with established colitis merits detailed exploration.   
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 Colo-rectal cancer cases Healthy controls 
Total number 983 1004 
Median (IQR) age (years) 
at diagnosis / recruitment 
50.0 (45.0-53.0) 52.0 (47.0-55.0) 
Male sex (%) 49.7% 52.6% 






   
Location of cancer   
Rectum  41.6%  
Left-sided 26.9%  
Right-sided 23.8%  
Not specified / unknown 7.7%  
 
Table 6-1 Demographics and phenotype of colo-rectal cancer cases and HCs. 
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SNP dbSNP ID & Position Location 
Allele 













































































































































































Table 6-2 Details of the 4 GLI1 tSNPs genotyped in the colo-rectal cancer (CRC) population and HCs. 
χ2 analysis of allelic frequency and homozygosity for each tSNP for CRC versus HC is presented with 
corresponding p-values, odds ratios (OR) and 95% confidence intervals (C.I.). 
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HAPLOTYPE 
 tSNP1 tSNP2 tSNP3 tSNP4 CRC HC p-value OR (C.I.) 
A 1 1 1 1 60.4% 60.9% 0.74 0.98 (0.86-1.11) 
B 2 2 2 2 31.4% 30.8% 0.65 1.03 (0.90-1.18) 
C 2 2 2 1 6.8% 7.0% 0.80 0.97 (0.76-1.25) 
 
Table 6-3 Haplotype analysis of colo-rectal cancer (CRC) cases versus HCs. 
Differences between CRC and HC frequencies are shown, calculated by χ2 test, with two-sided p-value, 
odds ratio (OR) and 95% confidence intervals (C.I.).  Estimated haplotype frequencies were calculated 
using Haploview, vers. 3.2. 
 
 
A.  Genotypes 
 tSNP4 11 12 22 
 tSNP3    
OR 11 1 8.7* ∞ 
 12 1 0.8 2.5 




B.  Genotypes 
 tSNP4 11 12 22 
 tSNP3    
OR 22 1.1 12.9* ∞ 
 12 1.3 1.6 2.3 
 11 1 1 1 
 
Table 6-4 Binomial logistic regression of GLI1 in colo-rectal cancer compared with healthy controls. 
A. Change of risk (odds ratio) for SNP4 given that a person is SNP3 genotype 11, 12 or 22.   
B.  Change of risk for SNP3 given that a person is SNP4 genotype 11, 12 or 22. For example, people 
with genotype 11 at SNP4 do not have a big increase in risk for being 22 homozygous for SNP3. 
However, there is a big increase in risk if the person is 12 or 22 for SNP4.   
* means is significant at the 5% level. 
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MAF Rectal vs. Left & 
Right-sided tumours Rectum Left & right 
p-value OR (C.I.) 
tSNP1 0.394 0.361 0.17 1.16 (0.95-1.41) 
tSNP2 0.403 0.374 0.23 1.13 (0.93-1.37) 
tSNP3 0.394 0.367 0.25 1.12 (0.92-1.37) 
tSNP4 0.329 0.301 0.23 1.14 (0.92-1.40) 
 
MAF Rectal vs. Left & 
Right-sided tumours Rectum Left & right 
p-value OR (C.I.) 
tSNP1 0.375 0.376 0.98 1.00 (0.79-1.25) 
tSNP2 0.388 0.387 0.97 1.00 (0.80-1.26) 
tSNP3 0.378 0.380 0.97 0.99 (0.79-1.25) 
tSNP4 0.302 0.318 0.53 0.93 (0.73-1.18) 
 
Table 6-5  Genotype-phenotype analysis of colo-rectal cancer cases (within-cases analysis) by 
tumour location of colonic tumour. 
Top panel: rectal tumours versus left and right-sided tumours 
Bottom panel: right-sided tumours versus rectal and left-sided tumours 
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Figure 6-1  Distribution of colo-rectal tumours in Scottish early-onset population. 
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Figure 6-2  Minor allelic frequencies for 4 tSNPs by tumour location. 
 
 










7 Gene-wide haplotype-tagging study 
of IHH in IBD. 
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7.1 Abstract 
Introduction:  It was demonstrated in Chapter 4, by analysis of HH pathway 
response elements (PTCH, GLI1 and HHIP) in IBD tissue, that HH pathway activity 
is decreased in established colonic inflammation in man.  The expression of the ligand 
IHH was notable in that it was down-regulated in the colons of patients with UC 
compared with HC, regardless of inflammatory status.  This raises the possibility that 
germ-line IHH variation may be associated with UC. 
Aims:  To determine whether IHH is associated with UC and CD in Scotland. 
Methods:  A gene-wide haplotype-tagging study was performed.  tSNPs were 
identified using the aggressive tagging algorithm embedded in Tagger with r2 
threshold set at > 0.8.  5 tSNPs (rs1378640, rs394452, rs3731881, rs427587 and 
rs3100776) were genotyped in a cohort of Scottish patients with IBD (448 CD, 549 
UC) and HC (n=428).  Overall contribution of IHH to IBD susceptibility was assessed 
by log-likelihood analysis with 1000 permutations.  Haplotype analysis was 
performed in Haploview.  Chi2 analysis was performed to assess the contribution of 
individual tSNPs to IBD susceptibility.    
Results:  On log-likelihood testing there was no overall association between IHH and 
IBD, CD or UC.  The 5 tSNPs described 5 haplotypes with frequency >1% in HC 
population.  There was no haplotype or tSNP association with IBD.  However, there 
was weak association of haplotype C with UC (OR 1.39, p=0.042), haplotype E with 
CD (OR 3.60, p=0.0072) and protection of haplotype D with UC (OR 0.58, p=0.041).  
Individual tSNP analysis demonstrated association at rs3100776 with UC (OR 0.58, 
p=0.043) and at rs427857 with CD (OR 3.57, p=0.0075).  The MAFs of both these 
SNPs is low in the Scottish HC population (0.039 and 0.006).  There were no 
significant associations on genotype-phenotype testing. 
Conclusions:  In the present study there is no evidence of association at IHH with 
IBD.  The borderline associations seen on haplotype and tSNP analysis in UC and CD 
are inconsistent and in relatively uncommon haplotypes and SNPs and are therefore of 
doubtful significance.  Alternative explanations (e.g. epigenetics) should therefore be 
sought to explain the expression differences seen for IHH in UC. 
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7.2 Introduction 
The detailed series of HH signalling pathway expression analyses presented in 
Chapter 4 demonstrated that PTCH and GLI1 are decreased in colonic inflammation 
in man.  These pathway response elements are direct transcriptional targets of the 
pathway and as such predict pathway activity.  Whilst no consistent expression 
changes were noted for SHH, IHH (the other major HH ligand in the intestine) was 
down-regulated in UC.   Moreover, the altered expression profile demonstrated down-
regulation in both inflamed and non-inflamed UC samples when compared with non-
inflamed HCs.  This suggests either that down-regulation of IHH in established UC 
persists despite resolution of inflammation, or that germ-line variation in IHH leads to 
lower expression of IHH in the gut predisposing patients to develop UC. 
 
The published literature suggest that IHH is the major HH ligand in the mammalian 
intestine. Van den Brink and colleagues demonstrated IHH to be critical to normal 
colonic enterocyte differentiation and that IHH expression is lost where WNT 
pathway is constitutively overexpressed in the context of FAP, as discussed in more 
detail in Chapter 1.318  This is further supported by the data presented in Chapter 4.  
Given that the expression pattern of SHH in the healthy colon does not mirror that of 
the HH pathway response genes (i.e. no gradient of increasing expression from 
proximal to distal colon) it is highly likely that changes in IHH expression in 
terminally differentiated enterocytes and not SHH is driving the expression changes in 
PTCH, GLI1 and HHIP.  Taken together, these observations argue for a major role for 
IHH in the pathogenesis of UC. 
 
To examine the role of IHH variation in IBD susceptibility, a gene-wide haplotype-
tagging study was performed in Scottish IBD.  
 
7.3 Methods 
7.3.1 IHH genotyping 
IHH is a small gene (6.0kb) located in a 194.7kb haplotype block on chromosome 
2q35 (Figure 7-1a-b).  5 other genes are located within this block: CCDC108 (coiled-
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coil domain containing 108), NHEJ1 (XRCC4-like factor), SLC23A3 (solute carrier 
family 23 (nucleobase transporters), member 3), C2orf24 (chromosome 2 open 
reading frame 24) and C2orf17 (chromosome 2 open reading frame 17).   
 
Tagger was used to select IHH tSNPs.  10kb of HapMap data (phase II CEU 
population) was imported into Haploview (version 4.2).  Of 13 HapMap SNPs in this 
region, 9 satisfied criteria (HWE >0.01, MAF >0.01).  The aggressive tagging 
algorithm embedded in Tagger was used with 2- and 3-marker haplotypes and r2 
threshold set at a minimum of 0.8.  6 tSNPs were selected: rs1378640, rs394452, 
rs3731881, rs3731878, rs427587 and rs3100776.  rs3731878 failed manufacture by 
ABI.  The remaining 5 tSNPs were genotyped by TaqMan in the Scottish IBD 
population consisting 448 patients with CD, 549 with UC and 428 HC.  This 
represents the same cohort genotyped for GLI1 in Chapter 4, with the exception of the 
reduced number of controls.  A total of 95 samples were successfully genotyped in 
duplicate, giving 99.6% concordance across all SNPs.  All SNPs were in HWE in the 
HC population (p>0.1).  Genotypes were called in 94.7% (rs1378640), 87.8% 
(rs394452), 97.0% (rs3731881), 99.3% (rs427587) and 99.3% (rs3100776) of the total 
population (n=1425). 
7.4 Results 
7.4.1 Log-likelihood analysis 
There was no overall association with IHH variation and IBD (p=0.13), UC (p=0.16) 
or CD (p=0.23) on log-likelihood analysis (model-free analysis) with 1000 
permutations and 31 degrees of freedom. 
7.4.2 Haplotype analysis 
In the HC population there were 5 common haplotypes (frequency >1.0%), designated 
A-E (Table 7-1).  The LD between the 5 tSNPs is demonstrated by D′ and r2 values in 
Figure 7-1.  There was no difference in the frequency of haplotypes A-E between 
IBD and HC populations (Table 7-1).  Analysis of haplotype frequencies in UC 
demonstrated association with haplotype C (10.4% vs. 7.7%, p=0.042, OR 1.39, C.I. 
1.01-1.92) and protection with haplotype D (2.3% vs. 3.9%, p=0.041, OR 0.58, C.I. 
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0.34-0.98).  Haplotype E was associated with CD (2.1% vs. 0.6%, p=0.0072, OR 
3.60, C.I. 1.33-9.73) but not with UC.   
7.4.3 tSNP analysis 
Analysis of the 5 individual tSNPs by chi2, demonstrated no association with tSNPs1-3 
(Table 7-2).  tSNP4 (rs427857) was associated with CD (MAFs 0.021 CD vs. 0.006 
HC, p=0.0075, OR 3.57, C.I. 1.32-9.66) but not with IBD or UC.  No patients or 
controls were homozygous mutant at rs427857.  tSNP5 (rs3100776) was associated 
with UC (MAFs 0.023 UC vs. 0.039 HC, p=0.043, OR 0.58, C.I. 0.34-0.99).  
However, only one UC patient and one HC was homozygous for the tSNP5 mutation. 
7.4.4 Genotype-phenotype analysis 
There were no significant genotype-phenotype associations when log-likelihood, 
haplotype and tSNP analysis was stratified for age at diagnosis, disease location or 
disease behaviour.  Specifically, given the borderline associations with CD and UC 
for haplotypes C-E and tSNPs4-5, analysis of colonic IBD was performed.  Case-
control analysis (colonic IBD vs. HC) demonstrated borderline association with tSNP5 
only (0.024 vs. 0.039, p=0.046, OR 0.61, C.I. 0.37-1.00).  There was, however, no 
association on a within cases analysis (colonic IBD vs. not colonic IBD) for this 
(p=0.21) or other SNPs. 
7.5 Discussion 
In the present study a gene-wide haplotype-tagging approach was taken to determine 
whether variation in IHH is associated with IBD in the Scottish population.  Overall 
gene variation, analysed by the log-likelihood test, was not associated with IBD, UC 
or CD.  There was no associated with IBD on analysis of individual haplotypes or 
genotypes.  However, given the down-regulated IHH mRNA expression documented 
in UC biopsies, it was of particular interest to determine whether or not there was any 
evidence of germ-line IHH variation association with UC.  Of note, association of 
borderline significance (p=0.04) was shown for haplotype C (11211) as well as 
protection with haplotype D (21212).  This association may in part be related to the 
protective association documented with tSNP5 (p=0.043).  The LD between this 
intronic SNP and the other tSNPs is 1.0 by D′ but 0.0 – 0.13 by r2.  The low r2 values 
would explain association at tSNP5 in UC in the absence of association at tSNPs1-4, 
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assuming this is real.  It would, however, critically require replication in an 
independent UC population. 
 
The associations seen for CD are of doubtful significance.  Both haplotype E and 
tSNP4 are present at very low frequencies in the HC population (0.6% for each).  In 
the absence of a CD replication cohort in this study it is therefore best to interpret 
these findings with caution. 
 
Overall, particularly given the negative log-likelihood analysis (the primary analysis 
designed for this type of gene-wide haplotype-tagging strategy), it is concluded that 
there is no substantial evidence for association of IHH with IBD in the Scottish 
population.  Alternative explanations for the decreased mRNA IHH expression in UC 
should therefore be offered, including the possibility of epigenetic modification. 
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Table 7-1 Haplotype structure of IHH tSNPs. 
All haplotypes with frequency >1% are shown (A-E).  Case-controlled analysis of haplotype frequency is demonstrated for IBD vs. HC, CD vs. HC, UC vs. HC (Chi2 
analysis of haplotype frequencies estimated by Haploview; 2-tailed p-values given with odds ratios and 95% confidence intervals). 
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Table 7-2 Minor allelic frequencies (MAF) of individual IHH tSNPs (1-5) in IBD, CD, UC and HC. 
Case-controlled analysis of allelic frequency is demonstrated for IBD vs. HC, CD vs. HC, UC vs. HC (Chi2 analysis, 2-tailed p-values given with odds ratios and 95% 
confidence intervals). 
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Figure 7-1  Representation of IHH haplotype structure from HapMap CEPH data in Haploview. 
INDIAN HEDGEHOG (IHH): 
10kb & 500kb views 
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Figure 7-2  Linkage disequilibrium by r2 (Left panel) and D′ (right panel) across IHH (HapMap CEPH data). 











8 Germ-line variation in 13 HH and 27 
WNT signalling genes in Crohn’s 
disease: analysis of WTCCC GWAS data. 
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8.1 Abstract 
Background.  It has been demonstrated that the expression of key HH response 
genes, notably GLI1 and PTCH, is dysregulated not only in UC, but also CD (Chapter 
4).  This is one of several lines of evidence that point to a potential role for HH 
signalling in CD pathogenesis.  In addition, several WNT pathway genes showed 
differential expression in CD, and there was further evidence of interaction between 
these pathways in the intestine. 
Aims.  The aim of the present study was to analyse WTCCC data for 13 HH and 27 
WNT signalling pathway genes for evidence of association with CD. 
Methods.  The WTCCC CD dataset was interrogated for all SNPs present within HH 
genes (SHH, IHH, DHH, DISP1, PTCH, PTCH2, SMO, HHIP, SUFU, GLI1, GLI2, 
GLI3 AND KCTD11), and those WNT signalling genes with known intestinal 
expression (WNT2B, WNT3, WNT4, WNT5A, WNT5B, WNT6, WNT9B, FZD4, FZD5, 
FZD6, FZD7, LRP5, LRP6, sFRP1, sFRP5, DKK3, DKK4, TCF1, TCF2, TCF3, 
TCF4, APC, CTNNB1, AXIN1, ATOH, GSK3α, and GSK3β).  A total of 1Mb of data 
was analysed at every gene location.  Two major analyses were performed for every 
SNP: CD (n=2000) vs. CC (consisting of non-CD WTCCC cases, n=12,000; analysis 
1) and CD vs. HC (WTCCC controls, n=3000; analysis 2).  A series of automated 
functions were generated in Microsoft Excel to process this data and generate chi2 
statistics with 2-tailed p-values and odds ratios with 95% confidence intervals.  A 
Bonferroni correction was applied separately to each pathway analysis giving α-
values of 0.00028 for HH pathway and 0.00019 for WNT pathway genes.  
Confirmatory data for SNPs significant in analysis 2 (α = 0.05) was sought from the 
meta-analysis of WTCCC, French / Belgium and N American GWAS.   
Results. 179 WTCCC SNPs were present in 10/13 HH genes (no SNPs in IHH, DHH 
and KCTD11) and 257 SNPs in 21/27 WNT genes (no SNPs in FZD5, FZD7, sFRP5, 
TCF3, ATOH and GSK3α).  24/179 (13.4%) HH pathway SNPs were significant at p 
< 0.05 on analysis 1; 17/24 remained significant on analysis 2 with no new signals 
detected.  Only one HH pathway gene was significant after Bonferonni correction: 
rs147172020, a rare SNP (MAF 0.0001) in GLI3 (p=9.4 x 10-6, OR 15.8) not present 
on the meta-analysis; 43 other SNPs in this gene were not associated with CD.  4 
GLI2 SNPs forming a single haplotype block in an intronic region were associated 
with CD (OR 1.09, p=0.043 on analysis 1), but lost significance in the meta-analysis 
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(p=0.23).  10 adjacent SNPs located within a large block of tight LD in SUFU were 
associated with CD (OR 0.92); this haplotype block extended into neighbouring 
genes.  All of these SNPs were significant on analysis of meta-analysis data (p 0.0047 
– 0.0093).   Of 36/257 WNT pathway SNPs associated with CD, only 2 remained 
significant after Bonferonni correction: rs2083798 (OR 1.20, p=0.00015) and 
rs2083797 (OR 1.20, p=0.00018) in two adjacent genes – WNT3 and WNT9b 
respectively.  Whilst these SNPs remained significant in the meta-analysis, there was 
evidence of convergene (p=0.010) due to lack of signal in the ileal only N American 
GWAS dataset. 
Conclusions.  This analysis of WTCCC data has provided preliminary evidence for 
association at SUFU and at the WNT3 / WNT9b locus.  SUFU is noteworthy as it is a 
direct binding partner of GLI1, but it is presently not possible to ascribe the 
association directly to SUFU as it is in a very large block of tight LD.  The WNT3 / 
WNT9b locus is of considerable interest as both of these genes are highly expressed in 
Paneth cells. However, given the absence of a signal in the purely ileal cohort it is 
difficult to argue biological plausibility for this association.  Both of these datasets 
would require urgent replication in large independent cohorts, with additional fine-
mapping studies, before firm conclusions can be drawn. 
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8.2 Introduction 
In Chapter 4 it was demonstrated that key HH pathway components are differently 
expressed in both CD and UC when compared with the healthy colon (Figures 4-4 
and 4-6).  Whilst there was no consistent expression changes between CD and HC for 
SHH and IHH, the HH pathway response elements PTCH and GLI1 were decreased 
in colonic CD compared with comparable HC biopsies (Figure 4-6).  The observed 
decrease in HH pathway activity in CD, coupled with the published report of an 
Ashkenazi pedigree with significant overlap of CD and basal cell naevus syndrome 
(mutant PTCH)414, 415 and the purported role of HH in Paneth cell differentiation,332 
suggest that HH may play an important role in CD pathogenesis. 
 
Whislt the WNT pathway has central roles in the maintenance of intestinal stem cells 
and in colon cancer pathogenesis, relatively little is known about its function in 
response to acute or chronic inflammatory challenge in the intestine.  The intestinal 
expression profiles of WNT pathway components have been carefully described.398  
In Chapter 4, relatively modest expression changes were noted in several of the 
intestinally expressed WNTs in UC and CD (Table 4-3 and Figure 4-11). 
 
The data from the WTCCC GWAS, discussed in detail in Chapter 1 (1.5.2.3), has 
been made publically available.81  In keeping with one of the stated aims of the study, 
the summary genotype statistics are free for download to anyone with an internet 
connection; the full raw datasets available on application to qualified researchers.  As 
such, data are available on the controls samples (1958 British Birth Cohort and UK 
Blood Service) and the diseases studied in phase I (CD, rheumatoid arthritis, coronary 
heart disease, hypertension, type I and type II diabetes mellitus, and bipolar disorder). 
 
Given the potential role of HH signalling in CD pathogenesis, and the documented 
role of germline GLI1 variation in IBD pathogenesis (Chapter 5), it was hypothesised 
that germ-line variation in other HH pathway genes was associated with CD.  The aim 
of this study was therefore to mine the available WTCCC data for SHH, IHH, DHH, 
DISP1, PTCH, PTCH2, SMO, HHIP, GLI1, GLI2, GLI3, SUFU and KCTD11 and 
perform a case-controlled study for all available SNPs.  Furthermore, given the likely 
cross-talk between HH and WNT signalling in the healthy and inflamed intestine 
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(Chapters 1, 2 and 4), all 27 WNT signalling genes with known intestinal expression 
signatures were analysed for association in the same manner.  For both datasets, the 
meta-analysis of U.K., European and N American CD GWAS data was used for initial 
replication of positive associations.103 
8.3 Methods 
8.3.1 Analysis of WTCCC data 
In the main WTCCC study, 17,000 samples (14,000 cases and 3,000 shared healthy 
controls) were genotyped on GeneChip 500K Mapping Array Set (Affymetrix chip), 
comprising 500,568 SNPs.81  Genotypes for each SNP for every individual were 
called using a new, custom-designed programme CHIAMO, with only 0.16% 
discordance on analysis of 108 duplicate genotypes.  93.8% of SNPs passed WTCCC 
quality control; of these, 392,575 had MAF >1%, 45,106 MAF <0.1%.81    
 
The summary genotype statistics for CD from the WTCCC study were downloaded 
from http://www.wtccc.org.uk/info/summary_stats.shtml.  These text files provide the 
following data for each SNP: SNP identification (Affymetrix id and rs number), 
chromosomal position and alleles, the average maximum posterior call (a measure of 
the certainty of the calls), genotypes for cases and controls (actual numbers given for 
11, 12 and 22 at each SNP), as well as p-values (calculated by both an additive and a 
general model) and an assessment of clustering (good or bad).  For CD, 2 main 
control datasets are available: 1) all other WTCCC cases combined (n=12,000; 
designated CC) and 2) the main WTCCC control cohort (n=3000; HC).  Replication 
of all SNPs that attained significance (p<0.05) on analysis 2 (CD vs. HC) was 
performed by analysis of CD vs. HC data from the meta-analysis of U.K., European 
and N American GWAS (full description of the meta-analysis and methods is detailed 
in 1.5.3), performed by Jeffrey Barrett.103 
 
The chromosomal location of all HH and WNT pathway genes was determined by 
HapMap / Ensembl, and the number / position of WTCCC SNPs within each gene 
noted (Tables 8-1 and 8-3 and Figures 8-1 – 8-10).  The haplotype structure for each 
gene was downloaded from HapMap (Data Release 23a/phaseII March 08, on NCBI 
B36 assembly, db SNP b126) and visualised in Haploview (version 4.2) with the 
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position of WTCCC SNPs plotted. 1Mb of WTCCC data around each gene was 
extracted into a Microsoft Excel spreadsheet for analysis.  Given the large amount of 
data requiring analysis, a series of functions were automated within Excel to calculate 
allelic call rates and frequencies, chi2 analysis (2-tailed, with and without Yates 
correction), odds ratio and 95% confidence intervals.  Data for all genes were 
processed through this algorithm for two primary analyses: CD vs. CC (analysis 1) 
and CD vs. HC (analysis 2).  A significance threshold was initially set at the 
conventional alpha level of < 0.05; given the candidate gene/pathway – based analysis 
performed, genome-wide levels of significance are not appropriate for this study.  In 
addition, a Bonferroni correction was made to each pathway dataset based on the 
number of SNPs analysed: p < 0.00028 for HH (179 SNPs) and p < 0.00019 for WNT 
(257 SNPs).  Further to identifying those SNPs within HH and WNT genes that 
reached significance in both analyses, SNPs in neighbouring regions were scanned to 
detect, for example, promoter polymorphisms that achieved significance.  
8.4 Results 
8.4.1 Analysis of WTCCC data for HH signalling components in CD 
Out of the 13 HH pathway genes analysed, no WTCCC SNPs were present in IHH, 
DHH and KCTD11 and there was only one SNP in SHH (Table 8-1).  The position of 
all WTCCC SNPs in the 10/13 genes with genotype data available are demonstrated 
on Haploview gene maps for GLI3 (Figure 8-1), SUFU (Figure 8-2 and 8-3), GLI2 
(Figure 8-4, 8-5 and 8-6), DISP1 (Figure 8-7), HHIP (Figure 8-8), SHH (Figure 8-
9), PTCH (Figure 8-10), PTCH2 (Figure 8-11), SMO (Figure 8-12) and GLI1 
(Figure 8-13).  
 
In total, 24 SNPs of 179 (13.4%) analysed within HH pathway genes attained 
significance on chi2 analysis of CD vs. CC (analysis 1): 1 in GLI3, 13 in SUFU, 8 in 
GLI2, 1 in DISP1 and 1 in HHIP (significant SNPs denoted with red arrows in 
Figures 8-1 – 8-8).  However, none of these SNPs remained significant after 
Bonferroni correction.  On analysis of CD vs. HC (analysis 2), 17/24 SNPs remained 
significant: 1 in GLI3, 10 in SUFU, 4 in GLI2, 1 in DISP1 and 1 in HHIP (Table 8-2).  
No additional SNPs were significant on analysis of CD vs. HC.  
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The most significant SNP was rs147172020 in GLI3 (p = 9.4 x 10-6 and 0.024 on 
analyses 1 and 2 respectively) with OR 15.79.  However, this was a very rare 
polymorphism with MAF of 0.0017 in the CD population and no mutant homozygotes 
in either population.  Furthermore, an additional 43 GLI3 SNPs analysed did not reach 
significance.  Meta-analysis data for rs147172020 was not available. 
 
10/22 SNPs in SUFU were significant on both analyses (Table 8-2).  There is a very 
large area of tight LD extending throughout and beyond this 129kb gene (Figures 8-2 
and 8-3).  As such the significance level for all of these genes was roughly equivalent 
(p = 0.016 – 0.036 on analysis 1) with a consistent OR of 0.92.  All these SNPs 
achieved greater levels of significance for association with CD on analysis of GWAS 
meta-analysis data (p = 0.0047 – 0.0082). Furthermore, the haplotype block extends 
into neighbouring genes, including ACTR1A (ARP1 actin-related protein 1 homolog 
A), TRIM8 (tripartite motif-containing 8) and NFKB2 (nuclear factor of kappa light 
polypeptide gene).  
 
8/47 SNPs in GLI2 reached significance on analysis 1, although 4/8 dropped out in 
analysis 2.  Of particular note was a cluster of 4 adjacent SNPs in an intronic region of 
GLI2, corresponding to a discrete block of LD (block 3 on Figure 8-5).  These 4 
SNPs were significant on both analysis 1 and 2 (p=0.02 and 0.04 respectively) with 
OR 1.09.  The other 4 GLI2 SNPs were only significant on analysis 1; 3 of these 
SNPs had MAF of < 0.01.  However, these 4 SNPs were no longer significant in the 
GWAS meta-analysis (Table 8-2). 
 
rs6668249, the one significant SNP in DISP1 out of 31 analysed, had a p-value of 
0.025 in both analyses with OR 0.92.  Of note, this SNP was in a haplotype block 
spanning a large intronic region in which the other 9 SNPs analysed did not attain 
significance.  rs6668249 was also not significant in the meta-analysis (Table 8-2).  
The HHIP SNP, rs973796, was located within the promoter region of the gene; 16 
other SNPs within the same large block of LD spanning HHIP were not associated 
with CD. 
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8.4.2 Analysis of WTCCC data for WNT signalling components in 
CD 
27 genes from the WNT / β-catenin signalling pathway were chosen for analysis 
based on detailed published healthy adult expression patterns in the murine 
intestine.398  Of these, 21 had WTCCC SNPs within the gene itself (Table 8-3).  As 
the HH analysis of CD vs. CC generated 7/24 2(9.2%) false positives but no false 
negative, only CD vs. HC analysis was performed for these WNT genes.  36/257 
(14.0%) SNPs were associated with CD; 2 were significant at the Bonferroni 
corrected threshold of p<0.00019 (in WNT3 and WNT9b), 4 at p<0.01 (in FZD6, 
sFRP1 and TCF4) and a further 30 at <0.05 (WNT6, LRP5, LRP6, and TCF-2).   
 
The two most significant SNPs were located at the WNT3 and WNT9b locus on 
chromosome 17: rs2083798 (p=0.00015, OR 1.20 (C.I. 1.09-1.32) and rs2083797 
(p=0.00018, OR 1.20, C.I. 1.09-1.32) (Figure 11a).  Whilst rs2083798 and rs2083797 
remained significant in the meta-analysis, there was evidence of convergence for both 
SNPs (p = 0.010).  
8.5 Discussion 
In the present study, preliminary evidence is provided from publically available 
WTCCC data for association of 5 HH pathway genes GLI3, SUFU, GLI2, DISP1, and 
HHIP with CD.  Only one SNP each in GLI3, DISP1 and HHIP was associated, and 
these may be of less significance.  In contrast, multiple adjacent SNPs were associated 
in SUFU and GLI2, and these should be prioritised for further analysis.  Along with 
GLI1 (Chapter 4), all 3 of these genes are involved in the cellular transduction of the 
HH signal.  It is noteworthy that SUFU binds directly to both GLI1 and GLI2, thus 
hinting at a potential functional mechanism to link with the association of these 3 HH 
pathway genes.  However, after analysing meta-analysis data from WTCCC, 
French/Belgium and N American GWAS studies, only SUFU remained as a potential 
CD susceptibility gene in the HH pathway, with evidence for a mild protective effect 
in 10 adjacent SNPs (OR 0.92).  This region requires further independent replication 
before reaching any firm conclusions.  However, given the strength of association 
observed any replication cohort will need to be suitably powered, such as the WTCCC 
CD replication cohort (n = 1,182 CD and 2,024 HC) within the UK.89   
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Were this association to hold up after further replication, fine-mapping studies would 
be required.  As SUFU is located in an area of extensive tight LD containing several 
other genes (ACTR1A, TRIM8 and NFKB2), it is presently not possible to attribute the 
association to this gene.  It is also of some interest that SUFU is located only 24.9Mb 
from DLG5 which, despite initial promise as a CD gene, has failed to be consistently 
replicated across multiple populations.78  Determination of causal variants in this 
region would require a very large study, with hundreds of SNPs genotyped in several 
thousand patients and controls.  Even then, it may be impossible to determine 
causality given the small effect size and tight LD.  For example, it has not yet been 
possible over the past 7 years to ascribe causality to an individual gene, let alone 
individual mutations in the IBD5 region. 
 
The design of the present study used two different control populations for comparison 
of SNPs within HH genes with the CD cohort.  The use of the combined cases as a 
control cohort provided increased power to detect small association signals, but none 
of the 12,000 samples are true HCs.  Thus, there is the possibility of both false 
positive and false negative results.  To counter this, all regions were additionally 
analysed against the true HC population.  No additional SNPs were associated with 
CD on analysis 2.  However, 29.2% of SNPs associated on analysis 1 dropped out at 
this stage.  The allelic frequencies were very similar between both ‘control’ 
populations with no significant differences between the populations.   
 
Because of this, on analysing 27 WNT pathway genes, only analysis 2 was performed.  
Whilst there were several genes with modest evidence for association with CD, the 
WNT3 / WNT9b region is notable for a number of reasons.  Firstly, the two mostly 
significant SNPs in this region satisfied stringent correction for multiple testing by 
Bonferroni method.  Secondly, the associated SNPs span two adjacent genes within 
the WNT pathway.  Thirdly, these genes are of significant biological interest as they 
are highly expressed in murine Paneth cells.398  It was therefore anticipated, that if the 
association at this loci were real, the significance level would increase in the meta-
analysis containing the N American cohort with ileal only disease.  However, the 
meta-analysis at the two most significant SNPs demonstrated substantial convergence.  
There are two possible explanations for this observation.  Either, the observed 
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association at this locus is not real, or the expression of WNT3 and WNT9b is 
misleading and these genes are associated with colonic disease.  The microarray 
analysis in Chapter 4 demonstrated up-regulation of WNT9b in inflamed UC 
(p=0.022), but no alterations for either gene in colonic or terminal ileal CD. 
 
Of the other WNT genes with significant associations described here, the expression 
profiles of WNT6, LRP6, TCF2 and TCF4 are of interest (Table 4-3).  WNT6 was 
decreased in colonic CD but, of note, only with non-inflamed samples (p=0.0003).  
LRP6 and TCF2 were both decreased in inflamed colonic CD (p=0.001 and 0.0025 
respectively).  TCF4 expression was higher in UC (p=0.021) and colonic CD 
(p=0.0038), but dysregulated expressed was not seen in terminal ileal CD.  This is in 
contrast to the report by Wehkamp and Stange, who have described decreased TCF4 
expressoin in terminal ileal CD, irrespective of inflammatory status and independent 
of NOD2 genotype.421 
 
This study additionally illustrates the variation in tagging density of certain genomic 
regions on the Affymetrix 500k chip (Figures 8-1 – 8-15).  As demonstrated, it is 
particularly poor at tagging small genes.  In addition to performing replication of the 
associated SNPs from this preliminary analysis, a detailed gene-wide haplotype-
tagging strategy should be employed for all of these genes before finally concluding 
lack of association.   
 
The use of the publically available WTCCC data has provided potentially important 
insights into the role of germ-line variation of HH signalling components (SUFU in 
addition to the previous evidence for association at GLI1) and WNT signalling genes 
(WNT3 / WNT9b) in CD pathogenesis.  All of these genes are critical to the normal 
development of the gastrointestinal tract, as is the homeodomain gene NKX2.3, a HH 
target and confirmed IBD susceptibility gene.  It would be of great interest to extend 
this approach to other developmental signalling pathways of established homeostatic 
importance in the GI tractment (e.g. Notch, BMP and hox and sox genes).  Given all 
of this data, a pathway-based analysis such as that recently reported for axon-
guidance pathway genes from GWAS data in Parkinson’s disease,464 could then be 
performed.   
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SNPs in gene 
Sonic hedgehog 
(SHH) 















1q41 221168406 – 
221245960 
77.6 31 
















4q31.2 145786623 – 
145879337 
92.7 17 
GLI1 12q13.3 56140201 – 
56152312 
12.1 3 
GLI2 2q14.2 121266327 – 
121466321 
200.0 47 





10q24 104253734 – 
104383282 
129.5 22 




Table 8-1  HH pathway genes. 
Details are given of the major HH pathway genes, including genomic location, and the number of SNPs 
from the WTCCC GWAS present within each gene. 
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CD vs CC: p 
Analysis 2: 
CD vs HC: p  
Meta-
analysis: p OR (CD vs HC1) 
GLI3 rs17172020 41980236 A/T 0.0017 0.0001 0.0002 9.4x10-6 0.024 n/t 15.79 (3.19-78.3) 
SUFU rs10786680 104307182 G/A 0.4118 0.4316 0.4322 0.028 0.051 0.0093 0.92 (0.86-0.99) 
SUFU rs10786682 104308312 A/C 0.4107 0.4316 0.4324 0.020 0.037 0.0068 0.92 (0.85-0.99) 
SUFU rs10883736 104310019 T/G 0.4109 0.4317 0.4325 0.021 0.039 0.0070 0.92 (0.85-0.99) 
SUFU rs10786684 104313018 A/C 0.4103 0.4316 0.4325 0.018 0.034 0.0058 0.92 (0.85-0.99) 
SUFU rs10786685 104313093 T/C 0.4103 0.4299 0.4315 0.029 0.043 0.0072 0.92 (0.86-0.99) 
SUFU rs729023 104331877 A/G 0.4110 0.4325 0.4332 0.017 0.034 0.0047 0.92 (0.85-0.98) 
SUFU rs11191347 104341607 T/C 0.3355 0.3537 0.3524 0.036 0.094 0.0064 0.92 (0.86-1.00) 
SUFU rs4917976 104350508 A/G 0.4101 0.4316 0.4323 0.016 0.033 0.0053 0.92 (0.85-0.98) 
SUFU rs7075269 104355714 T/C 0.4103 0.4314 0.4323 0.019 0.036 0.0058 0.92 (0.85-0.99) 
SUFU rs4919665 104356032 C/T 0.4109 0.4320 0.4324 0.019 0.040 0.0064 0.92 (0.85-0.99) 
SUFU rs4917978 104356343 C/T 0.4109 0.4317 0.4321 0.020 0.043 0.0069 0.92 (0.85-0.99) 
SUFU rs7907417 104360652 A/G 0.4106 0.4316 0.4322 0.019 0.038 0.0062 0.92 (0.85-0.99) 
SUFU rs12414407 104377009 A/G 0.3446 0.3637 0.3609 0.029 0.105 0.0082 0.92 (0.85-0.99) 
GLI2 --- 121277641 A/G 0.4048 0.3839 0.3836 0.020 0.044 n/t 1.09 (1.01-1.17) 
GLI2 rs12475334 121278033 T/C 0.4036 0.3834 0.3823 0.024 0.043 0.233 1.09 (1.01-1.17) 
GLI2 rs746345 121278448 C/A 0.4043 0.3836 0.3832 0.022 0.047 0.217 1.09 (1.01-1.17) 
GLI2 rs4848632 121278825 T/C 0.4042 0.3834 0.3833 0.020 0.047 0.207 1.09 (1.01-1.17) 
GLI2 rs4378815 121419363 G/C 0.0140 0.0099 0.0104 0.031 0.138 n/t 1.44 (1.05-1.97) 
GLI2 rs2311803 121419853 T/C 0.0137 0.0098 0.0102 0.042 0.149 n/t 1.42 (1.03-1.94) 
GLI2 rs17005499 121425671 A/G 0.0034 0.0014 0.0019 0.014 0.210 n/t 2.49 (1.27-4.86) 
GLI2 rs12711535 121425766 G/A 0.0607 0.0514 0.0518 0.025 0.074 0.058 1.20 (1.03-1.39) 
DISP1 rs6668249 221205568 A/G 0.4456 0.4658 0.4693 0.025 0.025 0.100 0.92 (0.86-0.99) 
HHIP rs973796 145781573 C/A 0.3670 0.3869 0.3927 0.024 0.013 0.042 0.92 (0.85-0.99) 
Table 8-2  WTCCC data analysis on HH pathway genes. 
Minor allelic frequencies (MAF) are given for WTCCC CD population, all non-CD WTCCC cases combined (CC) and WTCCC healthy controls (HC).  All SNPs within 
hedgehog pathway genes (detailed in Table 1) from WTCCC GWAS that reached significance (p < 0.05) on analysis 1 (CD vs. CC) are listed, followed by analysis 2 (CD vs. 
HC) along with odds ratio and 95% confidence intervals derived from analysis 1.  The meta-analysis p-values is presented for those SNPs present in the meta-analysis of 
WTCCC, French / Belgium and N American GWAS studies (data provided by Jeffrey Barrett). Those SNPs not tested in the meta-analysis are indicated by ‘n/t’.  
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GENE Chr. Position (bp) Gene Size 
(kb) 
No. WTCCC 
SNPs in gene 
WNT2b 1 112,811,563 – 112,865,428 53.9 4 (0) 
WNT3 17 42,196,859 – 42,251,081 54.2 6 (1+) *** 
WNT4 1 22,318,787 – 22,342,197 23.4 7 (0) 
WNT5a 3 55,474,784 – 55,496,371 21.6 3 (0) 
WNT5b 12 1,596,483 – 1,626,638 30.2 10 (0) 
WNT6 2 219,432,790 – 219,447,198 14.4 3 (1) * 
WNT9b 17 42,283,967 – 42,309,436 25.5 5 (2+) *** 
FZD4 11 86,334,370 – 86,344,081 9.71 1 (0) 
FZD5 2 208,335,557 – 208,342,388 6.83 0 (0) 
FZD6 8 104,380,276 – 104,414,268 34.0 7 (3) ** 
FZD7 2 202,607,555 – 202,611,405 3.85 0 (0) 
LRP5 11 67,836,684 – 67,973,319 136.6 12 (3) * 
LRP6 12 12,164,958 – 12,311,013 146.1 11 (3) * 
sFRP1 8 41,238,636 – 41,286,137 47.5 12 (4) ** 
sFRP5 10 99,516,508 – 99,521,760 5.25 0 (0) 
DKK3 11 11,941,121 – 11,986,762 45.6 19 (0) 
DKK4 8 42,350,744 – 42,353,831 3.09 1 (0) 
TCF1 12 119,900,932 – 119,924,695 23.8 5 (0) 
TCF2 17 33,120,548 – 33,179,182 58.6 20 (2) * 
TCF3 19 1,560,295 – 1,601,277 41.0 0 (0) 
TCF4 18 51,045,967 – 51,406,441 360.5 55 (10) ** 
APC 5 112,101,483 – 112,209,834 108.4 6 (0) 
CTNNB1 3 41,216,016 – 41,256,938 40.9 3 (0) 
AXIN1 16 277,441 – 342,465 65.0 10 (0)  
ATOH 4 94,969,101 – 94,970,165 1.07 0 (0) 
GSK3α 19 47,426,178 – 47,438,576 12.4 0 (0) 
GSK3β 3 121,028,238 – 121,295,203 360.0 18 (0) 
 
Table 8-3  WNT pathway genes. 
Details of the WNT genes included in analysis of WTCCC data, including chromosomal position, gene 
size, number of WTCCC SNPs in each gene (plus number of significant SNPs (p<0.05) in each gene).  
* p<0.05, ** p<0.01, *** p<0.00019 (Bonferroni correct significance threshold). 
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MAF CD vs. HC:p Meta-analysis: p OR (C.I.) 
WNT3 rs199515 42211804 C/G 0.193 0.223 0.0005 0.00051 0.83 (0.75-0.92) 
WNT3 rs2083798 42276896 C/T 0.289 0.253 0.0001 0.010 1.20 (1.09-1.32) 
WNT9b rs2083797 42276928 G/A 0.288 0.253 0.0002 0.010 1.20 (1.09-1.32) 
WNT9b rs12602434 42283052 C/G 0.157 0.139 0.0149 0.050 1.16 (1.03-1.30) 
WNT9b rs4968279 42285344 C/T 0.158 0.139 0.0129 0.056 1.16 (1.03-1.31) 
TCF2 rs11263756 33123933 A/G 0.027 0.036 0.0187 0.054 0.75 (0.59-0.96) 
TCF2 rs2189303 33134218 A/G 0.251 0.233 0.0442 n/t 1.11 (1.00-1.22) 
LRP6 rs12313200 12175857 A/G 0.155 0.174 0.0164 0.21 0.87 (0.78-0.98) 
LRP6 rs12422312 12239176 A/G 0.146 0.163 0.0269 n/t 0.88 (0.78-0.99) 
LRP6 rs12425946 12302231 T/C 0.145 0.163 0.0174 n/t 0.87 (0.77-0.98) 
WNT6 rs2059717 219425821 T/A 0.474 0.495 0.0465 n/t 0.92 (0.84-1.00) 
WNT6 rs608047 219441415 A/C 0.474 0.495 0.0463 n/t 0.92 (0.84-1.00) 
LRP5 rs312786 67876553 A/C 0.293 0.314 0.0333 n/t 0.91 (0.83-0.99) 
LRP5 rs576118 67934284 C/T 0.241 0.260 0.0404 n/t 0.90 (0.82-1.00) 
LRP5 rs3736228 67957871 A/G 0.133 0.151 0.0170 n/t 0.86 (0.76-0.97) 
LRP5 rs3867143 67979650 G/A 0.138 0.156 0.0158 n/t 0.86 (0.77-0.97) 
FZD6 rs827536 104392202 G/T 0.524 0.558 0.0020 0.043 0.87 (0.80-0.95) 
FZD6 rs703810 104403014 C/T 0.120 0.106 0.0454 n/t 1.14 (1.00-1.30) 
FZD6 rs3808554 104406272 C/T 0.452 0.480 0.0106 0.054 0.90 (0.82-0.97) 
sFRP1 rs4736959 41244318 G/A 0.432 0.408 0.0227 0.044 1.10 (1.01-1.20) 
sFRP1 rs7843510 41254926 G/A 0.418 0.393 0.0170 0.042 1.11 (1.02-1.21) 
sFRP1 rs7834090 41261852 T/C 0.043 0.032 0.0058 0.022 1.36 (1.09-1.69) 
sFRP1 rs7833518 41262183 T/G 0.414 0.388 0.0124 0.035 1.12 (1.02-1.22) 
TCF4 rs1942265 51066565 G/C 0.304 0.282 0.0297 n/t 1.11 (1.01-1.21) 
TCF4 rs4800988 51070904 A/T 0.303 0.283 0.0399 n/t 1.10 (1.00-1.21) 
TCF4 rs1539951 51072671 C/T 0.304 0.283 0.0318 n/t 1.11 (1.01-1.21) 
TCF4 rs1788027 51093825 T/C 0.470 0.448 0.0364 n/t 1.09 (1.01-1.19) 
TCF4 rs1660241 51186648 A/G 0.310 0.282 0.0042 0.021 1.14 (1.04-1.25) 
TCF4 rs1660242 51189674 T/A 0.437 0.414 0.0301 n/t 1.10 (1.01-1.20) 
TCF4 rs9320010 51204895 G/A 0.423 0.395 0.0156 n/t 1.11 (1.02-1.21) 
 - 208 - 
TCF4 rs7235757 51218952 T/C 0.345 0.320 0.0138 0.028 1.12 (1.02-1.22) 
TCF4 rs2919451 51235298 T/C 0.420 0.395 0.0182 n/t 1.11 (1.02-1.21) 
TCF4 rs2958163 51236410 C/T 0.481 0.457 0.0234 n/t 1.10 (1.01-1.20) 
 
Table 8-4  WTCCC data analysis on WNT pathway genes. 
WTCCC SNPs from WNT pathway genes reaching significance (p<0.05) on analysis of CD vs. WTCCC HC.  SNPs with MAF < 1.0% excluded from analysis.  The meta-
analysis p-values is presented for those SNPs present in the meta-analysis of WTCCC, French / Belgium and N American GWAS studies (data provided by Jeffrey Barrett). 
Those SNPs not tested in the meta-analysis are indicated by ‘n/t’.  
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CD vs. HC 
p-value OR 
rs199535 42177829 G/A 0.193 0.224 0.0004 0.83 (1.09-1.34 
rs13341140 42181223 G/C 0.188 0.222 7.38 x10-5 0.81 (0.73-0.90) 
rs199530 42191820 C/T 0.220 0.254 0.0002 0.83 (0.75-0.92) 
rs199515 42211804 C/G 0.193 0.223 0.0005 0.83 (0.75-0.92) 
rs199496 42221887 A/G 0.084 0.092 0.2137 0.91 (0.79-1.06) 
rs12452064 42223353 A/G 0.439 0.433 0.5945 1.02 (0.94-1.11) 
rs199495 42223596 A/G 0.422 0.424 0.8507 0.99 (0.91-1.08) 
rs199494 42224229 G/A 0.428 0.432 0.7261 0.98 (0.90-1.07) 
rs7207916 42234514 T/C 0.418 0.420 0.8258 0.99 (0.91-1.08) 
rs2083798 42276896 C/T 0.289 0.253 0.0001 1.20 (1.09-1.32) 
rs2083797 42276928 G/A 0.288 0.253 0.0002 1.20 (1.09-1.32) 
rs12602434 42283052 C/G 0.157 0.139 0.0149 1.16 (1.03-1.30) 
rs4968279 42285344 C/T 0.158 0.139 0.0129 1.16 (1.03-1.31) 
rs8082211 42296034 T/C 0.001 0.001 0.2776 2.24 (0.50-10.0) 
rs12952746 42298412 A/G 0.112 0.124 0.1014 0.90 (0.79-1.02) 
rs1530364 42306776 A/G 0.295 0.295 0.9603 1.00 (0.91-1.09) 
rs17603901 42313021 A/G 0.101 0.107 0.3407 0.94 (0.82-1.07) 
 
Table 8-5  Data analysis of WTCCC SNPs in region of WNT3 and WNT 9b on chromosome 17.
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Figure 8-1  Haplotype structure of GLI3; 276kb view. 
This, and all subsequent figures in the chapter, are generated in Haploview vers. 4.2, and derived from phase II CEPH (U.S. residents in 1980 of N and W European 
ancestry). HapMap data. LD values are calculated by D (red squares indicate tight LD).  
GLI3: 276kb view 
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Figure 8-2  Haplotype structure of SUFU; 1mb view. 
This figure demonstrates the extensive LD across SUFU: the 200kb area in the box is viewed in greater detail in Figure 8-3. 
SUPPRESSOR OF FUSED (SUFU): 1mb view
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Figure 8-3  Haplotype structure of SUFU; 200kb view. 
Expanded view of box in Figure 8-2.  The position of WTCCC SNPs is demonstrated by arrows. The red arrows are those that reached significance (p<0.05) on analysis 1. 
SUPPRESSOR OF FUSED (SUFU): 200kb view 
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Figure 8-4 Haplotype structure of GLI2; 200kb view.  
Magnified views of boxes A and B are depicted in Figures 8-5 and 8-6 respectively. 
 
GLI2: 200kb view 
A B
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Figure 8-5  Haplotype structure of GLI2 – fragment A from 8-4; 18kb view. 
The position of WTCCC SNPs is demonstrated by arrows. The red arrows are those that reached significance (p<0.05) on analysis 1. Those HapMap SNPs that were typed in 
the WTCCC study are outlined in red.
GLI2: 18kb fragment (A)
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Figure 8-6  Haplotype structure of GLI2 –fragment B from 8-4; 57kb view. 
The position of WTCCC SNPs is demonstrated by arrows. The red arrows are those that reached significance (p<0.05) on analysis 1. Those HapMap SNPs that were typed in 
the WTCCC study are outlined in red.
GLI2: 57kb fragment (B)
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Figure 8-7 Haplotype structure of DISP1; 100kb view. 
The position of WTCCC SNPs is demonstrated by arrows. The red arrows are those that reached significance (p<0.05) on analysis 1.  
DISPATCHED (DISP1): 100kb view
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Figure 8-8 Haplotype structure of HHIP; 100kb view. 
The position of WTCCC SNPs is demonstrated by arrows. The red arrows are those that reached significance (p<0.05) on analysis 1.  
 
 
Hedgehog-interacting Protein (HHIP): 100kb view 
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Figure 8-9 Haplotype structure of SHH; 40kb view. 
The position of the only WTCCC SNP is demonstrated by blue arrow. 
 
SONIC HEDGEHOG (SHH): 40kb view
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Figure 8-10 Haplotype structure of PTCH; 100kb view. 
The position of WTCCC SNPs is demonstrated by blue arrows.  
 
PATCHED (PTCH1): 100kb view
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Figure 8-11 Haplotype structure of PTCH2; 40kb view. 
The position of WTCCC SNPs is demonstrated by blue arrows.  
PATCHED-2 (PTCH2): 40kb view 
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Figure 8-12 Haplotype structure of SMO; 40kb view.  
The position of WTCCC SNPs is demonstrated by blue arrows.  
SMOOTHENED (SMO): 40kb view
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Figure 8-13 Haplotype structure of GLI1; 16kb view. 
The position of WTCCC SNPs is demonstrated by arrows.  Those HapMap SNPs that were typed in the 
WTCCC study are outlined in red.  The four tSNPs genotyped in the gene-wide haplotype-tagging 









GLI1: 16kb view 
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Figure 8-14 Haplotype structure of locus spanning WNT3 and WNT9b; 120kb view. 
The position of WTCCC SNPs is demonstrated by arrows. The red arrows are those that reached significance (*** p<0.00019, ** p<0.01, * p<0.05).  
 
 
WNT3 and WNT9b: 120kb view
****** ** *
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Figure 8-15 Haplotype structure of locus spanning WNT3 and WNT9b; 700kb view. 
WNT3 and WNT9b: 700kb view
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9.1 Abstract 
Introduction.  As shown in the expression studies in Chapter 4, HH pathway activity 
increases along the length of the healthy adult colon, mirroring the increased bacterial 
burden in the colonic lumen.  It was therefore hypothesised that HH pathway 
expression might be increased by pathogen-associated molecular patterns (PAMPs) in 
colonic epithelial cells in vitro.  Furthermore, NFκB activity has been shown to 
modulate SHH expression in keratinocytes and pancreatic cells in vitro.  In addition, 
HH pathway agonists and antagonists are known to modulate cytokine synthesis and 
secretion in peripheral CD4 T cells. The aims of the present study were therefore to 
assess the affect of PAMPs on HH pathway expression, and of HH agonists and 
antagonists on NFκB activity and cytokine synthesis and secretion in vitro.   
Methods.  Colonic epithelial adenocarcinoma cells (SW480) were stimulated in vitro 
with varying concentrations of LPS and MDP at different timepoints (up to 24 hours). 
The expression of SHH and PTCH mRNA was measured by Q-PCR (18s RNA was 
used as an internal control) and of nuclear GLI1 and p65 protein expression by 
immunohistochemistry.  NFκB luciferase reporter assays were performed in SW480 
cells treated with cyclopamine, rSHH and LPS for 24 hours.  SW480 cells and 
PBMCs from patients with acute active UC were treated with rSHH or the HH agonist 
purmporphomine for 24 hours.  Cytokine profiles (CCL20, IL8, IL1ß, IL10 and 
TNFα) were measured in culture supernatant by ELISA. 
Results.  SW480 cells express SHH, PTCH and GLI1 mRNA, NOD2 protein 
(cytoplasmic) and p65 protein (cytoplasmic and nuclear).  2.0µg/ml of LPS induced a 
modest increase in SHH at 2 hours (p<0.05).  2.0µg/ml of MDP resulted in a 
significant decrease in PTCH mRNA after 1 hour, peaking at 4 hours (p<0.05).  The 
increase in nuclear p65 staining induced by 2.0µg/ml LPS was abrogated with the HH 
antagonist cyclopamine.  However, neither rSHH nor cyclopamine significantly 
altered NFκB activity at 24 hours.  rSHH, but not purmorphamine, led to a robust 
increase in CCL20 in PBMCs from patients with active UC.  However, 
purmorphomine, but not rSHH, caused decreased CCL20 in SW480 cells. 
Conclusions.  Whilst some interesting effects were observed with respect PAMP 
stimulation and purmorphomine treatement of SW480 cells, no effect was seen on 
NFκB activity.  Recent advances highlighting the paracrine nature of HH signalling in 
the small intestine and colon have subsequently questioned the validity of SW480 
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cells as a model for studies of HH signalling and inflammation.  However, the studies 
of PBMCs with rSHH in patients with active UC have demonstrated a clear response 
in CCL20, suggesting exciting avenues for further exploration. 
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9.2 Introduction 
As discussed in Chapter 1, different groups have reported variable expression of HH 
signalling components within different colonic cell lines.  Between 2003 and 2006 
(when the present in vitro studies were conducted), there was hot debate within the 
published literature (in vivo and in vitro expression data) as to whether autocrine HH 
signalling occurred in colonic epithelial cells, particularly in colonic adenocarcinoma 
cell lines.  This has only very recently been conclusively disproven by the intricate 
and detailed series of experiments published by Yauch and colleagues in Nature in 
2008 (see 1.9.1.2),361 although some HH signalling experts still question these 
findings.362 
 
However, the historic studies were consistent at the time with autocrine HH signalling 
in at least some colonic adenocarcinoma cell lines.330, 346, 359  SW480 cells from our 
lab, shown to express SHH, PTCH and GLI1, were therefore used for a series of in 
vitro experiments.   
 
The gradients of HH pathway activity in the healthy adult human colon demonstrated 
in Chapter 4 (Figure 4-3) were striking for two reasons.  Not only does this mirror the 
clincial distrubtion of UC, but it also potentially reflects the increasing bacterial 
burden in the distal, compared with the proximal colon.  In addition, the linear 
regression analysis of GLI1 and potential HH target genes in Chapter 4 demonstrated 
close correlation with the peptidoglycan recognition proteins (PGLYRP1-4).  Firstly, 
therefore, the effect of PAMP (LPS and MDP) stimulation of SW480 cells on SHH, 
PTCH and GLI1 expression was assessed.  Secondly, given reports linking HH and 
NFκB signalling,373 the effect of HH agonists / antagonists on NFκB activity was 
assessed.   
 
Thirdly, given the historic reports linking HH signalling and inflammation, the effect 
of HH agonists on cytokine synthesis and secretion in SW480 cells was tested.  In 
addition, due to the published studies by the Howie group on HH pathway activity 
within peripheral CD4 T cells,365, 366 PBMCs from patients with active UC were used 
for these latter studies. 
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9.3 Methods 
9.3.1 SW480 cell stimulation 
LPS (Escherichia coli 026:B6, lyophilised, sterilised by γ-irradiation, prepared by 
TCA precipitation and gel filtration chromatography; Sigma) and MDP (N-
acetylmuramyl-L-alanyl-D-isoglutamine hydrate; ≥98%; Sigma) were reconstituted in 
1 ml of sterile Dulbecco’s modified eagle’s medium nutrient mixture (15mM HEPES, 
NaHCO3, pyridoxine; Sigma.)  Cells were treated in 25cm2 flasks at 70-80% 
confluence over 24 hours, except where indicated otherwise.  For timecourse 
experiments, all flasks were removed from the incubator at each treatment point (-
24h, -8h, -4h, -2h, -1h, -0.5h, -0.25h) and all harvested simultaneously at timepoint 0 
(24 hours).   
9.3.2 Patients for PBMC analysis 
5 patients (3 female) with acute severe UC were recruited within 24 hours of 
admission to hospital for iv corticosteroid therapy.  All were white Caucasian (4 
Scottish, 1 Polish).  For 3/5 this was the first presentation of UC.  The other 2 patients 
had both been diagnosed 3 years previously.  2 patients were completely treatment 
naïve at the point of PBMC extraction.  1 had been treated with iv steroid for <12 
hours.  2 patients were on long-term oral 5-ASA therapy and had taken 1 and 5 days 
of oral prednisolone.  3 patients were ex-smokers; 2 had never smoked.  Informed, 
written consent was obtained from all patients.   
9.3.3 Treatment of PBMCs 
The methods for extraction of PBMCs over a Ficoll gradient are described in Chapter 
3 (3.9.2). 
9.3.4 RT-PCR, Q-PCR, immunohistochemistry, ELISAs and NFκB 
reporter assay 
Full details on methods are given in chapter 3 (3.9.4 – 3.9.11).  
9.3.5 Statistical analyses 
The Kruskal Wallis one-way analysis of variance test followed by Dunn’s Multiple 
Comparison post-test was used on the non-parametric Q-PCR data, NFκB reporter 
assays and cytokine analysis.  Mann-Whitney U analysis was used to analyse 
proportions of cells with nuclear staining (GLI1 and p65).  2-tailed p-values are given 
throughout (α = 0.05). 
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9.4 Results 
9.4.1 Expression of HH signalling components in SW480 cells 
RT-PCR for SHH, PTCH and GLI1 on mRNA from unstimulated SW480 cells 
identified expression of transcripts for all 3 components of HH signalling (Figure 9-
1).  In addition, protein expression of NOD2 (cytoplasmic) and p65 (predominantly 
cytoplasmic with occasional nuclear expression) was characterised by 
immunofluoresence in unstimulated cells (Figure 9-2).  
9.4.2 HH expression in SW480 cells stimulated with LPS and MDP 
SW480 cells were first stimulated for 24 hours with 2.0 μg/ml LPS (Figure 9-3a).  As 
the greatest increase in SHH expression was noted at 2 hours (p<0.05), cells were then 
stimulated for 2 hours with a concentration gradient of LPS from 0.25 – 5.0 μg/ml 
(Figure 9-3b).  No significant differences were noted in SHH or PTCH expression at 
LPS concentrations of 0.25 – 2.0 μg/ml.  However, PTCH expression was 
significantly decreased at 5.0μg/ml (p<0.05) suggesting down-regulation of HH 
pathway activity with this high concentration of LPS at 2 hours.  Recognising 
previous reports that commercial LPS is contaminated with MDP and that this effect 
might be magnified with higher concentrations, cells were stimulated with 2.0μg/ml 
of MDP over a 4 hour timecourse (Figure 9-3c).  Significant down-regulation of 
PTCH expression was noted from 1 hour (Kruskall-Wallis p=0.065).  This effect was 
sustained to a peak at 4 hours (p<0.05) at the termination of the timecourse. 
 
To further assess the effect of PAMPs on HH pathway activity cells, GLI1 protein 
cellular location was assessed in cells stimulated for 2 hours with 2μg/ml of LPS 
(Figure 9-4a-b).  There was no effect on the percentage of cells with nuclear GLI1 
staining with LPS (25.2±3.2 vs. 23.0±1.7).  In addition there was evidence of 
persistent background staining with omission of primary antibody, although this was 
equivalent in both groups (Figure 9-4c-d). 
9.4.3 NFκB studies 
2.0μg/ml of LPS induced an increase in nuclear p65 accumulation in SW480 cells 
after 2 hours (% cells with nuclear p65 staining: 21.5±2.9 vs. 11.8±1.8, p<0.01) 
(Figure 9-4e-f).  This effect was abrogated with the addition of 2.0μg/ml cyclopamine 
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simultaneous to LPS treatment (13.5±1.1) (Figure 9-4g-h).  This suggested that HH 
may have an effect on NFκB activity. 
 
A NFκB luciferase reporter assay was optimised, with both LPS (Kruskall-Wallis 
p=0.0061) and TNFα (p<0.05) inducing robust increases in NFκB activity (Figure 9-
5a).  Whilst MDP had no effect on NFκB activity, it appeared to have a synergistic 
effect when added to TNFα.  Cyclopamine had no effect on baseline NFκB activity at 
doses of 10μM, 5μM and 1μM when compared with medium only and tomatadine 
(10μM) controls (Figure 9-5b).  Similarly, there was no effect with SHH at 100ng/ml.  
As basal NFκB activity in SW480 cells was low, cells were treated with cyclopamine 
30 minutes prior to LPS.  LPS was used at a physiological dose of 1μg/ml to avoid 
saturating NFκB activity; this produced a mean 1.70-fold increase in NFκB activity.  
Addition of cyclopmaine had no effect on LPS induced NFκB activity at 10μm, 5μm 
or 1μm concentrations (Figure 9-3c). 
9.4.4 Effect of HH agonism on cytokine profiles of SW480 cells and 
PBMCs from patients with UC 
PBMCs from 5 patients with acute active UC were treated with 50ng/ml and 
500ng/ml rSHH and 2.0μM and 10.0μM purmorphomine with 4μl DMSO as control 
for purmophromine and 1μg/ml MDP, 50ng/ml TNF as positive controls.  Culture 
supernatant, assayed for cytokine conentrations by ELISA, demonstrated significant 
increases in CCL20, IL1β, IL10 and TNFα with SHH 500ng/ml (complete cytokine 
profile for one representative patient depicted in Figure 9-6).  CCL20 profiles were 
examined in more detail as this was the most novel finding of greatest potential 
relevance to the colonic epithelial cells under study.   
 
CCL20 concentrations were significantly greater in PBMCs treated with rSHH 
(Figure 9-7a).  A dose-dependent response was observed (Kruskall-Wallis p=0.0086) 
with the maximum concentration at 1000ng/ml (p<0.05).  Purmorphomine had no 
effect on CCL20 (Figure 9-7b).  However, in SW480 cells the opposite effect was 
observed.  rSHH had no effect (Figure 9-7c), whilst purmorphomine decreased 
CCL20 (Kruskall-Wallis p=0.024) with maximal effect at 10.0mM (p<0.05) (Figure 
9-7d).  As basal secretion of CCL20 in SW480 cells was low (mean 62.4 
±13.3pg/ml)), MDP and TNFα were used to increase baseline secretion.  MDP had no 
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effect, but TNFα increased CCL20 (Kruskall-Wallis p=0.0090) with maximal effect at 
50ng/ml (p<0.01) (Figure 9-7e).  Purmorphomine (2μM and 10μM), but not rSHH, 
co-treatment with TNFα decreased CCL20 back to baseline levels (purmorphomine 
2μM and 10μM vs. TNFα 50ng/ml p=0.024). 
9.5 Discussion 
In the present study it has been shown that the NOD2 ligand MDP suppresses PTCH 
expression, that HH inhibition has no consistent effect on NFκB activity, and that 
exogenous SHH induces significant expression of CCL20 in PBMCs in patients with 
active UC. 
 
This series of in vitro studies has a number of problems that have largely come to 
light since 2006 as the published literature has substantially clarified the role of HH 
signalling in both the intestine and immune system.  Of greatest importance, the 
debate between autocrine and paracrine HH signalling in the intestine has now been 
resolved, thanks largely to carefully controlled in vivo experiments in WT and 
genetically modified mice.  HH signalling is exclusively paracrine in the intestine as 
has been demonstrated throughout mammalian development,303 homeostasis 
(Kolterud A et al, personal communication), inflammation (Lees et al, PLoS Medicine 
2008)423 and cancer (1.9.1.2).361   
 
As a result of these developments, it is now clear for a number of reasons that colonic 
adenocarcinoma cell lines, or indeed any intestinal epithelial cells in monoculture, are 
an inappropriate model to address the questions posed here.  Firstly, and most 
importantly, the system is too simple to address a complex and dynamic pathway like 
HH, that signals from epithelium (SHH and IHH) to its response network (PTCH, 
SMO, GLI1) in mesenchymal cells.  Co-culture models (e.g. SW480 cells and Jurkat 
T cells) could go some way to address this; although, a better solution would be to 
stimulate isolated mesenchyme with HH agonists / antagonists (as described in murine 
tissue by Zacharias and colleagues; personal communication).  The optimal models 
are genetically modified mice, as we have subsequently shown with Gli1+/LacZ mice 
(future plans are discussed in detail in Chapter 12).423   
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Secondly, the purtubations in HH signalling in colonic cancer bring into doubt the use 
of an adenocarcinoma cell line to address questions primarily pertaining to 
inflammation.318, 330, 346, 359, 361  This is a big potential flaw in a large body of the 
published IBD literature that has made use of a variety of different colonic 
adenocarcinoma lines over many years.  Thirdly, it is clear that the same cell lines (by 
name at least) vary widely not only between different laboratories but also between 
different passage numbers within the same laboratory.  This latter point, in part, 
contributes to some of the wide error bars plotted for some of the datasets in this 
chapter.  SW480 cells, themselves, are now notorious for their chromosomal 
duplications and high mutation rates with extreme genotyping differences between 
different groups.  Whilst our SW480 cells are similar in their expression of HH 
components to those studied by Qualtrough,359 the Chatel study found no expression 
in their SW480s.360 
 
These factors considered, the fact that PTCH and GLI1 are expressed in the SW480 
cell lines in our lab means that it is worth analysing the outcomes of these 
experiments in a little more depth.  The downregulation of PTCH with MDP is 
noteworthy for a couple of reasons.  Firstly, this seems to be the explanation for the 
change in PTCH expression with higher doses of LPS.  It is now increasingly 
recognised that a large number of standard LPS preparations (like the one used here 
from Sigma) are contaminated with endotoxin and MDP.  Ultra-pure preparations of 
LPS are now commercially available and these could be used to test this theory.  
Secondly, the identification of 2 copies of the GLI1 consensus motif upstream of 
NOD2 further supports the notion that HH modulates NOD2 expression.411  Whether 
HH is up- or down-stream of NOD2 (with or without a feedback loop, which the 
PTCH data may indicate) is not clear from the present data, and merits further testing 
in non-cancerous HH responsive cells (e.g. lamina propria myeloid cells)423 in the first 
instance. 
 
The studies in PBMCs from patients with active UC follow on firstly from data 
generated by the Howie group demonstrating the effects of exogenous rSHH on the 
secretion of cytokines in peripheral CD4 T cells in vitro (IL2, IL10 and IFNγ),366 and 
secondly from the dysregulated expression of HH signalling demonstrated in UC 
patients in Chapter 4.  The effects on CCL20 are novel and particularly noteworthy 
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given the important role this chemokine has been shown to play in IBD pathogenesis, 
as will be discussed in detail in the next chapter (where the contribution of CCL20 
promoter polymorphisms to IBD pathogenesis is explored).  The present cytokine 
studies are relatively preliminary and merit further testing in patients with quiescent 
UC, active and quiescent CD and a panel of controls.  In addition, the data we have 
recently generated identifying myeloid APCs as targets of HH signalling in reponse to 
inflammation in Gli1+/LacZ mice, suggest a series of future studies examining the 
effects of HH agonists on specific subsets of these cells in vitro (see Chapter 12).423 
 
Finally, the largely negative NFκB studies presented here do not exclude the 
possibility that HH and NFκB signalling interact in vivo for many of the reasons 
outlined above.  It has been demonstrated that SHH is downstream of NFκB in 
epidermal keratinocytes and the pancreas.371, 372  Most recently, it has been shown that 
SHH is directly regulated by NFκB.373   
 
In summary, the data presented herein provide interesting avenues for exploration 
particularly with regard the effect of PAMPs on HH pathway activity and the effect of 
HH agonists on cytokine synthesis and secretion in patients with active disease.  
However, as discussed, the significant limitations of using the cell culture models 
described warrant the detailed study of the potential mechanisms in vivo.  These 
avenues will be explored in more depth in Chapter 12. 
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Figure 9-1 Expression of SHH, PTCH and GLI1 mRNA in untreated SW480 cells. 
RT-PCR analysis of the expression of SHH (211bp product; lanes 1-3), PTCH (462bp product; lanes 5-
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Figure 9-3  Fold changes in SHH and PTCH mRNA expression in SW480 cells treated with LPS and MDP. 
A. SW480 cells were stimulated with 2.0μg/ml of LPS for 0.25h, 0.5h, 1h, 2h, 4h, 8h and 24h.  FAM and VIC values obtained from real-time amplication of cDNA 
sequences were normalised to unstimulated mRNA controls, assigned values of 1. For 0.25h cultures n=4; 0.5h cultures n=4; 1h cultures n=5; 2h cultures n=7; 4h cultures 
n=4; 8h cultures n=3; and 24h cultures n=6. B. SW480 cells were stimulated with 0.25μg/ml, 0.5μg/ml, 1.0μg/ml, 2.0μg/ml and 5.0μg/ml LPS for 2 hours.  N=3 (except for 
2.0μg/ml where n=8).  Relative expression plotted on a 1og10 scale.  PTCH Kruskall-Wallis p=0.31; 5μg/ml vs. control p<0.05.  SHH Kruskall-Wallis p=0.23,  C. Cells were 
stimulated with 2.0μg/ml MDP for 0.25h, 0.5h, 1h, 2h, and 4h. N=3.  Relative expression plotted on a 1og10 scale. PTCH Kruskall-Wallis p=0.065; 4h vs. 0h p<0.05.  SHH 
Kruskall-Wallis p=0.96. 
For all datasets, a Kruskal-Wallis test was performed followed by Dunn’s Multiple Comparison test, comparing untreated cells with treated cells at different timepoints and 
concentrations of LPS and MDP.  (*) denotes p< 0.05.  (**) denotes p<0.01. Each bar indicates the mean with error bars for ± SEM. 
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Figure 9-4 GLI1 and p65 immunohistochemistry on SW480 cells treated with LPS and 
cyclopamine. 
Cells were stained for GLI1 protein following stimulation with 2.0μg/ml LPS (A) or control (B) for 2 
hours.  Negative controls were included for each experiment with omission of primary antibody (with 
(C) and without (D) LPS).  Cells were stained for p65 protein following stimulation with 2.0μg/ml LPS 
only (E), control (F), 2.0μg/ml LPS plus 2.0μg/ml cyclopmaine (G) or 2.0μg/ml cyclopamine only (H).  
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Figure 9-5 NFκB luciferase reporter assay in SW480 cells treated with PAMPs, TNFα, cyclopamine and rSHH. 
A. SW480 cells were treated with 1.0μg/ml or 5.0μg/ml LPS, 2.0μg/ml MDP, 50ng/ml TNFα, or 2.0μg/ml MDP + 50ng/ml TNFα.  NFκB activity was normalised to medium 
only controls, designated 1.  Kruskall-Wallis (LPS 5μg/ml, LPS 1μg/ml and control) p=0.0061; LPS 5μg/ml vs. control p<0.01.  B. SW480 cells treated with 10μM, 5μM, 
1μm cyclopamine (cycl.), 10μM tomatadine (tomat.), and 100ng/ml SHH. NFκB activity normalised to medium only controls.  Methanol was included as an additional 
control.  C. SW480 cells treated with LPS 1.0μg/ml ± 10μM, 5μM or 1μM cyclopamine or 10μM tomatadine.  NFκB activity normalised to LPS 1.0μg/ml treated cells.  
Individual data points are plotted with mean  ± SEM. All treatment were for 24 hours. Statistical analysis was performed using Kruskall-Wallis test with Dunn’s multiple 
comparison test on selected columns.  Comparisons that remained significant using this test are indicated by * (p<0.01) and ** (p<0.01). 
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Figure 9-6  Cytokine profile after SHH and purmorphamine treatment of PBMCs from a patient 
with acute, severe UC. 
Cytokine profile (IL8, CCL20, IL1β, IL10 and TNFα) measured by ELISA in culture supernatant from 
a patient with severe active UC after 24 hours stimulation as shown.  Note that the y axis is split to 
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Figure 9-7 CCL20 in treated PBMCs and SW480 cells. 
CCL20 concentration (ELISA) in culture supernatant of PBMCs from patients with active UC and 
SW480 cells treated as shown.  A.  PBMCs from patients with active UC treated with rSHH at 
increasing concentrations from 50 – 1000ng/ml.  Kruskall-Wallis p=0.0086; 1000ng/ml rSHH vs. 
medium only p<0.05.  B.  PBMCs from patients with active UC treated with 2.0 or 10.0mM 
purmorphomine (PUR).  C.  SW480 cells treated with rSHH at increasing concentrations from 50 – 
1000ng/ml.  D.  SW480 cells treated with 2.0 or 10.0mM purmorphomine (PUR).  Kruskall-Wallis 
p=0.024; 10.0mM PUR vs. medium only p<0.05.  E.  SW480 cells treated with 100ng/ml and 1μg/ml 
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MDP and 10ng/ml and 50ng/ml TNFα.  Kruskall-Wallis test (medium only, 10ng/ml and 50ng/ml 
TNFα) p=0.0090; 50ng/ml TNFα vs. medium only p<0.01.  F. SW480 cells treated with 50ng/ml TNF 
+/- PUR or rSHH.  Purmorphomine co-treatment decreased CCL20 back to baseline levels compared 
with TNFα treatment alone (2μM and 10μM + TNFα vs. TNFα p=0.024, Mann-Whitney U test). 
All treatments were for 24 hours.  Statistical analysis was performed using Kruskall-Wallis test with 
Dunn’s multiple comparison test on selected columns.  Comparisons that remained significant using 
this test are indicated by * (p<0.01) and ** (p<0.01).  
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10   Analysis of CCL20 promoter 
variants in Japan, Sweden and the U.K. 
provides further evidence for genetic 
heterogeneity in IBD. 
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10.1  Abstract  
Introduction.  It was shown in Chapter 9 that rSHH induces expression of CCL20 in 
PBMCs from patients with acute severe UC. CCL20 is a good candidate gene for IBD 
susceptibility based on positional (2q33-37), functional and expression studies.  The 
CCL20 gene encodes an inducible chemokine involved in maturation and recruitment 
of dendritic cells and has antimicrobial activity.  Expression in intestinal epithelial 
cells and PBMCs is induced under inflammatory conditions.  CCL20 promoter 
polymorphisms were recently implicated in susceptibility to UC in a South Korean 
population.   
Aims and Methods.  The aim of the present study was to analyse the contribution of 
these variants to disease susceptibility in both Eastern and Western populations.  
Mutation screening revealed two SNPs (1706G→A and rs6749704T→C) in the 
CCL20 promoter that were genotyped in 1531 IBD patients and 833 HC, from two 
Northern European (Scotland and Sweden, 2492 individuals) and one Far Eastern 
population (Japan, 395 individuals).   
Results.  The 1706G→A variant frequencies were strikingly different in Japanese HC 
compared with N European populations (38.4% vs. 13.3%, p<0.00001).  The 
1706G→A variant was associated with disease susceptibility in Japanese patients with 
UC (47.3% UC vs. 38.4% HC, p=0.018, OR 1.44, C.I. 1.07-1.92) but not in the 
combined N European cohort (by case-control, p=0.09 and transmission 
disequilibrium testing, p>0.5).  The Japanese population-attributable risk of the 
1706G→A variant was 14.3%.  No association was seen in any of the populations for 
the rs6749704T→C SNP.  Genotype-phenotype analysis, revealed no significant 
associations in any population.   
Conclusions.  These data complement studies of NOD2, HLA and IBD5, providing 
compelling evidence for genetic heterogeneity in IBD susceptibility between Eastern 
and Western populations. 
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10.2   Introduction 
IBD was previously very uncommon in Far Eastern countries, but it is of considerable 
interest that incidence has increased rapidly in the past two decades as these countries 
adopt a more westernised lifestyle.1, 465-469   
 
Chemokines have been recognised to play important roles as mediators of intestinal 
homeostasis.  The CC chemokine CCL20 (macrophage inflammatory protein-3alpha 
[MIP-3α], liver and activation-regulated chemokine [LARC], Exodus) is noteworthy 
for its genomic location, protein structure, and its function.470  The CCL20 gene was 
identified independently by three groups in 1997 following a bioinformatics-based 
approach.471-473  CCL20 has 20-31% sequence similarity with other human CC 
chemokines.  It is expressed mainly in mucosal and lymphoid tissues, including adult 
small intestine and colon,471, 474-476 and PBMCs.472, 473, 477  CCR6 was identified as the 
CCL20 receptor in 1997.478  CCL20 is the only CCR6 triggering chemokine and 
CCL20 is unable to elicit a biological response through other known chemokine 
receptors.  This specificity contrasts with the general promiscuity of chemokines and 
their receptors.   
 
It is of great interest that CCR6 was recently confirmed as a CD susceptibility 
locus.103  Whilst it did not reach genome-wide levels of significance in the individual 
GWAS reports, association was confirmed at rs2301436 (p = 3.30 x 10-7) on meta-
analysis of UK, French/Belgium and N American studies and subsequent replication 
(preplication = 3.26 x 10-7; pTDT = 0.0057; pcombined = 5.22 x 10-13, ORcase-control 1.21, 
ORTDT 1.16), as well as at an adjacent SNP rs7749278 (p = 1.65 x 10-7, preplication = 
0.0012, pcombined = 1.58 x 10-9).103  Fine-mapping studies are required to confirm that 
this association is limited to CCR6 as the presently defined block contains two other 
genes. 
 
Together, CCL20 and CCR6 are involved in the maturation of DCs.470  They play a 
role in the recruitment of immature DCs and their precursors to sites of potential 
antigen-entry.  The Ccr6-/- mouse lacks any gross abnormalities in any major 
organ.479, 480  However, it has underdeveloped Peyer’s patches and CD11b+ myeloid 
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DCs, known for their functional CCR6 expression, are absent from the subepithelial 
dome.  Ccr6-/- mice also have increased subpopulations of T cells in the intestinal 
mucosa.  CCL20 expression, constitutively at low levels in human intestinal 
epithelium, is induced in inflamed colonic tissue from patients with IBD,476, 481 as well 
as in PBMCs of patients with active UC compared with HCs.477  CCL20 has been 
demonstrated to have antibacterial activity comparable to β-defensins.482  Indeed, 
human β-defensins have been reported as non-chemokine ligands for CCR6, 
mediating the in vitro chemotactic activity of β-defensins for immature DCs and T 
cells.   
 
The CCL20 gene maps to 2q33-37, away from the major chemokine cluster at 
17q11.2, suggesting that the gene was generated prior to amplification of the 
chromosome 17 chemokine cluster.470  Two original genome-wide linkage studies 
(UK and US populations)99, 150 and two meta-analyses in IBD97, 102 suggest a region of 
linkage on the long-arm of chromosome 2 (Figure 10-1 and Figure 1-4). CC 
chemokines genes are structurally similar with 3 exons and 2 introns.  In contrast, the 
CCL20 gene has 4 exons and 3 introns.  In addition, two potential splice sites at the 
intron 1 / exon 2 boundary have been identified resulting in the deletion of three 
bases.  The 96 amino acid precursor protein is cleaved between two alanine residues, 
giving rise to a mature protein of 70 amino acids.  Several cDNA clones lack one 
alanine residue in the precursor, leading to an alternative mature protein of 69 amino 
acids.  The CCL20 promoter is of some interest, containing possible binding sites for 
different transcription factors; NFκB, activator protein-1 (AP1) and AP2, 
CAAT/enhancer-binding protein (C-EBP), stimulating protein-1 (Sp1) and the 
epithelium-specific Ets nuclear factor ESE-1.483-486  In various different cell types 
NFκB has been demonstrated to bind and activate the CCL20 promoter.475, 483, 486, 487  
Of further relevance to IBD pathogenesis, IL23 and IL1β induce the development of 
Th17 cells expressing CCL20.488  Finally, IL21 stimulation of intestinal epithelial 
cells induces synthesis of CCL20 and treatment of IBD mucosal biopsies in organ 
culture anti anti-IL21 decreases synthesis of CCL20.489  
 
Preliminary data, not yet published as a full paper,490 demonstrated a highly 
significant association between CCL20 promoter polymorphisms and UC in a South 
Korean population.  We have set out to assess the contribution of CCL20 promoter 
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polymorphisms in four complementary and contrasting populations of IBD: Japanese 
UC and HC, Scottish CD, UC and HC, Scottish early-onset CD and UC, and Swedish 
UC and HC.  This has allowed not only substantial replication of the preliminary 
South Korean data, but in addition provides a thorough exploration of genetic 
heterogeneity between Far Eastern and Northern European populations in IBD 
susceptibility. 
10.3 Subjects and Methods  
10.3.1 Scottish subjects  
The Scottish population consisted of 1022 IBD cases (454 CD, 540 UC and 27 IBDU) 
and 370 HCs (Table 10-1).  This was made up of an adult IBD cohort (age 17 years or 
over at diagnosis), and an early-onset IBD cohort (age ≤16 years at diagnosis), 
collected prospectively and independently.   
Adult-onset subjects:  This cohort of 708 patients consisted of 249 with CD and 459 
with UC.  The population was 98.5% white, non-Jewish Caucasian.  The median age 
at diagnosis was 32.8 (IQR 25.0 – 47.5).   
Early-onset cohort:  There were 205 CD patients, 81 with UC and 27 with IBDU, 
recruited from across Scotland.  In addition, blood samples were collected from 523 
parents (293 mothers; 230 fathers) resulting in 69% complete family trios.  
Healthy controls:  The control group comprised 370 individuals; blood donors (n = 
260) and healthy control subjects (n = 110) all residing in SE Scotland.  There were 
187 males and 183 females; median age was 38.0 (IQR, 27.0-50.0). 
10.3.2 Swedish subjects 
296 UC patients were recruited from various hospitals in Stockholm County (Table 
10-1).  281 Swedish HC were healthy volunteers from the Karolinska University 
Hospital staff (n=170) and orthopaedic day-case surgery patients (n=111) with no 
previous medical conditions.   
10.3.3 Japanese subjects 
Japanese subjects were recruited from Osaka and Tokyo.  The population consisted of 
213 patients with UC and 182 Japanese HC (Table 10-1). 
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10.3.4 Genotyping 
Custom Taqman SNP Genotyping Assays for 1706G→A and rs6749704T→C SNPs 
were obtained from ABI by submitting the context sequence to the Assay By Design 
service.  Genotypes were derived by a combination of the Taqman system and direct 
sequencing. 
10.3.5 Data analysis 
Disease susceptibility was determined by case-control study of genotype frequency 
for each SNP in all populations described (Scottish adult-onset IBD, CD and UC; 
Scottish early-onset IBD, CD and UC; Swedish UC; and Japanese UC).  Minitab 
statistical software version 13 (Minitab Ltd, Coventry, UK) was used to analyse 
genotype-phenotype associations using chi2 test or Fisher exact test where appropriate 
for univariate analysis.  TDT analysis was performed on the early-onset trios using 
TRANSMIT version 2.5.491   
10.3.6 Initial Mutation Screening 
The promoter region of the CCL20 gene was sequenced in the Scottish adult 
population in 12 CD and 12 UC patients.  Of 4 SNPs previously identified in Choi’s 
study,490 only 1706G→A and rs6749704T→C were present in the Scottish 
population.  These 2 SNPs were analysed in the Scottish adult and early-onset IBD 
populations and HC, Swedish UC and HC, and Japanese UC and HC. 
10.3.7 Genotyping success rates 
Genotypes were derived in >96% of Scottish, Swedish and Japanese subjects for 
1706G→A and rs6749704T→C.  Genotyping failures were consistent for both assays, 
representing poor DNA quality in these samples and not affecting overall validity of 
the assays.  The validity of the assays were further verified by direct sequencing of 
10-20% of all HC’s, with 100% concordance with Taqman data.  All data derived 
from Scottish and Japanese patients and controls were consistent with HWE.  The 
Swedish HC population deviated significantly from HWE for rs6749704T→C 
(p<0.01); this most likely represents uneven sex distribution in this cohort 
(predominantly females) and not genotyping error.  The genotype-based analysis 
performed in this cohort does not assume HWE. 
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10.4  Results 
10.4.1 Expression of CCL20 and CCR6 in IBD tissue 
Expression analysis of microarray data demonstrated increased expression of CCL20 
in both UC and CD compared with HC, but this was limited to the inflamed group of 
biopsies (p<0.0001) with no difference between non-inflamed HC and non-inflamed 
UC or CD expression levels (Figure 10-2d-e).  There was no change in expression of 
CCR6 in UC (p=0.096) or CD (p=0.18) compared with HC (Figure 10-2c). 
10.4.2 1706G→A variant 
10.4.2.1 Japanese 
Analysis of the 1706G→A variant allele demonstrated a significant association with 
UC in Japanese patients when compared with Japanese HC (47.3% UC vs. 38.4% HC, 
p=0.018, OR 1.44, C.I. 1.07-1.92).  Genotype frequencies were significantly different 
between cases and controls (AA vs GG, p=0.027, OR 1.89, CI 1.07-3.33) (Table 10-
2a).  Analysis of genotypes as a 2x3 contingency table approached significance when 
tested for independence (p=0.057); however, chi2 testing for trend was significant 
(p=0.0196).  The population-attributable risk for the 1706G→A variant was 14.3%.   
10.4.2.2 Northern Europeans 
Analysis of the 1706G→A genotypes in the combined N European IBD cohort did not 
demonstrate any significant difference between cases and controls (GA vs. GG, 
p=0.09, OR 1.22, CI 0.97-1.54; AA vs. GG, p=0.22, OR 0.68, CI 0.36-1.28) (Table 
10-2a).  There was no association with this SNP in these populations when analysed 
independently (Scottish IBD, UC, CD vs. Scottish HC or Swedish UC vs. Swedish 
HC; full genotypic data available in Table 10-3) for differences in genotype 
frequencies by chi2 testing.  TDT of the Scottish early-onset IBD families revealed no 
significant deviation from expected transmission rates for all IBD cases, and for CD 
and UC independently (Table 10-4a-c). 
10.4.2.3 Genetic heterogeneity 
In the Japanese HC population 1706G→A variant allelic frequency was 38.4%, 
significantly higher than the N European frequencies (12.3% Scottish HC, p<0.00001; 
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14.8% Swedish HC, p<0.00001; combined 13.3%, p<0.00001).  Japanese UC allelic 
frequency was 47.3%, compared with 14.6% in N European UC (p<0.0001). 
 
There were no differences between the Scottish and Swedish datasets, with similar 
HC allelic frequencies for 1706G→A (14.8% vs. 12.3%, p=0.17).  rs6749704T→C 
HC allelic frequencies were similar in all three populations (Japanese HC 31.7%, 
Scottish HC 29.2%, Swedish HC 26.3%, p=0.22). 
10.4.2.4 Comparison with South Korean dataset 
In the previously reported S Korean dataset,490 HC 1706G→A variant allelic 
frequencies were 39.1%, similar to our Japanese allelic frequency (38.4%, p>0.5).  In 
the S Korean UC cases the 1706G→A variant allelic frequency was 60.7%, compared 
to 47.3% in Japanese UC patients (p=0.0007).  This result was significant comparing 
cases and controls in the S Korean population (60.7% vs. 39.1%, p<0.0001).  Variant 
homozygosity for this SNP was 38.6% in the S Korean UC cases, compared with 24% 
in Japanese cases (p<0.001), whilst HC frequencies were similar for both populations 
(16.3% vs 17.5%, p>0.5).  These data demonstrate a much stronger contribution to 
disease susceptibility in S Korea than detected in the Japanese population. 
10.4.3 rs6749704T→C variant 
There was no association with the rs6749704T→C SNP when genotype frequencies 
were compared between Japanese patients with UC and Japanese HC (TC vs TT, 
p=0.57, OR 0.88, CI 0.58-1.35; CC vs TT, p=0.88, OR 0.95, CI 0.49-1.85; chi2 test 
for independence, p=0.85) (Table 10-2b).  However, in the combined N European 
cohort there was a significant difference between genotype frequencies (CC vs. TT, 
p=0.016, OR 0.65, CI 0.46-0.92; chi2 test for independence, p=0.0022) (Table 10-2b; 
genotype frequencies for individual populations available in Table 10-3).  This 
finding is of uncertain significance given the very similar allelic frequencies in the N 
European populations, and the negative TDT analysis in the Scottish early-onset IBD 
cohort for this SNP (Table 10-4).   
10.4.3.1 Genotype-phenotype analysis 
There were no significant associations on univariate genotype-phenotype analysis 
(variant allelic frequency, carriage rate and homozygosity), when age of onset, disease 
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location, disease behaviour, surgery, family history, smoking, or history of joint 
problems were assessed separately in adult and early-onset Scottish IBD populations 
(data not shown). No genotype-phenotype associations of significance were identified 
in any of the populations, once corrections for multiple comparisons were made in 
analysis of the rs6749704T→C variant (data not shown). 
10.5  Discussion 
Following initial data from S Korea, now only available in abstract form,490 this is the 
first study to report formally on CCL20 promoter polymorphisms and susceptibility to 
IBD.  It has shown a positive association with the 1706G→A variant and inherited 
susceptibility to UC in a Japanese population.  However, in two independent N 
European populations no association was found with IBD, CD or UC for this variant 
by case-control analysis or TDT.  It is therefore of great interest that the only other 
group to report an association with this variant was from a similar geographical 
location to this Japanese population.490  However, the very striking positive 
association reported in preliminary data by a S Korean group (p<0.0001, OR 2.4) are 
in contrast to the relatively modest effect this variant has in determining susceptibility 
to UC in the Japanese population (p=0.018, OR 1.44).  Whilst variant allelic 
frequencies for 1706G→A were very similar in both S Korean and Japanese HC 
populations (39.1% and 38.4% respectively), the cohort of patients with UC from S 
Korea had significantly higher variant frequencies than those from Japan (60.7% vs. 
47.3%, p<0.0001).  There is a clear precedent for the strength of a genetic association 
being strongest in the index study than in subsequent replication cohorts.492  In IBD 
this was clearly demonstrated for NOD2.79, 80, 106  However, it is somewhat curious 
that over 3 years since the S Korean data was presented in abstract form, a full paper 
has yet to be published.   
 
Combined, these data present further compelling evidence for global genetic 
heterogeneity in the inherited susceptibility to IBD.  CD and UC are recognised to be 
diseases of the developed world, with highest incidence rates reported in Western 
Europe and N America.  Within Scotland, the incidence of early-onset CD has 
increased dramatically in recent decades.493  Intriguingly, there are latitudinal 
gradients of disease incidence reported, with higher rates documented not only in the 
north of Europe compared with the South,494 but also within Scotland,495 and within 
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France.496  Different genetic backgrounds may play a role in these geographical 
variations, although these remain to be elucidated.  NOD2 variants cannot explain 
this, as frequencies decrease with more northern latitudes in Europe,106, 107 where the 
PAR ranges from 7.9% (early-onset Scottish CD) to 11.4% (Swedish CD). Temporal 
trends are clearly not genetic, occurring over no more than a couple of generations.  
Environmental factors, such as increased hygiene, or refrigeration, have been 
postulated as aetiopathogenic mechanisms.497  It is clear that increased rates of IBD in 
the Far East have lagged behind those in the West, and have been largely attributed to 
these countries adopting a more Westernised lifestyle.   
 
Many dozens of centres worldwide now have established DNA banks from patients 
and controls, allowing the contribution of genetic variants to disease susceptibility to 
be observed in multiple, geographically and ethnically diverse populations.  In the Far 
East this has been catalysed by the increased incidence of IBD over the past two to 
three decades.1  In Japanese,110 Chinese,111 and S Korean112 populations the three 
common NOD2 mutations are absent (Figure 1-5).   A similar phenomenon has been 
noted with the MHC on chromosome 6 (1.5.4.1) and the IBD5 locus (1.5.1.2).  
Common variants identified in the IBD5 risk haplotype in European and N American 
populations are very rare in the Japanese cohorts studied.127, 498, 499  A degree of 
commonality in disease association was demonstrated with the TNFSF15 gene (9q32), 
identified by a limited GWAS in a Japanese cohort with replication in two UK 
cohorts,500 and subsequently confirmed as a CD susceptibility gene in the Barrett 
meta-analysis.103    
 
There are also interesting parallels with the chemokine receptor gene CCR5.  A 32bp 
deletion (denoted ΔCCR5) was demonstrated to prevent cell invasion by the primary 
transmitting strain of HIV1.501-503  Consequently, despite repeat exposure to HIV1, 
homozygotes appeared to be resistant to infection.502, 504  As demonstrated here for 
CCL20, there is significant variation in ΔCCR5 allele frequencies in different 
populations globally.  Within Europe, ΔCCR5 frequency is approximately 10%; 
however, a North-South gradient is evident with frequencies of 14.7% documented in 
Iceland compared with 2.4% in Greece.505  Further heterogeneity is demonstrated 
outside Europe; the variant is present in less than 1% of people of African origin, 2-
5% of people from the Middle East and the Indian subcontinent, and absent in the Far 
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East.505  CCR5 is located at 3p21, coinciding with an IBD susceptibility locus 
identified by genome-wide scanning.99  Several association studies in IBD and 
primary sclerosing cholangitis have failed to demonstrate a consistent association with 
ΔCCR5.506-512    
 
Our data support a role for CCL20 polymorphisms in susceptibility to UC in Eastern 
populations, but not in 2 independent N European cohorts.  The functionality of the 
1706G→A variant is unknown, but it may be in part due to altered binding of 
transcription factors such as NFκB to the CCL20 promoter.  The subtle genotypic 
association of rs6749704T→C between IBD and cases in the N European group is of 
uncertain significance given the flat allelic analysis and the negative TDT, but it may 
indicate that both this SNP and 1706G→A are in LD with a presently unidentified 
causal variant.  Data from phase II of the Hapmap project describe an area of low LD 
around the CCL20 gene (Figure 10-3).  The gene itself is very small (3.68kb) and is 
located in an area of relatively low gene-density.  We would suggest that further 
mutation screening across the entire CCL20 gene in Eastern populations is required to 
locate any true functional variant.  Additionally, before an established role for 
germline CCL20 variation in susceptibility to UC in Eastern populations is ascribed, 
functional data describing the effect of these mutations is required. 
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Table 10-1 Demographic data of cohorts genotyped for CCL20 promoter polymorphisms 
Demographic details of Scottish IBD patients (adult-onset and early-onset disease) and controls, Swedish UC patients and controls, and Japanese UC patients and controls.  
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 *2x3 chi2 for independence 0.057 *2x3 chi2 for independence 0.094 
 










































































 *2x3 chi2 for independence 0.85 *2x3 chi2 for independence 0.0022 
 
Table 10-2 Genotype data of CCL20 promoter polymorphisms in Eastern and N European 
populations. 
Genotype frequencies for A. 1706G→A and B.  rs6749704T→C SNPs in Eastern (Japanese) and 
combined N European (Scottish and Swedish) IBD  and HC populations.  P-values, OR and 95% 
confidence intervals (CI) are given for chi2 analysis of genotype frequencies using 2x2 contingency 
tables (12vs11 and 22vs11).  *P-value for 2x3 contingency table analysis. 
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 Scottish sub-populations Swedish 
A. 
 













Number 368 1022 708 314 454 249 205 540 459 81 280 294 
Failures 5 (1.4%) 29 (2.8%) 19 (2.7%) 10 (3.2%) 10 (2.2%) 5 (2.0%) 5 (2.4%) 17 (3.1%) 14 (3.1%) 3 (3.7%) 26 (9.3%) 2 (0.7%) 





















































































Failures 8(2.2%) 68 (6.7%) 50 (7.1%) 18(5.7%) 31 (6.7%) 23 (9.2%) 8 (3.9%) 35 (6.5%) 27 (5.9%) 8 (9.9%) 3 (1.1%) 7 (2.4%) 








































































Table 10-3 Detailed genotype analysis of CCL20 promoter polymorphisms in Scottish and Swedish IBD. 
Genotypes for Scottish IBD, CD, UC and HC in all patients, adult-onset (>17 years at diagnosis) and early-onset (<17 years at diagnosis) cohorts, Swedish UC and HC for A. 
1706G→A and B. rs6749704T→C SNPs. 
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A.  Outcome = IBD 1706G→A rs6749704T→C 
Number of Families 309 301 
Number of Affected Offspring 303 296 
Allele 1 
 




Allele2 77 / 74.9 157 / 154.0 
Global Chi2(1 df) 0.146 0.180 
Global p-value for  transmission 0.722 0.691 
 
B.  Outcome = CD 1706G→A rs6749704T→C 
Number of Families 309 301 
Number of Affected Offspring 199 196 
Allele 1 
 




Allele2 53 / 50.2 102 / 102.4 
Global Chi2 (1 df) 0.391 0.005 
Global p-value for  transmission 0.530 0.941 
 
C.  Outcome = UC 1706G→A rs6749704T→C 
Number of Families 309 301 
Number of Affected Offspring 78 73 
Allele 1 
 




Allele2 18 / 17.8 41 / 38.0 
Global Chi2  (1 df) 0.008 0.664 
Global p-value for  transmission 0.922 0.373 
 
Table 10-4  TDT analysis of CCL20 promoter polymorphisms in Scottish early-onset IBD cohort. 
Transmission disequilibrium testing for 1706 and rs6749704 SNPs in Scottish early-onset IBD 
families.  Analysis carried out with TRANSMIT.  The three different outcomes were defined as follows 
– A. IBD cases = all occurrences of CD, UC, indeterminate and non-specific colitis; B. CD cases = 
only definite CD cases: UC individuals were classed as being unaffected, while indeterminate/ non-
specific diagnoses were classed as unknown; C. UC cases = only definite UC cases: CD individuals 
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Figure 10-1 Evidence for linkage at chromosme 2q31. 
Position of markers and relevant LOD scores from genome-wide linkage studies in UK99 and US150 populations, and from two different meta-analyses of linkage data.97, 102  
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Figure 10-3 Haplotype structure of CCL20; 40kb view. 
This map was generated using Haploview ver3.12 with phase II Hapmap data (based on NCBI B35 assembly) from 30 CEPH trios.  
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11 Haplotype-tagging SNP analysis of 
germ-line variation and re-sequencing of 
NKX2.3, an IBD susceptibility gene and 
target of HH signalling. 
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11.1  Abstract 
Background.  The homeodomain-containing gene NKX2.3 (NK2 transcription factor 
related, locus 3) is a confirmed susceptibility gene for IBD (both CD and UC).  The 
knock-out mouse has a lethal post-natal phenotype with abnormalities in both the 
intestine and spleen and significantly down-regulated MadCAM-1 expression, 
suggesting a critical role for NKX2.3 in lymphocyte homing.  Furthermore, recent 
unpublished data indicate that NKX2.3 is a down-stream target of HH-GLI1 
signalling. 
Aims.  The aims of the present study were to ascertain the contribution of NKX2.3 
germ-line variation to IBD susceptibility in the Scottish population, re-sequence the 
gene and determine whether adequate power existed in this cohort for a formal fine-
mapping study. 
Methods.  The haplotype block containing NKX2.3 (and no other genes) associated 
with CD on the WTCCC study was tagged by 7 tSNPs and genotyped in a Scottish 
population of adult and early-onset IBD consisting of 1386 patients (688 CD, 633 
UC) and 363 HC.  Log-likelihood, haplotype and individual tSNP chi2 analysis was 
performed in this cohort.  Additional analysis was performed on the 5 SNPs 
genotyped as part of the WTCCC study using a HC cohort comprising 3000 WTCCC 
controls in addition to the Scottish controls.  1kb of the promoter region along with 
the 2 major NKX2.3 exons were re-sequenced in 96 CD patients.  In silico expression 
analysis of microarray data was performed for NKX2.3 in colonic biopsies from CD 
and UC patients and HC. 
Results.  NKX2.3 was not associated with IBD, CD or UC in the primary analysis in 
the Scottish adult-onset, early-onset or combined cohort versus the small panel of 
Scottish HC.  However, on subsequent analysis with the addition of WTCCC HCs, 
NKX2.3 was confirmed as an IBD susceptibility gene in Scotland with association 
noted at rs7095491, rs7081330 and rs1088371.  The strongest association was at 
rs1088371 (IBD vs. HC: p = 2.81 x 10-5, OR 1.22).  In the Scottish population, the 
association was notably stronger and more consistent for UC than CD.  There was no 
clear association specifically with colonic IBD on genotype-phenotype analysis.  On 
re-sequencing, 8 SNPs were detected within NKX2.3 including one novel synonymous 
SNP.  Expression analysis demonstrated up-regulation for one Agilent probe in CD 
regardless of inflammatory status, and for another probe with UC but only in inflamed 
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samples.  The different expression profiles for these two probes was thought to 
correspond to an alternative shortened NKX2.3 transcript missing exon 2. 
Conclusion.  NKX2.3 is associated with IBD and UC and to a lesser extent CD in the 
Scottish population, but this cohort is underpowered for fine-mapping studies.  
NKX2.3 is an excellent biological candidate for IBD and likely to play a major role in 
disease pathogenesis.  As such, re-sequencing and subsequent fine-mapping has been 
prioritised as part of the WTCCC follow-up studies and these data are eagerly 
awaited.  Finally, in the context of the other studies presented in this thesis, the links 
with HH-GLI1 signalling are very notable, and inform future studies. 
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11.2  Introduction 
Although it was previously demonstrated that expression patterns of NKX2.3 do not 
alter in the Shh-/- mouse during embryonic development,513 and that Shh and Ptch 
expression is unaltered in Nkx2.3-/- mice,226 multiple lines of recent evidence suggest 
that Nkx2.3 is in fact a HH target gene.  Firstly, it is notable that the expression 
pattern of NKX2.3 in the intestinal lamina propria (see Figure 3 in Wang et al, 
2000)226 mirrors that of GLI1 expression in human (Table 4-2) and mouse (Lees, 
Zacharias et al, 2008).423  Secondly, microarray analysis of isolated murine gut 
mesenchyme stimulated with exogenous HH demonstrates robust upregulation of 
NKX2.3 gene expression (Zacharias W, personal communication). 
 
As discussed in Chapter 1 (1.5.2.5), NKX2.3 was identified in the WTCCC GWAS 
and subsequent replication studies as a novel CD susceptibility gene (OR ~1.18).81, 89  
More recently, NKX2.3 has also been confirmed as a UC susceptibility gene in studies 
from the U.K. and Germany.84, 85  NKX2.3 is a small (3.6kb) gene at 10q24.  Whilst it 
has two small exons, there appear to be two transcripts in the mouse at least;225 the 
truncated transcript is predicted to lack exon 2. 
 
The aim of the present study was therefore to describe the specific contribution of the 
WTCCC-associated haplotype block spanning NKX2.3 to IBD susceptibility in the 
Scottish population, re-sequence the promoter and coding regions of the gene and then 
fine-map the associated region if suitably powered to do so in this cohort. 
11.3  Methods 
11.3.1 Genotyping 
The extent of the association around NKX2.3 from the WTCCC study was from 
101264048 (rs10883359) to 101317841 (rs7091572) on chromosome 10 (Table 11-
1).  This maps to a 52.6kb haplotype block from 101261779 - 101314426 in the CEU 
HapMap (release 22/phase II April 07 on NCBI B36 assembly, dbSNP b126) 
population (Figure 11-1 and 11-2).  tSNPs were derived in HapMap version 3.2 to 
tag SNPs in this block with MAF >0.1 and detecting haplotype frequencies of >5%.  6 
tSNPs were identified: rs7095491, rs7081330, rs4919345, rs10786560, rs2902288 and 
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rs7091572.  These 6 tSNPs plus rs10883371 (the second most significant WTCCC 
SNP in this block, but immediately upstream of the gene) were genotyped by TaqMan 
in both the Scottish adult and Scottish early-onset IBD populations and HCs.  The 
former cohort has been described in Chapters 5, 7 and 10, the latter in Chapter 10.   
11.3.2 Analysis 
Log-likelihood analysis (EH/PM platform as described in Chapter 3), haplotype 
analysis (Haploview version 4.0) and chi2 analysis on individual SNPs was performed 
for both cohorts of IBD, CD and UC patients separately and in combination.  WTCCC 
data was available for 5/7 SNPs genotyped: rs7095491, rs7081330, rs10883371, 
rs2902288 and rs7091572.  The summary genotype data was extracted for each of 
these SNPs.  A combined genotype count was made between WTCCC HC and 
Scottish HC subjects and was analysed by chi2 against the combined Scottish IBD 
cohort. 
11.3.3 Sequencing 
Primers were designed to sequence across the 2 NKX2.3 exons and 1kb of the 
promoter region to cover all promoter and exonic SNPs listed in dbSNP.  Sequencing 
was performed in 96 patients with CD from the main adult Scottish cohort.  Further 
deep re-sequencing including all intronic regions is scheduled as part of the WTCCC 
follow-on studies (details of primer pairs in Table 3-2).   
11.4  Results 
11.4.1 Analysis of NKX2.3 tSNPs in Scottish IBD and control 
populations 
In the Scottish adult population no association was seen with IBD, CD or UC on log-
likelihood testing (127 degrees of freedom, 1000 permutations, p=1.00), haplotype 
analysis (Table 11-2) or chi2 testing of individual tSNPs (Table 11-3).  Despite this 
lack of association, it was notable that a number of SNPs trended towards significance 
in the UC population, whereas the CD MAFs more closely mirrored the control 
population (Table 11-3).  Comparison of the Scottish early-onset population with 
Scottish HC again demonstrated no evidence for association on either analysis (Table 
11-4), and TDT analysis was negative (Table 11-5).  A combined analysis of all 
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Scottish IBD, CD and UC patients (adult plus early-onset) demonstrated no 
association but a trend was again noted with UC (Table 11-6). 
11.4.2 Analysis of NKX2.3 tSNPs in Scottish IBD populations 
utilising WTCCC control data. 
Comparison of allelic frequencies for 5 tSNPs in the present study with WTCCC data 
demonstrated broadly comparable MAFs for HC and CD populations.  It was 
therefore postulated that the lack of association in the Scottish study was primarily 
due to insufficient power in this smaller population.  The complete cohort of Scottish 
IBD patients (adult plus early-onset) was analysed for association against a 
combination of WTCCC and Scottish HC (Table 11-7).  Strong evidence for 
association was noted for rs7095491, rs7081330 and rs1088371 in IBD and UC, with 
modest association for CD at rs7095491 and rs1088371.  The most significantly 
associated SNP was rs1088371 (IBD vs. HC p=2.81x10-5, OR 1.22, C.I. 1.11-1.33).  
The effect size was greater in UC than in CD (OR 1.28 and 1.17 respectively).  There 
was no evidence for association at rs2902288 and rs7091572, despite both these SNPs 
achieving significance in the WTCCC study (p=0.0005 and p=0.0003).   
11.4.3 Genotype-phenotype analysis 
As a stronger association with NKX2.3 was noted for UC than CD in the Scottish 
population, a genotype-phenotype analysis was performed at rs1088371 (the most 
significant tSNP) stratified for disease location.  On analysis of all colonic IBD (UC 
plus CD colitis [L2]) versus the combined HC cohort, a similar association was noted 
as for UC alone (0.535 vs. 0.480, p=0.0001, OR 1.25, C.I. 1.12-1.40).  There was no 
association with colonic CD (0.517 vs. 0.480, p=0.17, OR 1.16, C.I. 0.74-1.43) or 
ileal CD (L1 plus L4 plus L1+L4) (0.509 vs. 0.480, p=0.30, OR 1.13, C.I. 0.90-1.41).  
A within-cases analysis in CD for purely colonic disease (L2) versus ileal disease (L1 
plus L4 plus L1+L4) demonstrated no significant difference between MAFs (0.517 vs. 
0.509, p=0.85, OR 1.03, C.I. 0.76-1.39).  No other genotype-phenotype associations 
were noted. 
11.4.4 Re-sequencing of NKX2.3 
Re-sequencing of NKX2.3 in 96 patients with CD from the Scottish cohort confirmed 
the presence of 8 SNPs from dbSNP: rs11190141, rs10883371, rs10883372, 
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rs10883373, rs7908704, rs7893840, rs7911680 and rs888208 (Table 11-8).  In 
addition, one novel synonymous SNP (C/A) was noted at position 101,283,025 
(Figure 11-3).  This SNP has subsequently been added to dbSNP128 and denoted 
rs41290504. 
11.4.5 Expression analysis by microarray  
Two probes from the Agilent Whole Genome Array microarray map to NKX2.3.  
A_23_P52425 (probe ‘A’) maps to exon 1 and A_24_P38702 (probe ‘B’) to exon 2.  
It is noteworthy that both EST evidence and the published literature identify a short 
transcriptional form that stops short of exon 2 (and is therefore not detected by probe 
B).  Expression analysis demonstrated up-regulation of NKX2.3 (A) in CD compared 
with HC (p=0.0003), regardless of inflammatory status, but no difference between UC 
and HC (Figure 11-4).  In contrast, NKX2.3 (B) was increased in inflamed UC 
samples versus HC (p<0.0001) but not non-inflamed UC (p=0.17) and only very 
minimally in CD (p=0.04). 
11.5  Discussion 
The present study describes further data on the association at NKX2.3 in IBD, 
specifically in the Scottish population, re-sequencing of the promoter and 2 exons, 
and expression analysis from microarray data.  The major issue highlighted is the lack 
of power inherent in the Scottish cohort.  This is a major limiting factor in achieving 
the aim set out to fine-map the region.  As such, further genotyping was not 
performed in this cohort.  Rather, this must be performed in the larger cohorts 
described in the WTCCC GWAS and replication study for CD,81, 89 and the UK 
consortium’s UC studies.84  Indeed, CD has been prioritised for re-sequencing and 
subsequent fine-mapping in the WTCCC and NKX2.3 re-sequencing is underway as 
part of this first phase.   
 
The combined Scottish cohorts of adult and early-onset IBD consists of a total of 
1386 patients, comprising 688 patients with CD and 633 with UC, but only 363 HCss.  
Case-controlled analysis in this cohort did not achieve significance on any analysis, 
but trends were noted towards significance for a number of SNPs in IBD and UC.  
Similarly, the case-controlled and TDT analysis in the early-onset IBD population 
demonstrated lack of association, but this cohort is not powered to detect odds ratios 
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of <1.20 (most significant OR in WTCCC 1.18).  Extracting the WTCCC HC data 
and combining this with the Scottish HC population confirmed that NKX2.3 is 
associated with IBD, CD and UC in Scotland.  Again, the effect was much greater for 
UC than for CD.  A genotype-phenotype analysis stratified for colonic IBD (colonic 
CD plus UC) did not clearly demonstrate any added significance, but this may again 
be related to power.  No genotype-phenotype data is currently available for NKX2.3 as 
this was not presented in the WTCCC CD studies.81, 89 
 
The re-sequencing data presented here has identified 9 SNPs within NKX2.3 (or in the 
promoter or immediately downstream) that should be included in future fine-mapping 
studies (Table 11-8).  The WTCCC re-sequencing data are eagerly awaited to 
determine if further variants should be added to this list.  It is noteworthy that at 
present this list does not include any SNPs conferring a change in the amino acid 
structure of either of the NKX2.3 transcripts.  However, as recently demonstrated for 
IRGM (where a 20kb deletion immediately up-stream of the gene is not only 
associated with CD but also confers decreased IRGM function),213 non-coding SNPs 
may be functional.  All confirmed plus any novel NKX2.3 SNPs will then be 
genotyped in the WTCCC CD and HC cohort (± replication cohorts) in an effort to 
identify the causal variant.   
 
Following on from the next stage of the genetic studies, functional experiments will 
be a priority to ascertain the function of the causal SNP(s).  Little is known about the 
expression and function of NKX2.3 in man.  The expression data presented here 
demonstrate an effect in both CD and UC, but are complicated by the different 
expression profiles for the two probes present on the Agilent whole-genome chip.  
The two typical reasons for a gene's probes to offer distinct, significant expression 
profiles is cross-hybridization to another locus, which these don't, or hybridization to 
parts of the gene that are related differently from each other to the gene's alternative 
splicing, which is unlikely in the present situation but hard to disprove.  A more 
intriguing possibility here is that these two probes are detecting the two different 
transcripts of Nkx2.3 first reported by Pabst and colleagues in the mouse in 1997.225  
This requires urgent evaluation by RT-PCR in a cohort genotyped for the NKX2.3 
variants as the alternative splicing required to truncate the protein short of exon 2 
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could go someway to explaining the underlying mechanism of NKX2.3 mutation in 
IBD. 
 
There is, however, presently a large body of published literature documenting the role 
of Nkx2.3 in the developing murine intestine and spleen with a striking phenotype 
noted for the knock-out mouse, as described above.  This animal model deserves re-
evaluation in the light of the association of NKX2.3 with CD and UC before a future 
model is generated based on cloning the IBD-associated mutation(s) into new mice. 
 
The apparently normal phenotype of the heterozygous Nkx2.3 mouse has striking 
parallels to the Gli+/LacZ mice studied.423  It would therefore seem logical to stress 
these animals with DSS to firstly ascertain their susceptibility to chemically-induced 
colitis and secondly use the LacZ reporter to describe the Nkx2.3 positive populations 
of mesenchymal signals responding to the acute inflammatory insult.  Little is known 
about the upstream regulation of Nkx2.3 so it is of great interest that its expression 
appears to be regulated by HH in the intestine.  Given the associations for both GLI1 
and NKX2.3 described with IBD, a detailed assessment of the cross-talk of both these 
pathways in both intestinal homeostasis and inflammation is an urgent priority for 
follow-up. 
 
In conclusion, NKX2.3 is associated with IBD, UC and to a lesser extent CD in the 
Scottish population but this cohort is under-powered to allow further fine-mapping of 
the region with the ultimate aim of identifying the causative mutation(s) in IBD.  This 
work is underway as part of the WTCCC follow-up studies and the data are eagerly 
awaited.  There are many intriguing aspects to Nkx2.3 expression and function in the 
mouse that make an important role in IBD pathogenesis seem very plausible indeed, 
not least its regulation of MadCAM-1 expression.  Finally, there is much to suggest a 
complex, but direct interaction between NKX2.3 and HH/GLI1 signalling in the 
response to acute inflammatory challenge in mouse that will form the major basis of 
future studies in man and mouse. 
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WTCCC 





rs4595481 101254152 C T 72.6% 74.0% 0.16 0.93 0.85 1.03 
rs10883359 101264023 C T 25.7% 28.6% 0.0022 0.86 0.78 0.95 
rs7095491 101264048 A G 52.7% 47.0% 5.79 x10-08 1.26 1.16 1.37 
rs7078219 101264355 A G 33.9% 38.7% 2.85 x10-06 0.81 0.74 0.89 
rs7081330 101264455 A G 66.1% 61.2% 2.27 x10-06 1.24 1.13 1.35 
rs10883365 101277754 C T 53.7% 47.7% 1.65 x10-08 1.27 1.17 1.38 
rs11190137 101277934 G T 25.4% 28.6% 0.00072 0.85 0.77 0.93 
rs10883367 101277980 A G 53.7% 47.7% 2.66 x10-08 1.27 1.17 1.38 
rs11190139 101278089 C G 75.4% 72.2% 0.00090 1.18 1.07 1.29 
rs7899176 101279113 C T 21.5% 24.5% 0.0011 0.85 0.77 0.94 
rs1548964 101279643 C G 46.7% 52.7% 2.21 x10-08 0.79 0.72 0.85 
rs1548962 101279725 C G 46.3% 52.3% 1.82 x10-08 0.79 0.72 0.85 
rs6584283 101280291 A G 52.0% 46.2% 4.35 x10-08 1.26 1.16 1.37 
rs10883371 101282445 G T 53.7% 47.7% 1.61 x10-08 1.27 1.17 1.38 
rs884144 101283846 A G 13.3% 14.3% 0.19 0.92 0.82 1.04 
rs7903232 101288792 C G 86.8% 85.7% 0.15 1.09 0.97 1.23 
rs7901565 101300855 C T 100.0% 100.0% 0.71 0.59 0.04 9.51 
rs989979 101312413 C G 59.2% 55.0% 7.80 x10-05 1.19 1.09 1.29 
rs2902288 101314355 C G 10.5% 13.0% 0.00055 0.79 0.69 0.90 
rs1332102 101314426 A T 77.9% 73.1% 3.45 x10-07 1.29 1.17 1.43 
rs1360522 101315787 A G 23.7% 27.5% 5.32 x10-05 0.82 0.74 0.90 
rs11190152 101315905 C T 2.1% 2.1% 1.00 1.00 0.75 1.35 
rs7091572 101317841 C T 24.5% 27.9% 0.00030 0.84 0.76 0.92 
rs12268645 101318008 G T 71.3% 70.9% 0.66 1.02 0.93 1.12 
 
Table 11-1  WTCCC SNPs associated with CD around NKX2.3. 
The limits of the associated region are denoted by the solid black line (101264048 – 101317841).  
SNPs genotyped in the Scottish population are highlighted in yellow.  The most significant SNP in the 
WTCCC study was rs10883371, and on the GWAS meta-analysis rs7078219. 
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1111111 0.280 0.276 0.284 0.275 0.78 0.90 0.69 
1111211 0.190 0.176 0.200 0.168 0.19 0.65 0.08 
2222112 0.124 0.126 0.122 0.119 0.74 0.67 0.84 
2221111 0.110 0.119 0.103 0.123 0.35 0.80 0.19 
2122111 0.099 0.092 0.106 0.105 0.67 0.42 0.93 
2222122 0.074 0.082 0.067 0.079 0.64 0.85 0.33 
 
Table 11-2  Haplotype structure of NKX2.3 tSNPs. 
The frequencies of the 6 haplotypes made by the 7 NKX2.3 tSNPs are demonstrated for the adult IBD 
population and Scottish HCs. P-values for association were generated in Haploview version 4.2. 
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Table 11-3  NKX2.3 MAFs in adult-onset Scottish IBD population and HCs. 
P-values, odds ratios (OR) and 95% confidence intervals are given for chi2 analysis of IBD, CD and UC versus HC. 
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Table 11-4 NKX2.3 MAFs in early-onset Scottish IBD population (paed.) and HCs. 
P-values, odds ratios (OR) and 95% confidence intervals are given for chi2 analysis of IBD, CD and UC versus HC. 
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SNP Transmitted Untransmitted p-value 
rs7095491 111:99 99 0.4076 
rs7081330 113:106 106 0.6362 
rs1088371 104:97 97 0.6215 
rs4919345 102:88 88 0.3098 
 
Table 11-5 TDT analysis of NKX2.3 tSNPs in early-onset Scottish IBD population. 
TDT analysis was performing using the standard algorithm embedded in Haploview (version 4.2). 
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Table 11-6 NKX2.3 MAFs in combined Scottish IBD population (adult plus early-onset) and HCs. 
P-values, odds ratios (OR) and 95% confidence intervals are given for chi2 analysis of IBD, CD and UC versus HC. 
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rs7095491 0.520 0.510 0.530 0.472 4.59 x10-5 
OR 1.21  
(1.10-1.33) 
0.015 
OR 1.16  
(1.03-1.31) 
0.0003  
OR 1.26  
(1.11-1.43) 
rs7081330 0.346 0.362 0.329 0.386 0.0004 
OR 0.84  
(0.77-0.93) 
0.11 
OR 0.90  
(0.80-1.02) 
0.0002 
OR 0.78  
(0.69-0.89) 
rs1088371 0.529 0.518 0.541 0.480 2.81 x10-5 
OR 1.22  
(1.11-1.33) 
0.012 
OR 1.17  
(1.03-1.32) 
0.0001 
OR 1.28  
(1.13-1.45) 
rs2902288 0.126 0.142 0.111 0.130 0.60 






OR 0.84  
(0.69-1.02) 
rs7091572 0.261 0.272 0.253 0.279 0.079 
OR 0.91  
(0.82-1.01) 
0.62 
OR 0.97  
(0.84-1.11) 
0.065 
OR 0.87  
(0.76-1.01) 
 
Table 11-7 NKX2.3 MAFs in combined Scottish IBD population (adult plus early-onset) and combined HC (Scotland and WTCCC). 
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rs11190141 101,282,382 C/T Promoter N Y 
rs10883371 101,282,445 A/C Promoter Y Y 
rs10883372 101,282,473 T/A Promoter N Y 
rs10883373 101,282,474 G/A Promoter N Y 
rs41290504 101,283,025 C/A Synonymous 
(Exon1) 
N Y 
rs11340647 101,283,246 G/- Ins/Del N N 
rs7908704 101,283,308 G/A Intronic N Y 
rs7893840 101,283,331 T/C Intronic N Y 
rs7911680 101,283,458 A/C Intronic N Y 
rs884144 101,283,846 C/T Intronic Y N 
rs12247368 101,284,620 A/C Intronic N N 
rs10082511 101,285,216 C/A Synonymous 
(Exon 2) 
N N 
rs888208 101,285,853 A/G Downstream N Y 
 
Table 11-8 Position and location of all known SNPs within NKX2.3. 
Includes 1kb of promoter region.  Those SNPs validated on re-sequencing indicated.  rs41290504 was a 
novel SNP at time of sequencing (2007) but is now listed on dbSNP128 (ENSEMBL:Watson).  Two of 
these SNPs were genotyped in the WTCCC study (rs1088371 and rs884144). 
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Figure 11-1 Haplotype structure of NKX2.3 (68.4 view, D′). 
HapMap data visualised on HaploView (version 4.2).  68.4kb region spanning NKX2.3 including position of tSNPs. 
NKX2.3: 68.4kb view; D′ 
A
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Figure 11-2 Haplotype structure of NKX2.3 (42.6kb view, r2). 
42.6kb segment (box A in Figure 1A) with LD structure denoted by r^2 values demonstrates decreased 











Position Chr 10: 101,283,025 C/A 
 
Figure 11-3 Position of novel synonymous SNP from re-sequencing of NKX2.3. 
 
NKX2.3: 20kb view; r^2 (box A) 
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Figure 11-4 mRNA expression of NKX2.3 in UC and CD by microarray. 
Quantitative analysis of mRNA levels by microarray of NKX2.3 in UC and CD compared with non-
inflamed HC.  For UC and CD, sub-categorisation is made for inflamed (I) and non-inflamed (N-I) 
samples.  Individual datapoints are plotted with horizontal lines representing medians of each dataset.  
P-values, plotted where significant, are derived by Mann-Whitney U test. 
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12   Implications and future work 
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12.1 Implications  
In the past 2 years, I have initiated a series of collaborative studies with William 
Zacharias and Professor Deborah Gumucio (Department of Cell and Developmental 
Biology, Ann Arbor, MI).  Exploiting their expertise in gastrointestinal development 
and animal modelling, we have further explored the role of HH in IBD pathogenesis 
using the Gli1+/LacZ mouse.  Whilst these experiments were performed in Ann Arbor, I 
conceived the hypotheses and study aims, and all aspects of study design and analysis 
were worked on in conjunction with Zacharias and Gumucio.  The results of these 
studies, recently published (Lees, Zacharias et al, PLoS Medicine 2008; attached as 
appendix),423 will be discussed in conjunction with the body of work presented in this 
thesis when considering the important implications herein.  This lays the groundwork 
for the exciting future studies planned in Edinburgh and Ann Arbor. 
 
As discussed in Chapter 2, multiple lines of evidence now indicate that HH plays an 
important role in inflammation.  The data presented in the present thesis, along with 
recent data generated with the Gumucio lab now present a compelling argument that 
down-regulation of Hh ligand in the intestinal epithelium, with associated decreased 
pathway activity in the lamina propria, is associated with a pro-inflammatory state: 
• Mice engineered in the Gumucio lab to have reduced intestinal Hh signalling 
(over-expression of the pan-Hh inhibitor Hhip [Villin-Hhip]) have spontaneous 
ileal inflammation303 
• Microarray studies performed in Villin-Hhip ileum303 (Table 13-1) and in isolated 
ileal mesenchyme treated with recombinant Hh demonstrate: 
o CX3CR1, LTC4S, CD28 and NKX2.3 are all increased by recombinant Hh 
and decreased in villin-Hhip; 
o IL1β, IL6, TLR2, MARCO and CXCL2 are decreased by recombinant Hh 
and increased in villin-Hhip. 
• GLI1 expression is decreased in colonic inflammation.  GLI1 mRNA (and by 
inference Hh pathway activity) increased along the length of the healthy adult 
colon in man (mirroring the increasing luminal bacterial load in the distal colon) 
and was reduced in all forms of colonic inflammation studied (UC, colonic CD 
and non-IBD inflammation).   
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• Germ-line variation in GLI1 (within IBD2 on 12q13) is associated with IBD. 
This was demonstrated in 3 independent N European populations (Scotland, 
England, Sweden).   
o A non-synonymous SNP (rs2228226) in a highly conserved region of 
GLI1, next to a known transactivation domain, is associated with IBD 
(pooled odds ratio 1.194, C.I. 1.09-1.31, p=0.0002) and is functionally 
defective in vitro.   
• Gli1+/LacZ develop early, severe colitis.423 Gli1-/- mice develop normally, in 
contrast to lines deficient in all other Hh components. We have shown, in 
collaboration with the Gumucio lab, that stressing mice with a 50% reduction in 
functional Gli1 (Gli1+/LacZ) with 3% DSS for 6 days leads to early, severe colitis 
with substantial mortality compared to WT littermates.  To date, this is the only 
described phenotype for reduced Gli1 function in vivo.   
• Myeloid CD11b and CD11c positive cells are direct targets of Hh signalling in 
the lamina propria.423  The poor specificity of commercially available Hh 
pathway antibodies is now well documented.334 Given that Gli1+/LacZ animals 
contain a copy of bacterial β-galactosidase under control of the Gli1 promoter, 
they represent an excellent model to identify cell types that are Hh-responsive 
prior to and during inflammatory disease. Initial analysis has demonstrated that 
whilst CD3 lymphocytes, and CD11b and CD11c myeloid cells co-localize LacZ 
in the steady state, only myeloid APCs are responding to Hh signals in response to 
acute DSS challenge. This was accompanied by significant up-regulation of IL12, 
IL17 and IL23 on analysis of whole intestinal mRNA. No co-localisation was seen 
with CD19-positive B lymphocytes at any stage. 
12.2 Current working hypothesis 
On the basis of this body of evidence, I have generated the hypothesis that paracrine 
Hh signalling from epithelium to myeloid antigen presenting cells (APCs) is critical to 
the maintenance of intestinal mucosal immune homeostasis (Figure 12-1). In the 
steady state, soluble Hh protein in the intestinal epithelium instructs resident myeloid 
APCs to adopt a tolerogenic phenotype, which in turn leads to expansion of the 
regulatory T cell pool.  In response to inflammatory challenge, down-regulated 
epithelial Hh, acting as a danger signal, results in a pro-inflammatory myeloid cell 
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phenotype and expansion of Th17 lymphocytes in the lamina propria. Dysregulation 
of this homeostatic hedgehog signalling can result in IBD. 
 
Planned future studies will now aim to: 
1. Characterise the aberrant inflammatory signalling in lamina propria myeloid APCs 
downstream of the Hh signal in Gli1+/LacZ and Gli1-/- mice; 
2. Elucidate the upstream regulators of epithelial Indian (Ihh) and Sonic hedgehog 
(Shh) gene expression; and 
3. Examine whether Hh agonists represent a novel therapeutic modality in IBD. 
12.3 Future HH studies 
12.3.1 Characterise aberrant inflammatory signalling in Gli1-/- mice 
1a) DSS challenge of Gli1-/- mice.  I will first stress Gli1-/- mice and WT littermate 
controls (bred for at least 3 generations onto a C57BL/6 background) with 3% DSS 
administered in drinking water for 1-6 days.  Animals will be monitored daily for 
signs of diarrhoea, bloody stool and weight loss. To establish the early mechanisms in 
this acute model of colonic inflammation, mice will be sacrificed at days 1, 2, 3 and 6 
after initiation of DSS.    
1b) Molecular and cellular targets of Hh. mRNA analysis and 
immunohistochemistry for Gli1 LacZ will be performed on whole colonic tissue 
sections from Gli1-/- mice and WT at baseline and at various timepoints after 
inflammatory challenge. Q-PCR will be performed for a variety of cytokines (incl. 
IL1β, IL4, IL6, IL8, IL10, IL12, IL17, IL23, IFNγ, & TNFα), chemokines (incl. 
CX3CR1, CCL20), murine cryptdins, TGFβ1, NKX2.3, and NOD2. To extend the 
LacZ observations in Gli1+/LacZ mice 4 days after DSS, I will characterise the cellular 
targets of Hh signalling early (days 1, 2 and 3) in Gli1-/- mice with antibodies to CD3, 
CD11b, CD11c, CD103 and MHCII (co-staining with β-galactosidase).  
1c)  In vitro characterisation of myeloid cell phenotypes.  Whist the experiments 
already performed in Gli1+/LacZ mice demonstrate lamina propria myeloid cells 
responding to epithelial Hh signals and up-regulation of Th17 cytokines in total 
colonic mRNA, they do not directly connect these two observations. It is therefore not 
presently clear which cell type is responsible for the altered cytokine profile and 
precisely how defective Gli1 expression contributes to this.  I will therefore isolate 
colonic lamina propria DCs and macrophages from Gli1-/- and WT mice at baseline 
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and 1, 2 and 3 days following DSS challenge.  The cytokine profiles (IL6, IL10, IL23, 
IFNγ, CX3CR1, TGFβ) of these cells will be determined by ELISA in culture 
supernatant. 
1d) Analysis of regulatory T cell (TREG) populations.  It is anticipated that the in 
vitro experiments in 1c will demonstrate increased secretion of pro-Th17 cytokines in 
Gli1-/- DCs and macrophages.  In my working hypothesis the ultimate effect of these 
Hh conditioned myeloid cells is the determination of CD4 T cell phenotype (Figure 
12-1). In order to ascertain the relative TREG subset in the lamina propria of Gli1-/- 
mice, I will perform immunohistochemistry for Foxp3 and quantify relative to number 
of CD3 +ve cells.  To further characterise the TREG population in these animals I will 
isolate immune cells from spleen, mLNs and colon and measure TREG subset by FACS 
(CD3+, FoxP3+), both with and without prior sorting for LacZ status and examine 
this for signs of Hh activity. If these initial approaches demonstrate a difference in the 
TREG population, I will perform co-culture experiments to formally test this aspect of 
the hypothesis. Lamina propria DCs and/or macrophages (depending on the results 
from 1c) from WT and Gli1-/- mice will be co-cultured with naïve CD4 T cells to see 
if they are instructed to a Th17 or TREG phenotype.  
1e) Il10-/- mice.  I will first establish the level of Hh signalling in Il10-/- mice in SPF 
conditions by Q-PCR and in situ hybridisation for Gli1 at different timepoints.  We 
will then inter-breed Il10-/- and Gli1-/- mice and utilise clinical and histological 
parameters (as above) to determine whether Il10-/-;Gli1+/- mice develop more severe 
colitis when compared with Il10-/- littermates.  Furthermore, the role of the Hh 
signalling pathway will be established in this model by elucidating cellular (LacZ 
immunostaining) and molecular (Q-PCR) targets of Hh as outlined for the DSS 
experiments above.  
12.3.2 Elucidation of upstream regulators of HH gene expression in 
the epithelium 
Shh and Ihh ligands are exclusively expressed in the epithelium in the intestine. Very 
little remains known about the upstream regulation of ligand expression. I plan to 
address this using Shh & Ihh reporter mice (Shh-CRE-GFP and Ihh-LacZ) in 3 
settings: i) response to DSS inflammatory challenge ii) antibiotic treatment to 
obliterate commensal bacterial flora and iii) following obliteration of intestinal 
epithelial cell NFκB expression.  Mice heterozygous for the Shh-GFP insertion allele 
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(Shh+/GFP) will be used as they develop normally, are available on B6 background and 
are indistinguishable from WT littermates.  
2a) DSS challenge of Shh+/GFP and Ihh+/LacZ mice.  3% DSS will be administered in 
the drinking water to Shh+/GFP, Ihh+/LacZ and WT mice, and compared with control 
groups of both reporter strains and WT mice given normal drinking water.  DSS 
treated animals will be sacrificed at days 1, 2, 3 and 6, and Shh and Ihh expression 
patterns and levels will be determined on frozen sections by confocal microscopy of 
GFP & β-galactosidase staining for Shh & Ihh respectively. 
2b) Antibiotic treatment.  The increasing gradient of Hh ligand expression and Hh 
pathway activity demonstrated in healthy human colon reflects the increasing 
bacterial burden of the commensal flora in the distal colon.  To ascertain whether 
commensal bacteria directly affects expression of Hh ligand in the epithelium 
Shh+/GFP and Ihh+/LacZ mice raised in SPF conditions, will be treated with vancomycin 
(1mg/L), neomycin sulphate (500mg/L) and metronidazole (1g/L) in drinking water 
for 7 days.  7 days following antibiotic treatment, these mice will be sacrificed and the 
expression pattern of GFP / LacZ and Gli1 mRNA levels in ileum and colon will be 
compared with control mice (not antibiotic treated).  If a significant alteration in Shh 
and/or Ihh expression is determined with antibiotic treatment I will then proceed to 
administer antibiotics to Gli1+/LacZ mice and monitor Hh pathway activity by 
analysing LacZ expression and QPCR for Gli1. 
2c) Intestinal epithelial cell specific knock-down of NFκB activity.  Gumucio and 
colleagues have previously demonstrated that intestinal epithelial cell specific knock-
down of NEMO (leading to absent epithelial NFκB signalling) results in spontaneous 
intestinal inflammation.514 However, the level of Hh signalling activity has not yet 
been determined in this model.  Despite the largely negative studies presented in 
Chapter 9, it is anticipated that Hh ligand expression will be decreased as there is 
good evidence that Shh is a direct target of NFκB in different tissues (although not yet 
tested in the gut or with Ihh).  I will therefore analyse Hh ligand expression and Hh 
pathway activity by QPCR for Shh, Ihh, and Gli1 isolated from whole ileal and 
colonic tissue at 1 week (prior to the onset of inflammation), 3 weeks (onset of 
colonic inflammation) and 6 weeks (severe colitis).  As these mice do not develop 
ileal inflammation it will be of interest to compare Hh expression in ileum as well as 
colon in this model.   
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12.3.3 HH as a therapeutic target: do HH agonists modulate 
inflammatory pathways? 
The human genetic and expression data along with the murine data generated to date 
all supports down-regulated Hh signalling in response to mammalian intestinal 
inflammation. I will therefore examine, both in vitro & in vivo, whether the use of Hh 
agonists modulates intestinal inflammatory pathways to a tolerogenic phenotype and 
is therefore a potential therapeutic strategy in IBD. 
3a) In vitro approach.  I will first analyse the effects of Hh pre-treatment on the 
phenotype of human DCs and macrophages in culture, specifically the cytokine 
profile of treated DCs and their ability to instruct T cells.  Initially, PBMCs from non-
smoking healthy volunteers will be used.  DCs (and macrophages if indicated by 1c) 
and CD4 T cells will be isolated using negative selection affinity columns.  5x105 
DCs (CD11c+ MHCII+) will be pre-treated with exogenous recombinant Shh or Ihh. 
The cytokine profiles (IL6, IL10, IL23, IFNγ, CX3CR1, TGFβ) of treated & control 
DCs will be determined by ELISA of culture supernatants. I will next co-culture DCs 
with 5x105 unstimulated, allogeneic CD4 T cells, and enumerate TREGs & Th17 cells 
by FACS. If this approach proves informative, I will proceed to repeat these 
experiments in patients with quiescent UC and CD (non-smokers with no recent (3 
months) exposure to corticosteroids, immunosuppressants or biological therapy). IBD 
patients will be genotyped for the causative mutation (rs2228226) in GLI1.  
3b) In vivo approach.  I will subsequently assess whether the administration of Hh 
agonists can ameliorate acute colitis induced by 3% DSS.  Commercially available 
agonists include agents from Curis Inc. (Cur199567) and Novartis. I will administer 
Hh agonist and PBS as a control intra-peritoneally both before and 6 days after the 
induction of colitis to see if a) increased Hh levels protect against colitis and b) 
whether established colitis can be treated by increasing Hh signalling activity. Clinical 
parameters will then be monitored and histological analysis performed as described 
above 
12.4 HH and MDR1 (ABCB1) 
Given the roles described for germline variation for both GLI1 (presently)423 and 
MDR1 (Ho and colleagues in Edinburgh, see 1.5.4.2)260, 515-517 in UC pathogenesis, it 
is of great interest to note two papers in the literature that describe links between the 
two.  Noting that inhibition of HH signalling increased the reponsiveness of various 
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cancer cell lines to chemotherapy, Sims-Mourtada and colleagues demonstrated that 
HH also regulated the expression of MDR1.518  siRNA knock-down of MDR1 
partially reversed HH-induced chemoresistance.  Most recently, it was demonstrated 
that inhibition of HH (SMO-acting HhAntag691) potently decreased the expression 
and function of MDR1.519  It will therefore be of great interest to assess whether HH-
GLI1 signalling and MDR1 interact in the context of acute and chronic colonic 
inflammation and / or corticosteroid resistance in IBD.  Ho is presently further 
exploring the function of MDR1 in UC (MRC Clinician Scientist Award) so this 
hypothesis will be eminently testable in Edinburgh in the near future. 
12.5 IHH and WNT in colitis-associated cancer 
The role of recapitulated embryonic HH signalling in response to injury in a number 
of different organs / tissues was discussed in Chapter 1 (1.9.3).  Furthermore, it was 
proposed that in these scenarios HH may play a role in cancers arising in regions of 
chronic inflammation in, for example, the hepato-biliary sytem and the pancreas.  In 
the colon however the present data would suggest a different model that requires 
testing in vivo.  Down-regulation of HH pathway activity was noted in all forms of 
colonic inflammation studied in man and mouse.  In UC, down-regulated IHH 
appeared to be driving this decrease.  Given the evidence linking HH and WNT 
(negative regulation) laid out in Chapter 2, it is proposed that down-regulated IHH – 
GLI1 signalling results in unrestricted WNT signalling in colonic inflammation.  In 
the acute setting this is most likely an appropriate response to resolve the acute 
inflammatory / infectious insult.  However, in the scenario of chronic colitis, this 
results in chronic inappropriate upregulation of WNT signalling and the risk of 
malignant transformation (+/- somatic mutation in WNT signalling components). 
12.6 Future studies into the genetic basis of IBD 
We are presently performing a full GWAS in UC as part of the on-going WTCCC 
project.  It is anticipated that these data will be combined with German and N 
American UC GWAS (see 1.5.4.5 and 1.5.4.6) to perform a meta-analysis, given the 
success of this approach in CD.  The WTCCC has prioritised CD for follow-up of hits 
in the second phase of this study designed to fine-map associated loci following deep 
re-sequencing in a large number of CD patients and HCs.  The HH target gene 
NKX2.3 is amongst those presently being re-sequenced.  Our unit is presently also 
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involved in a large, multi-national collaborative GWAS in paediatric IBD 
(CHOPSTICKS), due to report soon. 
12.6.1 Follow-up of HH and WNT pathway genetic studies 
The haplotype-tagging study of GLI1 has provided robust evidence for association 
with IBD.  In addition, it has been shown that a nsSNP, that we have shown to result 
in a mutant protein that is a subfunctional transactivator of GLI1, largely accounts for 
the variation observed.  However, deep re-sequencing of the entire GLI1 gene remains 
a priority.  In addition, it will be of considerable interest to type the CNV that has 
been documented at the GLI1 locus.   
 
The data presented in Chapter 8 provide a limited survey of HH and WNT pathway 
genes for association with CD from pre-existing WTCCC GWAS data and the CD 
meta-analysis.  This has produced some very interesting leads, notably the 
associations between SUFU and the WNT3/9b locus with CD that merit follow-up by 
fine-mapping studies, although tight LD in both regions will make such an approach 
difficult.  Given the predominant association of GLI1 with UC, it will be of great 
interest to analyse the forth-coming WTCCC UC GWAS data for associations with 
other HH (and WNT) pathway genes.  However, a more robust and formal approach 
would be to perform large-scale haplotype-tagging studies of all HH and WNT 
pathway genes in UC and CD in a suitably powered Scottish or UK-wide cohort to 
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Figure 12-1  Current working hypothesis for the role of HH signalling pathway in the regulation of colonic inflammatory pathways 
↓HH / 
↓GLI1 
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Gene 


















AI323594 small inducible cytokine A2 
GO:6954; GO:7165; 
GO:6935; GO:6955 1.79 0.005 20.90 0.013 32.43 0.000 
Pap 
pancreatitis-associated 
protein GO:6954; GO:6953; 1.40 0.020 10.78 0.001 29.40 0.006 
AW546964 
S100 calcium binding 
protein A9 (calgranulin B)  1.37 0.036 12.82 0.026 23.76 0.003 
Gro1 GRO1 oncogene 
GO:6954; GO:6955; 
GO:74; GO:8151 1.58 0.020 15.34 0.012 22.58 0.000 
S100a8 
S100 calcium binding 
protein A8 (calgranulin A) GO:6935 2.33 0.002 7.80 0.025 10.57 0.001 
Pglyrp 
peptidoglycan recognition 
protein GO:6955; GO:6915 2.51 0.002 3.90 0.025 5.27 0.001 
Areg amphiregulin  1.39 0.243 3.57 0.027 4.97 0.009 
Scya7 small inducible cytokine A7 
GO:6954; GO:7165; 





GO:16337 -1.13 0.546 3.25 0.004 4.27 0.007 
Scyb5 
small inducible cytokine B, 
5 GO:7165; GO:6955 -1.10 0.823 3.36 0.044 3.99 0.005 
Serping1 
serine proteinase 
inhibitorclade G, 1 GO:6956; GO:6958 2.33 0.032 2.58 0.038 3.58 0.002 
AI385595 
cytokine inducible SH2-
containing protein GO:7242; GO:1558 -1.07 0.634 2.30 0.038 3.38 0.037 
S100a6 
S100 calcium binding 
protein A6 (calcyclin) GO:8283; GO:7049 3.67 0.005 2.97 0.086 2.96 0.011 
Ifrd1 
interferon-related 
developmental regulator 1  1.10 0.369 2.43 0.008 2.54 0.002 
Slpi 
secretory leukocyte protease 
inhibitor  2.18 0.028 2.32 0.036 2.32 0.140 
Nrp immediate early response 5  1.03 0.655 2.25 0.037 2.20 0.015 
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Il1r1 interleukin 1 receptortype I GO:7166 -1.02 0.918 1.74 0.007 2.00 0.026 
Scya25 
small inducible cytokine 
A25 
GO:6935; GO:6954; 
GO:7165; GO:6955 1.47 0.002 1.71 0.203 1.79 0.067 
Cd24a CD24a antigen GO:6952 1.88 0.070 1.55 0.011 1.72 0.004 
AW546738 
B-cell translocation gene 
1anti-proliferative  1.15 0.377 1.64 0.050 1.63 0.018 
Cnlp cathelin-like protein GO:6952; GO:6805 -1.19 0.041 1.13 0.793 1.07 0.736 
H2-T18 
histocompatibility 2T 
region locus 3 
GO:6952; GO:6955; 
GO:19883; GO:19885 -1.33 0.033 -1.31 0.557 -1.26 0.177 
Bet3-pendi 
Bet3 homolog (S. 
cerevisiae)  -1.22 0.047 -1.38 0.038 -1.33 0.085 
Ifrg15-pen 
interferon alpha responsive 
gene15 kDa  -1.15 0.025 -1.26 0.277 -1.37 0.194 
AI528744 interleukin 10 receptorbeta GO:7166 -1.45 0.018 -1.49 0.072 -1.47 0.025 
H2-L 
histocompatibility 2D 
region locus 1 
GO:6952; GO:6955; 
GO:19883; GO:19885 -1.78 0.005 -1.60 0.109 -1.62 0.009 
Enpep glutamyl aminopeptidase GO:6952; GO:6508 -1.95 0.020 -2.00 0.265 -1.64 0.079 
H2-D1 
histocompatibility 2D 
region locus 1 
GO:6952; GO:6955; 
GO:19883; GO:19885 -1.14 0.331 -1.72 0.029 -1.69 0.002 
H2-K 
histocompatibility 2K 
region GO:6952 -1.45 0.018 -1.65 0.007 -1.72 0.006 
H2-Q2 
histocompatibility 2Q 
region locus 2 GO:6952 -1.29 0.010 -1.77 0.091 -1.73 0.024 
H2-T18 
histocompatibility 2T 
region locus 18 GO:6952 -1.45 0.019 -1.66 0.010 -1.83 0.015 
Ly64 lymphocyte antigen 64 GO:6952  -2.04 0.003 -1.72 0.002 -1.83 0.010 
H2-L 
histocompatibility 2L 
region GO:6952   -1.41 0.022 -1.92 0.045 -1.84 0.003 
Tcrb-V13 
T-cell receptor germline 
beta-chain geneV-region 
promoter  -1.47 0.034 -1.81 0.027 -1.92 0.004 
H2-Q1 
histocompatibility 2Q 
region locus 1 GO:6952 -1.50 0.005 -2.26 0.017 -2.06 0.002 
AI266795 S100 calcium binding  -1.32 0.018 -2.23 0.100 -2.26 0.002 
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protein A1 
H2-Eb1 
histocompatibility 2class II 
antigen E beta 
GO:6952; GO:6955; 








repeats 1 GO:6955 -1.58 0.020 -4.45 0.001 -6.16 0.001 
 
Table 13-1  Dysregulated inflammatory genes in microarray of villin-Hhip total small intestine vs. WT 
Madison and Gumucio performed a microarray on total small intestine from villin-Hhip mice vs. WT at birth.303   In this model, transgenic villin drives over-expression of the 
pan-Hh inhibitor, Hhip in the intestine from embryonic day 14-15, thus resulting in decreased Hh pathway activity. Professor Gumucio has provided this list of inflammatory 
genes (made by searching for relevant GO terms – see below) dysregulated in this model (unpublished data).  The 3 columns that state fold-change relate to the 3 different 
microarray platforms used in this study: Affy 4.0, Affy 5.0 and RMA (Terry Speed’s algorithm). The RMA is thought to be the most robust analysis.  For example, in this 
model it is the only system that picked up a change in PTCH (a robust marker of altered HH pathway activity).   
 
GO terms:  6954  inflammatory response; 7165  signal transduction; 6935  chemotaxis; 6955  immune response; 6953  acute-phase response; 74    cell cycle control; 8151  
cell growth and/or maintenance; 6915  apoptosis; 6956  complement activation; 6958  complement activation, classical pathway; 7242  intracellular signaling cascade; 
1558  regulation of cell growth; 8283  cell proliferation; 7049  cell cycle; 7166   cell surface receptor linked signal transduction; 6952  defense response; 6805  xenobiotic 
metabolism; 19883  antigen presentation, endogenous antigen via  MHC class I; 6508   proteolysis and peptidolysis; 19884  antigen presentation, exogenous antigen via  
MHC class II 
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Figure 13-1  WNT signalling expression in healthy (non-inflamed) human colon – Part 1 
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Figure 13-2 WNT signalling in healthy (non-inflamed) human intestine – Part 2 
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Figure 13-3 WNT signalling in healthy (non-inflamed) human colon – Part 3 
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Figure 13-4 WNT signalling in non-IBD colonic inflammation – Part 1 
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Figure 13-5 WNT signalling in non-IBD colonic inflammation – Part 2 
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Figure 13-6 WNT signalling in non-IBD colonic inflammation – Part 3 
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Figure 13-7  WNT signalling in UC versus HC – Part 1 
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Figure 13-8  WNT signalling in UC versus HC – Part 2 
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Figure 13-9 WNT signalling in UC versus HC – Part 3 
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Figure 13-10 WNT signalling in colonic CD versus colonic HC – Part 1 
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Figure 13-11 WNT signalling in colonic CD versus colonic HC – Part 2 
 - 305 - 
 - 305 - 
 
Figure 13-12 WNT signalling in colonic CD versus colonic HC – Part 3 
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Figure 13-13 WNT signalling in ileal CD versus ileal HC – Part 1 
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Figure 13-14 WNT signalling in ileal CD versus ileal HC – Part 2 
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Figure 13-15 WNT signalling in ileal CD versus ileal HC – Part 3 
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